



(51) International Patent Classification:

C12Q 1/6844 (2018.01)

(21) International Application Number:

PCT/US2020/015059

(22) International Filing Date:

24 January 2020 (24.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/796,384

24 January 2019 (24.01.2019)

US

(71) Applicants: **MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH** [US/US]; 200 First Street S.W., Rochester, Minnesota 55905 (US). **EX-ACT SCIENCES DEVELOPMENT COMPANY, LLC** [US/US]; 441 Charmany Drive, Madison, Wisconsin 53719 (US).

(72) Inventors: **TAYLOR, William R.**; c/o Mayo Foundation for Medical Education and Research, 200 First Street S.W., Rochester, Minnesota 55905 (US). **KISIEL, John B.**; c/o Mayo Foundation for Medical Education and Research, 200 First Street S.W., Rochester, Minnesota 55905 (US). **MAHONEY, Douglas W.**; c/o Mayo Foundation for Medical Education and Research, 200 First Street S.W., Rochester, Minnesota 55905 (US). **AHLQUIST, David A.**; c/o Mayo Foundation for Medical Education and Research, 200 First Street S.W., Rochester, Minnesota 55905 (US). **ALLAWI, Hatim T.**; c/o Exact Sciences Development Company, LLC, 441 Charmany Drive, Madison, Wisconsin 53719 (US). **GIAKOUMOPOULOS, Maria**; c/o Exact Sciences Development Company, LLC, 441 Charmany Drive, Madison, Wisconsin 53719 (US).

(74) Agent: **GOETZ, Robert A.**; Casimir Jones, S.C., 2275 Deming Way, Ste 310, Middleton, Wisconsin 53562 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: DETECTING ENDOMETRIAL CANCER

(57) Abstract: Provided herein is technology for endometrial cancer (EC) screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of endometrial cancer and various subtypes of endometrial cancer.

DETECTING ENDOMETRIAL CANCER

CROSS-REFERENCE TO RELATED APPLICATION

The present application claims priority to U.S. Provisional Patent Application No. 62/796,384, filed January 24, 2019, which is hereby incorporated by reference in its entirety.

FIELD OF INVENTION

Provided herein is technology for endometrial cancer (EC) screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of endometrial cancer and various subtypes of endometrial cancer.

BACKGROUND

Early detection approaches for endometrial cancer (EC) are lacking, despite the fact that EC is the most common gynecologic malignancy in the United States and in many other developed countries (see, Siegel, R.L., et al., Cancer statistics, 2016. CA Cancer J Clin, 2016. 66(1): p. 7-30; Parkin, D., et al., Global cancer statistics, 2002. CA Cancer J Clin. , 2005. 55(2): p. 74-108). While low-risk, early stage EC has an excellent prognosis with 5-year overall survival (OS) >95%, 5-year OS when diagnosed at stage III or IV is sobering at 68% and 17%, respectively (see, Fridley, B.L., et al., PLoS ONE, 2010. 5(9): p. e12693). Most EC are low-grade endometrioid histology and preceded by hyperplasia precursors; however, the more aggressive grade 3 endometrioid, serous, clear cell, and carcinosarcoma histologies comprise 10-15% of newly diagnosed EC and can be highly lethal (see, Felix, A.S., et al., Cancer Causes Control, 2010. 21(11): p. 1851-6; Moore, K.N. and A.N. Fader, Clin Obstet Gynecol, 2011. 54(2): p. 278-91; Cancer Genome Atlas Research, N., et al., Nature, 2013. 497(7447): p. 67-73; Hussein, Y.R., et al., Int J Gynecol Pathol, 2016. 35(1): p. 16-24). Early detection increases the chance of cure (see, Mariani, A., et al., Gynecologic Oncology, 2008. 109(1): p. 11-18).

Improved methods for detecting EC and various subtypes of EC are needed.

The present invention addresses these needs.

SUMMARY

Methylated DNA has been studied as a potential class of biomarkers in the tissues of most tumor types. In many instances, DNA methyltransferases add a methyl group to DNA at

cytosine-phosphate-guanine (CpG) island sites as an epigenetic control of gene expression. In a biologically attractive mechanism, acquired methylation events in promoter regions of tumor suppressor genes are thought to silence expression, thus contributing to oncogenesis. DNA methylation may be a more chemically and biologically stable diagnostic tool than RNA or protein expression (Laird (2010) *Nat Rev Genet* 11: 191–203). Furthermore, in other cancers like sporadic colon cancer, methylation markers offer excellent specificity and are more broadly informative and sensitive than are individual DNA mutations (Zou et al (2007) *Cancer Epidemiol Biomarkers Prev* 16: 2686–96).

Analysis of CpG islands has yielded important findings when applied to animal models and human cell lines. For example, Zhang and colleagues found that amplicons from different parts of the same CpG island may have different levels of methylation (Zhang et al. (2009) *PLoS Genet* 5: e1000438). Further, methylation levels were distributed bi-modally between highly methylated and unmethylated sequences, further supporting the binary switch-like pattern of DNA methyltransferase activity (Zhang et al. (2009) *PLoS Genet* 5: e1000438). Analysis of murine tissues in vivo and cell lines in vitro demonstrated that only about 0.3% of high CpG density promoters (HCP, defined as having >7% CpG sequence within a 300 base pair region) were methylated, whereas areas of low CpG density (LCP, defined as having <5% CpG sequence within a 300 base pair region) tended to be frequently methylated in a dynamic tissue-specific pattern (Meissner et al. (2008) *Nature* 454: 766–70). HCPs include promoters for ubiquitous housekeeping genes and highly regulated developmental genes. Among the HCP sites methylated at >50% were several established markers such as Wnt 2, NDRG2, SFRP2, and BMP3 (Meissner et al. (2008) *Nature* 454: 766–70).

Epigenetic methylation of DNA at cytosine-phosphate-guanine (CpG) island sites by DNA methyltransferases has been studied as a potential class of biomarkers in the tissues of most tumor types. In a biologically attractive mechanism, acquired methylation events in promoter regions of tumor suppressor genes are thought to silence expression, contributing to oncogenesis. DNA methylation may be a more chemically and biologically stable diagnostic tool than RNA or protein expression. Furthermore, in other cancers like sporadic colon cancer, aberrant methylation markers are more broadly informative and sensitive than are individual DNA mutations and offer excellent specificity.

Several methods are available to search for novel methylation markers. While micro-array based interrogation of CpG methylation is a reasonable, high-throughput approach, this

strategy is biased towards known regions of interest, mainly established tumor suppressor promoters. Alternative methods for genome-wide analysis of DNA methylation have been developed in the last decade. There are three basic approaches. The first employs digestion of DNA by restriction enzymes which recognize specific methylated sites, followed by several possible analytic techniques which provide methylation data limited to the enzyme recognition site or the primers used to amplify the DNA in quantification steps (such as methylation-specific PCR; MSP). A second approach enriches methylated fractions of genomic DNA using anti-bodies directed to methyl-cytosine or other methylation-specific binding domains followed by microarray analysis or sequencing to map the fragment to a reference genome. This approach does not provide single nucleotide resolution of all methylated sites within the fragment. A third approach begins with bisulfite treatment of the DNA to convert all unmethylated cytosines to uracil, followed by restriction enzyme digestion and complete sequencing of all fragments after coupling to an adapter ligand. The choice of restriction enzymes can enrich the fragments for CpG dense regions, reducing the number of redundant sequences which may map to multiple gene positions during analysis.

RRBS yields CpG methylation status data at single nucleotide resolution of 80-90% of all CpG islands and a majority of tumor suppressor promoters at medium to high read coverage. In cancer case - control studies, analysis of these reads results in the identification of differentially methylated regions (DMRs). In previous RRBS analysis of pancreatic cancer specimens, hundreds of DMRs were uncovered, many of which had never been associated with carcinogenesis and many of which were unannotated. Further validation studies on independent tissue samples sets confirmed marker CpGs which were 100% sensitive and specific in terms of performance.

EC spontaneously sheds tumor cells (see, Chin, A.B., et al., *American Journal of Obstetrics and Gynecology*, 2000. 182(6): p. 1278-1282) and detection of EC biomarkers via minimally invasive methods is a promising approach (see, Kinde, I., et al., *Science Translational Medicine*, 2013. 5(167): p. 167ra4; Bakkum-Gamez, J.N., et al., *Gynecologic Oncology*, 2015. 137(1): p. 14-22; Wentzensen, N., et al., *International Journal of Cancer*, 2014. 135(8): p. 1860-1868; Fiegl H, G.C., et al., *Cancer Epidemiol Biomarkers Prev*, 2004. 13(5): p. 882-8); however, optimization of markers, standardization of collection methods, and improvement in specificity are needed. DNA methylation is an early event in EC carcinogenesis (see, Tao, M.H. and J.L. Freudenheim, *Epigenetics*, 2010. 5(6): p. 491-8); RASSF1 is methylated in morphologically normal appearing endometrium adjacent to ECs

(see, Fiegl H, G.C., et al., *Cancer Epidemiol Biomarkers Prev*, 2004. 13(5): p. 882-8; Pijnenborg, J., et al., *Annals of Oncology*, 2007. 18(3): p. 491-497; Suehiro, Y., et al., *Clinical Cancer Research*, 2008. 14(11): p. 3354-3361; Arafa, M., et al., *Histopathology*, 2008. 53(5): p. 525-532); MLH1 methylation occurs in atypical hyperplasia (see, Suehiro, Y., et al., *Clinical Cancer Research*, 2008. 14(11): p. 3354-3361; Horowitz, N., et al., *Gynecologic Oncology*, 2002. 86(1): p. 62-68; Xiong, Y., et al., *Gynecologic Oncology*, 2006. 103(1): p. 321-328; Banno K, Y.M., et al., *Oncol Rep*, 2006. 16(6): p. 1189-96; Zigelboim, I., et al., *Clinical Cancer Research*, 2007. 13(10): p. 2882-2889; Guida M, S.F., et al., *Eur J Gynaecol Oncol.*, 2009. 30(3): p. 267-70). These and other genes are established as methylated in EC (see, Fiegl H, G.C., et al., *Cancer Epidemiol Biomarkers Prev*, 2004. 13(5): p. 882-8; Suehiro, Y., et al., *Clinical Cancer Research*, 2008. 14(11): p. 3354-3361; Zigelboim, I., et al., *Clinical Cancer Research*, 2007. 13(10): p. 2882-2889; Wentzensen, N., et al., *International Journal of Cancer*, 2014: p. [Epub ahead of print]; Tao MH, F.J., *DNA methylation in EC. Epigenetics*, 2010. 5(6): p. 491-8; Integrated genomic characterization of endometrial carcinoma. *Nature*, 2013. 497(7447): p. 67-73; Huang, Y.-W., et al., *Gynecologic Oncology*, 2010. 117(2): p. 239-247; Xiong, Y., et al., *Gynecologic Oncology*, 2005. 99(1): p. 135-141; Sasaki, M., et al., *Cancer Research*, 2001. 61(1): p. 97-102; Sasaki, M., et al., *Molecular and Cellular Endocrinology*, 2003. 202(1-2): p. 201-207) and cell-free methylated DNA released from necrotic tumor cells is an attractive target and has been detected in a variety of biological fluids, including sputum, plasma, peritoneal fluid, stool, nipple aspirates, urine, pancreatic juice, and vaginal fluid (see, Bakkum-Gamez, J.N., et al., *Gynecologic Oncology*, 2015. 137(1): p. 14-22; Fiegl H, G.C., et al., *Cancer Epidemiol Biomarkers Prev*, 2004. 13(5): p. 882-8; Duffy MJ, N.R., et al., *Eur J Cancer*, 2009. 45(3): p. 335-46; Ahlquist, D.A., et al., *Gastroenterology*, 2012. 142(2): p. 248-256; Duffy, M.J., et al., *Eur J Cancer*, 2009. 45(3): p. 335-46; Kisiel, J.B., et al., *Clinical Cancer Research*, 2015. 21(19): p. 4473-4481).

Provided herein is technology for EC screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of EC and various subtypes of EC (e.g., clear cell EC, carcinosarcoma EC, endometrioid EC, serous EC).

Indeed, as described in Examples I, II and III, experiments conducted during the course for identifying embodiments for the present invention identified a novel set of differentially methylated regions (DMRs) for discriminating cancer of the endometrium derived DNA from non-neoplastic control DNA.

Such experiments list and describe 499 novel DNA methylation markers distinguishing EC tissue (and various subtypes of EC tissue) from benign endometrial tissue (see, Tables 1, 8, and 21, Examples 1, 2 and 3).

From these 499 novel DNA methylation markers, further experiments identified the following markers and/or panels of markers capable of distinguishing EC tissue from benign endometrial tissue:

- AFF3, AIM1_A, AMIGO3_A, BMP4_B, C17orf107_A, C1orf70_B, C5orf52, CLDN7, DIDO1_A, EEF1A2, EMX2OS, FEV, FKBP11_A, GDF6, GDF7_A, JSRP1_A, KCTD15_A, KLHL21, LRRC8D_A, NBPF8, MAX.chr10.130339363-130339534, MAX.chr10.22624479-22624553, MAX.chr14.103021656-103021718, MAX.chr8.145103829-145103992, MAX.chr8.145104263-145104422, MDFI_B, MIAT_A, MMP23B, NDRG2, OBSCN_A, PCOLCE, PYCARD, SEPT9_B, SLC6A3_A, SLC8A3_B, SQSTM1, VILL, ZNF302, ZNF323_A, ZNF506, and ZNF90 (see, Table 2, Example 1);
- EMX2OS, CYTH2, C17orf107_A, DIDO1_A, GDF6, NBPF8, MAX.chr14.103021656-103021718, JSRP1_A, GATA2_B, and SFMBT2_B (see, Table 3, Example 1);
- SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and MPZ_A (see, Table 15, Example 1); and
- EMX2OS, CYTH2, NBPF8, MAX.chr10.22624479-22624553 (see, Table 20, Example 1).

From these 499 novel DNA methylation markers, further experiments identified the following markers and/or panels of markers for detecting EC in blood samples (e.g., plasma samples, whole blood samples, leukocyte samples, serum samples):

- ANKRD35, ARL5C, ARRB1, BCL2L11_A, BCL2L11_B, BCL2L11_C, BZRAP1, C16orf54, C17orf101, C6orf132, CACNA2D4, DEDD2, EPS15L1, FAIM2, FAM125B, FAM189B, FAM78A, FOXP4, GYPC_A, GYPC_B, IFFO1_A, IFFO1_B, ITPKA, KLF16, LIMD2, LOC389333, LOC440925_A, LOC646278, LYL1, LYPLAL1, MAX.chr11.32355226-32355251, MAX.chr14.102172621-102172686, MAX.chr14.105512122-105512239, MAX.chr15.95128144-95128248, MAX.chr16.11327016-11327312,

MAX.chr3.187676577-187676668, MAX.chr4.174430676-174430847, MAX.chr8.145900783-145900914, MAX.chr8.80804237-80804301, N4BP3, NCOR2, NFATC1_A, NFATC1_B, NKX2-6, NR2F6, OSM, PALLD_C, PIK3CD, PRKAR1B, RAD52, STX16_A, SUCLG2, TNFRSF1B, TNFRSF4, ZDHHC18, and ZNF671_A (see, Table 9, Example 1).

From these 499 novel DNA methylation markers, further experiments identified the following markers and/or panels of markers capable of distinguishing clear cell EC tissue from benign endometrial tissue:

- DIDO1_A, NDRG4, MAX.chr14.103021656-103021718, MMP23B, EMX2OS, SEPT9_B, NBPf8, EEF1A2, AIM1_A, BMP4_B, MAX.chr8.145103829-145103992, OBSCN, PYCARD, GDF6, MDFI_B, MIAT_A, SCL8A3, ZNF323_A, SQSTM1, AFF3, C1orf70, GDF7_A, JSRP1_A, LRRC8D_A, FEV, and MAX.chr8.145104263-145104422 (see, Table 4, Example 1);
- ZNF323_A, MAX.chr7.104624356-104624730, NDRG2, DIDO1_A, MDFI_B, MAX.chr14.103021656-103021718, MMP23B, SEPT9_B, and STX16_A (see, Table 11, Example 1);
- SFMBT2_B, SQSTM1, ZNF323_A, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MDFI_B, GDF7_A, MAX.chr10.22624479-22624553, JSRP1_A, MAX.chr14.103021656-103021718, EMX2OS, LRRC34, NBPf8, SEPT9_B, EEF1A2, LRRC41_C, VILL, and MPZ_A (see, Table 16, Example 1); and
- MAX.chr7:104624386-104624529, EMX2OS, DIDO1_B, and OBSCN_B (see, Table 24, Example 3).

From these 499 novel DNA methylation markers, further experiments identified the following markers and/or panels of markers for detecting clear cell EC in blood samples (e.g., plasma samples, whole blood samples, leukocyte samples, serum samples):

- SFMBT2_B, SQSTM1, ZNF323_A, ZNF506, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, NDRG2, CYP11A1, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, MDFI_B, DLL4, GDF7_A, MIAT_A, PYCARD, BMP4_B, JSRP1_A,

MAX.chr14.103021656-103021718, EMX2, MMP23B, EMX2OS, MAX.chr17.73073716-73073814, NBPf8, SEPT9_B, LOC440925_A, STX16_A, ITPKA, EEF1A2, FEV, LRRC41_C, and NFIC.

From these 499 novel DNA methylation markers, further experiments identified the following markers and/or panels of markers capable of distinguishing carcinosarcoma EC tissue from benign endometrial tissue:

- EMX2OS, DDO1_A, SBNO2, AMIGO3_A, PCOLCE, CLDN7, CYTH2, OBSCN_A, AHSA2, DLL4, EMX2, MAX.chr14.74100620-74100870, LRRC4, PPP2R5C_A, SQSTM1, MAX.chr17.73073716-73073814, CYP11A1, ACOXL_A, and AIM1_B (see, Table 5, Example 1);
- EMX2OS, and LRRC34 (see, Table 13, Example 1);
- ZNF506, ZNF90, MAX.chr8.145103829-145103992, LRRC8D_A, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPf8, and VILL (see, Table 18, Example 1); and
- TRH, MAX.chr7:104624386-104624529, EMX2OS, DDO1_B, and ST3GAL2_B (see, Table 24, Example 3).

From these 499 novel DNA methylation markers, further experiments identified the following markers and/or panels of markers for detecting carcinosarcoma EC in blood samples (e.g., plasma samples, whole blood samples, leukocyte samples, serum samples):

- SFMBT2_B, SMTN, ZNF506, ZNF90, CLDN7, LRRC41_B, CYP11A1, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DDO1_A, GDF6, DLL4, MAX.chr10.22624479-22624553, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, EMX2OS, LRRC34, NBPf8, LOC440925_A, ITPKA, NFIC, and VILL (see, Table 13, Example 1).

From these 499 novel DNA methylation markers, further experiments identified the following markers and/or panels of markers capable of distinguishing serous EC tissue from benign endometrial tissue:

- EMX2OS, KANK1, C1orf70_B, AMIGO3_A, DIDO1_A, LRRC41_C, NFIC, FKBP11_A, C17orf107_A, SMTN, LRRC41_B, LRRC8D_A, OBSCN_A, MAX.chr7.104624356-104624730, MIAT_B (see, Table 7, Example 1);
- MAX.chr7.104624356-104624730, EMX2OS, and LRRC41_C (see, Table 12, Example 1);
- MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, EMX2OS, LRRC41_C, and VILL (see, Table 17, Example 1); and
- EMX2OS, and LRRC41_D (see, Table 24, Example 3).

From these 499 novel DNA methylation markers, further experiments identified the following markers and/or panels of markers for detecting serous EC in blood samples (e.g., plasma samples, whole blood samples, leukocyte samples, serum samples):

- SFMBT2_B, SMTN, SQSTM1, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, CYP11A1, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, GDGF6, DLL4, PYCARD, BMP4_B, JSRP1_A, MIAT_B, KANK1, EMX2OS, NBPF8, LOC440925_A, ITPKA, EEF1A2, FEV, LRRC41_C, NFIC, VILL, MPZ_A (see, Table 12, Example 1).

From these 499 novel DNA methylation markers, further experiments identified the following markers and/or panels of markers capable of distinguishing endometrioid EC tissue from benign endometrial tissue:

- MAX.chr10.130339363-130339534, SFMBT2_C, CYTH2, SLC6A3, VILL, EMX2OS, MAX.chr10.22624479-22624553, GDF6, ZNF90, ZNF506, JSRP1_A, c5orf52, SFMBT2_B, NBPF8, RHBDL1_A, DIDO1_A, KANK1, and GATA2_B (see, Table 6, Example 1);
- MAX.chr8.145103829-145103992, CYTH2, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, SBNO2, NBPF8, and VILL (see, Table 14, Example 1); and
- SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, MAX.chr8.145104263-145104422, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and MPZ_A (see, Table 19, Example 1).

From these 499 novel DNA methylation markers, further experiments identified the following markers and/or panels of markers for detecting endometrioid EC in blood samples (e.g., plasma samples, whole blood samples, leukocyte samples, serum samples):

- SFMBT2_B, SMTN, SQSTM1, ZNF506, ZNF90, CLDN7, LRRC41_B, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, DDO1_A, GDF6, MAX.chr10.130339363-130339534, DLL4, MAX.chr10.22624479-22624553, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, KANK1, SBNO2, c5orf52, EMX2O6, LRRC34, NBPf8, LOC440925_A, ITPKA, NFIC, VILL, and MPZ_A (see, Table 14, Example 1).

From these 499 novel DNA methylation markers, further experiments identified the following markers and/or panels of markers capable of distinguishing endometrioid EC Grade 1 tissue from benign endometrial tissue:

- TSPYL5, TRH, JAM3, FAM19A5, PTGDR, SFMBT2_E, JSRP1_B, and ARL5C (see, Table 25, Example 3).

From these 499 novel DNA methylation markers, further experiments identified the following markers and/or panels of markers capable of distinguishing endometrioid EC Grade 2 tissue from benign endometrial tissue:

- TSPYL5, MPZ_B, TRH, CNTN4, FAM19A5, GLT1D1, RYR2_F, PTGDR, EMX2OS, MAX.chr10:22624470-22624553, SPDYA_B, SFMBT2_E, and JSRP1_B (see, Table 25, Example 3).

From these 499 novel DNA methylation markers, further experiments identified the following markers and/or panels of markers capable of distinguishing endometrioid EC Grade 3 tissue from benign endometrial tissue:

- TSPYL5, MPZ_B, TRH, and PTGDR (see, Table 25, Example 3).

As described herein, the technology provides a number of methylated DNA markers and subsets thereof (e.g., sets of 2, 3, 4, 5, 6, 7, or 8 markers) with high discrimination for EC overall and various types of EC (e.g., clear cell EC, carcinosarcoma EC, endometrioid EC,

serous EC). Experiments applied a selection filter to candidate markers to identify markers that provide a high signal to noise ratio and a low background level to provide high specificity for purposes of EC screening or diagnosis.

In some embodiments, the technology is related to assessing the presence of and methylation state of one or more of the markers identified herein in a biological sample (e.g., endometrial tissue sample, blood sample). These markers comprise one or more differentially methylated regions (DMR) as discussed herein, e.g., as provided in Tables 1, 8 and 21. Methylation state is assessed in embodiments of the technology. As such, the technology provided herein is not restricted in the method by which a gene's methylation state is measured. For example, in some embodiments the methylation state is measured by a genome scanning method. For example, one method involves restriction landmark genomic scanning (Kawai et al. (1994) *Mol. Cell. Biol.* 14: 7421–7427) and another example involves methylation-sensitive arbitrarily primed PCR (Gonzalzo et al. (1997) *Cancer Res.* 57: 594–599). In some embodiments, changes in methylation patterns at specific CpG sites are monitored by digestion of genomic DNA with methylation-sensitive restriction enzymes followed by Southern analysis of the regions of interest (digestion-Southern method). In some embodiments, analyzing changes in methylation patterns involves a PCR-based process that involves digestion of genomic DNA with methylation-sensitive restriction enzymes or methylation-dependent restriction enzymes prior to PCR amplification (Singer-Sam et al. (1990) *Nucl. Acids Res.* 18: 687). In addition, other techniques have been reported that utilize bisulfite treatment of DNA as a starting point for methylation analysis. These include methylation-specific PCR (MSP) (Herman et al. (1992) *Proc. Natl. Acad. Sci. USA* 93: 9821–9826) and restriction enzyme digestion of PCR products amplified from bisulfite-converted DNA (Sadri and Hornsby (1996) *Nucl. Acids Res.* 24: 5058–5059; and Xiong and Laird (1997) *Nucl. Acids Res.* 25: 2532–2534). PCR techniques have been developed for detection of gene mutations (Kuppuswamy et al. (1991) *Proc. Natl. Acad. Sci. USA* 88: 1143–1147) and quantification of allelic-specific expression (Szabo and Mann (1995) *Genes Dev.* 9: 3097–3108; and Singer-Sam et al. (1992) *PCR Methods Appl.* 1: 160–163). Such techniques use internal primers, which anneal to a PCR-generated template and terminate immediately 5' of the single nucleotide to be assayed. Methods using a “quantitative Ms-SNuPE assay” as described in U.S. Pat. No. 7,037,650 are used in some embodiments.

Upon evaluating a methylation state, the methylation state is often expressed as the fraction or percentage of individual strands of DNA that is methylated at a particular site

(e.g., at a single nucleotide, at a particular region or locus, at a longer sequence of interest, e.g., up to a ~100-bp, 200-bp, 500-bp, 1000-bp subsequence of a DNA or longer) relative to the total population of DNA in the sample comprising that particular site. Traditionally, the amount of the unmethylated nucleic acid is determined by PCR using calibrators. Then, a known amount of DNA is bisulfite treated and the resulting methylation-specific sequence is determined using either a real-time PCR or other exponential amplification, e.g., a QuARTS assay (e.g., as provided by U.S. Pat. No. 8,361,720; and U.S. Pat. Appl. Pub. Nos. 2012/0122088 and 2012/0122106, incorporated herein by reference).

For example, in some embodiments methods comprise generating a standard curve for the unmethylated target by using external standards. The standard curve is constructed from at least two points and relates the real-time Ct value for unmethylated DNA to known quantitative standards. Then, a second standard curve for the methylated target is constructed from at least two points and external standards. This second standard curve relates the Ct for methylated DNA to known quantitative standards. Next, the test sample Ct values are determined for the methylated and unmethylated populations and the genomic equivalents of DNA are calculated from the standard curves produced by the first two steps. The percentage of methylation at the site of interest is calculated from the amount of methylated DNAs relative to the total amount of DNAs in the population, e.g., $(\text{number of methylated DNAs}) / (\text{the number of methylated DNAs} + \text{number of unmethylated DNAs}) \times 100$.

Also provided herein are compositions and kits for practicing the methods. For example, in some embodiments, reagents (e.g., primers, probes) specific for one or more markers are provided alone or in sets (e.g., sets of primers pairs for amplifying a plurality of markers). Additional reagents for conducting a detection assay may also be provided (e.g., enzymes, buffers, positive and negative controls for conducting QuARTS, PCR, sequencing, bisulfite, or other assays). In some embodiments, the kits contain a reagent capable of modifying DNA in a methylation-specific manner (e.g., a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent). In some embodiments, the kits containing one or more reagent necessary, sufficient, or useful for conducting a method are provided. Also provided are reactions mixtures containing the reagents. Further provided are master mix reagent sets containing a plurality of reagents that may be added to each other and/or to a test sample to complete a reaction mixture.

In some embodiments, the technology described herein is associated with a programmable machine designed to perform a sequence of arithmetic or logical operations as

provided by the methods described herein. For example, some embodiments of the technology are associated with (e.g., implemented in) computer software and/or computer hardware. In one aspect, the technology relates to a computer comprising a form of memory, an element for performing arithmetic and logical operations, and a processing element (e.g., a microprocessor) for executing a series of instructions (e.g., a method as provided herein) to read, manipulate, and store data. In some embodiments, a microprocessor is part of a system for determining a methylation state (e.g., of one or more DMR, e.g., DMR 1-499 as provided in Tables 1, 8 and 21); comparing methylation states (e.g., of one or more DMR, e.g., DMR 1-499 as provided in Tables 1, 8 and 21); generating standard curves; determining a Ct value; calculating a fraction, frequency, or percentage of methylation (e.g., of one or more DMR, e.g., DMR 1-499 as provided in Tables 1, 8 and 21); identifying a CpG island; determining a specificity and/or sensitivity of an assay or marker; calculating an ROC curve and an associated AUC; sequence analysis; all as described herein or is known in the art.

In some embodiments, a microprocessor or computer uses methylation state data in an algorithm to predict a site of a cancer.

In some embodiments, a software or hardware component receives the results of multiple assays and determines a single value result to report to a user that indicates a cancer risk based on the results of the multiple assays (e.g., determining the methylation state of multiple DMR, e.g., as provided in Tables 2, 18 and 26). Related embodiments calculate a risk factor based on a mathematical combination (e.g., a weighted combination, a linear combination) of the results from multiple assays, e.g., determining the methylation states of multiple markers (such as multiple DMR, e.g., as provided in Tables 1, 8 and 21). In some embodiments, the methylation state of a DMR defines a dimension and may have values in a multidimensional space and the coordinate defined by the methylation states of multiple DMR is a result, e.g., to report to a user, e.g., related to a cancer risk.

Some embodiments comprise a storage medium and memory components. Memory components (e.g., volatile and/or nonvolatile memory) find use in storing instructions (e.g., an embodiment of a process as provided herein) and/or data (e.g., a work piece such as methylation measurements, sequences, and statistical descriptions associated therewith). Some embodiments relate to systems also comprising one or more of a CPU, a graphics card, and a user interface (e.g., comprising an output device such as display and an input device such as a keyboard).

Programmable machines associated with the technology comprise conventional extant technologies and technologies in development or yet to be developed (e.g., a quantum computer, a chemical computer, a DNA computer, an optical computer, a spintronics based computer, etc.).

In some embodiments, the technology comprises a wired (e.g., metallic cable, fiber optic) or wireless transmission medium for transmitting data. For example, some embodiments relate to data transmission over a network (e.g., a local area network (LAN), a wide area network (WAN), an ad-hoc network, the internet, etc.). In some embodiments, programmable machines are present on such a network as peers and in some embodiments the programmable machines have a client/server relationship.

In some embodiments, data are stored on a computer-readable storage medium such as a hard disk, flash memory, optical media, a floppy disk, etc.

In some embodiments, the technology provided herein is associated with a plurality of programmable devices that operate in concert to perform a method as described herein. For example, in some embodiments, a plurality of computers (e.g., connected by a network) may work in parallel to collect and process data, e.g., in an implementation of cluster computing or grid computing or some other distributed computer architecture that relies on complete computers (with onboard CPUs, storage, power supplies, network interfaces, etc.) connected to a network (private, public, or the internet) by a conventional network interface, such as Ethernet, fiber optic, or by a wireless network technology.

For example, some embodiments provide a computer that includes a computer-readable medium. The embodiment includes a random access memory (RAM) coupled to a processor. The processor executes computer-executable program instructions stored in memory. Such processors may include a microprocessor, an ASIC, a state machine, or other processor, and can be any of a number of computer processors, such as processors from Intel Corporation of Santa Clara, California and Motorola Corporation of Schaumburg, Illinois. Such processors include, or may be in communication with, media, for example computer-readable media, which stores instructions that, when executed by the processor, cause the processor to perform the steps described herein.

Embodiments of computer-readable media include, but are not limited to, an electronic, optical, magnetic, or other storage or transmission device capable of providing a processor with computer-readable instructions. Other examples of suitable media include, but are not limited to, a floppy disk, CD-ROM, DVD, magnetic disk, memory chip, ROM, RAM,

an ASIC, a configured processor, all optical media, all magnetic tape or other magnetic media, or any other medium from which a computer processor can read instructions. Also, various other forms of computer-readable media may transmit or carry instructions to a computer, including a router, private or public network, or other transmission device or channel, both wired and wireless. The instructions may comprise code from any suitable computer-programming language, including, for example, C, C++, C#, Visual Basic, Java, Python, Perl, and JavaScript.

Computers are connected in some embodiments to a network. Computers may also include a number of external or internal devices such as a mouse, a CD-ROM, DVD, a keyboard, a display, or other input or output devices. Examples of computers are personal computers, digital assistants, personal digital assistants, cellular phones, mobile phones, smart phones, pagers, digital tablets, laptop computers, internet appliances, and other processor-based devices. In general, the computers related to aspects of the technology provided herein may be any type of processor-based platform that operates on any operating system, such as Microsoft Windows, Linux, UNIX, Mac OS X, etc., capable of supporting one or more programs comprising the technology provided herein. Some embodiments comprise a personal computer executing other application programs (e.g., applications). The applications can be contained in memory and can include, for example, a word processing application, a spreadsheet application, an email application, an instant messenger application, a presentation application, an Internet browser application, a calendar/organizer application, and any other application capable of being executed by a client device.

All such components, computers, and systems described herein as associated with the technology may be logical or virtual.

Accordingly, provided herein is technology related to a method of screening for EC and/or various forms of EC (e.g., clear cell EC, carcinosarcoma EC, endometrioid EC, serous EC) in a sample obtained from a subject, the method comprising assaying a methylation state of a marker in a sample obtained from a subject (e.g., endometrial tissue) (e.g., a blood sample) and identifying the subject as having EC and/or a specific form of EC when the methylation state of the marker is different than a methylation state of the marker assayed in a subject that does not have EC, wherein the marker comprises a base in a differentially methylated region (DMR) selected from a group consisting of DMR 1–499 as provided in Tables 1, 8 and 21.

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has EC: AFF3, AIM1_A, AMIGO3_A, BMP4_B, C17orf107_A, C1orf70_B, C5orf52, CLDN7, DIDO1_A, EEF1A2, EMX2OS, FEV, FKBP11_A, GDF6, GDF7_A, JSRP1_A, KCTD15_A, KLHL21, LRRC8D_A, NBPF8, MAX.chr10.130339363-130339534, MAX.chr10.22624479-22624553, MAX.chr14.103021656-103021718, MAX.chr8.145103829-145103992, MAX.chr8.145104263-145104422, MDFI_B, MIAT_A, MMP23B, NDRG2, OBSCN_A, PCOLCE, PYCARD, SEPT9_B, SLC6A3_A, SLC8A3_B, SQSTM1, VILL, ZNF302, ZNF323_A, ZNF506, and ZNF90 (see, Table 2, Example 1).

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has EC: EMX2OS, CYTH2, C17orf107_A, DIDO1_A, GDF6, NBPF8, MAX.chr14.103021656-103021718, JSRP1_A, GATA2_B, and SFMBT2_B (see, Table 3, Example 1).

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has EC: SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and MPZ_A (see, Table 15, Example 1).

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has EC: EMX2OS, CYTH2, NBPF8, MAX.chr10.22624479-22624553 (see, Table 20, Example 1).

In some embodiments wherein the sample obtained from the subject is a blood sample (e.g., plasma sample, whole blood sample, leukocyte sample, serum sample) and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has EC: ANKRD35, ARL5C, ARRB1, BCL2L11_A, BCL2L11_B, BCL2L11_C, BZRAP1, C16orf54, C17orf101, C6orf132, CACNA2D4, DEDD2, EPS15L1, FAIM2, FAM125B,

FAM189B, FAM78A, FOXP4, GYPC_A, GYPC_B, IFFO1_A, IFFO1_B, ITPKA, KLF16, LIMD2, LOC389333, LOC440925_A, LOC646278, LYL1, LYPLAL1, MAX.chr11.32355226-32355251, MAX.chr14.102172621-102172686, MAX.chr14.105512122-105512239, MAX.chr15.95128144-95128248, MAX.chr16.11327016-11327312, MAX.chr3.187676577-187676668, MAX.chr4.174430676-174430847, MAX.chr8.145900783-145900914, MAX.chr8.80804237-80804301, N4BP3, NCOR2, NFATC1_A, NFATC1_B, NKX2-6, NR2F6, OSM, PALLD_C, PIK3CD, PRKAR1B, RAD52, STX16_A, SUCLG2, TNFRSF1B, TNFRSF4, ZDHHC18, and ZNF671_A (see, Table 9, Example 1).

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has clear cell EC: DIDO1_A, NDRG4, MAX.chr14.103021656-103021718, MMP23B, EMX2OS, SEPT9_B, NBPf8, EEF1A2, AIM1_A, BMP4_B, MAX.chr8.145103829-145103992, OBSCN, PYCARD, GDF6, MDFI_B, MIAT_A, SCL8A3, ZNF323_A, SQSTM1, AFF3, C1orf70, GDF7_A, JSRP1_A, LRRC8D_A, FEV, and MAX.chr8.145104263-145104422 (see, Table 4, Example 1).

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has clear cell EC: ZNF323_A, MAX.chr7.104624356-104624730, NDRG2, DIDO1_A, MDFI_B, MAX.chr14.103021656-103021718, MMP23B, SEPT9_B, and STX16_A (see, Table 11, Example 1).

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has clear cell EC: SFMBT2_B, SQSTM1, ZNF323_A, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MDFI_B, GDF7_A, MAX.chr10.22624479-22624553, JSRP1_A, MAX.chr14.103021656-103021718, EMX2OS, LRRC34, NBPf8, SEPT9_B, EEF1A2, LRRC41_C, VILL, and MPZ_A (see, Table 16, Example 1).

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a

methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has clear cell EC: MAX.chr7:104624386-104624529, EMX2OS, DIDO1_B, and OBSCN_B (see, Table 24, Example 3).

In some embodiments wherein the sample obtained from the subject is a blood sample (e.g., plasma sample, whole blood sample, leukocyte sample, serum sample) and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has clear cell EC: SFMBT2_B, SQSTM1, ZNF323_A, ZNF506, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, NDRG2, CYP11A1, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, MDFI_B, DLL4, GDF7_A, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, EMX2, MMP23B, EMX2OS, MAX.chr17.73073716-73073814, NBPf8, SEPT9_B, LOC440925_A, STX16_A, ITPKA, EEF1A2, FEV, LRRC41_C, and NFIC.

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has carcinosarcoma EC: EMX2OS, DIDO1_A, SBNO2, AMIGO3_A, PCOLCE, CLDN7, CYTH2, OBSCN_A, AHSA2, DLL4, EMX2, MAX.chr14.74100620-74100870, LRRC4, PPP2R5C_A, SQSTM1, MAX.chr17.73073716-73073814, CYP11A1, ACOXL_A, and AIM1_B (see, Table 5, Example 1).

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has carcinosarcoma EC: EMX2OS, and LRRC34 (see, Table 13, Example 1).

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has carcinosarcoma EC: ZNF506, ZNF90, MAX.chr8.145103829-145103992, LRRC8D_A, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPf8, and VILL (see, Table 18, Example 1).

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has carcinosarcoma EC: TRH, MAX.chr7:104624386-104624529, EMX2OS, DIDO1_B, and ST3GAL2_B (see, Table 24, Example 3).

In some embodiments wherein the sample obtained from the subject is a blood sample (e.g., plasma sample, whole blood sample, leukocyte sample, serum sample) and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has carcinosarcoma EC: SFMBT2_B, SMTN, ZNF506, ZNF90, CLDN7, LRRC41_B, CYP11A1, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, DLL4, MAX.chr10.22624479-22624553, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, EMX2OS, LRRC34, NBPF8, LOC440925_A, ITPKA, NFIC, and VILL (see, Table 13, Example 1).

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has serous EC: EMX2OS, KANK1, C1orf70_B, AMIGO3_A, DIDO1_A, LRRC41_C, NFIC, FKBP11_A, C17orf107_A, SMTN, LRRC41_B, LRRC8D_A, OBSCN_A, MAX.chr7.104624356-104624730, MIAT_B (see, Table 7, Example 1).

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has serous EC: MAX.chr7.104624356-104624730, EMX2OS, and LRRC41_C (see, Table 12, Example 1).

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has serous EC: MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, EMX2OS, LRRC41_C, and VILL (see, Table 17, Example 1).

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has serous EC: EMX2OS, and LRRC41_D (see, Table 24, Example 3).

In some embodiments wherein the sample obtained from the subject is a blood sample (e.g., plasma sample, whole blood sample, leukocyte sample, serum sample) and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has serous EC: SFMBT2_B, SMTN, SQSTM1, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, CYP11A1, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, GDGF6, DLL4, PYCARD, BMP4_B, JSRP1_A, MIAT_B, KANK1, EMX2OS, NBPF8, LOC440925_A, ITPKA, EEF1A2, FEV, LRRC41_C, NFIC, VILL, MPZ_A (see, Table 12, Example 1).

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has endometrioid EC: MAX.chr10.130339363-130339534, SFMBT2_C, CYTH2, SLC6A3, VILL, EMX2OS, MAX.chr10.22624479-22624553, GDF6, ZNF90, ZNF506, JSRP1_A, c5orf52, SFMBT2_B, NBPF8, RHBDL1_A, DIDO1_A, KANK1, and GATA2_B (see, Table 6, Example 1).

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has endometrioid EC: MAX.chr8.145103829-145103992, CYTH2, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, SBNO2, NBPF8, and VILL (see, Table 14, Example 1).

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has endometrioid EC: SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, MAX.chr8.145104263-145104422, OBSCN_A,

MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and MPZ_A (see, Table 19, Example 1).

In some embodiments wherein the sample obtained from the subject is a blood sample (e.g., plasma sample, whole blood sample, leukocyte sample, serum sample) and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has endometrioid EC: SFMBT2_B, SMTN, SQSTM1, ZNF506, ZNF90, CLDN7, LRRC41_B, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, DLL4, MAX.chr10.22624479-22624553, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, KANK1, SBNO2, c5orf52, EMX2O6, LRRC34, NBPF8, LOC440925_A, ITPKA, NFIC, VILL, and MPZ_A (see, Table 14, Example 1).

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has endometrioid Grade 1 EC: TSPYL5, TRH, JAM3, FAM19A5, PTGDR, SFMBT2_E, JSRP1_B, and ARL5C (see, Table 25, Example 3).

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has endometrioid Grade 2 EC: TSPYL5, MPZ_B, TRH, CNTN4, FAM19A5, GLT1D1, RYR2_F, PTGDR, EMX2OS, MAX.chr10.22624470-22624553, SPDYA_B, SFMBT2_E, and JSRP1_B (see, Table 25, Example 3).

In some embodiments wherein the sample obtained from the subject is endometrial tissue and the methylation state of one or more of the following markers is different than a methylation state of the one or more markers assayed in a subject that does not have EC indicates the subject has endometrioid Grade 3 EC: TSPYL5, MPZ_B, TRH, and PTGDR (see, Table 25, Example 3).

The technology is related to identifying and discriminating EC and/or various forms of EC (e.g., clear cell EC, carcinosarcoma EC, endometrioid EC, serous EC). Some embodiments provide methods comprising assaying a plurality of markers, e.g., comprising assaying 2 to 11 to 100 or 120 or 499 markers.

The technology is not limited in the methylation state assessed. In some embodiments assessing the methylation state of the marker in the sample comprises determining the methylation state of one base. In some embodiments, assaying the methylation state of the marker in the sample comprises determining the extent of methylation at a plurality of bases. Moreover, in some embodiments the methylation state of the marker comprises an increased methylation of the marker relative to a normal methylation state of the marker. In some embodiments, the methylation state of the marker comprises a decreased methylation of the marker relative to a normal methylation state of the marker. In some embodiments the methylation state of the marker comprises a different pattern of methylation of the marker relative to a normal methylation state of the marker.

Furthermore, in some embodiments the marker is a region of 100 or fewer bases, the marker is a region of 500 or fewer bases, the marker is a region of 1000 or fewer bases, the marker is a region of 5000 or fewer bases, or, in some embodiments, the marker is one base. In some embodiments the marker is in a high CpG density promoter.

The technology is not limited by sample type. For example, in some embodiments the sample is a stool sample, a tissue sample (e.g., endometrial tissue sample), a blood sample (e.g., plasma, leukocyte, serum, whole blood), an excretion, or a urine sample.

Furthermore, the technology is not limited in the method used to determine methylation state. In some embodiments the assaying comprises using methylation specific polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation specific nuclease, mass-based separation, or target capture. In some embodiments, the assaying comprises use of a methylation specific oligonucleotide. In some embodiments, the technology uses massively parallel sequencing (e.g., next-generation sequencing) to determine methylation state, e.g., sequencing-by-synthesis, real-time (e.g., single-molecule) sequencing, bead emulsion sequencing, nanopore sequencing, etc.

The technology provides reagents for detecting a DMR, e.g., in some embodiments are provided a set of oligonucleotides comprising the sequences provided by SEQ ID NO: 1–499 (see, Tables 1, 8 and 21). In some embodiments are provided an oligonucleotide comprising a sequence complementary to a chromosomal region having a base in a DMR, e.g., an oligonucleotide sensitive to methylation state of a DMR.

The technology provides various panels of markers use for identifying EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is AFF3, AIM1_A, AMIGO3_A, BMP4_B, C17orf107_A, C1orf70_B, C5orf52, CLDN7,

DIDO1_A, EEF1A2, EMX2OS, FEV, FKBP11_A, GDF6, GDF7_A, JSRP1_A, KCTD15_A, KLHL21, LRRC8D_A, NBPF8, MAX.chr10.130339363-130339534, MAX.chr10.22624479-22624553, MAX.chr14.103021656-103021718, MAX.chr8.145103829-145103992, MAX.chr8.145104263-145104422, MDFI_B, MIAT_A, MMP23B, NDRG2, OBSCN_A, PCOLCE, PYCARD, SEPT9_B, SLC6A3_A, SLC8A3_B, SQSTM1, VILL, ZNF302, ZNF323_A, ZNF506, and ZNF90 (see, Table 2, Example 1).

The technology provides various panels of markers use for identifying EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is EMX2OS, CYTH2, C17orf107_A, DIDO1_A, GDF6, NBPF8, MAX.chr14.103021656-103021718, JSRP1_A, GATA2_B, and SFMBT2_B (see, Table 3, Example 1).

The technology provides various panels of markers use for identifying EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and MPZ_A (see, Table 15, Example 1)

The technology provides various panels of markers use for identifying EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is EMX2OS, CYTH2, NBPF8, MAX.chr10.22624479-22624553 (see, Table 20, Example 1).

The technology provides various panels of markers use for identifying EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is ANKRD35, ARL5C, ARRB1, BCL2L11_A, BCL2L11_B, BCL2L11_C, BZRAP1, C16orf54, C17orf101, C6orf132, CACNA2D4, DEDD2, EPS15L1, FAIM2, FAM125B, FAM189B, FAM78A, FOXP4, GYPC_A, GYPC_B, IFFO1_A, IFFO1_B, ITPKA, KLF16, LIMD2, LOC389333, LOC440925_A, LOC646278, LYL1, LYPLAL1, MAX.chr11.32355226-32355251, MAX.chr14.102172621-102172686, MAX.chr14.105512122-105512239, MAX.chr15.95128144-95128248, MAX.chr16.11327016-11327312, MAX.chr3.187676577-187676668, MAX.chr4.174430676-174430847, MAX.chr8.145900783-145900914, MAX.chr8.80804237-80804301, N4BP3, NCOR2, NFATC1_A, NFATC1_B, NKX2-6, NR2F6, OSM, PALLD_C, PIK3CD, PRKAR1B, RAD52, STX16_A, SUCLG2, TNFRSF1B, TNFRSF4, ZDHHC18, and ZNF671_A (see, Table 9, Example 1).

The technology provides various panels of markers use for identifying clear cell EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation

that is DIDO1_A, NDRG4, MAX.chr14.103021656-103021718, MMP23B, EMX2OS, SEPT9_B, NBPF8, EEF1A2, AIM1_A, BMP4_B, MAX.chr8.145103829-145103992, OBSCN, PYCARD, GDF6, MDFI_B, MIAT_A, SCL8A3, ZNF323_A, SQSTM1, AFF3, C1orf70, GDF7_A, JSRP1_A, LRRC8D_A, FEV, and MAX.chr8.145104263-145104422 (see, Table 4, Example 1).

The technology provides various panels of markers use for identifying clear cell EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is ZNF323_A, MAX.chr7.104624356-104624730, NDRG2, DIDO1_A, MDFI_B, MAX.chr14.103021656-103021718, MMP23B, SEPT9_B, and STX16_A (see, Table 11, Example 1).

The technology provides various panels of markers use for identifying clear cell EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is SFMBT2_B, SQSTM1, ZNF323_A, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MDFI_B, GDF7_A, MAX.chr10.22624479-22624553, JSRP1_A, MAX.chr14.103021656-103021718, EMX2OS, LRRC34, NBPF8, SEPT9_B, EEF1A2, LRRC41_C, VILL, and MPZ_A (see, Table 16, Example 1).

The technology provides various panels of markers use for identifying clear cell EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is MAX.chr7.104624386-104624529, EMX2OS, DIDO1_B, and OBSCN_B (see, Table 24, Example 3).

The technology provides various panels of markers use for identifying clear cell EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is SFMBT2_B, SQSTM1, ZNF323_A, ZNF506, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, NDRG2, CYP11A1, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, MDFI_B, DLL4, GDF7_A, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, EMX2, MMP23B, EMX2OS, MAX.chr17.73073716-73073814, NBPF8, SEPT9_B, LOC440925_A, STX16_A, ITPKA, EEF1A2, FEV, LRRC41_C, and NFIC (see, Table 11, Example 1).

The technology provides various panels of markers use for identifying carcinosarcoma EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is EMX2OS, DIDO1_A, SBNO2, AMIGO3_A, PCOLCE, CLDN7, CYTH2, OBSCN_A, AHSA2, DLL4, EMX2, MAX.chr14.74100620-74100870, LRRC4,

PPP2R5C_A, SQSTM1, MAX.chr17.73073716-73073814, CYP11A1, ACOXL_A, and AIM1_B (see, Table 5, Example 1).

The technology provides various panels of markers use for identifying carcinosarcoma EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is EMX2OS, and LRRC34 (see, Table 13, Example 1).

The technology provides various panels of markers use for identifying carcinosarcoma EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is ZNF506, ZNF90, MAX.chr8.145103829-145103992, LRRC8D_A, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and VILL (see, Table 18, Example 1).

The technology provides various panels of markers use for identifying carcinosarcoma EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is TRH, MAX.chr7:104624386-104624529, EMX2OS, DIDO1_B, and ST3GAL2_B (see, Table 24, Example 3).

The technology provides various panels of markers use for identifying carcinosarcoma EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is SFMBT2_B, SMTN, ZNF506, ZNF90, CLDN7, LRRC41_B, CYP11A1, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, DLL4, MAX.chr10.22624479-22624553, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, EMX2OS, LRRC34, NBPF8, LOC440925_A, ITPKA, NFIC, and VILL (see, Table 13, Example 1).

The technology provides various panels of markers use for identifying serous EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is EMX2OS, KANK1, C1orf70_B, AMIGO3_A, DIDO1_A, LRRC41_C, NFIC, FKBP11_A, C17orf107_A, SMTN, LRRC41_B, LRRC8D_A, OBSCN_A, MAX.chr7.104624356-104624730, MIAT_B (see, Table 7, Example 1).

The technology provides various panels of markers use for identifying serous EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is MAX.chr7.104624356-104624730, EMX2OS, and LRRC41_C (see, Table 12, Example 1).

The technology provides various panels of markers use for identifying serous EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation

that is MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, EMX2OS, LRRC41_C, and VILL (see, Table 17, Example 1).

The technology provides various panels of markers use for identifying serous EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is EMX2OS, and LRRC41_D (see, Table 24, Example 3).

The technology provides various panels of markers use for identifying serous EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is SFMBT2_B, SMTN, SQSTM1, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, CYP11A1, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, GDF6, DLL4, PYCARD, BMP4_B, JSRP1_A, MIAT_B, KANK1, EMX2OS, NBPF8, LOC440925_A, ITPKA, EEF1A2, FEV, LRRC41_C, NFIC, VILL, MPZ_A (see, Table 12, Example 1).

The technology provides various panels of markers use for identifying endometrioid EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is MAX.chr10.130339363-130339534, SFMBT2_C, CYTH2, SLC6A3, VILL, EMX2OS, MAX.chr10.22624479-22624553, GDF6, ZNF90, ZNF506, JSRP1_A, c5orf52, SFMBT2_B, NBPF8, RHBDL1_A, DIDO1_A, KANK1, and GATA2_B (see, Table 6, Example 1).

The technology provides various panels of markers use for identifying endometrioid EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is MAX.chr8.145103829-145103992, CYTH2, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, SBNO2, NBPF8, and VILL (see, Table 14, Example 1).

The technology provides various panels of markers use for identifying endometrioid EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, MAX.chr8.145104263-145104422, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and MPZ_A (see, Table 19, Example 1).

The technology provides various panels of markers use for identifying endometrioid EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is SFMBT2_B, SMTN, SQSTM1, ZNF506, ZNF90, CLDN7, LRRC41_B, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, DIDO1_A, GDF6, MAX.chr10.130339363-130339534,

DLL4, MAX.chr10.22624479-22624553, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, KANK1, SBNO2, c5orf52, EMX2O6, LRRC34, NBPf8, LOC440925_A, ITPKA, NFIC, VILL, and MPZ_A (see, Table 14, Example 1).

The technology provides various panels of markers use for identifying endometrioid Grade 1 EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is TSPYL5, TRH, JAM3, FAM19A5, PTGDR, SFMBT2_E, JSRP1_B, and ARL5C (see, Table 25, Example 3).

The technology provides various panels of markers use for identifying endometrioid Grade 2 EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is TSPYL5, MPZ_B, TRH, CNTN4, FAM19A5, GLT1D1, RYR2_F, PTGDR, EMX2OS, MAX.chr10:22624470-22624553, SPDYA_B, SFMBT2_E, and JSRP1_B (see, Table 25, Example 3).

The technology provides various panels of markers use for identifying endometrioid Grade 3 EC, e.g., in some embodiments the marker comprises a chromosomal region having an annotation that is TSPYL5, MPZ_B, TRH, and PTGDR (see, Table 25, Example 3).

Kit embodiments are provided, e.g., a kit comprising a reagent capable of modifying DNA in a methylation-specific manner (e.g., a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent); and a control nucleic acid comprising a sequence from a DMR selected from a group consisting of DMR 1–499 (from Tables 1, 8 and 21) and having a methylation state associated with a subject who does not have EC. In some embodiments, kits comprise a bisulfite reagent and an oligonucleotide as described herein. In some embodiments, kits comprise a reagent capable of modifying DNA in a methylation-specific manner (e.g., a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent); and a control nucleic acid comprising a sequence from a DMR selected from a group consisting of of DMR 1–499 (from Tables 1, 8 and 21) and having a methylation state associated with a subject who has EC. Some kit embodiments comprise a sample collector for obtaining a sample from a subject (e.g., a stool sample; endometrial tissue sample; blood sample); a reagent capable of modifying DNA in a methylation-specific manner (e.g., a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent); and an oligonucleotide as described herein.

The technology is related to embodiments of compositions (e.g., reaction mixtures). In some embodiments are provided a composition comprising a nucleic acid comprising a DMR and a reagent capable of modifying DNA in a methylation-specific manner (e.g., a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent). Some embodiments provide a composition comprising a nucleic acid comprising a DMR and an oligonucleotide as described herein. Some embodiments provide a composition comprising a nucleic acid comprising a DMR and a methylation-sensitive restriction enzyme. Some embodiments provide a composition comprising a nucleic acid comprising a DMR and a polymerase.

Additional related method embodiments are provided for screening for EC and/or various forms of EC (e.g., clear cell EC, carcinosarcoma EC, endometrioid EC, serous EC) in a sample obtained from a subject (e.g., endometrial tissue sample; blood sample; stool sample), e.g., a method comprising determining a methylation state of a marker in the sample comprising a base in a DMR that is one or more of DMR 1–499 (from Tables 1, 8 and 21); comparing the methylation state of the marker from the subject sample to a methylation state of the marker from a normal control sample from a subject who does not have EC (e.g., EC, clear cell EC, carcinosarcoma EC, endometrioid EC, serous EC); and determining a confidence interval and/or a p value of the difference in the methylation state of the subject sample and the normal control sample. In some embodiments, the confidence interval is 90%, 95%, 97.5%, 98%, 99%, 99.5%, 99.9% or 99.99% and the p value is 0.1, 0.05, 0.025, 0.02, 0.01, 0.005, 0.001, or 0.0001. Some embodiments of methods provide steps of reacting a nucleic acid comprising a DMR with a reagent capable of modifying nucleic acid in a methylation-specific manner (e.g., a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent) to produce, for example, nucleic acid modified in a methylation-specific manner; sequencing the nucleic acid modified in a methylation-specific manner to provide a nucleotide sequence of the nucleic acid modified in a methylation-specific manner; comparing the nucleotide sequence of the nucleic acid modified in a methylation-specific manner with a nucleotide sequence of a nucleic acid comprising the DMR from a subject who does not have EC and/or a form of EC to identify differences in the two sequences; and identifying the subject as having EC (e.g., EC and/or a form of EC: clear cell EC, carcinosarcoma EC, endometrioid EC, serous EC) when a difference is present.

Systems for screening for EC in a sample obtained from a subject are provided by the technology. Exemplary embodiments of systems include, e.g., a system for screening for EC and/or types of EC (e.g., clear cell EC, carcinosarcoma EC, endometrioid EC, serous EC) in a sample obtained from a subject (e.g., endometrial tissue sample; plasma sample; stool sample), the system comprising an analysis component configured to determine the methylation state of a sample, a software component configured to compare the methylation state of the sample with a control sample or a reference sample methylation state recorded in a database, and an alert component configured to alert a user of a EC-associated methylation state. An alert is determined in some embodiments by a software component that receives the results from multiple assays (e.g., determining the methylation states of multiple markers, e.g., DMR, e.g., as provided in Tables 1, 8 and 21) and calculating a value or result to report based on the multiple results. Some embodiments provide a database of weighted parameters associated with each DMR provided herein for use in calculating a value or result and/or an alert to report to a user (e.g., such as a physician, nurse, clinician, etc.). In some embodiments all results from multiple assays are reported and in some embodiments one or more results are used to provide a score, value, or result based on a composite of one or more results from multiple assays that is indicative of a cancer risk in a subject.

In some embodiments of systems, a sample comprises a nucleic acid comprising a DMR. In some embodiments the system further comprises a component for isolating a nucleic acid, a component for collecting a sample such as a component for collecting a stool sample. In some embodiments, the system comprises nucleic acid sequences comprising a DMR. In some embodiments the database comprises nucleic acid sequences from subjects who do not have EC and/or specific types of EC (e.g., clear cell EC, carcinosarcoma EC, endometrioid EC, serous EC). Also provided are nucleic acids, e.g., a set of nucleic acids, each nucleic acid having a sequence comprising a DMR. In some embodiments the set of nucleic acids wherein each nucleic acid has a sequence from a subject who does not have EC and/or specific types of EC. Related system embodiments comprise a set of nucleic acids as described and a database of nucleic acid sequences associated with the set of nucleic acids. Some embodiments further comprise a reagent capable of modifying DNA in a methylation-specific manner (e.g., a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent). And, some embodiments further comprise a nucleic acid sequencer.

In certain embodiments, methods for characterizing a sample (e.g., endometrial tissue sample; blood sample; stool sample) from a human patient are provided. For example, in some embodiments such embodiments comprise obtaining DNA from a sample of a human patient; assaying a methylation state of a DNA methylation marker comprising a base in a differentially methylated region (DMR) selected from a group consisting of DMR 1–499 from Tables 1, 8 and 21; and comparing the assayed methylation state of the one or more DNA methylation markers with methylation level references for the one or more DNA methylation markers for human patients not having EC and/or specific types of EC (e.g., clear cell EC, carcinosarcoma EC, endometrioid EC, serous EC).

Such methods are not limited to a particular type of sample from a human patient. In some embodiments, the sample is an endometrial tissue sample. In some embodiments, the sample is a plasma sample. In some embodiments, the sample is a stool sample, a tissue sample, an endometrial tissue sample, a blood sample (e.g., leukocyte sample, plasma sample, whole blood sample, serum sample), or a urine sample.

In some embodiments, such methods comprise assaying a plurality of DNA methylation markers. In some embodiments, such methods comprise assaying 2 to 11 DNA methylation markers. In some embodiments, such methods comprise assaying 12 to 120 DNA methylation markers. In some embodiments, such methods comprise assaying 2 to 499 DNA methylation markers. In some embodiments, such methods comprise assaying the methylation state of the one or more DNA methylation markers in the sample comprises determining the methylation state of one base. In some embodiments, such methods comprise assaying the methylation state of the one or more DNA methylation markers in the sample comprises determining the extent of methylation at a plurality of bases. In some embodiments, such methods comprise assaying a methylation state of a forward strand or assaying a methylation state of a reverse strand.

In some embodiments, the DNA methylation marker is a region of 100 or fewer bases. In some embodiments, the DNA methylation marker is a region of 500 or fewer bases. In some embodiments, the DNA methylation marker is a region of 1000 or fewer bases. In some embodiments, the DNA methylation marker is a region of 5000 or fewer bases. In some embodiments, the DNA methylation marker is one base. In some embodiments, the DNA methylation marker is in a high CpG density promoter.

In some embodiments, the assaying comprises using methylation specific polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation specific nuclease, mass-based separation, or target capture.

In some embodiments, the assaying comprises use of a methylation specific oligonucleotide. In some embodiments, the methylation specific oligonucleotide is selected from the group consisting of SEQ ID NO: 1–499 (Tables 1, 8 and 21).

In some embodiments, a chromosomal region having an annotation selected from the group consisting of AFF3, AIM1_A, AMIGO3_A, BMP4_B, C17orf107_A, C1orf70_B, C5orf52, CLDN7, DIDO1_A, EEF1A2, EMX2OS, FEV, FKBP11_A, GDF6, GDF7_A, JSRP1_A, KCTD15_A, KLHL21, LRRC8D_A, NBPf8, MAX.chr10.130339363-130339534, MAX.chr10.22624479-22624553, MAX.chr14.103021656-103021718, MAX.chr8.145103829-145103992, MAX.chr8.145104263-145104422, MDFI_B, MIAT_A, MMP23B, NDRG2, OBSCN_A, PCOLCE, PYCARD, SEPT9_B, SLC6A3_A, SLC8A3_B, SQSTM1, VILL, ZNF302, ZNF323_A, ZNF506, and ZNF90 (see, Table 2, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of EMX2OS, CYTH2, C17orf107_A, DIDO1_A, GDF6, NBPf8, MAX.chr14.103021656-103021718, JSRP1_A, GATA2_B, and SFMBT2_B (see, Table 3, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPf8, and MPZ_A (see, Table 15, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of EMX2OS, CYTH2, NBPf8, MAX.chr10.22624479-22624553 (see, Table 20, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of ANKRD35, ARL5C, ARRB1, BCL2L11_A, BCL2L11_B, BCL2L11_C, BZRAP1, C16orf54, C17orf101, C6orf132, CACNA2D4, DEDD2, EPS15L1, FAIM2, FAM125B, FAM189B, FAM78A, FOXP4, GYPC_A, GYPC_B, IFFO1_A, IFFO1_B, ITPKA, KLF16, LIMD2, LOC389333, LOC440925_A, LOC646278, LYL1, LYPLAL1, MAX.chr11.32355226-32355251, MAX.chr14.102172621-102172686,

MAX.chr14.105512122-105512239, MAX.chr15.95128144-95128248, MAX.chr16.11327016-11327312, MAX.chr3.187676577-187676668, MAX.chr4.174430676-174430847, MAX.chr8.145900783-145900914, MAX.chr8.80804237-80804301, N4BP3, NCOR2, NFATC1_A, NFATC1_B, NKX2-6, NR2F6, OSM, PALLD_C, PIK3CD, PRKAR1B, RAD52, STX16_A, SUCLG2, TNFRSF1B, TNFRSF4, ZDHHC18, and ZNF671_A (see, Table 9, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of DIDO1_A, NDRG4, MAX.chr14.103021656-103021718, MMP23B, EMX2OS, SEPT9_B, NBPF8, EEF1A2, AIM1_A, BMP4_B, MAX.chr8.145103829-145103992, OBSCN, PYCARD, GDF6, MDFI_B, MIAT_A, SCL8A3, ZNF323_A, SQSTM1, AFF3, C1orf70, GDF7_A, JSRP1_A, LRRC8D_A, FEV, and MAX.chr8.145104263-145104422 (see, Table 4, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of ZNF323_A, MAX.chr7.104624356-104624730, NDRG2, DIDO1_A, MDFI_B, MAX.chr14.103021656-103021718, MMP23B, SEPT9_B, and STX16_A (see, Table 11, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of SFMBT2_B, SQSTM1, ZNF323_A, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MDFI_B, GDF7_A, MAX.chr10.22624479-22624553, JSRP1_A, MAX.chr14.103021656-103021718, EMX2OS, LRRC34, NBPF8, SEPT9_B, EEF1A2, LRRC41_C, VILL, and MPZ_A (see, Table 16, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of MAX.chr7.104624386-104624529, EMX2OS, DIDO1_B, and OBSCN_B (see, Table 24, Example 3) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of SFMBT2_B, SQSTM1, ZNF323_A, ZNF506, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, NDRG2, CYP11A1, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, MDFI_B, DLL4, GDF7_A, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-

103021718, EMX2, MMP23B, EMX2OS, MAX.chr17.73073716-73073814, NBPF8, SEPT9_B, LOC440925_A, STX16_A, ITPKA, EEF1A2, FEV, LRRC41_C, and NFIC (see, Table 11, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of EMX2OS, DIDO1_A, SBNO2, AMIGO3_A, PCOLCE, CLDN7, CYTH2, OBSCN_A, AHSA2, DLL4, EMX2, MAX.chr14.74100620-74100870, LRRC4, PPP2R5C_A, SQSTM1, MAX.chr17.73073716-73073814, CYP11A1, ACOXL_A, and AIM1_B (see, Table 5, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of EMX2OS, and LRRC34 (see, Table 13, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of ZNF506, ZNF90, MAX.chr8.145103829-145103992, LRRC8D_A, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and VILL (see, Table 18, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of TRH, MAX.chr7.104624386-104624529, EMX2OS, DIDO1_B, and ST3GAL2_B (see, Table 24, Example 3) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of SFMBT2_B, SMTN, ZNF506, ZNF90, CLDN7, LRRC41_B, CYP11A1, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, DLL4, MAX.chr10.22624479-22624553, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, EMX2OS, LRRC34, NBPF8, LOC440925_A, ITPKA, NFIC, and VILL (see, Table 13, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of EMX2OS, KANK1, C1orf70_B, AMIGO3_A, DIDO1_A, LRRC41_C, NFIC, FKBP11_A, C17orf107_A, SMTN, LRRC41_B, LRRC8D_A, OBSCN_A, MAX.chr7.104624356-104624730, MIAT_B (see, Table 7, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of MAX.chr7.104624356-104624730, EMX2OS, and LRRC41_C (see, Table 12, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, EMX2OS, LRRC41_C, and VILL (see, Table 17, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of EMX2OS, and LRRC41_D (see, Table 24, Example 3) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of SFMBT2_B, SMTN, SQSTM1, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, CYP11A1, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, GDGF6, DLL4, PYCARD, BMP4_B, JSRP1_A, MIAT_B, KANK1, EMX2OS, NBPF8, LOC440925_A, ITPKA, EE1A2, FEV, LRRC41_C, NFIC, VILL, MPZ_A (see, Table 12, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of MAX.chr10.130339363-130339534, SFMBT2_C, CYTH2, SLC6A3, VILL, EMX2OS, MAX.chr10.22624479-22624553, GDF6, ZNF90, ZNF506, JSRP1_A, c5orf52, SFMBT2_B, NBPF8, RHBDL1_A, DIDO1_A, KANK1, and GATA2_B (see, Table 6, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of MAX.chr8.145103829-145103992, CYTH2, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, SBNO2, NBPF8, and VILL (see, Table 14, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, MAX.chr8.145104263-145104422, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and MPZ_A (see, Table 19, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of SFMBT2_B, SMTN, SQSTM1, ZNF506, ZNF90, CLDN7, LRRC41_B, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, DLL4, MAX.chr10.22624479-22624553, MIAT_A, PYCARD, BMP4_B, JSRP1_A,

MAX.chr14.103021656-103021718, MIAT_B, KANK1, SBNO2, c5orf52, EMX2O6, LRRC34, NBPf8, LOC440925_A, ITPKA, NFIC, VILL, and MPZ_A (see, Table 14, Example 1) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of TSPYL5, TRH, JAM3, FAM19A5, PTGDR, SFMBT2_E, JSRP1_B, and ARL5C (see, Table 25, Example 3) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of TSPYL5, MPZ_B, TRH, CNTN4, FAM19A5, GLT1D1, RYR2_F, PTGDR, EMX2OS, MAX.chr10:22624470-22624553, SPDYA_B, SFMBT2_E, and JSRP1_B (see, Table 25, Example 3) comprises the DNA methylation marker.

In some embodiments, a chromosomal region having an annotation selected from the group consisting of TSPYL5, MPZ_B, TRH, and PTGDR (see, Table 25, Example 3) comprises the DNA methylation marker.

In some embodiments, such methods comprise determining the methylation state of two DNA methylation markers. In some embodiments, such methods comprise determining the methylation state of a pair of DNA methylation markers provided in a row of Tables 1, 8 and/or 21.

In certain embodiments, the technology provides methods for characterizing a sample (e.g., endometrial tissue sample; leukocyte sample; plasma sample; whole blood sample; serum sample; stool sample) obtained from a human patient. In some embodiments, such methods comprise determining a methylation state of a DNA methylation marker in the sample comprising a base in a DMR selected from a group consisting of DMR 1–499 from Tables 1, 8 or 21; comparing the methylation state of the DNA methylation marker from the patient sample to a methylation state of the DNA methylation marker from a normal control sample from a human subject who does not have a EC and/or a specific form of EC (e.g., clear cell EC, carcinosarcoma EC, endometrioid EC, serous EC); and determining a confidence interval and/or a *p* value of the difference in the methylation state of the human patient and the normal control sample. In some embodiments, the confidence interval is 90%, 95%, 97.5%, 98%, 99%, 99.5%, 99.9% or 99.99% and the *p* value is 0.1, 0.05, 0.025, 0.02, 0.01, 0.005, 0.001, or 0.0001.

In certain embodiments, the technology provides methods for characterizing a sample obtained from a human subject (e.g., endometrial tissue sample; leukocyte sample; plasma sample; whole blood sample; serum sample; stool sample), the method comprising reacting a

nucleic acid comprising a DMR with a reagent capable of modifying DNA in a methylation-specific manner (e.g., a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent) to produce nucleic acid modified in a methylation-specific manner; sequencing the nucleic acid modified in a methylation-specific manner to provide a nucleotide sequence of the nucleic acid modified in a methylation-specific manner; comparing the nucleotide sequence of the nucleic acid modified in a methylation-specific manner with a nucleotide sequence of a nucleic acid comprising the DMR from a subject who does not have EC to identify differences in the two sequences.

In certain embodiments, the technology provides systems for characterizing a sample obtained from a human subject (e.g., endometrial tissue sample; plasma sample; stool sample), the system comprising an analysis component configured to determine the methylation state of a sample, a software component configured to compare the methylation state of the sample with a control sample or a reference sample methylation state recorded in a database, and an alert component configured to determine a single value based on a combination of methylation states and alert a user of a EC-associated methylation state. In some embodiments, the sample comprises a nucleic acid comprising a DMR.

In some embodiments, such systems further comprise a component for isolating a nucleic acid. In some embodiments, such systems further comprise a component for collecting a sample.

In some embodiments, the sample is a stool sample, a tissue sample, an endometrial tissue sample, a blood sample (e.g., plasma sample, leukocyte sample, whole blood sample, serum sample), or a urine sample.

In some embodiments, the database comprises nucleic acid sequences comprising a DMR. In some embodiments, the database comprises nucleic acid sequences from subjects who do not have EC.

Additional embodiments will be apparent to persons skilled in the relevant art based on the teachings contained herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: A cross-validated 3-MDM panel was derived from rPART modeling (*EMX2OS*, *NBPF8*, *SFMBT2*) which discriminated overall EC from BE with 97% specificity and 97% sensitivity with an AUC of 0.98. The data was plotted in a heat matrix format which allowed complementarity visualization.

FIG. 2: Marker chromosomal regions used for the 61 methylation markers (e.g., methylated regions distinguishing EC tissue from normal endometrial tissue) and related primer and probe information.

DEFINITIONS

To facilitate an understanding of the present technology, a number of terms and phrases are defined below. Additional definitions are set forth throughout the detailed description.

Throughout the specification and claims, the following terms take the meanings explicitly associated herein, unless the context clearly dictates otherwise. The phrase “in one embodiment” as used herein does not necessarily refer to the same embodiment, though it may. Furthermore, the phrase “in another embodiment” as used herein does not necessarily refer to a different embodiment, although it may. Thus, as described below, various embodiments of the invention may be readily combined, without departing from the scope or spirit of the invention.

In addition, as used herein, the term “or” is an inclusive “or” operator and is equivalent to the term “and/or” unless the context clearly dictates otherwise. The term “based on” is not exclusive and allows for being based on additional factors not described, unless the context clearly dictates otherwise. In addition, throughout the specification, the meaning of “a”, “an”, and “the” include plural references. The meaning of “in” includes “in” and “on.”

The transitional phrase “consisting essentially of” as used in claims in the present application limits the scope of a claim to the specified materials or steps “and those that do not materially affect the basic and novel characteristic(s)” of the claimed invention, as discussed in *In re Herz*, 537 F.2d 549, 551-52, 190 USPQ 461, 463 (CCPA 1976). For example, a composition “consisting essentially of” recited elements may contain an unrecited contaminant at a level such that, though present, the contaminant does not alter the function of the recited composition as compared to a pure composition, *i.e.*, a composition “consisting of” the recited components.

As used herein, a “nucleic acid” or “nucleic acid molecule” generally refers to any ribonucleic acid or deoxyribonucleic acid, which may be unmodified or modified DNA or RNA. “Nucleic acids” include, without limitation, single- and double-stranded nucleic acids. As used herein, the term “nucleic acid” also includes DNA as described above that contains one or more modified bases. Thus, DNA with a backbone modified for stability or for other

reasons is a “nucleic acid”. The term “nucleic acid” as it is used herein embraces such chemically, enzymatically, or metabolically modified forms of nucleic acids, as well as the chemical forms of DNA characteristic of viruses and cells, including for example, simple and complex cells.

The terms “oligonucleotide” or “polynucleotide” or “nucleotide” or “nucleic acid” refer to a molecule having two or more deoxyribonucleotides or ribonucleotides, preferably more than three, and usually more than ten. The exact size will depend on many factors, which in turn depends on the ultimate function or use of the oligonucleotide. The oligonucleotide may be generated in any manner, including chemical synthesis, DNA replication, reverse transcription, or a combination thereof. Typical deoxyribonucleotides for DNA are thymine, adenine, cytosine, and guanine. Typical ribonucleotides for RNA are uracil, adenine, cytosine, and guanine.

As used herein, the terms “locus” or “region” of a nucleic acid refer to a subregion of a nucleic acid, e.g., a gene on a chromosome, a single nucleotide, a CpG island, etc.

The terms “complementary” and “complementarity” refer to nucleotides (e.g., 1 nucleotide) or polynucleotides (e.g., a sequence of nucleotides) related by the base-pairing rules. For example, the sequence 5'-A-G-T-3' is complementary to the sequence 3'-T-C-A-5'. Complementarity may be “partial,” in which only some of the nucleic acids' bases are matched according to the base pairing rules. Or, there may be “complete” or “total” complementarity between the nucleic acids. The degree of complementarity between nucleic acid strands effects the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions and in detection methods that depend upon binding between nucleic acids.

The term “gene” refers to a nucleic acid (e.g., DNA or RNA) sequence that comprises coding sequences necessary for the production of an RNA, or of a polypeptide or its precursor. A functional polypeptide can be encoded by a full length coding sequence or by any portion of the coding sequence as long as the desired activity or functional properties (e.g., enzymatic activity, ligand binding, signal transduction, etc.) of the polypeptide are retained. The term “portion” when used in reference to a gene refers to fragments of that gene. The fragments may range in size from a few nucleotides to the entire gene sequence minus one nucleotide. Thus, “a nucleotide comprising at least a portion of a gene” may comprise fragments of the gene or the entire gene.

The term “gene” also encompasses the coding regions of a structural gene and includes sequences located adjacent to the coding region on both the 5' and 3' ends, e.g., for a distance of about 1 kb on either end, such that the gene corresponds to the length of the full-length mRNA (e.g., comprising coding, regulatory, structural and other sequences). The sequences that are located 5' of the coding region and that are present on the mRNA are referred to as 5' non-translated or untranslated sequences. The sequences that are located 3' or downstream of the coding region and that are present on the mRNA are referred to as 3' non-translated or 3' untranslated sequences. The term “gene” encompasses both cDNA and genomic forms of a gene. In some organisms (e.g., eukaryotes), a genomic form or clone of a gene contains the coding region interrupted with non-coding sequences termed “introns” or “intervening regions” or “intervening sequences.” Introns are segments of a gene that are transcribed into nuclear RNA (hnRNA); introns may contain regulatory elements such as enhancers. Introns are removed or “spliced out” from the nuclear or primary transcript; introns therefore are absent in the messenger RNA (mRNA) transcript. The mRNA functions during translation to specify the sequence or order of amino acids in a nascent polypeptide.

In addition to containing introns, genomic forms of a gene may also include sequences located on both the 5' and 3' ends of the sequences that are present on the RNA transcript. These sequences are referred to as “flanking” sequences or regions (these flanking sequences are located 5' or 3' to the non-translated sequences present on the mRNA transcript). The 5' flanking region may contain regulatory sequences such as promoters and enhancers that control or influence the transcription of the gene. The 3' flanking region may contain sequences that direct the termination of transcription, posttranscriptional cleavage, and polyadenylation.

The term “wild-type” when made in reference to a gene refers to a gene that has the characteristics of a gene isolated from a naturally occurring source. The term “wild-type” when made in reference to a gene product refers to a gene product that has the characteristics of a gene product isolated from a naturally occurring source. The term “naturally-occurring” as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by the hand of a person in the laboratory is naturally-occurring. A wild-type gene is often that gene or allele that is most frequently observed in a population and is thus arbitrarily designated the “normal” or “wild-type” form of the gene. In contrast, the term “modified” or “mutant” when

made in reference to a gene or to a gene product refers, respectively, to a gene or to a gene product that displays modifications in sequence and/or functional properties (e.g., altered characteristics) when compared to the wild-type gene or gene product. It is noted that naturally-occurring mutants can be isolated; these are identified by the fact that they have altered characteristics when compared to the wild-type gene or gene product.

The term “allele” refers to a variation of a gene; the variations include but are not limited to variants and mutants, polymorphic loci, and single nucleotide polymorphic loci, frameshift, and splice mutations. An allele may occur naturally in a population or it might arise during the lifetime of any particular individual of the population.

Thus, the terms “variant” and “mutant” when used in reference to a nucleotide sequence refer to a nucleic acid sequence that differs by one or more nucleotides from another, usually related, nucleotide acid sequence. A “variation” is a difference between two different nucleotide sequences; typically, one sequence is a reference sequence.

“Amplification” is a special case of nucleic acid replication involving template specificity. It is to be contrasted with non-specific template replication (e.g., replication that is template-dependent but not dependent on a specific template). Template specificity is here distinguished from fidelity of replication (e.g., synthesis of the proper polynucleotide sequence) and nucleotide (ribo- or deoxyribo-) specificity. Template specificity is frequently described in terms of “target” specificity. Target sequences are “targets” in the sense that they are sought to be sorted out from other nucleic acid. Amplification techniques have been designed primarily for this sorting out.

The term “amplifying” or “amplification” in the context of nucleic acids refers to the production of multiple copies of a polynucleotide, or a portion of the polynucleotide, typically starting from a small amount of the polynucleotide (e.g., a single polynucleotide molecule), where the amplification products or amplicons are generally detectable. Amplification of polynucleotides encompasses a variety of chemical and enzymatic processes. The generation of multiple DNA copies from one or a few copies of a target or template DNA molecule during a polymerase chain reaction (PCR) or a ligase chain reaction (LCR; see, e.g., U.S. Patent No. 5,494,810; herein incorporated by reference in its entirety) are forms of amplification. Additional types of amplification include, but are not limited to, allele-specific PCR (see, e.g., U.S. Patent No. 5,639,611; herein incorporated by reference in its entirety), assembly PCR (see, e.g., U.S. Patent No. 5,965,408; herein incorporated by reference in its entirety), helicase-dependent amplification (see, e.g., U.S. Patent No.

7,662,594; herein incorporated by reference in its entirety), hot-start PCR (see, *e.g.*, U.S. Patent Nos. 5,773,258 and 5,338,671; each herein incorporated by reference in their entireties), intersequence-specific PCR, inverse PCR (see, *e.g.*, Triglia, *et al.* (1988) *Nucleic Acids Res.*, 16:8186; herein incorporated by reference in its entirety), ligation-mediated PCR (see, *e.g.*, Guilfoyle, R. *et al.*, *Nucleic Acids Research*, 25:1854-1858 (1997); U.S. Patent No. 5,508,169; each of which are herein incorporated by reference in their entireties), methylation-specific PCR (see, *e.g.*, Herman, *et al.*, (1996) *PNAS* 93(13) 9821-9826; herein incorporated by reference in its entirety), miniprimer PCR, multiplex ligation-dependent probe amplification (see, *e.g.*, Schouten, *et al.*, (2002) *Nucleic Acids Research* 30(12): e57; herein incorporated by reference in its entirety), multiplex PCR (see, *e.g.*, Chamberlain, *et al.*, (1988) *Nucleic Acids Research* 16(23) 11141-11156; Ballabio, *et al.*, (1990) *Human Genetics* 84(6) 571-573; Hayden, *et al.*, (2008) *BMC Genetics* 9:80; each of which are herein incorporated by reference in their entireties), nested PCR, overlap-extension PCR (see, *e.g.*, Higuchi, *et al.*, (1988) *Nucleic Acids Research* 16(15) 7351-7367; herein incorporated by reference in its entirety), real time PCR (see, *e.g.*, Higuchi, *et al.*, (1992) *Biotechnology* 10:413-417; Higuchi, *et al.*, (1993) *Biotechnology* 11:1026-1030; each of which are herein incorporated by reference in their entireties), reverse transcription PCR (see, *e.g.*, Bustin, S.A. (2000) *J. Molecular Endocrinology* 25:169-193; herein incorporated by reference in its entirety), solid phase PCR, thermal asymmetric interlaced PCR, and Touchdown PCR (see, *e.g.*, Don, *et al.*, *Nucleic Acids Research* (1991) 19(14) 4008; Roux, K. (1994) *Biotechniques* 16(5) 812-814; Hecker, *et al.*, (1996) *Biotechniques* 20(3) 478-485; each of which are herein incorporated by reference in their entireties). Polynucleotide amplification also can be accomplished using digital PCR (see, *e.g.*, Kalinina, *et al.*, *Nucleic Acids Research*. 25; 1999-2004, (1997); Vogelstein and Kinzler, *Proc Natl Acad Sci USA*. 96; 9236-41, (1999); International Patent Publication No. WO05023091A2; US Patent Application Publication No. 20070202525; each of which are incorporated herein by reference in their entireties).

The term “polymerase chain reaction” (“PCR”) refers to the method of K.B. Mullis U.S. Patent Nos. 4,683,195, 4,683,202, and 4,965,188, that describe a method for increasing the concentration of a segment of a target sequence in a mixture of genomic or other DNA or RNA, without cloning or purification. This process for amplifying the target sequence consists of introducing a large excess of two oligonucleotide primers to the DNA mixture containing the desired target sequence, followed by a precise sequence of thermal cycling in the presence of a DNA polymerase. The two primers are complementary to their respective

strands of the double stranded target sequence. To effect amplification, the mixture is denatured and the primers then annealed to their complementary sequences within the target molecule. Following annealing, the primers are extended with a polymerase so as to form a new pair of complementary strands. The steps of denaturation, primer annealing, and polymerase extension can be repeated many times (*i.e.*, denaturation, annealing and extension constitute one “cycle”; there can be numerous “cycles”) to obtain a high concentration of an amplified segment of the desired target sequence. The length of the amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter. By virtue of the repeating aspect of the process, the method is referred to as the “polymerase chain reaction” (“PCR”). Because the desired amplified segments of the target sequence become the predominant sequences (in terms of concentration) in the mixture, they are said to be “PCR amplified” and are “PCR products” or “amplicons.” Those of skill in the art will understand the term “PCR” encompasses many variants of the originally described method using, *e.g.*, real time PCR, nested PCR, reverse transcription PCR (RT-PCR), single primer and arbitrarily primed PCR, *etc.*

Template specificity is achieved in most amplification techniques by the choice of enzyme. Amplification enzymes are enzymes that, under conditions they are used, will process only specific sequences of nucleic acid in a heterogeneous mixture of nucleic acid. For example, in the case of Q-beta replicase, MDV-1 RNA is the specific template for the replicase (Kacian et al., Proc. Natl. Acad. Sci. USA, 69:3038 [1972]). Other nucleic acid will not be replicated by this amplification enzyme. Similarly, in the case of T7 RNA polymerase, this amplification enzyme has a stringent specificity for its own promoters (Chamberlin et al, Nature, 228:227 [1970]). In the case of T4 DNA ligase, the enzyme will not ligate the two oligonucleotides or polynucleotides, where there is a mismatch between the oligonucleotide or polynucleotide substrate and the template at the ligation junction (Wu and Wallace (1989) Genomics 4:560). Finally, thermostable template-dependant DNA polymerases (*e.g.*, Taq and Pfu DNA polymerases), by virtue of their ability to function at high temperature, are found to display high specificity for the sequences bounded and thus defined by the primers; the high temperature results in thermodynamic conditions that favor primer hybridization with the target sequences and not hybridization with non-target sequences (H. A. Erlich (ed.), PCR Technology, Stockton Press [1989]).

As used herein, the term “nucleic acid detection assay” refers to any method of determining the nucleotide composition of a nucleic acid of interest. Nucleic acid detection assay include but are not limited to, DNA sequencing methods, probe hybridization methods, structure specific cleavage assays (*e.g.*, the INVADER assay, (Hologic, Inc.) and are described, *e.g.*, in U.S. Patent Nos. 5,846,717, 5,985,557, 5,994,069, 6,001,567, 6,090,543, and 6,872,816; Lyamichev et al., *Nat. Biotech.*, 17:292 (1999), Hall et al., *PNAS, USA*, 97:8272 (2000), and US Pat. No. 9,096,893, each of which is herein incorporated by reference in its entirety for all purposes); enzyme mismatch cleavage methods (*e.g.*, Variagenics, U.S. Pat. Nos. 6,110,684, 5,958,692, 5,851,770, herein incorporated by reference in their entirety); polymerase chain reaction (PCR), described above; branched hybridization methods (*e.g.*, Chiron, U.S. Pat. Nos. 5,849,481, 5,710,264, 5,124,246, and 5,624,802, herein incorporated by reference in their entirety); rolling circle replication (*e.g.*, U.S. Pat. Nos. 6,210,884, 6,183,960 and 6,235,502, herein incorporated by reference in their entirety); NASBA (*e.g.*, U.S. Pat. No. 5,409,818, herein incorporated by reference in its entirety); molecular beacon technology (*e.g.*, U.S. Pat. No. 6,150,097, herein incorporated by reference in its entirety); E-sensor technology (Motorola, U.S. Pat. Nos. 6,248,229, 6,221,583, 6,013,170, and 6,063,573, herein incorporated by reference in their entirety); cycling probe technology (*e.g.*, U.S. Pat. Nos. 5,403,711, 5,011,769, and 5,660,988, herein incorporated by reference in their entirety); Dade Behring signal amplification methods (*e.g.*, U.S. Pat. Nos. 6,121,001, 6,110,677, 5,914,230, 5,882,867, and 5,792,614, herein incorporated by reference in their entirety); ligase chain reaction (*e.g.*, Baranay *Proc. Natl. Acad. Sci USA* 88, 189-93 (1991)); and sandwich hybridization methods (*e.g.*, U.S. Pat. No. 5,288,609, herein incorporated by reference in its entirety).

The term “amplifiable nucleic acid” refers to a nucleic acid that may be amplified by any amplification method. It is contemplated that “amplifiable nucleic acid” will usually comprise “sample template.”

The term “sample template” refers to nucleic acid originating from a sample that is analyzed for the presence of “target” (defined below). In contrast, “background template” is used in reference to nucleic acid other than sample template that may or may not be present in a sample. Background template is most often inadvertent. It may be the result of carryover or it may be due to the presence of nucleic acid contaminants sought to be purified away from the sample. For example, nucleic acids from organisms other than those to be detected may be present as background in a test sample.

The term “primer” refers to an oligonucleotide, whether occurring naturally as, *e.g.*, a nucleic acid fragment from a restriction digest, or produced synthetically, that is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product that is complementary to a nucleic acid template strand is induced, (*e.g.*, in the presence of nucleotides and an inducing agent such as a DNA polymerase, and at a suitable temperature and pH). The primer is preferably single stranded for maximum efficiency in amplification, but may alternatively be double stranded. If double stranded, the primer is first treated to separate its strands before being used to prepare extension products. Preferably, the primer is an oligodeoxyribonucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the inducing agent. The exact lengths of the primers will depend on many factors, including temperature, source of primer, and the use of the method.

The term “probe” refers to an oligonucleotide (*e.g.*, a sequence of nucleotides), whether occurring naturally as in a purified restriction digest or produced synthetically, recombinantly, or by PCR amplification, that is capable of hybridizing to another oligonucleotide of interest. A probe may be single-stranded or double-stranded. Probes are useful in the detection, identification, and isolation of particular gene sequences (*e.g.*, a “capture probe”). It is contemplated that any probe used in the present invention may, in some embodiments, be labeled with any “reporter molecule,” so that is detectable in any detection system, including, but not limited to enzyme (*e.g.*, ELISA, as well as enzyme-based histochemical assays), fluorescent, radioactive, and luminescent systems. It is not intended that the present invention be limited to any particular detection system or label.

The term “target,” as used herein refers to a nucleic acid sought to be sorted out from other nucleic acids, *e.g.*, by probe binding, amplification, isolation, capture, *etc.* For example, when used in reference to the polymerase chain reaction, “target” refers to the region of nucleic acid bounded by the primers used for polymerase chain reaction, while when used in an assay in which target DNA is not amplified, *e.g.*, in some embodiments of an invasive cleavage assay, a target comprises the site at which a probe and invasive oligonucleotides (*e.g.*, INVADER oligonucleotide) bind to form an invasive cleavage structure, such that the presence of the target nucleic acid can be detected. A “segment” is defined as a region of nucleic acid within the target sequence.

As used herein, “methylation” refers to cytosine methylation at positions C5 or N4 of cytosine, the N6 position of adenine, or other types of nucleic acid methylation. In vitro

amplified DNA is usually unmethylated because typical in vitro DNA amplification methods do not retain the methylation pattern of the amplification template. However, “unmethylated DNA” or “methylated DNA” can also refer to amplified DNA whose original template was unmethylated or methylated, respectively.

Accordingly, as used herein a “methylated nucleotide” or a “methylated nucleotide base” refers to the presence of a methyl moiety on a nucleotide base, where the methyl moiety is not present in a recognized typical nucleotide base. For example, cytosine does not contain a methyl moiety on its pyrimidine ring, but 5-methylcytosine contains a methyl moiety at position 5 of its pyrimidine ring. Therefore, cytosine is not a methylated nucleotide and 5-methylcytosine is a methylated nucleotide. In another example, thymine contains a methyl moiety at position 5 of its pyrimidine ring; however, for purposes herein, thymine is not considered a methylated nucleotide when present in DNA since thymine is a typical nucleotide base of DNA.

As used herein, a “methylated nucleic acid molecule” refers to a nucleic acid molecule that contains one or more methylated nucleotides.

As used herein, a “methylation state”, “methylation profile”, and “methylation status” of a nucleic acid molecule refers to the presence or absence of one or more methylated nucleotide bases in the nucleic acid molecule. For example, a nucleic acid molecule containing a methylated cytosine is considered methylated (e.g., the methylation state of the nucleic acid molecule is methylated). A nucleic acid molecule that does not contain any methylated nucleotides is considered unmethylated.

The methylation state of a particular nucleic acid sequence (e.g., a gene marker or DNA region as described herein) can indicate the methylation state of every base in the sequence or can indicate the methylation state of a subset of the bases (e.g., of one or more cytosines) within the sequence, or can indicate information regarding regional methylation density within the sequence with or without providing precise information of the locations within the sequence the methylation occurs.

The methylation state of a nucleotide locus in a nucleic acid molecule refers to the presence or absence of a methylated nucleotide at a particular locus in the nucleic acid molecule. For example, the methylation state of a cytosine at the 7th nucleotide in a nucleic acid molecule is methylated when the nucleotide present at the 7th nucleotide in the nucleic acid molecule is 5-methylcytosine. Similarly, the methylation state of a cytosine at the 7th

nucleotide in a nucleic acid molecule is unmethylated when the nucleotide present at the 7th nucleotide in the nucleic acid molecule is cytosine (and not 5-methylcytosine).

The methylation status can optionally be represented or indicated by a “methylation value” (e.g., representing a methylation frequency, fraction, ratio, percent, etc.) A methylation value can be generated, for example, by quantifying the amount of intact nucleic acid present following restriction digestion with a methylation dependent restriction enzyme or by comparing amplification profiles after bisulfite reaction or by comparing sequences of bisulfite-treated and untreated nucleic acids. Accordingly, a value, e.g., a methylation value, represents the methylation status and can thus be used as a quantitative indicator of methylation status across multiple copies of a locus. This is of particular use when it is desirable to compare the methylation status of a sequence in a sample to a threshold or reference value.

As used herein, “methylation frequency” or “methylation percent (%)” refer to the number of instances in which a molecule or locus is methylated relative to the number of instances the molecule or locus is unmethylated.

As such, the methylation state describes the state of methylation of a nucleic acid (e.g., a genomic sequence). In addition, the methylation state refers to the characteristics of a nucleic acid segment at a particular genomic locus relevant to methylation. Such characteristics include, but are not limited to, whether any of the cytosine (C) residues within this DNA sequence are methylated, the location of methylated C residue(s), the frequency or percentage of methylated C throughout any particular region of a nucleic acid, and allelic differences in methylation due to, e.g., difference in the origin of the alleles. The terms “methylation state”, “methylation profile”, and “methylation status” also refer to the relative concentration, absolute concentration, or pattern of methylated C or unmethylated C throughout any particular region of a nucleic acid in a biological sample. For example, if the cytosine (C) residue(s) within a nucleic acid sequence are methylated it may be referred to as “hypermethylated” or having “increased methylation”, whereas if the cytosine (C) residue(s) within a DNA sequence are not methylated it may be referred to as “hypomethylated” or having “decreased methylation”. Likewise, if the cytosine (C) residue(s) within a nucleic acid sequence are methylated as compared to another nucleic acid sequence (e.g., from a different region or from a different individual, etc.) that sequence is considered hypermethylated or having increased methylation compared to the other nucleic acid sequence. Alternatively, if the cytosine (C) residue(s) within a DNA sequence are not methylated as compared to

another nucleic acid sequence (e.g., from a different region or from a different individual, etc.) that sequence is considered hypomethylated or having decreased methylation compared to the other nucleic acid sequence. Additionally, the term “methylation pattern” as used herein refers to the collective sites of methylated and unmethylated nucleotides over a region of a nucleic acid. Two nucleic acids may have the same or similar methylation frequency or methylation percent but have different methylation patterns when the number of methylated and unmethylated nucleotides are the same or similar throughout the region but the locations of methylated and unmethylated nucleotides are different. Sequences are said to be “differentially methylated” or as having a “difference in methylation” or having a “different methylation state” when they differ in the extent (e.g., one has increased or decreased methylation relative to the other), frequency, or pattern of methylation. The term “differential methylation” refers to a difference in the level or pattern of nucleic acid methylation in a cancer positive sample as compared with the level or pattern of nucleic acid methylation in a cancer negative sample. It may also refer to the difference in levels or patterns between patients that have recurrence of cancer after surgery versus patients who not have recurrence. Differential methylation and specific levels or patterns of DNA methylation are prognostic and predictive biomarkers, e.g., once the correct cut-off or predictive characteristics have been defined.

Methylation state frequency can be used to describe a population of individuals or a sample from a single individual. For example, a nucleotide locus having a methylation state frequency of 50% is methylated in 50% of instances and unmethylated in 50% of instances. Such a frequency can be used, for example, to describe the degree to which a nucleotide locus or nucleic acid region is methylated in a population of individuals or a collection of nucleic acids. Thus, when methylation in a first population or pool of nucleic acid molecules is different from methylation in a second population or pool of nucleic acid molecules, the methylation state frequency of the first population or pool will be different from the methylation state frequency of the second population or pool. Such a frequency also can be used, for example, to describe the degree to which a nucleotide locus or nucleic acid region is methylated in a single individual. For example, such a frequency can be used to describe the degree to which a group of cells from a tissue sample are methylated or unmethylated at a nucleotide locus or nucleic acid region.

As used herein a “nucleotide locus” refers to the location of a nucleotide in a nucleic acid molecule. A nucleotide locus of a methylated nucleotide refers to the location of a methylated nucleotide in a nucleic acid molecule.

Typically, methylation of human DNA occurs on a dinucleotide sequence including an adjacent guanine and cytosine where the cytosine is located 5' of the guanine (also termed CpG dinucleotide sequences). Most cytosines within the CpG dinucleotides are methylated in the human genome, however some remain unmethylated in specific CpG dinucleotide rich genomic regions, known as CpG islands (see, e.g., Antequera et al. (1990) *Cell* **62**: 503–514).

As used herein, a “CpG island” refers to a G:C-rich region of genomic DNA containing an increased number of CpG dinucleotides relative to total genomic DNA. A CpG island can be at least 100, 200, or more base pairs in length, where the G:C content of the region is at least 50% and the ratio of observed CpG frequency over expected frequency is 0.6; in some instances, a CpG island can be at least 500 base pairs in length, where the G:C content of the region is at least 55%) and the ratio of observed CpG frequency over expected frequency is 0.65. The observed CpG frequency over expected frequency can be calculated according to the method provided in Gardiner-Garden et al (1987) *J. Mol. Biol.* **196**: 261–281. For example, the observed CpG frequency over expected frequency can be calculated according to the formula $R = (A \times B) / (C \times D)$, where R is the ratio of observed CpG frequency over expected frequency, A is the number of CpG dinucleotides in an analyzed sequence, B is the total number of nucleotides in the analyzed sequence, C is the total number of C nucleotides in the analyzed sequence, and D is the total number of G nucleotides in the analyzed sequence. Methylation state is typically determined in CpG islands, e.g., at promoter regions. It will be appreciated though that other sequences in the human genome are prone to DNA methylation such as CpA and CpT (see Ramsahoye (2000) *Proc. Natl. Acad. Sci. USA* **97**: 5237–5242; Salmon and Kaye (1970) *Biochim. Biophys. Acta.* **204**: 340–351; Grafstrom (1985) *Nucleic Acids Res.* **13**: 2827–2842; Nyce (1986) *Nucleic Acids Res.* **14**: 4353–4367; Woodcock (1987) *Biochem. Biophys. Res. Commun.* **145**: 888-894).

As used herein, a “methylation-specific reagent” refers to a reagent that modifies a nucleotide of the nucleic acid molecule as a function of the methylation state of the nucleic acid molecule, or a methylation-specific reagent, refers to a compound or composition or other agent that can change the nucleotide sequence of a nucleic acid molecule in a manner that reflects the methylation state of the nucleic acid molecule. Methods of treating a nucleic acid molecule with such a reagent can include contacting the nucleic acid molecule with the

reagent, coupled with additional steps, if desired, to accomplish the desired change of nucleotide sequence. Such methods can be applied in a manner in which unmethylated nucleotides (*e.g.*, each unmethylated cytosine) is modified to a different nucleotide. For example, in some embodiments, such a reagent can deaminate unmethylated cytosine nucleotides to produce deoxy uracil residues. Examples of such reagents include, but are not limited to, a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent.

A change in the nucleic acid nucleotide sequence by a methylation –specific reagent can also result in a nucleic acid molecule in which each methylated nucleotide is modified to a different nucleotide.

The term “methylation assay” refers to any assay for determining the methylation state of one or more CpG dinucleotide sequences within a sequence of a nucleic acid.

The term “MS AP-PCR” (Methylation-Sensitive Arbitrarily-Primed Polymerase Chain Reaction) refers to the art-recognized technology that allows for a global scan of the genome using CG-rich primers to focus on the regions most likely to contain CpG dinucleotides, and described by Gonzalgo et al. (1997) *Cancer Research* **57**: 594–599.

The term “MethyLight™” refers to the art-recognized fluorescence-based real-time PCR technique described by Eads et al. (1999) *Cancer Res.* **59**: 2302–2306.

The term “HeavyMethyl™” refers to an assay wherein methylation specific blocking probes (also referred to herein as blockers) covering CpG positions between, or covered by, the amplification primers enable methylation-specific selective amplification of a nucleic acid sample.

The term “HeavyMethyl™ MethyLight™” assay refers to a HeavyMethyl™ MethyLight™ assay, which is a variation of the MethyLight™ assay, wherein the MethyLight™ assay is combined with methylation specific blocking probes covering CpG positions between the amplification primers.

The term “Ms-SNuPE” (Methylation-sensitive Single Nucleotide Primer Extension) refers to the art-recognized assay described by Gonzalgo & Jones (1997) *Nucleic Acids Res.* **25**: 2529–2531.

The term “MSP” (Methylation-specific PCR) refers to the art-recognized methylation assay described by Herman et al. (1996) *Proc. Natl. Acad. Sci. USA* **93**: 9821–9826, and by U.S. Pat. No. 5,786,146.

The term “COBRA” (Combined Bisulfite Restriction Analysis) refers to the art-recognized methylation assay described by Xiong & Laird (1997) *Nucleic Acids Res.* **25**: 2532–2534.

The term “MCA” (Methylated CpG Island Amplification) refers to the methylation assay described by Toyota et al. (1999) *Cancer Res.* **59**: 2307–12, and in WO 00/26401A1.

As used herein, a “selected nucleotide” refers to one nucleotide of the four typically occurring nucleotides in a nucleic acid molecule (C, G, T, and A for DNA and C, G, U, and A for RNA), and can include methylated derivatives of the typically occurring nucleotides (e.g., when C is the selected nucleotide, both methylated and unmethylated C are included within the meaning of a selected nucleotide), whereas a methylated selected nucleotide refers specifically to a methylated typically occurring nucleotide and an unmethylated selected nucleotides refers specifically to an unmethylated typically occurring nucleotide.

The term “methylation-specific restriction enzyme” refers to a restriction enzyme that selectively digests a nucleic acid dependent on the methylation state of its recognition site. In the case of a restriction enzyme that specifically cuts if the recognition site is not methylated or is hemi-methylated (a methylation-sensitive enzyme), the cut will not take place (or will take place with a significantly reduced efficiency) if the recognition site is methylated on one or both strands. In the case of a restriction enzyme that specifically cuts only if the recognition site is methylated (a methylation-dependent enzyme), the cut will not take place (or will take place with a significantly reduced efficiency) if the recognition site is not methylated. Preferred are methylation-specific restriction enzymes, the recognition sequence of which contains a CG dinucleotide (for instance a recognition sequence such as CGCG or CCCGGG). Further preferred for some embodiments are restriction enzymes that do not cut if the cytosine in this dinucleotide is methylated at the carbon atom C5.

As used herein, a “different nucleotide” refers to a nucleotide that is chemically different from a selected nucleotide, typically such that the different nucleotide has Watson-Crick base-pairing properties that differ from the selected nucleotide, whereby the typically occurring nucleotide that is complementary to the selected nucleotide is not the same as the typically occurring nucleotide that is complementary to the different nucleotide. For example, when C is the selected nucleotide, U or T can be the different nucleotide, which is exemplified by the complementarity of C to G and the complementarity of U or T to A. As used herein, a nucleotide that is complementary to the selected nucleotide or that is complementary to the different nucleotide refers to a nucleotide that base-pairs, under high

stringency conditions, with the selected nucleotide or different nucleotide with higher affinity than the complementary nucleotide's base-pairing with three of the four typically occurring nucleotides. An example of complementarity is Watson-Crick base pairing in DNA (e.g., A-T and C-G) and RNA (e.g., A-U and C-G). Thus, for example, G base-pairs, under high stringency conditions, with higher affinity to C than G base-pairs to G, A, or T and, therefore, when C is the selected nucleotide, G is a nucleotide complementary to the selected nucleotide.

As used herein, the “sensitivity” of a given marker (or set of markers used together) refers to the percentage of samples that report a DNA methylation value above a threshold value that distinguishes between neoplastic and non-neoplastic samples. In some embodiments, a positive is defined as a histology-confirmed neoplasia that reports a DNA methylation value above a threshold value (e.g., the range associated with disease), and a false negative is defined as a histology-confirmed neoplasia that reports a DNA methylation value below the threshold value (e.g., the range associated with no disease). The value of sensitivity, therefore, reflects the probability that a DNA methylation measurement for a given marker obtained from a known diseased sample will be in the range of disease-associated measurements. As defined here, the clinical relevance of the calculated sensitivity value represents an estimation of the probability that a given marker would detect the presence of a clinical condition when applied to a subject with that condition.

As used herein, the “specificity” of a given marker (or set of markers used together) refers to the percentage of non-neoplastic samples that report a DNA methylation value below a threshold value that distinguishes between neoplastic and non-neoplastic samples. In some embodiments, a negative is defined as a histology-confirmed non-neoplastic sample that reports a DNA methylation value below the threshold value (e.g., the range associated with no disease) and a false positive is defined as a histology-confirmed non-neoplastic sample that reports a DNA methylation value above the threshold value (e.g., the range associated with disease). The value of specificity, therefore, reflects the probability that a DNA methylation measurement for a given marker obtained from a known non-neoplastic sample will be in the range of non-disease associated measurements. As defined here, the clinical relevance of the calculated specificity value represents an estimation of the probability that a given marker would detect the absence of a clinical condition when applied to a patient without that condition.

The term “AUC” as used herein is an abbreviation for the “area under a curve”. In particular it refers to the area under a Receiver Operating Characteristic (ROC) curve. The ROC curve is a plot of the true positive rate against the false positive rate for the different possible cut points of a diagnostic test. It shows the trade-off between sensitivity and specificity depending on the selected cut point (any increase in sensitivity will be accompanied by a decrease in specificity). The area under an ROC curve (AUC) is a measure for the accuracy of a diagnostic test (the larger the area the better; the optimum is 1; a random test would have a ROC curve lying on the diagonal with an area of 0.5; for reference: J. P. Egan. (1975) *Signal Detection Theory and ROC Analysis*, Academic Press, New York).

The term "neoplasm" as used herein refers to any new and abnormal growth of tissue. Thus, a neoplasm can be a premalignant neoplasm or a malignant neoplasm.

The term "neoplasm-specific marker," as used herein, refers to any biological material or element that can be used to indicate the presence of a neoplasm. Examples of biological materials include, without limitation, nucleic acids, polypeptides, carbohydrates, fatty acids, cellular components (*e.g.*, cell membranes and mitochondria), and whole cells. In some instances, markers are particular nucleic acid regions (*e.g.*, genes, intragenic regions, specific loci, etc.). Regions of nucleic acid that are markers may be referred to, *e.g.*, as "marker genes," "marker regions," "marker sequences," "marker loci," etc.

As used herein, the term “adenoma” refers to a benign tumor of glandular origin. Although these growths are benign, over time they may progress to become malignant.

The term “pre-cancerous” or “pre-neoplastic” and equivalents thereof refer to any cellular proliferative disorder that is undergoing malignant transformation.

A “site” of a neoplasm, adenoma, cancer, etc. is the tissue, organ, cell type, anatomical area, body part, etc. in a subject’s body where the neoplasm, adenoma, cancer, etc. is located.

As used herein, a “diagnostic” test application includes the detection or identification of a disease state or condition of a subject, determining the likelihood that a subject will contract a given disease or condition, determining the likelihood that a subject with a disease or condition will respond to therapy, determining the prognosis of a subject with a disease or condition (or its likely progression or regression), and determining the effect of a treatment on a subject with a disease or condition. For example, a diagnostic can be used for detecting the presence or likelihood of a subject contracting a neoplasm or the likelihood that such a

subject will respond favorably to a compound (e.g., a pharmaceutical, e.g., a drug) or other treatment.

The term “isolated” when used in relation to a nucleic acid, as in “an isolated oligonucleotide” refers to a nucleic acid sequence that is identified and separated from at least one contaminant nucleic acid with which it is ordinarily associated in its natural source. Isolated nucleic acid is present in a form or setting that is different from that in which it is found in nature. In contrast, non-isolated nucleic acids, such as DNA and RNA, are found in the state they exist in nature. Examples of non-isolated nucleic acids include: a given DNA sequence (e.g., a gene) found on the host cell chromosome in proximity to neighboring genes; RNA sequences, such as a specific mRNA sequence encoding a specific protein, found in the cell as a mixture with numerous other mRNAs which encode a multitude of proteins. However, isolated nucleic acid encoding a particular protein includes, by way of example, such nucleic acid in cells ordinarily expressing the protein, where the nucleic acid is in a chromosomal location different from that of natural cells, or is otherwise flanked by a different nucleic acid sequence than that found in nature. The isolated nucleic acid or oligonucleotide may be present in single-stranded or double-stranded form. When an isolated nucleic acid or oligonucleotide is to be utilized to express a protein, the oligonucleotide will contain at a minimum the sense or coding strand (i.e., the oligonucleotide may be single-stranded), but may contain both the sense and anti-sense strands (i.e., the oligonucleotide may be double-stranded). An isolated nucleic acid may, after isolation from its natural or typical environment, be combined with other nucleic acids or molecules. For example, an isolated nucleic acid may be present in a host cell in which it has been placed, e.g., for heterologous expression.

The term “purified” refers to molecules, either nucleic acid or amino acid sequences that are removed from their natural environment, isolated, or separated. An “isolated nucleic acid sequence” may therefore be a purified nucleic acid sequence. “Substantially purified” molecules are at least 60% free, preferably at least 75% free, and more preferably at least 90% free from other components with which they are naturally associated. As used herein, the terms “purified” or “to purify” also refer to the removal of contaminants from a sample. The removal of contaminating proteins results in an increase in the percent of polypeptide or nucleic acid of interest in the sample. In another example, recombinant polypeptides are expressed in plant, bacterial, yeast, or mammalian host cells and the polypeptides are purified

by the removal of host cell proteins; the percent of recombinant polypeptides is thereby increased in the sample.

The term “composition comprising” a given polynucleotide sequence or polypeptide refers broadly to any composition containing the given polynucleotide sequence or polypeptide. The composition may comprise an aqueous solution containing salts (e.g., NaCl), detergents (e.g., SDS), and other components (e.g., Denhardt’s solution, dry milk, salmon sperm DNA, etc.).

The term “sample” is used in its broadest sense. In one sense it can refer to an animal cell or tissue. In another sense, it refers to a specimen or culture obtained from any source, as well as biological and environmental samples. Biological samples may be obtained from plants or animals (including humans) and encompass fluids, solids, tissues, and gases. Environmental samples include environmental material such as surface matter, soil, water, and industrial samples. These examples are not to be construed as limiting the sample types applicable to the present invention.

As used herein, a “remote sample” as used in some contexts relates to a sample indirectly collected from a site that is not the cell, tissue, or organ source of the sample.

As used herein, the terms “patient” or “subject” refer to organisms to be subject to various tests provided by the technology. The term “subject” includes animals, preferably mammals, including humans. In a preferred embodiment, the subject is a primate. In an even more preferred embodiment, the subject is a human. Further with respect to diagnostic methods, a preferred subject is a vertebrate subject. A preferred vertebrate is warm-blooded; a preferred warm-blooded vertebrate is a mammal. A preferred mammal is most preferably a human. As used herein, the term “subject” includes both human and animal subjects. Thus, veterinary therapeutic uses are provided herein. As such, the present technology provides for the diagnosis of mammals such as humans, as well as those mammals of importance due to being endangered, such as Siberian tigers; of economic importance, such as animals raised on farms for consumption by humans; and/or animals of social importance to humans, such as animals kept as pets or in zoos. Examples of such animals include but are not limited to: carnivores such as cats and dogs; swine, including pigs, hogs, and wild boars; ruminants and/or ungulates such as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels; pinnipeds; and horses. Thus, also provided is the diagnosis and treatment of livestock, including, but not limited to, domesticated swine, ruminants, ungulates, horses (including race horses), and the like. The presently-disclosed subject matter further includes a system for

diagnosing a lung cancer in a subject. The system can be provided, for example, as a commercial kit that can be used to screen for a risk of lung cancer or diagnose a lung cancer in a subject from whom a biological sample has been collected. An exemplary system provided in accordance with the present technology includes assessing the methylation state of a marker described herein.

As used herein, the term “kit” refers to any delivery system for delivering materials. In the context of reaction assays, such delivery systems include systems that allow for the storage, transport, or delivery of reaction reagents (e.g., oligonucleotides, enzymes, etc. in the appropriate containers) and/or supporting materials (e.g., buffers, written instructions for performing the assay etc.) from one location to another. For example, kits include one or more enclosures (e.g., boxes) containing the relevant reaction reagents and/or supporting materials. As used herein, the term “fragmented kit” refers to delivery systems comprising two or more separate containers that each contain a subportion of the total kit components. The containers may be delivered to the intended recipient together or separately. For example, a first container may contain an enzyme for use in an assay, while a second container contains oligonucleotides. The term “fragmented kit” is intended to encompass kits containing Analyte specific reagents (ASR's) regulated under section 520(e) of the Federal Food, Drug, and Cosmetic Act, but are not limited thereto. Indeed, any delivery system comprising two or more separate containers that each contains a subportion of the total kit components are included in the term “fragmented kit.” In contrast, a “combined kit” refers to a delivery system containing all of the components of a reaction assay in a single container (e.g., in a single box housing each of the desired components). The term “kit” includes both fragmented and combined kits.

As used herein, the term “information” refers to any collection of facts or data. In reference to information stored or processed using a computer system(s), including but not limited to internets, the term refers to any data stored in any format (e.g., analog, digital, optical, *etc.*). As used herein, the term “information related to a subject” refers to facts or data pertaining to a subject (e.g., a human, plant, or animal). The term “genomic information” refers to information pertaining to a genome including, but not limited to, nucleic acid sequences, genes, percentage methylation, allele frequencies, RNA expression levels, protein expression, phenotypes correlating to genotypes, *etc.* “Allele frequency information” refers to facts or data pertaining to allele frequencies, including, but not limited to, allele identities, statistical correlations between the presence of an allele and a characteristic of a subject (e.g.,

a human subject), the presence or absence of an allele in an individual or population, the percentage likelihood of an allele being present in an individual having one or more particular characteristics, *etc.*

DETAILED DESCRIPTION

In this detailed description of the various embodiments, for purposes of explanation, numerous specific details are set forth to provide a thorough understanding of the embodiments disclosed. One skilled in the art will appreciate, however, that these various embodiments may be practiced with or without these specific details. In other instances, structures and devices are shown in block diagram form. Furthermore, one skilled in the art can readily appreciate that the specific sequences in which methods are presented and performed are illustrative and it is contemplated that the sequences can be varied and still remain within the spirit and scope of the various embodiments disclosed herein.

Provided herein is technology for EC screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of EC and/or specific forms of EC (e.g., clear cell EC, carcinosarcoma EC, endometrioid EC, serous EC). As the technology is described herein, the section headings used are for organizational purposes only and are not to be construed as limiting the subject matter in any way.

Indeed, as described in Examples 1, 2 and 3, experiments conducted during the course for identifying embodiments for the present invention identified a novel set of 499 differentially methylated regions (DMRs) for discriminating cancer of the endometrium derived DNA from non-neoplastic control DNA. From these 499 novel DNA methylation markers, further experiments identified markers capable of distinguishing different types of EC from normal endometrial tissue. For example, separate sets of DMRs were identified capable of distinguishing 1) EC from normal endometrial tissue; 2) clear cell EC from normal endometrial tissue; 3) serous EC from normal endometrial tissue; 4) carcinosarcoma EC from normal endometrial tissue; and 5) endometrioid EC from normal endometrial tissue.

Although the disclosure herein refers to certain illustrated embodiments, it is to be understood that these embodiments are presented by way of example and not by way of limitation.

In particular aspects, the present technology provides compositions and methods for identifying, determining, and/or classifying a cancer such as EC. The methods comprise determining the methylation status of at least one methylation marker in a biological sample

isolated from a subject (e.g., stool sample, endometrial tissue sample, plasma sample), wherein a change in the methylation state of the marker is indicative of the presence, class, or site of EC. Particular embodiments relate to markers comprising a differentially methylated region (DMR, e.g., DMR 1–499, see Tables 1, 8 and 21) that are used for diagnosis (e.g., screening) of EC and various types of EC (e.g., clear cell EC, carcinosarcoma EC, endometrioid EC, serous EC).

In addition to embodiments wherein the methylation analysis of at least one marker, a region of a marker, or a base of a marker comprising a DMR (e.g., DMR, e.g., DMR 1–499) provided herein and listed in Tables 1, 8 and 21 is analyzed, the technology also provides panels of markers comprising at least one marker, region of a marker, or base of a marker comprising a DMR with utility for the detection of cancers, in particular EC.

Some embodiments of the technology are based upon the analysis of the CpG methylation status of at least one marker, region of a marker, or base of a marker comprising a DMR.

In some embodiments, the present technology provides for the use of a reagent that modifies DNA in a methylation-specific manner (e.g., a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent) in combination with one or more methylation assays to determine the methylation status of CpG dinucleotide sequences within at least one marker comprising a DMR (e.g., DMR 1–499, see Tables 1, 8 and 21). Genomic CpG dinucleotides can be methylated or unmethylated (alternatively known as up- and down-methylated respectively). However the methods of the present invention are suitable for the analysis of biological samples of a heterogeneous nature, e.g., a low concentration of tumor cells, or biological materials therefrom, within a background of a remote sample (e.g., blood, organ effluent, or stool). Accordingly, when analyzing the methylation status of a CpG position within such a sample one may use a quantitative assay for determining the level (e.g., percent, fraction, ratio, proportion, or degree) of methylation at a particular CpG position.

According to the present technology, determination of the methylation status of CpG dinucleotide sequences in markers comprising a DMR has utility both in the diagnosis and characterization of cancers such as EC.

Combinations of markers

In some embodiments, the technology relates to assessing the methylation state of combinations of markers comprising a DMR from Tables 1, 8 and 21 (e.g., DMR Nos. 1-499). In some embodiments, assessing the methylation state of more than one marker increases the specificity and/or sensitivity of a screen or diagnostic for identifying a neoplasm in a subject (e.g., EC).

Various cancers are predicted by various combinations of markers, e.g., as identified by statistical techniques related to specificity and sensitivity of prediction. The technology provides methods for identifying predictive combinations and validated predictive combinations for some cancers.

Methods for assaying methylation state

In certain embodiments, methods for analyzing a nucleic acid for the presence of 5-methylcytosine involves treatment of DNA with a reagent that modifies DNA in a methylation-specific manner. Examples of such reagents include, but are not limited to, a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent.

A frequently used method for analyzing a nucleic acid for the presence of 5-methylcytosine is based upon the bisulfite method described by Frommer, et al. for the detection of 5-methylcytosines in DNA (Frommer et al. (1992) *Proc. Natl. Acad. Sci. USA* 89: 1827–31 explicitly incorporated herein by reference in its entirety for all purposes) or variations thereof. The bisulfite method of mapping 5-methylcytosines is based on the observation that cytosine, but not 5-methylcytosine, reacts with hydrogen sulfite ion (also known as bisulfite). The reaction is usually performed according to the following steps: first, cytosine reacts with hydrogen sulfite to form a sulfonated cytosine. Next, spontaneous deamination of the sulfonated reaction intermediate results in a sulfonated uracil. Finally, the sulfonated uracil is desulfonated under alkaline conditions to form uracil. Detection is possible because uracil base pairs with adenine (thus behaving like thymine), whereas 5-methylcytosine base pairs with guanine (thus behaving like cytosine). This makes the discrimination of methylated cytosines from non-methylated cytosines possible by, e.g., bisulfite genomic sequencing (Grigg G, & Clark S, *Bioessays* (1994) 16: 431–36; Grigg G, *DNA Seq.* (1996) 6: 189–98), methylation-specific PCR (MSP) as is disclosed, e.g., in U.S. Patent No. 5,786,146, or using an assay comprising sequence-specific probe cleavage, e.g., a

QuARTS flap endonuclease assay (see, *e.g.*, Zou et al. (2010) “Sensitive quantification of methylated markers with a novel methylation specific technology” *Clin Chem* **56**: A199; and in U.S. Pat. Nos. 8,361,720; 8,715,937; 8,916,344; and 9,212,392.

Some conventional technologies are related to methods comprising enclosing the DNA to be analyzed in an agarose matrix, thereby preventing the diffusion and renaturation of the DNA (bisulfite only reacts with single-stranded DNA), and replacing precipitation and purification steps with a fast dialysis (Olek A, et al. (1996) “A modified and improved method for bisulfite based cytosine methylation analysis” *Nucleic Acids Res.* 24: 5064-6). It is thus possible to analyze individual cells for methylation status, illustrating the utility and sensitivity of the method. An overview of conventional methods for detecting 5-methylcytosine is provided by Rein, T., et al. (1998) *Nucleic Acids Res.* 26: 2255.

The bisulfite technique typically involves amplifying short, specific fragments of a known nucleic acid subsequent to a bisulfite treatment, then either assaying the product by sequencing (Olek & Walter (1997) *Nat. Genet.* 17: 275-6) or a primer extension reaction (Gonzalzo & Jones (1997) *Nucleic Acids Res.* 25: 2529-31; WO 95/00669; U.S. Pat. No. 6,251,594) to analyze individual cytosine positions. Some methods use enzymatic digestion (Xiong & Laird (1997) *Nucleic Acids Res.* 25: 2532-4). Detection by hybridization has also been described in the art (Olek et al., WO 99/28498). Additionally, use of the bisulfite technique for methylation detection with respect to individual genes has been described (Grigg & Clark (1994) *Bioessays* 16: 431-6; Zeschnigk et al. (1997) *Hum Mol Genet.* 6: 387-95; Feil et al. (1994) *Nucleic Acids Res.* 22: 695; Martin et al. (1995) *Gene* 157: 261-4; WO 9746705; WO 9515373).

Various methylation assay procedures can be used in conjunction with bisulfite treatment according to the present technology. These assays allow for determination of the methylation state of one or a plurality of CpG dinucleotides (*e.g.*, CpG islands) within a nucleic acid sequence. Such assays involve, among other techniques, sequencing of bisulfite-treated nucleic acid, PCR (for sequence-specific amplification), Southern blot analysis, and use of methylation-specific restriction enzymes, *e.g.*, methylation-sensitive or methylation-dependent enzymes.

For example, genomic sequencing has been simplified for analysis of methylation patterns and 5-methylcytosine distributions by using bisulfite treatment (Frommer et al. (1992) *Proc. Natl. Acad. Sci. USA* 89: 1827-1831). Additionally, restriction enzyme digestion of PCR products amplified from bisulfite-converted DNA finds use in assessing

methylation state, e.g., as described by Sadri & Hornsby (1997) *Nucl. Acids Res.* 24: 5058–5059 or as embodied in the method known as COBRA (Combined Bisulfite Restriction Analysis) (Xiong & Laird (1997) *Nucleic Acids Res.* 25: 2532–2534).

COBRA™ analysis is a quantitative methylation assay useful for determining DNA methylation levels at specific loci in small amounts of genomic DNA (Xiong & Laird, *Nucleic Acids Res.* 25:2532-2534, 1997). Briefly, restriction enzyme digestion is used to reveal methylation-dependent sequence differences in PCR products of sodium bisulfite-treated DNA. Methylation-dependent sequence differences are first introduced into the genomic DNA by standard bisulfite treatment according to the procedure described by Frommer et al. (*Proc. Natl. Acad. Sci. USA* 89:1827-1831, 1992). PCR amplification of the bisulfite converted DNA is then performed using primers specific for the CpG islands of interest, followed by restriction endonuclease digestion, gel electrophoresis, and detection using specific, labeled hybridization probes. Methylation levels in the original DNA sample are represented by the relative amounts of digested and undigested PCR product in a linearly quantitative fashion across a wide spectrum of DNA methylation levels. In addition, this technique can be reliably applied to DNA obtained from microdissected paraffin-embedded tissue samples.

Typical reagents (e.g., as might be found in a typical COBRA™-based kit) for COBRA™ analysis may include, but are not limited to: PCR primers for specific loci (e.g., specific genes, markers, DMR, regions of genes, regions of markers, bisulfite treated DNA sequence, CpG island, etc.); restriction enzyme and appropriate buffer; gene-hybridization oligonucleotide; control hybridization oligonucleotide; kinase labeling kit for oligonucleotide probe; and labeled nucleotides. Additionally, bisulfite conversion reagents may include: DNA denaturation buffer; sulfonation buffer; DNA recovery reagents or kits (e.g., precipitation, ultrafiltration, affinity column); desulfonation buffer; and DNA recovery components. Assays such as “MethyLight™” (a fluorescence-based real-time PCR technique) (Eads et al., *Cancer Res.* 59:2302-2306, 1999), Ms-SNuPE™ (Methylation-sensitive Single Nucleotide Primer Extension) reactions (Gonzalgo & Jones, *Nucleic Acids Res.* 25:2529-2531, 1997), methylation-specific PCR (“MSP”; Herman et al., *Proc. Natl. Acad. Sci. USA* 93:9821-9826, 1996; U.S. Pat. No. 5,786,146), and methylated CpG island amplification (“MCA”; Toyota et al., *Cancer Res.* 59:2307-12, 1999) are used alone or in combination with one or more of these methods.

The “HeavyMethyl™” assay, technique is a quantitative method for assessing methylation differences based on methylation-specific amplification of bisulfite-treated DNA. Methylation-specific blocking probes (“blockers”) covering CpG positions between, or covered by, the amplification primers enable methylation-specific selective amplification of a nucleic acid sample.

The term “HeavyMethyl™ MethyLight™” assay refers to a HeavyMethyl™ MethyLight™ assay, which is a variation of the MethyLight™ assay, wherein the MethyLight™ assay is combined with methylation specific blocking probes covering CpG positions between the amplification primers. The HeavyMethyl™ assay may also be used in combination with methylation specific amplification primers.

Typical reagents (*e.g.*, as might be found in a typical MethyLight™-based kit) for HeavyMethyl™ analysis may include, but are not limited to: PCR primers for specific loci (*e.g.*, specific genes, markers, regions of genes, regions of markers, bisulfite treated DNA sequence, CpG island, or bisulfite treated DNA sequence or CpG island, *etc.*); blocking oligonucleotides; optimized PCR buffers and deoxynucleotides; and Taq polymerase. MSP (methylation-specific PCR) allows for assessing the methylation status of virtually any group of CpG sites within a CpG island, independent of the use of methylation-sensitive restriction enzymes (Herman et al. Proc. Natl. Acad. Sci. USA 93:9821-9826, 1996; U.S. Pat. No. 5,786,146). Briefly, DNA is modified by sodium bisulfite, which converts unmethylated, but not methylated cytosines, to uracil, and the products are subsequently amplified with primers specific for methylated versus unmethylated DNA. MSP requires only small quantities of DNA, is sensitive to 0.1% methylated alleles of a given CpG island locus, and can be performed on DNA extracted from paraffin-embedded samples. Typical reagents (*e.g.*, as might be found in a typical MSP-based kit) for MSP analysis may include, but are not limited to: methylated and unmethylated PCR primers for specific loci (*e.g.*, specific genes, markers, regions of genes, regions of markers, bisulfite treated DNA sequence, CpG island, *etc.*); optimized PCR buffers and deoxynucleotides, and specific probes.

The MethyLight™ assay is a high-throughput quantitative methylation assay that utilizes fluorescence-based real-time PCR (*e.g.*, TaqMan®) that requires no further manipulations after the PCR step (Eads et al., Cancer Res. 59:2302-2306, 1999). Briefly, the MethyLight™ process begins with a mixed sample of genomic DNA that is converted, in a sodium bisulfite reaction, to a mixed pool of methylation-dependent sequence differences according to standard procedures (the bisulfite process converts unmethylated cytosine

residues to uracil). Fluorescence-based PCR is then performed in a “biased” reaction, *e.g.*, with PCR primers that overlap known CpG dinucleotides. Sequence discrimination occurs both at the level of the amplification process and at the level of the fluorescence detection process.

The MethyLight™ assay is used as a quantitative test for methylation patterns in a nucleic acid, *e.g.*, a genomic DNA sample, wherein sequence discrimination occurs at the level of probe hybridization. In a quantitative version, the PCR reaction provides for a methylation specific amplification in the presence of a fluorescent probe that overlaps a particular putative methylation site. An unbiased control for the amount of input DNA is provided by a reaction in which neither the primers, nor the probe, overlie any CpG dinucleotides. Alternatively, a qualitative test for genomic methylation is achieved by probing the biased PCR pool with either control oligonucleotides that do not cover known methylation sites (*e.g.*, a fluorescence-based version of the HeavyMethyl™ and MSP techniques) or with oligonucleotides covering potential methylation sites.

The MethyLight™ process is used with any suitable probe (*e.g.* a “TaqMan®” probe, a Lightcycler® probe, *etc.*) For example, in some applications double-stranded genomic DNA is treated with sodium bisulfite and subjected to one of two sets of PCR reactions using TaqMan® probes, *e.g.*, with MSP primers and/or HeavyMethyl blocker oligonucleotides and a TaqMan® probe. The TaqMan® probe is dual-labeled with fluorescent “reporter” and “quencher” molecules and is designed to be specific for a relatively high GC content region so that it melts at about a 10°C higher temperature in the PCR cycle than the forward or reverse primers. This allows the TaqMan® probe to remain fully hybridized during the PCR annealing/extension step. As the Taq polymerase enzymatically synthesizes a new strand during PCR, it will eventually reach the annealed TaqMan® probe. The Taq polymerase 5' to 3' endonuclease activity will then displace the TaqMan® probe by digesting it to release the fluorescent reporter molecule for quantitative detection of its now unquenched signal using a real-time fluorescent detection system.

Typical reagents (*e.g.*, as might be found in a typical MethyLight™-based kit) for MethyLight™ analysis may include, but are not limited to: PCR primers for specific loci (*e.g.*, specific genes, markers, regions of genes, regions of markers, bisulfite treated DNA sequence, CpG island, *etc.*); TaqMan® or Lightcycler® probes; optimized PCR buffers and deoxynucleotides; and Taq polymerase.

The QMTM (quantitative methylation) assay is an alternative quantitative test for methylation patterns in genomic DNA samples, wherein sequence discrimination occurs at the level of probe hybridization. In this quantitative version, the PCR reaction provides for unbiased amplification in the presence of a fluorescent probe that overlaps a particular putative methylation site. An unbiased control for the amount of input DNA is provided by a reaction in which neither the primers, nor the probe, overlie any CpG dinucleotides. Alternatively, a qualitative test for genomic methylation is achieved by probing the biased PCR pool with either control oligonucleotides that do not cover known methylation sites (a fluorescence-based version of the HeavyMethylTM and MSP techniques) or with oligonucleotides covering potential methylation sites.

The QMTM process can be used with any suitable probe, *e.g.*, “TaqMan®” probes, Lightcycler® probes, in the amplification process. For example, double-stranded genomic DNA is treated with sodium bisulfite and subjected to unbiased primers and the TaqMan® probe. The TaqMan® probe is dual-labeled with fluorescent “reporter” and “quencher” molecules, and is designed to be specific for a relatively high GC content region so that it melts out at about a 10°C higher temperature in the PCR cycle than the forward or reverse primers. This allows the TaqMan® probe to remain fully hybridized during the PCR annealing/extension step. As the Taq polymerase enzymatically synthesizes a new strand during PCR, it will eventually reach the annealed TaqMan® probe. The Taq polymerase 5' to 3' endonuclease activity will then displace the TaqMan® probe by digesting it to release the fluorescent reporter molecule for quantitative detection of its now unquenched signal using a real-time fluorescent detection system. Typical reagents (*e.g.*, as might be found in a typical QMTM-based kit) for QMTM analysis may include, but are not limited to: PCR primers for specific loci (*e.g.*, specific genes, markers, regions of genes, regions of markers, bisulfite treated DNA sequence, CpG island, *etc.*); TaqMan® or Lightcycler® probes; optimized PCR buffers and deoxynucleotides; and Taq polymerase.

The Ms-SNuPETM technique is a quantitative method for assessing methylation differences at specific CpG sites based on bisulfite treatment of DNA, followed by single-nucleotide primer extension (Gonzalzo & Jones, *Nucleic Acids Res.* 25:2529-2531, 1997). Briefly, genomic DNA is reacted with sodium bisulfite to convert unmethylated cytosine to uracil while leaving 5-methylcytosine unchanged. Amplification of the desired target sequence is then performed using PCR primers specific for bisulfite-converted DNA, and the resulting product is isolated and used as a template for methylation analysis at the CpG site of

interest. Small amounts of DNA can be analyzed (*e.g.*, microdissected pathology sections) and it avoids utilization of restriction enzymes for determining the methylation status at CpG sites.

Typical reagents (*e.g.*, as might be found in a typical Ms-SNuPE™-based kit) for Ms-SNuPE™ analysis may include, but are not limited to: PCR primers for specific loci (*e.g.*, specific genes, markers, regions of genes, regions of markers, bisulfite treated DNA sequence, CpG island, *etc.*); optimized PCR buffers and deoxynucleotides; gel extraction kit; positive control primers; Ms-SNuPE™ primers for specific loci; reaction buffer (for the Ms-SNuPE reaction); and labeled nucleotides. Additionally, bisulfite conversion reagents may include: DNA denaturation buffer; sulfonation buffer; DNA recovery reagents or kit (*e.g.*, precipitation, ultrafiltration, affinity column); desulfonation buffer; and DNA recovery components.

Reduced Representation Bisulfite Sequencing (RRBS) begins with bisulfite treatment of nucleic acid to convert all unmethylated cytosines to uracil, followed by restriction enzyme digestion (*e.g.*, by an enzyme that recognizes a site including a CG sequence such as MspI) and complete sequencing of fragments after coupling to an adapter ligand. The choice of restriction enzyme enriches the fragments for CpG dense regions, reducing the number of redundant sequences that may map to multiple gene positions during analysis. As such, RRBS reduces the complexity of the nucleic acid sample by selecting a subset (*e.g.*, by size selection using preparative gel electrophoresis) of restriction fragments for sequencing. As opposed to whole-genome bisulfite sequencing, every fragment produced by the restriction enzyme digestion contains DNA methylation information for at least one CpG dinucleotide. As such, RRBS enriches the sample for promoters, CpG islands, and other genomic features with a high frequency of restriction enzyme cut sites in these regions and thus provides an assay to assess the methylation state of one or more genomic loci.

A typical protocol for RRBS comprises the steps of digesting a nucleic acid sample with a restriction enzyme such as MspI, filling in overhangs and A-tailing, ligating adaptors, bisulfite conversion, and PCR. See, *e.g.*, et al. (2005) “Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution” *Nat Methods* 7: 133–6; Meissner et al. (2005) “Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis” *Nucleic Acids Res.* 33: 5868–77.

In some embodiments, a quantitative allele-specific real-time target and signal amplification (QuARTS) assay is used to evaluate methylation state. Three reactions

sequentially occur in each QuARTS assay, including amplification (reaction 1) and target probe cleavage (reaction 2) in the primary reaction; and FRET cleavage and fluorescent signal generation (reaction 3) in the secondary reaction. When target nucleic acid is amplified with specific primers, a specific detection probe with a flap sequence loosely binds to the amplicon. The presence of the specific invasive oligonucleotide at the target binding site causes a 5' nuclease, *e.g.*, a FEN-1 endonuclease, to release the flap sequence by cutting between the detection probe and the flap sequence. The flap sequence is complementary to a non-hairpin portion of a corresponding FRET cassette. Accordingly, the flap sequence functions as an invasive oligonucleotide on the FRET cassette and effects a cleavage between the FRET cassette fluorophore and a quencher, which produces a fluorescent signal. The cleavage reaction can cut multiple probes per target and thus release multiple fluorophore per flap, providing exponential signal amplification. QuARTS can detect multiple targets in a single reaction well by using FRET cassettes with different dyes. See, *e.g.*, in Zou et al. (2010) "Sensitive quantification of methylated markers with a novel methylation specific technology" *Clin Chem* **56**: A199), and U.S. Pat. Nos. 8,361,720; 8,715,937; 8,916,344; and 9,212,392, each of which is incorporated herein by reference for all purposes.

The term "bisulfite reagent" refers to a reagent comprising bisulfite, disulfite, hydrogen sulfite, or combinations thereof, useful as disclosed herein to distinguish between methylated and unmethylated CpG dinucleotide sequences. Methods of said treatment are known in the art (*e.g.*, PCT/EP2004/011715 and WO 2013/116375, each of which is incorporated by reference in its entirety). In some embodiments, bisulfite treatment is conducted in the presence of denaturing solvents such as but not limited to n-alkyleneglycol or diethylene glycol dimethyl ether (DME), or in the presence of dioxane or dioxane derivatives. In some embodiments the denaturing solvents are used in concentrations between 1% and 35% (v/v). In some embodiments, the bisulfite reaction is carried out in the presence of scavengers such as but not limited to chromane derivatives, *e.g.*, 6-hydroxy-2,5,7,8-tetramethylchromane 2-carboxylic acid or trihydroxybenzone acid and derivatives thereof, *e.g.*, Gallic acid (see: PCT/EP2004/011715, which is incorporated by reference in its entirety). In certain preferred embodiments, the bisulfite reaction comprises treatment with ammonium hydrogen sulfite, *e.g.*, as described in WO 2013/116375.

In some embodiments, fragments of the treated DNA are amplified using sets of primer oligonucleotides according to the present invention (*e.g.*, see Tables 10, 19 and 20) and an amplification enzyme. The amplification of several DNA segments can be carried out

simultaneously in one and the same reaction vessel. Typically, the amplification is carried out using a polymerase chain reaction (PCR). Amplicons are typically 100 to 2000 base pairs in length.

In another embodiment of the method, the methylation status of CpG positions within or near a marker comprising a DMR (e.g., DMR 1–499, Tables 1, 8 and 21) may be detected by use of methylation-specific primer oligonucleotides. This technique (MSP) has been described in U.S. Pat. No. 6,265,171 to Herman. The use of methylation status specific primers for the amplification of bisulfite treated DNA allows the differentiation between methylated and unmethylated nucleic acids. MSP primer pairs contain at least one primer that hybridizes to a bisulfite treated CpG dinucleotide. Therefore, the sequence of said primers comprises at least one CpG dinucleotide. MSP primers specific for non-methylated DNA contain a “T” at the position of the C position in the CpG.

The fragments obtained by means of the amplification can carry a directly or indirectly detectable label. In some embodiments, the labels are fluorescent labels, radionuclides, or detachable molecule fragments having a typical mass that can be detected in a mass spectrometer. Where said labels are mass labels, some embodiments provide that the labeled amplicons have a single positive or negative net charge, allowing for better detectability in the mass spectrometer. The detection may be carried out and visualized by means of, e.g., matrix assisted laser desorption/ionization mass spectrometry (MALDI) or using electron spray mass spectrometry (ESI).

Methods for isolating DNA suitable for these assay technologies are known in the art. In particular, some embodiments comprise isolation of nucleic acids as described in U.S. Pat. Appl. Ser. No. 13/470,251 (“Isolation of Nucleic Acids”), incorporated herein by reference in its entirety.

In some embodiments, the markers described herein find use in QUARTS assays performed on stool samples. In some embodiments, methods for producing DNA samples and, in particular, to methods for producing DNA samples that comprise highly purified, low-abundance nucleic acids in a small volume (*e.g.*, less than 100, less than 60 microliters) and that are substantially and/or effectively free of substances that inhibit assays used to test the DNA samples (*e.g.*, PCR, INVADER, QuARTS assays, *etc.*) are provided. Such DNA samples find use in diagnostic assays that qualitatively detect the presence of, or quantitatively measure the activity, expression, or amount of, a gene, a gene variant (*e.g.*, an allele), or a gene modification (*e.g.*, methylation) present in a sample taken from a patient.

For example, some cancers are correlated with the presence of particular mutant alleles or particular methylation states, and thus detecting and/or quantifying such mutant alleles or methylation states has predictive value in the diagnosis and treatment of cancer.

Many valuable genetic markers are present in extremely low amounts in samples and many of the events that produce such markers are rare. Consequently, even sensitive detection methods such as PCR require a large amount of DNA to provide enough of a low-abundance target to meet or supersede the detection threshold of the assay. Moreover, the presence of even low amounts of inhibitory substances compromise the accuracy and precision of these assays directed to detecting such low amounts of a target. Accordingly, provided herein are methods providing the requisite management of volume and concentration to produce such DNA samples.

In some embodiments, the sample comprises blood, serum, leukocytes, plasma, or saliva. In some embodiments, the subject is human. Such samples can be obtained by any number of means known in the art, such as will be apparent to the skilled person. Cell free or substantially cell free samples can be obtained by subjecting the sample to various techniques known to those of skill in the art which include, but are not limited to, centrifugation and filtration. Although it is generally preferred that no invasive techniques are used to obtain the sample, it still may be preferable to obtain samples such as tissue homogenates, tissue sections, and biopsy specimens. The technology is not limited in the methods used to prepare the samples and provide a nucleic acid for testing. For example, in some embodiments, a DNA is isolated from a stool sample or from blood or from a plasma sample using direct gene capture, *e.g.*, as detailed in U.S. Pat. Nos. 8,808,990 and 9,169,511, and in WO 2012/155072, or by a related method.

The analysis of markers can be carried out separately or simultaneously with additional markers within one test sample. For example, several markers can be combined into one test for efficient processing of multiple samples and for potentially providing greater diagnostic and/or prognostic accuracy. In addition, one skilled in the art would recognize the value of testing multiple samples (for example, at successive time points) from the same subject. Such testing of serial samples can allow the identification of changes in marker methylation states over time. Changes in methylation state, as well as the absence of change in methylation state, can provide useful information about the disease status that includes, but is not limited to, identifying the approximate time from onset of the event, the presence and

amount of salvageable tissue, the appropriateness of drug therapies, the effectiveness of various therapies, and identification of the subject's outcome, including risk of future events. The analysis of biomarkers can be carried out in a variety of physical formats. For example, the use of microtiter plates or automation can be used to facilitate the processing of large numbers of test samples. Alternatively, single sample formats could be developed to facilitate immediate treatment and diagnosis in a timely fashion, for example, in ambulatory transport or emergency room settings.

It is contemplated that embodiments of the technology are provided in the form of a kit. The kits comprise embodiments of the compositions, devices, apparatuses, *etc.* described herein, and instructions for use of the kit. Such instructions describe appropriate methods for preparing an analyte from a sample, *e.g.*, for collecting a sample and preparing a nucleic acid from the sample. Individual components of the kit are packaged in appropriate containers and packaging (*e.g.*, vials, boxes, blister packs, ampules, jars, bottles, tubes, and the like) and the components are packaged together in an appropriate container (*e.g.*, a box or boxes) for convenient storage, shipping, and/or use by the user of the kit. It is understood that liquid components (*e.g.*, a buffer) may be provided in a lyophilized form to be reconstituted by the user. Kits may include a control or reference for assessing, validating, and/or assuring the performance of the kit. For example, a kit for assaying the amount of a nucleic acid present in a sample may include a control comprising a known concentration of the same or another nucleic acid for comparison and, in some embodiments, a detection reagent (*e.g.*, a primer) specific for the control nucleic acid. The kits are appropriate for use in a clinical setting and, in some embodiments, for use in a user's home. The components of a kit, in some embodiments, provide the functionalities of a system for preparing a nucleic acid solution from a sample. In some embodiments, certain components of the system are provided by the user.

Methods

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (*e.g.*, genomic DNA, *e.g.*, isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at

least one marker selected from a chromosomal region having an annotation selected from the group consisting of AFF3, AIM1_A, AMIGO3_A, BMP4_B, C17orf107_A, C1orf70_B, C5orf52, CLDN7, DIDO1_A, EEF1A2, EMX2OS, FEV, FKBP11_A, GDF6, GDF7_A, JSRP1_A, KCTD15_A, KLHL21, LRRC8D_A, NBPF8, MAX.chr10.130339363-130339534, MAX.chr10.22624479-22624553, MAX.chr14.103021656-103021718, MAX.chr8.145103829-145103992, MAX.chr8.145104263-145104422, MDFI_B, MIAT_A, MMP23B, NDRG2, OBSCN_A, PCOLCE, PYCARD, SEPT9_B, SLC6A3_A, SLC8A3_B, SQSTM1, VILL, ZNF302, ZNF323_A, ZNF506, and ZNF90, and

- 2) detecting EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting of EMX2OS, CYTH2, C17orf107_A, DIDO1_A, GDF6, NBPF8, MAX.chr14.103021656-103021718, JSRP1_A, GATA2_B, and SFMBT2_B, and
- 2) detecting EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting of SFMBT2_B, ZNF90, MAX.chr8.145103829-

145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and MPZ_A, and

- 2) detecting EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting of EMX2OS, CYTH2, NBPF8, MAX.chr10.22624479-22624553, and
- 2) detecting EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from a blood sample (e.g., plasma sample, whole blood sample, leukocyte sample, serum sample) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting of ANKRD35, ARL5C, ARRB1, BCL2L11_A, BCL2L11_B, BCL2L11_C, BZRAP1, C16orf54, C17orf101, C6orf132, CACNA2D4, DEDD2, EPS15L1, FAIM2, FAM125B, FAM189B, FAM78A, FOXP4, GYPC_A, GYPC_B, IFFO1_A, IFFO1_B, ITPKA, KLF16, LIMD2, LOC389333, LOC440925_A, LOC646278, LYL1, LYPLAL1, MAX.chr11.32355226-32355251, MAX.chr14.102172621-102172686, MAX.chr14.105512122-105512239, MAX.chr15.95128144-95128248, MAX.chr16.11327016-11327312, MAX.chr3.187676577-187676668, MAX.chr4.174430676-174430847,

MAX.chr8.145900783-145900914, MAX.chr8.80804237-80804301, N4BP3, NCOR2, NFATC1_A, NFATC1_B, NKX2-6, NR2F6, OSM, PALLD_C, PIK3CD, PRKAR1B, RAD52, STX16_A, SUCLG2, TNFRSF1B, TNFRSF4, ZDHHC18, and ZNF671_A, and

- 2) detecting EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting of DIDO1_A, NDRG4, MAX.chr14.103021656-103021718, MMP23B, EMX2OS, SEPT9_B, NBPf8, EEF1A2, AIM1_A, BMP4_B, MAX.chr8.145103829-145103992, OBSCN, PYCARD, GDF6, MDFI_B, MIAT_A, SCL8A3, ZNF323_A, SQSTM1, AFF3, C1orf70, GDF7_A, JSRP1_A, LRRC8D_A, FEV, and MAX.chr8.145104263-145104422, and
- 2) detecting clear cell EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting of ZNF323_A, MAX.chr7.104624356-104624730, NDRG2, DIDO1_A, MDFI_B, MAX.chr14.103021656-103021718, MMP23B, SEPT9_B, and STX16_A, and

- 2) detecting clear cell EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting SFMBT2_B, SQSTM1, ZNF323_A, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MDFI_B, GDF7_A, MAX.chr10.22624479-22624553, JSRP1_A, MAX.chr14.103021656-103021718, EMX2OS, LRRC34, NBPF8, SEPT9_B, EEF1A2, LRRC41_C, VILL, and MPZ_A, and
- 2) detecting clear cell EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting MAX.chr7:104624386-104624529, EMX2OS, DIDO1_B, and OBSCN_B, and
- 2) detecting clear cell EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from a blood sample (e.g., plasma sample, whole blood sample, leukocyte sample, serum sample)) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting SFMBT2_B, SQSTM1, ZNF323_A, ZNF506, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, NDRG2, CYP11A1, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, MDFI_B, DLL4, GDF7_A, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, EMX2, MMP23B, EMX2OS, MAX.chr17.73073716-73073814, NBPF8, SEPT9_B, LOC440925_A, STX16_A, ITPKA, EEF1A2, FEV, LRRC41_C, and NFIC, and
- 2) detecting clear cell EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting EMX2OS, DIDO1_A, SBNO2, AMIGO3_A, PCOLCE, CLDN7, CYTH2, OBSCN_A, AHSA2, DLL4, EMX2, MAX.chr14.74100620-74100870, LRRC4, PPP2R5C_A, SQSTM1, MAX.chr17.73073716-73073814, CYP11A1, ACOXL_A, and AIM1_B, and
- 2) detecting carcinosarcoma EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting EMX2OS, and LRRC34, and
- 2) detecting carcinosarcoma EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting ZNF506, ZNF90, MAX.chr8.145103829-145103992, LRRC8D_A, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and VILL, and
- 2) detecting carcinosarcoma EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting TRH, MAX.chr7:104624386-104624529, EMX2OS, DIDO1_B, and ST3GAL2_B, and
- 2) detecting carcinosarcoma EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from a blood sample (e.g., plasma sample, whole blood sample, leukocyte sample, serum sample)) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting SFMBT2_B, SMTN, ZNF506, ZNF90, CLDN7, LRRC41_B, CYP11A1, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, DLL4, MAX.chr10.22624479-22624553, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, EMX2OS, LRRC34, NBPf8, LOC440925_A, ITPKA, NFIC, and VILL, and
- 2) detecting carcinosarcoma EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting EMX2OS, KANK1, C1orf70_B, AMIGO3_A, DIDO1_A, LRRC41_C, NFIC, FKBP11_A, C17orf107_A, SMTN, LRRC41_B, LRRC8D_A, OBSCN_A, MAX.chr7.104624356-104624730, MIAT_B, and
- 2) detecting serous EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting MAX.chr7.104624356-104624730, EMX2OS, and LRRC41_C, and
- 2) detecting serous EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, EMX2OS, LRRC41_C, and VILL, and
- 2) detecting serous EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting EMX2OS, and LRRC41_D, and
- 2) detecting serous EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from a blood sample (e.g., plasma sample, whole blood sample, leukocyte sample, serum sample)) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting SFMBT2_B, SMTN, SQSTM1, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, CYP11A1, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, GDGF6, DLL4, PYCARD, BMP4_B, JSRP1_A, MIAT_B, KANK1, EMX2OS, NBPF8, LOC440925_A, ITPKA, EEF1A2, FEV, LRRC41_C, NFIC, VILL, MPZ_A, and
- 2) detecting serous EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting MAX.chr10.130339363-130339534, SFMBT2_C, CYTH2, SLC6A3, VILL, EMX2OS, MAX.chr10.22624479-22624553, GDF6, ZNF90, ZNF506, JSRP1_A, c5orf52, SFMBT2_B, NBPF8, RHBDL1_A, DIDO1_A, KANK1, and GATA2_B, and
- 2) detecting endometrioid EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting MAX.chr8.145103829-145103992, CYTH2, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, SBNO2, NBPF8, and VILL, and
- 2) detecting endometrioid EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, MAX.chr8.145104263-145104422, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and MPZ_A, and
- 2) detecting endometrioid EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from a blood sample (e.g., plasma sample, whole blood sample, leukocyte sample, serum sample)) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting SFMBT2_B, SMTN, SQSTM1, ZNF506, ZNF90, CLDN7, LRRC41_B, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B,

LRRC8D_A, MAX.chr8.145104263-145104422, DIDO1_A, GDF6,
 MAX.chr10.130339363-130339534, DLL4, MAX.chr10.22624479-22624553,
 MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718,
 MIAT_B, KANK1, SBNO2, c5orf52, EMX2O6, LRRC34, NBPF8, LOC440925_A,
 ITPKA, NFIC, VILL, and MPZ_A, and

- 2) detecting endometrioid EC (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting TSPYL5, TRH, JAM3, FAM19A5, PTGDR, SFMBT2_E, JSRP1_B, and ARL5C, and
- 2) detecting endometrioid EC Grade 1 (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting TSPYL5, MPZ_B, TRH, CNTN4, FAM19A5, GLT1D1, RYR2_F, PTGDR, EMX2OS, MAX.chr10:22624470-22624553, SPDYA_B, SFMBT2_E, and JSRP1_B, and
- 2) detecting endometrioid EC Grade 2 (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) contacting a nucleic acid (e.g., genomic DNA, e.g., isolated from endometrial tissue) obtained from the subject with at least one reagent or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker selected from a chromosomal region having an annotation selected from the group consisting TSPYL5, MPZ_B, TRH, and PTGDR, and
- 2) detecting endometrioid EC Grade 3 (e.g., afforded with a sensitivity of greater than or equal to 80% and a specificity of greater than or equal to 80%).

In some embodiments of the technology, methods are provided that comprise the following steps:

1) measuring a methylation level for one or more genes in a biological sample of a human individual through treating genomic DNA in the biological sample with a reagent that modifies DNA in a methylation-specific manner (e.g., wherein the reagent is a bisulfite reagent, a methylation-sensitive restriction enzyme, or a methylation-dependent restriction enzyme), wherein the one or more genes is selected from one of the following groups:

- (i) AFF3, AIM1_A, AMIGO3_A, BMP4_B, C17orf107_A, C1orf70_B, C5orf52, CLDN7, DIDO1_A, EEF1A2, EMX2OS, FEV, FKBP11_A, GDF6, GDF7_A, JSRP1_A, KCTD15_A, KLHL21, LRRC8D_A, NBPF8, MAX.chr10.130339363-130339534, MAX.chr10.22624479-22624553, MAX.chr14.103021656-103021718, MAX.chr8.145103829-145103992, MAX.chr8.145104263-145104422, MDFI_B, MIAT_A, MMP23B, NDRG2, OBSCN_A, PCOLCE, PYCARD, SEPT9_B, SLC6A3_A, SLC8A3_B, SQSTM1, VILL, ZNF302, ZNF323_A, ZNF506, and ZNF90;
- (ii) EMX2OS, CYTH2, C17orf107_A, DIDO1_A, GDF6, NBPF8, MAX.chr14.103021656-103021718, JSRP1_A, GATA2_B, and SFMBT2_B;
- (iii) SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and MPZ_A;

- (iv) EMX2OS, CYTH2, NBPF8, MAX.chr10.22624479-22624553;
and
 - (v) ANKRD35, ARL5C, ARRB1, BCL2L1_A, BCL2L1_B, BCL2L1_C, BZRAP1, C16orf54, C17orf101, C6orf132, CACNA2D4, DEDD2, EPS15L1, FAIM2, FAM125B, FAM189B, FAM78A, FOXP4, GYPC_A, GYPC_B, IFFO1_A, IFFO1_B, ITPKA, KLF16, LIMD2, LOC389333, LOC440925_A, LOC646278, LYL1, LYPLAL1, MAX.chr11.32355226-32355251, MAX.chr14.102172621-102172686, MAX.chr14.105512122-105512239, MAX.chr15.95128144-95128248, MAX.chr16.11327016-11327312, MAX.chr3.187676577-187676668, MAX.chr4.174430676-174430847, MAX.chr8.145900783-145900914, MAX.chr8.80804237-80804301, N4BP3, NCOR2, NFATC1_A, NFATC1_B, NKX2-6, NR2F6, OSM, PALLD_C, PIK3CD, PRKAR1B, RAD52, STX16_A, SUCLG2, TNFRSF1B, TNFRSF4, ZDHHC18, and ZNF671_A;
- 2) amplifying the treated genomic DNA using a set of primers for the selected one or more genes; and
 - 3) determining the methylation level of the one or more genes by polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation-specific nuclease, mass-based separation, and target capture.

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) measuring a methylation level for one or more genes in a biological sample of a human individual through treating genomic DNA in the biological sample with a reagent that modifies DNA in a methylation-specific manner (e.g., wherein the reagent is a bisulfite reagent, a methylation-sensitive restriction enzyme, or a methylation-dependent restriction enzyme), wherein the one or more genes is selected from one of the following groups:

- (i) DIDO1_A, NDRG4, MAX.chr14.103021656-103021718, MMP23B, EMX2OS, SEPT9_B, NBPF8, EEF1A2, AIM1_A, BMP4_B, MAX.chr8.145103829-145103992, OBSCN, PYCARD, GDF6, MDFI_B, MIAT_A, SCL8A3, ZNF323_A, SQSTM1, AFF3, C1orf70, GDF7_A, JSRP1_A, LRRC8D_A, FEV, and MAX.chr8.145104263-145104422;

- (ii) ZNF323_A, MAX.chr7.104624356-104624730, NDRG2, DIDO1_A, MDFI_B, MAX.chr14.103021656-103021718, MMP23B, SEPT9_B, and STX16_A;
 - (iii) SFMBT2_B, SQSTM1, ZNF323_A, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MDFI_B, GDF7_A, MAX.chr10.22624479-22624553, JSRP1_A, MAX.chr14.103021656-103021718, EMX2OS, LRRC34, NBPF8, SEPT9_B, EEF1A2, LRRC41_C, VILL, and MPZ_A;
 - (iv) MAX.chr7:104624386-104624529, EMX2OS, DIDO1_B, and OBSCN_B; and
 - (v) SFMBT2_B, SQSTM1, ZNF323_A, ZNF506, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, NDRG2, CYP11A1, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, MDFI_B, DLL4, GDF7_A, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, EMX2, MMP23B, EMX2OS, MAX.chr17.73073716-73073814, NBPF8, SEPT9_B, LOC440925_A, STX16_A, ITPKA, EEF1A2, FEV, LRRC41_C, and NFIC;
- 2) amplifying the treated genomic DNA using a set of primers for the selected one or more genes; and
- 3) determining the methylation level of the one or more genes by polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation-specific nuclease, mass-based separation, and target capture.

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) measuring a methylation level for one or more genes in a biological sample of a human individual through treating genomic DNA in the biological sample with a reagent that modifies DNA in a methylation-specific manner (e.g., wherein the reagent is a bisulfite reagent, a methylation-sensitive restriction enzyme, or a methylation-dependent restriction enzyme), wherein the one or more genes is selected from one of the following groups:

- (i) EMX2OS, DIDO1_A, SBNO2, AMIGO3_A, PCOLCE, CLDN7, CYTH2, OBSCN_A, AHSA2, DLL4, EMX2,

MAX.chr14.74100620-74100870, LRRC4, PPP2R5C_A, SQSTM1,
MAX.chr17.73073716-73073814, CYP11A1, ACOXL_A, and AIM1_B;

(ii) EMX2OS, and LRRC34;

(iii) ZNF506, ZNF90, MAX.chr8.145103829-145103992,
LRRC8D_A, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A,
EMX2OS, NBPF8, and VILL;

(iv) TRH, MAX.chr7:104624386-104624529, EMX2OS,
DIDO1_B, and ST3GAL2_B; and

(v) SFMBT2_B, SMTN, ZNF506, ZNF90, CLDN7, LRRC41_B,
CYP11A1, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B,
LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A,
GDF6, DLL4, MAX.chr10.22624479-22624553, PYCARD, BMP4_B,
JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, EMX2OS,
LRRC34, NBPF8, LOC440925_A, ITPKA, NFIC, and VILL;

2) amplifying the treated genomic DNA using a set of primers for the selected one or more genes; and

3) determining the methylation level of the one or more genes by polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation-specific nuclease, mass-based separation, and target capture.

In some embodiments of the technology, methods are provided that comprise the following steps:

1) measuring a methylation level for one or more genes in a biological sample of a human individual through treating genomic DNA in the biological sample with a reagent that modifies DNA in a methylation-specific manner (e.g., wherein the reagent is a bisulfite reagent, a methylation-sensitive restriction enzyme, or a methylation-dependent restriction enzyme), wherein the one or more genes is selected from one of the following groups:

(i) EMX2OS, KANK1, C1orf70_B, AMIGO3_A, DIDO1_A,
LRRC41_C, NFIC, FKBP11_A, C17orf107_A, SMTN, LRRC41_B,
LRRC8D_A, OBSCN_A, MAX.chr7.104624356-104624730, MIAT_B;

(ii) MAX.chr7.104624356-104624730, EMX2OS, and
LRRC41_C;

- (iii) MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, EMX2OS, LRRC41_C, and VILL;
 - (iv) EMX2OS, and LRRC41_D; and
 - (v) SFMBT2_B, SMTN, SQSTM1, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, CYP11A1, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, GDGF6, DLL4, PYCARD, BMP4_B, JSRP1_A, MIAT_B, KANK1, EMX2OS, NBPF8, LOC440925_A, ITPKA, EEF1A2, FEV, LRRC41_C, NFIC, VILL, MPZ_A;
- 2) amplifying the treated genomic DNA using a set of primers for the selected one or more genes; and
- 3) determining the methylation level of the one or more genes by polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation-specific nuclease, mass-based separation, and target capture.

In some embodiments of the technology, methods are provided that comprise the following steps:

1) measuring a methylation level for one or more genes in a biological sample of a human individual through treating genomic DNA in the biological sample with a reagent that modifies DNA in a methylation-specific manner (e.g., wherein the reagent is a bisulfite reagent, a methylation-sensitive restriction enzyme, or a methylation-dependent restriction enzyme), wherein the one or more genes is selected from one of the following groups:

- (i) MAX.chr10.130339363-130339534, SFMBT2_C, CYTH2, SLC6A3, VILL, EMX2OS, MAX.chr10.22624479-22624553, GDF6, ZNF90, ZNF506, JSRP1_A, c5orf52, SFMBT2_B, NBPF8, RHBDL1_A, DIDO1_A, KANK1, and GATA2_B;
- (ii) MAX.chr8.145103829-145103992, CYTH2, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, SBNO2, NBPF8, and VILL;
- (iii) SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, MAX.chr8.145104263-145104422, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and MPZ_A;
- (iv) SFMBT2_B, SMTN, SQSTM1, ZNF506, ZNF90, CLDN7, LRRC41_B, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2,

CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, DLL4, MAX.chr10.22624479-22624553, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, KANK1, SBNO2, c5orf52, EMX2O6, LRRC34, NBPf8, LOC440925_A, ITPKA, NFIC, VILL, and MPZ_A;

(v) TSPYL5, TRH, JAM3, FAM19A5, PTGDR, SFMBT2_E, JSRP1_B, and ARL5C;

(vi) TSPYL5, MPZ_B, TRH, CNTN4, FAM19A5, GLT1D1, RYR2_F, PTGDR, EMX2OS, MAX.chr10:22624470-22624553, SPDYA_B, SFMBT2_E, and JSRP1_B; and

(vii) TSPYL5, MPZ_B, TRH, and PTGDR.

2) amplifying the treated genomic DNA using a set of primers for the selected one or more genes; and

3) determining the methylation level of the one or more genes by polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation-specific nuclease, mass-based separation, and target capture.

In some embodiments of the technology, methods are provided that comprise the following steps:

1) measuring an amount of at least one methylated marker gene in DNA from the sample, wherein the one or more genes is selected from one of the following groups:

(i) AFF3, AIM1_A, AMIGO3_A, BMP4_B, C17orf107_A, C1orf70_B, C5orf52, CLDN7, DIDO1_A, EEF1A2, EMX2OS, FEV, FKBP11_A, GDF6, GDF7_A, JSRP1_A, KCTD15_A, KLHL21, LRRC8D_A, NBPf8, MAX.chr10.130339363-130339534, MAX.chr10.22624479-22624553, MAX.chr14.103021656-103021718, MAX.chr8.145103829-145103992, MAX.chr8.145104263-145104422, MDFI_B, MIAT_A, MMP23B, NDRG2, OBSCN_A, PCOLCE, PYCARD, SEPT9_B, SLC6A3_A, SLC8A3_B, SQSTM1, VILL, ZNF302, ZNF323_A, ZNF506, and ZNF90;

(ii) EMX2OS, CYTH2, C17orf107_A, DIDO1_A, GDF6, NBPf8, MAX.chr14.103021656-103021718, JSRP1_A, GATA2_B, and SFMBT2_B;

(iii) SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and MPZ_A;

(iv) EMX2OS, CYTH2, NBPF8, MAX.chr10.22624479-22624553; and

(v) ANKRD35, ARL5C, ARRB1, BCL2L11_A, BCL2L11_B, BCL2L11_C, BZRAP1, C16orf54, C17orf101, C6orf132, CACNA2D4, DEDD2, EPS15L1, FAIM2, FAM125B, FAM189B, FAM78A, FOXP4, GYPC_A, GYPC_B, IFFO1_A, IFFO1_B, ITPKA, KLF16, LIMD2, LOC389333, LOC440925_A, LOC646278, LYL1, LYPLAL1, MAX.chr11.32355226-32355251, MAX.chr14.102172621-102172686, MAX.chr14.105512122-105512239, MAX.chr15.95128144-95128248, MAX.chr16.11327016-11327312, MAX.chr3.187676577-187676668, MAX.chr4.174430676-174430847, MAX.chr8.145900783-145900914, MAX.chr8.80804237-80804301, N4BP3, NCOR2, NFATC1_A, NFATC1_B, NKX2-6, NR2F6, OSM, PALLD_C, PIK3CD, PRKAR1B, RAD52, STX16_A, SUCLG2, TNFRSF1B, TNFRSF4, ZDHHC18, and ZNF671_A;

2) measuring the amount of at least one reference marker in the DNA; and

3) calculating a value for the amount of the at least one methylated marker gene measured in the DNA as a percentage of the amount of the reference marker gene measured in the DNA, wherein the value indicates the amount of the at least one methylated marker DNA measured in the sample.

In some embodiments of the technology, methods are provided that comprise the following steps:

1) measuring an amount of at least one methylated marker gene in DNA from the sample, wherein the one or more genes is selected from one of the following groups:

(i) DIDO1_A, NDRG4, MAX.chr14.103021656-103021718, MMP23B, EMX2OS, SEPT9_B, NBPF8, EEF1A2, AIM1_A, BMP4_B, MAX.chr8.145103829-145103992, OBSCN, PYCARD, GDF6, MDFI_B, MIAT_A, SCL8A3, ZNF323_A, SQSTM1, AFF3, C1orf70, GDF7_A, JSRP1_A, LRRC8D_A, FEV, and MAX.chr8.145104263-145104422;

- (ii) ZNF323_A, MAX.chr7.104624356-104624730, NDRG2, DIDO1_A, MDFI_B, MAX.chr14.103021656-103021718, MMP23B, SEPT9_B, and STX16_A;
 - (iii) SFMBT2_B, SQSTM1, ZNF323_A, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MDFI_B, GDF7_A, MAX.chr10.22624479-22624553, JSRP1_A, MAX.chr14.103021656-103021718, EMX2OS, LRRC34, NBPf8, SEPT9_B, EEF1A2, LRRC41_C, VILL, and MPZ_A;
 - (iv) MAX.chr7:104624386-104624529, EMX2OS, DIDO1_B, and OBSCN_B; and
 - (v) SFMBT2_B, SQSTM1, ZNF323_A, ZNF506, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, NDRG2, CYP11A1, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, MDFI_B, DLL4, GDF7_A, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, EMX2, MMP23B, EMX2OS, MAX.chr17.73073716-73073814, NBPf8, SEPT9_B, LOC440925_A, STX16_A, ITPKA, EEF1A2, FEV, LRRC41_C, and NFIC;
- 2) measuring the amount of at least one reference marker in the DNA; and
 - 3) calculating a value for the amount of the at least one methylated marker gene measured in the DNA as a percentage of the amount of the reference marker gene measured in the DNA, wherein the value indicates the amount of the at least one methylated marker DNA measured in the sample.

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) measuring an amount of at least one methylated marker gene in DNA from the sample, wherein the one or more genes is selected from one of the following groups:
 - (i) EMX2OS, DIDO1_A, SBNO2, AMIGO3_A, PCOLCE, CLDN7, CYTH2, OBSCN_A, AHS2, DLL4, EMX2, MAX.chr14.74100620-74100870, LRRC4, PPP2R5C_A, SQSTM1, MAX.chr17.73073716-73073814, CYP11A1, ACOXL_A, and AIM1_B;
 - (ii) EMX2OS, and LRRC34;

- (iii) ZNF506, ZNF90, MAX.chr8.145103829-145103992, LRRC8D_A, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and VILL;
 - (iv) TRH, MAX.chr7:104624386-104624529, EMX2OS, DIDO1_B, and ST3GAL2_B; and
 - (v) SFMBT2_B, SMTN, ZNF506, ZNF90, CLDN7, LRRC41_B, CYP11A1, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, DLL4, MAX.chr10.22624479-22624553, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, EMX2OS, LRRC34, NBPF8, LOC440925_A, ITPKA, NFIC, and VILL;
- 2) measuring the amount of at least one reference marker in the DNA; and
 - 3) calculating a value for the amount of the at least one methylated marker gene measured in the DNA as a percentage of the amount of the reference marker gene measured in the DNA, wherein the value indicates the amount of the at least one methylated marker DNA measured in the sample.

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) measuring an amount of at least one methylated marker gene in DNA from the sample, wherein the one or more genes is selected from one of the following groups:
 - (i) EMX2OS, KANK1, C1orf70_B, AMIGO3_A, DIDO1_A, LRRC41_C, NFIC, FKBP11_A, C17orf107_A, SMTN, LRRC41_B, LRRC8D_A, OBSCN_A, MAX.chr7.104624356-104624730, MIAT_B;
 - (ii) MAX.chr7.104624356-104624730, EMX2OS, and LRRC41_C;
 - (iii) MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, EMX2OS, LRRC41_C, and VILL;
 - (iv) EMX2OS, and LRRC41_D; and
 - (v) SFMBT2_B, SMTN, SQSTM1, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, CYP11A1, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, GDF6, DLL4, PYCARD,

BMP4_B, JSRP1_A, MIAT_B, KANK1, EMX2OS, NBPF8, LOC440925_A, ITPKA, EEF1A2, FEV, LRRC41_C, NFIC, VILL, MPZ_A;

- 2) measuring the amount of at least one reference marker in the DNA; and
- 3) calculating a value for the amount of the at least one methylated marker gene measured in the DNA as a percentage of the amount of the reference marker gene measured in the DNA, wherein the value indicates the amount of the at least one methylated marker DNA measured in the sample.

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) measuring an amount of at least one methylated marker gene in DNA from the sample, wherein the one or more genes is selected from one of the following groups:
 - (i) MAX.chr10.130339363-130339534, SFMBT2_C, CYTH2, SLC6A3, VILL, EMX2OS, MAX.chr10.22624479-22624553, GDF6, ZNF90, ZNF506, JSRP1_A, c5orf52, SFMBT2_B, NBPF8, RHBDL1_A, DIDO1_A, KANK1, and GATA2_B;
 - (ii) MAX.chr8.145103829-145103992, CYTH2, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, SBNO2, NBPF8, and VILL;
 - (iii) SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, MAX.chr8.145104263-145104422, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and MPZ_A;
 - (iv) SFMBT2_B, SMTN, SQSTM1, ZNF506, ZNF90, CLDN7, LRRC41_B, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, DLL4, MAX.chr10.22624479-22624553, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, KANK1, SBNO2, c5orf52, EMX2O6, LRRC34, NBPF8, LOC440925_A, ITPKA, NFIC, VILL, and MPZ_A;
 - (v) TSPYL5, TRH, JAM3, FAM19A5, PTGDR, SFMBT2_E, JSRP1_B, and ARL5C;

- (vi) TSPYL5, MPZ_B, TRH, CNTN4, FAM19A5, GLT1D1, RYR2_F, PTGDR, EMX2OS, MAX.chr10:22624470-22624553, SPDYA_B, SFMBT2_E, and JSRP1_B; and
- (vii) TSPYL5, MPZ_B, TRH, and PTGDR;
- 2) measuring the amount of at least one reference marker in the DNA; and
- 3) calculating a value for the amount of the at least one methylated marker gene measured in the DNA as a percentage of the amount of the reference marker gene measured in the DNA, wherein the value indicates the amount of the at least one methylated marker DNA measured in the sample.

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) measuring a methylation level of a CpG site for one or more genes in a biological sample of a human individual through treating genomic DNA in the biological sample with bisulfite a reagent capable of modifying DNA in a methylation-specific manner (e.g., a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent);
- 2) amplifying the modified genomic DNA using a set of primers for the selected one or more genes; and
- 3) determining the methylation level of the CpG site by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, or bisulfite genomic sequencing PCR;

wherein the one or more genes is selected from one of the following groups:

- (i) AFF3, AIM1_A, AMIGO3_A, BMP4_B, C1orf107_A, C1orf70_B, C5orf52, CLDN7, DIDO1_A, EEF1A2, EMX2OS, FEV, FKBP11_A, GDF6, GDF7_A, JSRP1_A, KCTD15_A, KLHL21, LRRC8D_A, NBPf8, MAX.chr10.130339363-130339534, MAX.chr10.22624479-22624553, MAX.chr14.103021656-103021718, MAX.chr8.145103829-145103992, MAX.chr8.145104263-145104422, MDFI_B, MIAT_A, MMP23B, NDRG2, OBSCN_A, PCOLCE, PYCARD, SEPT9_B, SLC6A3_A, SLC8A3_B, SQSTM1, VILL, ZNF302, ZNF323_A, ZNF506, and ZNF90;

- (ii) EMX2OS, CYTH2, C17orf107_A, DIDO1_A, GDF6, NBPF8, MAX.chr14.103021656-103021718, JSRP1_A, GATA2_B, and SFMBT2_B;
- (iii) SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and MPZ_A;
- (iv) EMX2OS, CYTH2, NBPF8, MAX.chr10.22624479-22624553; and
- (v) ANKRD35, ARL5C, ARRB1, BCL2L11_A, BCL2L11_B, BCL2L11_C, BZRAP1, C16orf54, C17orf101, C6orf132, CACNA2D4, DEDD2, EPS15L1, FAIM2, FAM125B, FAM189B, FAM78A, FOXP4, GYPC_A, GYPC_B, IFFO1_A, IFFO1_B, ITPKA, KLF16, LIMD2, LOC389333, LOC440925_A, LOC646278, LYL1, LYPLAL1, MAX.chr11.32355226-32355251, MAX.chr14.102172621-102172686, MAX.chr14.105512122-105512239, MAX.chr15.95128144-95128248, MAX.chr16.11327016-11327312, MAX.chr3.187676577-187676668, MAX.chr4.174430676-174430847, MAX.chr8.145900783-145900914, MAX.chr8.80804237-80804301, N4BP3, NCOR2, NFATC1_A, NFATC1_B, NKX2-6, NR2F6, OSM, PALLD_C, PIK3CD, PRKAR1B, RAD52, STX16_A, SUCLG2, TNFRSF1B, TNFRSF4, ZDHHC18, and ZNF671_A.

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) measuring a methylation level of a CpG site for one or more genes in a biological sample of a human individual through treating genomic DNA in the biological sample with bisulfite a reagent capable of modifying DNA in a methylation-specific manner (e.g., a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent);
 - 2) amplifying the modified genomic DNA using a set of primers for the selected one or more genes; and
 - 3) determining the methylation level of the CpG site by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, or bisulfite genomic sequencing PCR;
- wherein the one or more genes is selected from one of the following groups:

- (i) DIDO1_A, NDRG4, MAX.chr14.103021656-103021718, MMP23B, EMX2OS, SEPT9_B, NBPf8, EEF1A2, AIM1_A, BMP4_B, MAX.chr8.145103829-145103992, OBSCN, PYCARD, GDF6, MDFI_B, MIAT_A, SCL8A3, ZNF323_A, SQSTM1, AFF3, C1orf70, GDF7_A, JSRP1_A, LRRC8D_A, FEV, and MAX.chr8.145104263-145104422;
- (ii) ZNF323_A, MAX.chr7.104624356-104624730, NDRG2, DIDO1_A, MDFI_B, MAX.chr14.103021656-103021718, MMP23B, SEPT9_B, and STX16_A;
- (iii) SFMBT2_B, SQSTM1, ZNF323_A, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MDFI_B, GDF7_A, MAX.chr10.22624479-22624553, JSRP1_A, MAX.chr14.103021656-103021718, EMX2OS, LRRC34, NBPf8, SEPT9_B, EEF1A2, LRRC41_C, VILL, and MPZ_A;
- (iv) MAX.chr7.104624386-104624529, EMX2OS, DIDO1_B, and OBSCN_B; and
- (v) SFMBT2_B, SQSTM1, ZNF323_A, ZNF506, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, NDRG2, CYP11A1, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, MDFI_B, DLL4, GDF7_A, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, EMX2, MMP23B, EMX2OS, MAX.chr17.73073716-73073814, NBPf8, SEPT9_B, LOC440925_A, STX16_A, ITPKA, EEF1A2, FEV, LRRC41_C, and NFIC.

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) measuring a methylation level of a CpG site for one or more genes in a biological sample of a human individual through treating genomic DNA in the biological sample with bisulfite a reagent capable of modifying DNA in a methylation-specific manner (e.g., a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent);
- 2) amplifying the modified genomic DNA using a set of primers for the selected one or more genes; and

3) determining the methylation level of the CpG site by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, or bisulfite genomic sequencing PCR;

wherein the one or more genes is selected from one of the following groups:

- (i) EMX2OS, DIDO1_A, SBNO2, AMIGO3_A, PCOLCE, CLDN7, CYTH2, OBSCN_A, AHSA2, DLL4, EMX2, MAX.chr14.74100620-74100870, LRRC4, PPP2R5C_A, SQSTM1, MAX.chr17.73073716-73073814, CYP11A1, ACOXL_A, and AIM1_B;
- (ii) EMX2OS, and LRRC34;
- (iii) ZNF506, ZNF90, MAX.chr8.145103829-145103992, LRRC8D_A, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and VILL;
- (iv) TRH, MAX.chr7:104624386-104624529, EMX2OS, DIDO1_B, and ST3GAL2_B; and
- (v) SFMBT2_B, SMTN, ZNF506, ZNF90, CLDN7, LRRC41_B, CYP11A1, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, DLL4, MAX.chr10.22624479-22624553, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, EMX2OS, LRRC34, NBPF8, LOC440925_A, ITPKA, NFIC, and VILL.

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) measuring a methylation level of a CpG site for one or more genes in a biological sample of a human individual through treating genomic DNA in the biological sample with bisulfite a reagent capable of modifying DNA in a methylation-specific manner (e.g., a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent);
- 2) amplifying the modified genomic DNA using a set of primers for the selected one or more genes; and
- 3) determining the methylation level of the CpG site by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, or bisulfite genomic sequencing PCR;

wherein the one or more genes is selected from one of the following groups:

- (i) EMX2OS, KANK1, C1orf70_B, AMIGO3_A, DIDO1_A, LRRC41_C, NFIC, FKBP11_A, C17orf107_A, SMTN, LRRC41_B, LRRC8D_A, OBSCN_A, MAX.chr7.104624356-104624730, MIAT_B;
- (ii) MAX.chr7.104624356-104624730, EMX2OS, and LRRC41_C;
- (iii) MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, EMX2OS, LRRC41_C, and VILL;
- (iv) EMX2OS, and LRRC41_D; and
- (v) SFMBT2_B, SMTN, SQSTM1, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, CYP11A1, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, GDGF6, DLL4, PYCARD, BMP4_B, JSRP1_A, MIAT_B, KANK1, EMX2OS, NBPF8, LOC440925_A, ITPKA, EEF1A2, FEV, LRRC41_C, NFIC, VILL, MPZ_A.

In some embodiments of the technology, methods are provided that comprise the following steps:

- 1) measuring a methylation level of a CpG site for one or more genes in a biological sample of a human individual through treating genomic DNA in the biological sample with bisulfite a reagent capable of modifying DNA in a methylation-specific manner (e.g., a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent);
- 2) amplifying the modified genomic DNA using a set of primers for the selected one or more genes; and
- 3) determining the methylation level of the CpG site by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, or bisulfite genomic sequencing PCR;

wherein the one or more genes is selected from one of the following groups:

- (i) MAX.chr10.130339363-130339534, SFMBT2_C, CYTH2, SLC6A3, VILL, EMX2OS, MAX.chr10.22624479-22624553, GDF6, ZNF90, ZNF506, JSRP1_A, c5orf52, SFMBT2_B, NBPF8, RHBDL1_A, DIDO1_A, KANK1, and GATA2_B;

- (ii) MAX.chr8.145103829-145103992, CYTH2, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, SBNO2, NBPF8, and VILL;
- (iii) SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, MAX.chr8.145104263-145104422, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and MPZ_A;
- (iv) SFMBT2_B, SMTN, SQSTM1, ZNF506, ZNF90, CLDN7, LRRC41_B, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, DLL4, MAX.chr10.22624479-22624553, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, KANK1, SBNO2, c5orf52, EMX2O6, LRRC34, NBPF8, LOC440925_A, ITPKA, NFIC, VILL, and MPZ_A;
- (v) TSPYL5, TRH, JAM3, FAM19A5, PTGDR, SFMBT2_E, JSRP1_B, and ARL5C;
- (vi) TSPYL5, MPZ_B, TRH, CNTN4, FAM19A5, GLT1D1, RYR2_F, PTGDR, EMX2OS, MAX.chr10:22624470-22624553, SPDYA_B, SFMBT2_E, and JSRP1_B; and
- (vii) TSPYL5, MPZ_B, TRH, and PTGDR.

Preferably, the sensitivity for such methods is from about 70% to about 100%, or from about 80% to about 90%, or from about 80% to about 85%. Preferably, the specificity is from about 70% to about 100%, or from about 80% to about 90%, or from about 80% to about 85%.

Genomic DNA may be isolated by any means, including the use of commercially available kits. Briefly, wherein the DNA of interest is encapsulated in by a cellular membrane the biological sample must be disrupted and lysed by enzymatic, chemical or mechanical means. The DNA solution may then be cleared of proteins and other contaminants, e.g., by digestion with proteinase K. The genomic DNA is then recovered from the solution. This may be carried out by means of a variety of methods including salting out, organic extraction, or binding of the DNA to a solid phase support. The choice of method will be affected by several factors including time, expense, and required quantity of DNA. All clinical sample types comprising neoplastic matter or pre-neoplastic matter are suitable for use in the present

method, e.g., cell lines, histological slides, biopsies, paraffin-embedded tissue, body fluids, stool, breast tissue, endometrial tissue, leukocytes, colonic effluent, urine, blood plasma, blood serum, whole blood, isolated blood cells, cells isolated from the blood, and combinations thereof.

The technology is not limited in the methods used to prepare the samples and provide a nucleic acid for testing. For example, in some embodiments, a DNA is isolated from a stool sample or from blood or from a plasma sample using direct gene capture, e.g., as detailed in U.S. Pat. Appl. Ser. No. 61/485386 or by a related method.

The genomic DNA sample is then treated with at least one reagent, or series of reagents, that distinguishes between methylated and non-methylated CpG dinucleotides within at least one marker comprising a DMR (e.g., DMR 1–499 e.g., as provided by Tables 1, 8 and 21).

In some embodiments, the reagent converts cytosine bases which are unmethylated at the 5'-position to uracil, thymine, or another base which is dissimilar to cytosine in terms of hybridization behavior. However in some embodiments, the reagent may be a methylation sensitive restriction enzyme.

In some embodiments, the genomic DNA sample is treated in such a manner that cytosine bases that are unmethylated at the 5' position are converted to uracil, thymine, or another base that is dissimilar to cytosine in terms of hybridization behavior. In some embodiments, this treatment is carried out with bisulfite (hydrogen sulfite, disulfite) followed by alkaline hydrolysis.

The treated nucleic acid is then analyzed to determine the methylation state of the target gene sequences (at least one gene, genomic sequence, or nucleotide from a marker comprising a DMR, e.g., at least one DMR chosen from DMR 1–499, e.g., as provided in Tables 1, 8 and 21). The method of analysis may be selected from those known in the art, including those listed herein, e.g., QuARTS and MSP as described herein.

Aberrant methylation, more specifically hypermethylation of a marker comprising a DMR (e.g., DMR 1–499, e.g., as provided by Tables 1, 8 and 21) is associated with EC and/or a type of EC (e.g., clear cell EC, carcinosarcoma EC, endometrioid EC, serous EC).

The technology relates to the analysis of any sample associated with an EC. For example, in some embodiments the sample comprises a tissue and/or biological fluid obtained from a patient. In some embodiments, the sample comprises a secretion. In some embodiments, the sample comprises blood, serum, plasma, gastric secretions, pancreatic

juice, a gastrointestinal biopsy sample, microdissected cells from a breast biopsy, and/or cells recovered from stool. In some embodiments, the sample comprises endometrial tissue. In some embodiments, the subject is human. The sample may include cells, secretions, or tissues from the endometrium, breast, liver, bile ducts, pancreas, stomach, colon, rectum, esophagus, small intestine, appendix, duodenum, polyps, gall bladder, anus, and/or peritoneum. In some embodiments, the sample comprises cellular fluid, ascites, urine, feces, pancreatic fluid, fluid obtained during endoscopy, blood, mucus, or saliva. In some embodiments, the sample is a stool sample. In some embodiments, the sample is an endometrial tissue sample.

Such samples can be obtained by any number of means known in the art, such as will be apparent to the skilled person. For instance, urine and fecal samples are easily attainable, while blood, ascites, serum, or pancreatic fluid samples can be obtained parenterally by using a needle and syringe, for instance. Cell free or substantially cell free samples can be obtained by subjecting the sample to various techniques known to those of skill in the art which include, but are not limited to, centrifugation and filtration. Although it is generally preferred that no invasive techniques are used to obtain the sample, it still may be preferable to obtain samples such as tissue homogenates, tissue sections, and biopsy specimens

In some embodiments, the technology relates to a method for treating a patient (e.g., a patient with EC, with early stage EC, or who may develop EC) (e.g., a patient with one or more clear cell EC, carcinosarcoma EC, endometrioid EC, serous EC), the method comprising determining the methylation state of one or more DMR as provided herein and administering a treatment to the patient based on the results of determining the methylation state. The treatment may be administration of a pharmaceutical compound, a vaccine, performing a surgery, imaging the patient, performing another test. Preferably, said use is in a method of clinical screening, a method of prognosis assessment, a method of monitoring the results of therapy, a method to identify patients most likely to respond to a particular therapeutic treatment, a method of imaging a patient or subject, and a method for drug screening and development.

In some embodiments of the technology, a method for diagnosing an EC in a subject is provided. The terms “diagnosing” and “diagnosis” as used herein refer to methods by which the skilled artisan can estimate and even determine whether or not a subject is suffering from a given disease or condition or may develop a given disease or condition in the future. The skilled artisan often makes a diagnosis on the basis of one or more diagnostic

indicators, such as for example a biomarker (e.g., a DMR as disclosed herein), the methylation state of which is indicative of the presence, severity, or absence of the condition.

Along with diagnosis, clinical cancer prognosis relates to determining the aggressiveness of the cancer and the likelihood of tumor recurrence to plan the most effective therapy. If a more accurate prognosis can be made or even a potential risk for developing the cancer can be assessed, appropriate therapy, and in some instances less severe therapy for the patient can be chosen. Assessment (e.g., determining methylation state) of cancer biomarkers is useful to separate subjects with good prognosis and/or low risk of developing cancer who will need no therapy or limited therapy from those more likely to develop cancer or suffer a recurrence of cancer who might benefit from more intensive treatments.

As such, “making a diagnosis” or “diagnosing”, as used herein, is further inclusive of determining a risk of developing cancer or determining a prognosis, which can provide for predicting a clinical outcome (with or without medical treatment), selecting an appropriate treatment (or whether treatment would be effective), or monitoring a current treatment and potentially changing the treatment, based on the measure of the diagnostic biomarkers (e.g., DMR) disclosed herein. Further, in some embodiments of the presently disclosed subject matter, multiple determination of the biomarkers over time can be made to facilitate diagnosis and/or prognosis. A temporal change in the biomarker can be used to predict a clinical outcome, monitor the progression of EC, and/or monitor the efficacy of appropriate therapies directed against the cancer. In such an embodiment for example, one might expect to see a change in the methylation state of one or more biomarkers (e.g., DMR) disclosed herein (and potentially one or more additional biomarker(s), if monitored) in a biological sample over time during the course of an effective therapy.

The presently disclosed subject matter further provides in some embodiments a method for determining whether to initiate or continue prophylaxis or treatment of a cancer in a subject. In some embodiments, the method comprises providing a series of biological samples over a time period from the subject; analyzing the series of biological samples to determine a methylation state of at least one biomarker disclosed herein in each of the biological samples; and comparing any measurable change in the methylation states of one or more of the biomarkers in each of the biological samples. Any changes in the methylation states of biomarkers over the time period can be used to predict risk of developing cancer, predict clinical outcome, determine whether to initiate or continue the prophylaxis or therapy of the cancer, and whether a current therapy is effectively treating the cancer. For example, a

first time point can be selected prior to initiation of a treatment and a second time point can be selected at some time after initiation of the treatment. Methylation states can be measured in each of the samples taken from different time points and qualitative and/or quantitative differences noted. A change in the methylation states of the biomarker levels from the different samples can be correlated with EC risk, prognosis, determining treatment efficacy, and/or progression of the cancer in the subject.

In preferred embodiments, the methods and compositions of the invention are for treatment or diagnosis of disease at an early stage, for example, before symptoms of the disease appear. In some embodiments, the methods and compositions of the invention are for treatment or diagnosis of disease at a clinical stage.

As noted, in some embodiments, multiple determinations of one or more diagnostic or prognostic biomarkers can be made, and a temporal change in the marker can be used to determine a diagnosis or prognosis. For example, a diagnostic marker can be determined at an initial time, and again at a second time. In such embodiments, an increase in the marker from the initial time to the second time can be diagnostic of a particular type or severity of cancer, or a given prognosis. Likewise, a decrease in the marker from the initial time to the second time can be indicative of a particular type or severity of cancer, or a given prognosis. Furthermore, the degree of change of one or more markers can be related to the severity of the cancer and future adverse events. The skilled artisan will understand that, while in certain embodiments comparative measurements can be made of the same biomarker at multiple time points, one can also measure a given biomarker at one time point, and a second biomarker at a second time point, and a comparison of these markers can provide diagnostic information.

As used herein, the phrase “determining the prognosis” refers to methods by which the skilled artisan can predict the course or outcome of a condition in a subject. The term “prognosis” does not refer to the ability to predict the course or outcome of a condition with 100% accuracy, or even that a given course or outcome is predictably more or less likely to occur based on the methylation state of a biomarker (e.g., a DMR). Instead, the skilled artisan will understand that the term “prognosis” refers to an increased probability that a certain course or outcome will occur; that is, that a course or outcome is more likely to occur in a subject exhibiting a given condition, when compared to those individuals not exhibiting the condition. For example, in individuals not exhibiting the condition (e.g., having a normal methylation state of one or more DMR), the chance of a given outcome (e.g., suffering from an EC) may be very low.

In some embodiments, a statistical analysis associates a prognostic indicator with a predisposition to an adverse outcome. For example, in some embodiments, a methylation state different from that in a normal control sample obtained from a patient who does not have a cancer can signal that a subject is more likely to suffer from a cancer than subjects with a level that is more similar to the methylation state in the control sample, as determined by a level of statistical significance. Additionally, a change in methylation state from a baseline (e.g., “normal”) level can be reflective of subject prognosis, and the degree of change in methylation state can be related to the severity of adverse events. Statistical significance is often determined by comparing two or more populations and determining a confidence interval and/or a *p* value. See, e.g., Dowdy and Wearden, *Statistics for Research*, John Wiley & Sons, New York, 1983, incorporated herein by reference in its entirety. Exemplary confidence intervals of the present subject matter are 90%, 95%, 97.5%, 98%, 99%, 99.5%, 99.9% and 99.99%, while exemplary *p* values are 0.1, 0.05, 0.025, 0.02, 0.01, 0.005, 0.001, and 0.0001.

In other embodiments, a threshold degree of change in the methylation state of a prognostic or diagnostic biomarker disclosed herein (e.g., a DMR) can be established, and the degree of change in the methylation state of the biomarker in a biological sample is simply compared to the threshold degree of change in the methylation state. A preferred threshold change in the methylation state for biomarkers provided herein is about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 50%, about 75%, about 100%, and about 150%. In yet other embodiments, a “nomogram” can be established, by which a methylation state of a prognostic or diagnostic indicator (biomarker or combination of biomarkers) is directly related to an associated disposition towards a given outcome. The skilled artisan is acquainted with the use of such nomograms to relate two numeric values with the understanding that the uncertainty in this measurement is the same as the uncertainty in the marker concentration because individual sample measurements are referenced, not population averages.

In some embodiments, a control sample is analyzed concurrently with the biological sample, such that the results obtained from the biological sample can be compared to the results obtained from the control sample. Additionally, it is contemplated that standard curves can be provided, with which assay results for the biological sample may be compared. Such standard curves present methylation states of a biomarker as a function of assay units, e.g., fluorescent signal intensity, if a fluorescent label is used. Using samples taken from multiple

donors, standard curves can be provided for control methylation states of the one or more biomarkers in normal tissue, as well as for “at-risk” levels of the one or more biomarkers in tissue taken from donors with metaplasia or from donors with an EC. In certain embodiments of the method, a subject is identified as having metaplasia upon identifying an aberrant methylation state of one or more DMR provided herein in a biological sample obtained from the subject. In other embodiments of the method, the detection of an aberrant methylation state of one or more of such biomarkers in a biological sample obtained from the subject results in the subject being identified as having cancer.

The analysis of markers can be carried out separately or simultaneously with additional markers within one test sample. For example, several markers can be combined into one test for efficient processing of a multiple of samples and for potentially providing greater diagnostic and/or prognostic accuracy. In addition, one skilled in the art would recognize the value of testing multiple samples (for example, at successive time points) from the same subject. Such testing of serial samples can allow the identification of changes in marker methylation states over time. Changes in methylation state, as well as the absence of change in methylation state, can provide useful information about the disease status that includes, but is not limited to, identifying the approximate time from onset of the event, the presence and amount of salvageable tissue, the appropriateness of drug therapies, the effectiveness of various therapies, and identification of the subject's outcome, including risk of future events.

The analysis of biomarkers can be carried out in a variety of physical formats. For example, the use of microtiter plates or automation can be used to facilitate the processing of large numbers of test samples. Alternatively, single sample formats could be developed to facilitate immediate treatment and diagnosis in a timely fashion, for example, in ambulatory transport or emergency room settings.

In some embodiments, the subject is diagnosed as having an EC if, when compared to a control methylation state, there is a measurable difference in the methylation state of at least one biomarker in the sample. Conversely, when no change in methylation state is identified in the biological sample, the subject can be identified as not having EC, not being at risk for the cancer, or as having a low risk of the cancer. In this regard, subjects having the cancer or risk thereof can be differentiated from subjects having low to substantially no cancer or risk thereof. Those subjects having a risk of developing an EC can be placed on a more intensive and/or regular screening schedule, including endoscopic surveillance. On the other hand,

those subjects having low to substantially no risk may avoid being subjected to additional testing for EC (e.g., invasive procedure), until such time as a future screening, for example, a screening conducted in accordance with the present technology, indicates that a risk of EC has appeared in those subjects.

As mentioned above, depending on the embodiment of the method of the present technology, detecting a change in methylation state of the one or more biomarkers can be a qualitative determination or it can be a quantitative determination. As such, the step of diagnosing a subject as having, or at risk of developing, an EC indicates that certain threshold measurements are made, e.g., the methylation state of the one or more biomarkers in the biological sample varies from a predetermined control methylation state. In some embodiments of the method, the control methylation state is any detectable methylation state of the biomarker. In other embodiments of the method where a control sample is tested concurrently with the biological sample, the predetermined methylation state is the methylation state in the control sample. In other embodiments of the method, the predetermined methylation state is based upon and/or identified by a standard curve. In other embodiments of the method, the predetermined methylation state is a specifically state or range of state. As such, the predetermined methylation state can be chosen, within acceptable limits that will be apparent to those skilled in the art, based in part on the embodiment of the method being practiced and the desired specificity, etc.

Further with respect to diagnostic methods, a preferred subject is a vertebrate subject. A preferred vertebrate is warm-blooded; a preferred warm-blooded vertebrate is a mammal. A preferred mammal is most preferably a human. As used herein, the term “subject” includes both human and animal subjects. Thus, veterinary therapeutic uses are provided herein. As such, the present technology provides for the diagnosis of mammals such as humans, as well as those mammals of importance due to being endangered, such as Siberian tigers; of economic importance, such as animals raised on farms for consumption by humans; and/or animals of social importance to humans, such as animals kept as pets or in zoos. Examples of such animals include but are not limited to: carnivores such as cats and dogs; swine, including pigs, hogs, and wild boars; ruminants and/or ungulates such as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels; and horses. Thus, also provided is the diagnosis and treatment of livestock, including, but not limited to, domesticated swine, ruminants, ungulates, horses (including race horses), and the like.

The presently-disclosed subject matter further includes a system for diagnosing a EC and/or a specific form of EC (e.g., clear cell EC, carcinosarcoma EC, endometrioid EC, serous EC) in a subject. The system can be provided, for example, as a commercial kit that can be used to screen for a risk of an EC or diagnose an EC cancer in a subject from whom a biological sample has been collected. An exemplary system provided in accordance with the present technology includes assessing the methylation state of a DMR as provided in Tables 1, 8 and 21.

EXAMPLES

Example I.

This example describes the discovery and validation of novel DNA methylation markers for the detection of endometrial cancer (EC) and histological subtypes of EC (e.g., serous EC, clear cell EC, carcinosarcoma EC, and endometrioid EC) through methylome-wide analysis selection.

A proprietary methodology of sample preparation, sequencing, analyses pipelines, and filters were utilized to identify and narrow differentially methylated regions (DMRs) to those which would pinpoint EC and various histological subtypes of EC (e.g., serous EC, clear cell EC, carcinosarcoma EC, and endometrioid EC) and excel in a clinical testing environment.

From the tissue to tissue analysis 318 hypermethylated EC DMRs were identified (Table 1). Table 2 shows the area-under-the-curve and fold-change in comparison to EC controls for the markers recited in Table 1.

Table 1. Identified methylated regions distinguishing endometrial cancer tissue from normal endometrial tissue.

DMR No.	Gene Annotation	Chromosome No.	Region on Chromosome (starting base-ending base)
1	ACCN1	17	31619687-31619729
2	ACOXL_A	2	111875367-111875453
3	ADAL_A	15	43622287-43622368
4	ADAL_B	15	43622411-43622462
5	ADAL_C	15	43622604-43622732
6	AES	19	3061334-3061694
7	AFF3	2	100721707-100721817
8	AGBL2	11	47736766-47736965

9	AGRN_A	1	975957-976051
10	AHSA2	2	61405232-61405286
11	AIM1_A	6	106960032-106960380
12	AIM1_B	6	106960531-106960593
13	AMIGO3_A	3	49756685-49756736
14	AMIGO3_B	3	49757071-49757168
15	ANKAR	2	190539103-190539193
16	ANKRD33B	5	10563557-10563627
17	ANO8	19	17439445-17439539
18	ARHGAP20_A	11	110582609-110582670
19	ARHGAP20_B	11	110583216-110583345
20	ARL10	5	175792690-175792780
21	ARMC4	10	28287932-28287982
22	ATP10A	15	26108587-26108685
23	BCAT1	12	25102116-25102197
24	BCL6	3	187456434-187456528
25	BMP4_A	14	54421048-54421118
26	BMP4_B	14	54421619-54421918
27	C14orf169	14	73957777-73957867
28	C17orf107_A	17	4802544-4802828
29	C18orf18_A	18	5237508-5237617
30	C18orf18_B	18	5237862-5237960
31	C18orf18_C	18	5238088-5238139
32	C1orf103	1	111506798-111506903
33	C1orf177	1	55266904-55266944
34	C1orf70_A	1	1475622-1475650
35	C1orf70_B	1	1475957-1476127
36	C1QL3	10	16563604-16563702
37	C21orf58	21	47743021-47743081
38	C2orf43	2	21022503-21022588
39	C2orf62	2	219232460-219232543
40	C5orf52	5	157098189-157098379
41	C7orf51	7	100091227-100091353
42	C8orf73_A	8	144650834-144650918
43	CABP7	22	30116807-30116866
44	CACNA1A	19	13318767-13318855
45	CCDC102A	16	57571055-57571105
46	CCDC48	3	128720910-128720950
47	CCDC85B	11	65658914-65658969
48	CCND2_A	12	4380216-4380297
49	CCND2_B	12	4384302-4384354
50	CCNI2	5	132082878-132082968
51	CD14	5	140012292-140012386
52	CELSR3	3	48693776-48694065

53	CES4A	16	67034701-67034744
54	CHMP2A	19	59066468-59066653
55	CLDN7	17	7164898-7164949
56	CLIP4	2	29338393-29338448
57	CYP11A1	15	74658391-74658452
58	CYP2R1	11	14912680-14912762
59	CYTH2	19	48984043-48984140
60	DAB2IP_A	9	124461305-124461390
61	DAB2IP_B	9	124461600-124461696
62	DEM1	1	40974518-40974785
63	DIDO1_A	20	61560557-61560728
64	DLEC1_A	3	38080673-38080754
65	DLEC1_B	3	38080864-38081010
66	DLEC1_C	3	38081058-38081100
67	DLL4	15	41218290-41218501
68	DNAJC6	1	65731433-65731660
69	DPP7	9	140008731-140008820
70	DSCAML1	11	117667818-117667979
71	DSEL	18	65184250-65184305
72	DTX1	12	113494626-113494665
73	DTX3L	3	122283010-122283080
74	EDARADD	1	236558654-236558751
75	EEF1A2	20	62119741-62119795
76	EGR2	10	64574899-64574948
77	EME2	16	1821271-1821566
78	EMILIN2_A	18	2906050-2906082
79	EMILIN2_B	18	2906258-2906313
80	EMX2	10	119297161-119297228
81	EMX2OS	10	119294950-119295039
82	EPN3	17	48619601-48619768
83	FAM109B	22	42470299-42470599
84	FAM89A	1	231175193-231175307
85	FER1L4_A	20	34189084-34189184
86	FER1L4_B	20	34189488-34189566
87	FEV	2	219849013-219849064
88	FKBP11_A	12	49318865-49319221
89	FLJ22184	19	7933862-7934065
90	FLJ22536	6	21666442-21666683
91	FLJ42875	1	2985432-2985534
92	FLJ43390	14	62584120-62584204
93	FLOT1	6	30711556-30711726
94	FUT11	10	75532571-75532762
95	GABBR2_A	9	101471226-101471281
96	GABBR2_B	9	101471435-101471481

97	GABBR2_C	9	101471498-101471518
98	GALR3	22	38214828-38214926
99	GATA2_A	3	128211202-128211292
100	GATA2_B	3	128216370-128216468
101	GBGT1	9	136039231-136039283
102	GDF6	8	97157670-97157756
103	GDF7_A	2	20866007-20866400
104	GHITM	10	85899387-85899545
105	GNB2	7	100273805-100273883
106	GNE	9	36258402-36258585
107	GPR135	14	59931440-59931647
108	GPX1_A	3	49394997-49395054
109	GPX1_B	3	49395134-49395366
110	GRASP	12	52400510-52400570
111	GSTM4	1	110198575-110198883
112	HLA-A	6	29910301-29910371
113	HNRNPF	10	43892386-43892538
114	HOPX_A	4	57521826-57521992
115	HOXB2	17	46621333-46621372
116	HOXC8	12	54403025-54403114
117	HS3ST3B1_A	17	14202739-14202781
118	HS3ST3B1_B	17	14203182-14203258
119	IL12RB2	1	67773620-67773674
120	IL13	5	131992171-131992245
121	ITGA4_A	2	182322199-182322409
122	ITGB2	21	46352018-46352116
123	ITPKB	1	226925140-226925336
124	JSRP1_A	19	2253201-2253345
125	JUN	1	59247951-59248035
126	KANK1	9	706956-707230
127	KBTBD11_A	8	1949493-1949584
128	KCNA3	1	111217656-111217716
129	KCNK17	6	39281347-39281518
130	KCNK9	8	140716494-140716600
131	KCNQ5	6	73331959-73332019
132	KCTD15_A	19	34288324-34288423
133	KCTD15_B	19	34288611-34288741
134	KLHL21	1	6663497-6663683
135	KREMEN1	22	29467629-29467716
136	KRT86	12	52702379-52702559
137	LHFPL2_A	5	77806193-77806291
138	LOC100192379_A	4	122686333-122686376
139	LOC100507463	6	32811543-32811624
140	LOC157627_A	8	9763927-9763997

141	LOC157627_B	8	9764220-9764309
142	LOC338799	12	122243001-122243268
143	LOC402778	11	1770349-1770441
144	LOC729678	5	180258409-180258505
145	LRRC32	11	76381971-76382070
146	LRRC34	3	169530340-169530527
147	LRRC41_A	1	46767677-46767761
148	LRRC41_B	1	46767939-46768016
149	LRRC41_C	1	46768188-46768283
150	LRRC41_D	1	46768830-46768913
151	LRRC41_E	1	46769340-46769650
152	LRRC8D_A	1	90308856-90308955
153	LRRK2	12	40618745-40618814
154	LRRN1	3	3841364-3841692
155	MACROD1	11	63767975-63768042
156	MAST1	19	12978432-12978558
157	MATK	19	3786252-3786339
158	MAX.chr1.110627072-110627257	1	110627072-110627257
159	MAX.chr1.111098121-111098213	1	111098121-111098213
160	MAX.chr1.116710856-116710945	1	116710856-116710945
161	MAX.chr1.148000592-148000777	1	148000592-148000777
162	NBPF8	1	148247951-148248032
163	MAX.chr1.61519712-61519821	1	61519712-61519821
164	MAX.chr10.102497246-102497372	10	102497246-102497372
165	MAX.chr10.130339363-130339534	10	130339363-130339534
166	MAX.chr10.22541502-22541587	10	22541502-22541587
167	MAX.chr10.22624479-22624553	10	22624479-22624553
168	MAX.chr11.123301058-123301153	11	123301058-123301153
169	MAX.chr11.8040594-8040647	11	8040594-8040647
170	MAX.chr12.125534393-125534458	12	125534393-125534458
171	MAX.chr12.133485161-133485240	12	133485161-133485240
172	MAX.chr12.133485417-133485505	12	133485417-133485505
173	MAX.chr12.133485542-133485675	12	133485542-133485675
174	MAX.chr14.103021656-103021718	14	103021656-103021718
175	MAX.chr14.103557994-103558154	14	103557994-103558154

176	MAX.chr14.103558061-103558154	14	103558061-103558154
177	MAX.chr14.74100620-74100870	14	74100620-74100870
178	MAX.chr17.29335358-29335628	17	29335358-29335628
179	MAX.chr17.46089738-46089851	17	46089738-46089851
180	MAX.chr17.73073716-73073814	17	73073716-73073814
181	MAX.chr19.31210519-31210593	19	31210519-31210593
182	MAX.chr19.37288607-37288752	19	37288607-37288752
183	MAX.chr2.102867766-102867826	2	102867766-102867826
184	MAX.chr2.127783244-127783311	2	127783244-127783311
185	MAX.chr2.233283604-233283736	2	233283604-233283736
186	MAX.chr2.43038072-43038159	2	43038072-43038159
187	MAX.chr2.96192422-96192520	2	96192422-96192520
188	MAX.chr2.96192422-96192610	2	96192422-96192610
189	MAX.chr20.37302903-37302984	20	37302903-37302984
190	MAX.chr21.30375011-30375136	21	30375011-30375136
191	MAX.chr21.38936278-38936494	21	38936278-38936494
192	MAX.chr22.42679801-42679979	22	42679801-42679979
193	MAX.chr3.128336893-128336988	3	128336893-128336988
194	MAX.chr3.18486889-18486958	3	18486889-18486958
195	MAX.chr3.44038012-44038064	3	44038012-44038064
196	MAX.chr4.186049532-186049660	4	186049532-186049660
197	MAX.chr5.177371520-177371612	5	177371520-177371612
198	MAX.chr5.42950901-42951088	5	42950901-42951088
199	MAX.chr5.64398959-64399179	5	64398959-64399179
200	MAX.chr6.130687108-130687268	6	130687108-130687268
201	MAX.chr6.26171901-26172479	6	26171901-26172479
202	MAX.chr6.26172225-26172432	6	26172225-26172432
203	MAX.chr6.30923280-30923382	6	30923280-30923382
204	MAX.chr7.104624356-104624730	7	104624356-104624730

205	MAX.chr8.142216090-142216173	8	142216090-142216173
206	MAX.chr8.143532758-143532822	8	143532758-143532822
207	MAX.chr8.145103829-145103992	8	145103829-145103992
208	MAX.chr8.145104263-145104422	8	145104263-145104422
209	MAZ	16	29818932-29819149
210	MBLAC1	7	99725558-99725690
211	MDFI_A	6	41606074-41606165
212	MDFI_B	6	41606379-41606439
213	MFSD2B	2	24232924-24233011
214	MIAT_A	22	27053316-27053559
215	MIAT_B	22	27068733-27069240
216	MIDN	19	1252654-1252814
217	MIR155HG	21	26934273-26934466
218	MMP23B	1	1567450-1567633
219	MRPS21	1	150266158-150266227
220	MRPS33	7	140714767-140714925
221	MYOZ3	5	150036505-150036584
222	N4BP2L1_A	13	33001508-33001672
223	N4BP2L1_B	13	33001696-33001851
224	NCKIPSD	3	48723553-48723614
225	NCRNA00085	19	52207418-52207571
226	NDRG2	14	21493523-21494033
227	NEAT1_A	11	65189991-65190140
228	NEAT1_B	11	65190826-65190987
229	NEK9	14	75593252-75593340
230	NFIC	19	3361080-3361200
231	NR1I2	3	119528931-119529062
232	NTRK3_A	15	88799070-88799125
233	NTRK3_B	15	88799973-88800085
234	OBSCN_A	1	228463593-228463692
235	OLFM1	9	137979377-137979461
236	PALLD_A	4	169753101-169753185
237	PALLD_B	4	169753319-169753406
238	PCOLCE	7	100202395-100202728
239	PDGFRA	4	55092628-55092682
240	PHLDB1_A	11	118481753-118481830
241	PISD	22	32026307-32026516
242	PODN	1	53528224-53528302
243	PPP2R5C_A	14	102247689-102247929
244	PPP2R5C_B	14	102248127-102248216
245	PTCH2	1	45285985-45286035
246	PTPRN2	7	157361644-157361762

247	PXMP4	20	32307913-32308002
248	PYCARD	16	31213623-31213709
249	RAI1	17	17627101-17627256
250	RBM20	10	112432331-112432394
251	RFTN1	3	16554709-16554808
252	RHBDL1_A	16	725291-725617
253	RIMS2	8	104512743-104512831
254	RLTPR	16	67678899-67678952
255	RTN4RL2	11	57244132-57244225
256	SBNO2	19	1131812-1132072
257	SEPT11	4	77869938-77870029
258	SEPT9_A	17	75447455-75447554
259	SEPT9_B	17	75447656-75448049
260	SERPINB9	6	2903415-2903513
261	SFMBT2_A	10	7450743-7450831
262	SFMBT2_B	10	7451000-7451098
263	SFMBT2_C	10	7451771-7451869
264	SFMBT2_D	10	7452346-7452367
265	SIGIRR	11	407086-407183
266	SIX4	14	61188239-61188329
267	SLC12A8	3	124860700-124860798
268	SLC13A5_A	17	6616764-6616852
269	SLC43A3	11	57194548-57194650
270	SLC6A3	5	1445562-1445659
271	SLC8A3	14	70654774-70654899
272	SLCO4C1	5	101632152-101632237
273	SMTN	22	31481122-31481208
274	SNTG2	2	946417-946458
275	SPOCK2_A	10	73847389-73847446
276	SPOCK2_B	10	73847890-73848209
277	SPON1	11	13985007-13985088
278	SQSTM1	5	179243864-179243955
279	ST3GAL2_A	16	70415734-70415777
280	SV2A	1	149889374-149889466
281	TBX1	22	19754292-19754349
282	TCF3	19	1651268-1651408
283	TECR	19	14667597-14667690
284	TEPP	16	58018744-58018831
285	TFR2	7	100230996-100231069
286	THAP4	2	242549705-242549757
287	TICAM2	5	114937802-114937980
288	TMCO1_A	1	165737880-165737973
289	TMCO1_B	1	165738121-165738246
290	TMEM130	7	98467740-98467817

291	TMEM163	2	135475828-135475890
292	TMEM63B	6	44119717-44119780
293	TNFRSF10D	8	23021299-23021396
294	TRIM71_A	3	32859463-32859793
295	TSHZ3_A	19	31839967-31840038
296	TSHZ3_B	19	31840244-31840330
297	TSHZ3_C	19	31841427-31841476
298	TSPAN2	1	115632183-115632276
299	TTBK1	6	43242971-43243178
300	TTC14	3	180320089-180320177
301	UST_A	6	149068948-149069040
302	VILL	3	38035645-38035743
303	WNT1	12	49373374-49373532
304	WNT7B	22	46366771-46366866
305	ZMIZ1_A	10	81002372-81002568
306	ZMIZ1_B	10	81002818-81003006
307	ZMIZ1_C	10	81002928-81002991
308	ZNF167	3	44596832-44596885
309	ZNF292	6	87861730-87861807
310	ZNF302	19	35168826-35168915
311	ZNF304	19	57862463-57862983
312	ZNF323_A	6	28303870-28304162
313	ZNF354C	5	178487210-178487466
314	ZNF506	19	19932386-19932525
315	ZNF568_A	19	37407197-37407284
316	ZNF586_B	19	58281309-58281368
317	ZNF880	19	52873064-52873107
318	ZNF90	19	20189032-20189134

Table 2. Area-under-the-curve, fold-change, and p-value for EC tissue in comparison to EC controls for the markers recited in Table 1.

DMR No.	Gene Annotation	AUC EC vs. EC control	Fold Change EC vs. EC control	p value EC vs. EC control
1	ACCN1	0.6618	21.88	0.0005565
2	ACOXL_A	0.8597	50.89	0.007356
3	ADAL_A	0.6656	110	0.006193
4	ADAL_B	0.6627	21.39	0.0005691
5	ADAL_C	0.7773	47.72	0.0001428
6	AES	0.6948	83.12	4.00E-08
7	AFF3	0.9188	31.72	2.95E-09

8	AGBL2	0.6667	375.3	3.74E-05
9	AGRN_A	0.863	597.6	1.36E-05
10	AHSA2	0.8978	59.27	0.001032
11	AIM1_A	0.9408	369.2	5.34E-06
12	AIM1_B	0.7828	21.43	0.0003948
13	AMIGO3_A	0.9306	40	0.00008386
14	AMIGO3_B	0.6818	101.4	0.003578
15	ANKAR	0.703	99.07	0.001126
16	ANKRD33B	0.6869	143	3.54E-05
17	ANO8	0.765	5.712	0.001607
18	ARHGAP20_A	0.6516	33.86	0.000001454
19	ARHGAP20_B	0.7344	23.35	0.0004238
20	ARL10	0.8325	255.7	1.05E-07
21	ARMC4	0.7164	17.89	0.005436
22	ATP10A	0.7597	66.21	0.0002969
23	BCAT1	0.8932	47.95	1.49E-07
24	BCL6	0.7222	30.29	0.002576
25	BMP4_A	0.6585	21.31	0.0003743
26	BMP4_B	0.9408	33.04	1.179E-08
27	C14orf169	0.6655	90.03	0.00124
28	C17orf107_A	0.907	93.14	6.96E-12
29	C18orf18_A	0.75	15.49	2.14E-05
30	C18orf18_B	0.7507	66.92	0.00001497
31	C18orf18_C	0.8582	107	0.00003015
32	C1orf103	0.6555	15.58	4.442E-08
33	C1orf177	0.6508	506.2	0.001782
34	C1orf70_A	0.7483	97.16	2.41E-07
35	C1orf70_B	0.9134	252.1	1.56E-07
36	C1QL3	0.852	43.14	1.45E-07
37	C21orf58	0.7227	23.94	9.62E-05
38	C2orf43	0.677	7.064	0.0004705
39	C2orf62	0.8221	41.27	2.974E-07
40	C5orf52	0.9047	165.5	1.655E-07
41	C7orf51	0.8093	29.63	0.0001685
42	C8orf73_A	0.8768	48.29	7.25E-07
43	CABP7	0.821	490	0.003538
44	CACNA1A	0.745	32.19	5.80E-05
45	CCDC102A	0.7417	13.76	8.518E-10
46	CCDC48	0.6835	20.97	0.003088
47	CCDC85B	0.6688	17.2	0.0002735
48	CCND2_A	0.7801	12.08	7.18E-06
49	CCND2_B	0.6608	9.469	8.33E-06
50	CCNI2	0.6574	16.09	0.0006968
51	CD14	0.6903	458.2	0.003672

52	CELSR3	0.8034	33.68	0.00002479
53	CES4A	0.6623	22.78	0.0006918
54	CHMP2A	0.7432	123.8	0.001936
55	CLDN7	0.913	61.86	0.005037
56	CLIP4	0.6758	72.6	0.004004
57	CYP11A1	0.8646	60.77	0.001696
58	CYP2R1	0.6638	61.08	6.43E-05
59	CYTH2	0.8351	10.35	0.00007307
60	DAB2IP_A	0.7647	287.3	0.0005537
61	DAB2IP_B	0.7273	48.72	3.44E-05
62	DEM1	0.7546	307.8	0.003765
63	DIDO1_A	0.9809	238.3	5.6E-12
64	DLEC1_A	0.6568	34.04	7.97E-06
65	DLEC1_B	0.7992	99.03	3.00E-05
66	DLEC1_C	0.6941	551.8	2.79E-05
67	DLL4	0.8963	16.68	0.0001774
68	DNAJC6	0.8065	70.75	7.229E-07
69	DPP7	0.8643	97.69	2.89E-05
70	DSCAML1	0.6913	37.53	1.26E-06
71	DSEL	0.6707	45.39	0.001035
72	DTX1	0.7321	865.9	0.001687
73	DTX3L	0.6583	152.6	4.39E-05
74	EDARADD	0.7337	236.2	0.005977
75	EEF1A2	0.9532	67.76	0.000003221
76	EGR2	0.7083	25.5	0.000008596
77	EME2	0.6861	139.5	0.00005428
78	EMILIN2_A	0.7266	265	8.81E-05
79	EMILIN2_B	0.6722	102.4	5.74E-07
80	EMX2	0.6606	160.6	6.34E-05
81	EMX2OS	0.9709	235.4	1.486E-07
82	EPN3	0.6991	47.75	0.0005864
83	FAM109B	0.8416	56.4	0.000003558
84	FAM89A	0.7633	119.1	0.005136
85	FER1L4_A	0.8381	115.3	1.34E-06
86	FER1L4_B	0.8457	418.6	0.0001132
87	FEV	0.9004	14.43	1.075E-09
88	FKBP11_A	0.9091	721.9	0.001236
89	FLJ22184	0.7844	53.15	8.099E-08
90	FLJ22536	0.7792	49.09	6.41E-05
91	FLJ42875	0.6562	64.58	0.000001282
92	FLJ43390	0.6647	13.09	0.001351
93	FLOT1	0.7566	34.14	1.308E-08
94	FUT11	0.6861	1144	0.004405
95	GABBR2_A	0.7711	58.41	0.00001818

96	GABBR2_B	0.7276	24.2	0.0001021
97	GABBR2_C	0.6635	30.79	0.0000827
98	GALR3	0.8157	169.5	0.009018
99	GATA2_A	0.7206	6.751	0.0006726
100	GATA2_B	0.888	24.4	9.709E-09
101	GBGT1	0.6765	32.52	0.001294
102	GDF6	0.929	38.04	7.975E-07
103	GDF7_A	0.9133	53.71	2.737E-08
104	GHITM	0.6536	76.28	0.0037
105	GNB2	0.7125	93.16	1.05E-05
106	GNE	0.7	360.7	0.001421
107	GPR135	0.6529	106.8	8.52E-05
108	GPX1_A	0.7786	61.03	1.89E-06
109	GPX1_B	0.7716	42.37	0.0008024
110	GRASP	0.7014	53.88	0.004852
111	GSTM4	0.6722	73.93	0.001751
112	HLA-A	0.6709	123	0.003296
113	HNRNPF	0.8736	533.7	0.007898
114	HOPX	0.6616	33.21	0.000002593
115	HOXB2	0.7143	45.08	0.000256
116	HOXC8	0.6599	21.32	0.000192
117	HS3ST3B1_A	0.7727	7.377	0.0005749
118	HS3ST3B1_B	0.8182	12.17	2.44E-06
119	IL12RB2	0.701	445.5	0.005105
120	IL13	0.8421	85.78	0.009485
121	ITGA4	0.6935	53.03	0.00001091
122	ITGB2	0.7078	9.851	0.000122
123	ITPKB	0.8362	105.4	1.38E-05
124	JSRP1_A	0.907	72.11	5.16E-10
125	JUN	0.6875	59.16	0.000889
126	KANK1	0.8884	135.4	0.000001051
127	KBTBD11_A	0.8143	278.1	0.0001492
128	KCNA3	0.7775	45.7	0.000001416
129	KCNK17	0.7758	21.29	5.81E-06
130	KCNK9	0.8312	54.29	0.00002916
131	KCNQ5	0.7401	17.31	0.0006638
132	KCTD15_A	0.9266	27.56	0.002706
133	KCTD15_B	0.87	64.21	0.0003926
134	KLHL21	0.9277	115.9	0.0003778
135	KREMEN1	0.7411	49.03	0.0005224
136	KRT86	0.6819	47.5	0.002128
137	LHFPL2_A	0.8115	928.7	0.001375
138	LOC100192379_A	0.6905	41.04	0.00005452

139	LOC100507463	0.6883	24.82	6.97E-05
140	LOC157627_A	0.6999	22.5	0.00001095
141	LOC157627_B	0.7064	25.83	0.001724
142	LOC338799	0.6984	108.8	0.001105
143	LOC402778	0.7145	79.33	0.0002123
144	LOC729678	0.7667	113.4	0.00001356
145	LRRC32	0.7805	10.73	1.389E-07
146	LRRC34	0.7909	155.5	0.00003603
147	LRRC41_A	0.7716	29.68	3.37E-09
148	LRRC41_B	0.7955	237	6.97E-07
149	LRRC41_C	0.789	69.55	3.11E-08
150	LRRC41_D	0.7677	133.1	4.95E-06
151	LRRC41_E	0.7316	479.6	5.30E-05
152	LRRC8D_A	0.9026	27.37	9.12E-05
153	LRRK2	0.7284	53.89	0.005952
154	LRRN1	0.7202	14.85	0.00000822
155	MACROD1	0.7012	200.4	0.0003994
156	MAST1	0.7232	50.03	0.00318
157	MATK	0.6571	21.21	0.00007402
158	MAX.chr1.110627 072-110627257	0.8366	36.7	1.23E-07
159	MAX.chr1.111098 121-111098213	0.7737	166	0.004094
160	MAX.chr1.116710 856-116710945	0.8219	22.41	0.0000407
161	MAX.chr1.148000 592-148000777	0.7051	77.72	0.00004245
162	NBPF8	0.9697	53.41	1.606E-08
163	MAX.chr1.615197 12-61519821	0.7167	43.36	2.02E-08
164	MAX.chr10.10249 7246-102497372	0.7528	18.98	1.14E-05
165	MAX.chr10.13033 9363-130339534	0.9709	29.28	0.000001534
166	MAX.chr10.22541 502-22541587	0.6588	11.22	0.001261
167	MAX.chr10.22624 479-22624553	0.9172	62.87	1.417E-10
168	MAX.chr11.12330 1058-123301153	0.6975	28.22	4.74E-06
169	MAX.chr11.80405 94-8040647	0.8311	40.67	0.00003799
170	MAX.chr12.12553 4393-125534458	0.8414	23.5	7.617E-07
171	MAX.chr12.13348 5161-133485240	0.7591	40.03	0.0001313
172	MAX.chr12.13348 5417-133485505	0.7125	57.66	0.0001017
173	MAX.chr12.13348 5542-133485675	0.6853	40.55	0.00001341
174	MAX.chr14.10302 1656-103021718	0.9766	127	5.89E-07

175	MAX.chr14.10355 7994-103558154	0.7488	113.7	0.0001156
176	MAX.chr14.10355 8061-103558154	0.6882	49.76	0.0003841
177	MAX.chr14.74100 620-74100870	0.8808	49.39	0.0005545
178	MAX.chr17.29335 358-29335628	0.8279	201.5	0.002438
179	MAX.chr17.46089 738-46089851	0.7339	287.6	0.0001518
180	MAX.chr17.73073 716-73073814	0.8737	394.1	1.38E-05
181	MAX.chr19.31210 519-31210593	0.6504	41.46	0.00398
182	MAX.chr19.37288 607-37288752	0.811	88.11	0.000003103
183	MAX.chr2.102867 766-102867826	0.6968	28.75	0.0002521
184	MAX.chr2.127783 244-127783311	0.7289	30.07	0.00003288
185	MAX.chr2.233283 604-233283736	0.875	45.08	0.0001526
186	MAX.chr2.430380 72-43038159	0.6579	40.43	0.005182
187	MAX.chr2.961924 22-96192520	0.667	9.372	0.003974
188	MAX.chr2.961924 22-96192610	0.827	37.66	1.602E-08
189	MAX.chr20.37302 903-37302984	0.7703	19.49	0.00000328
190	MAX.chr21.30375 011-30375136	0.6519	118.9	0.002865
191	MAX.chr21.38936 278-38936494	0.6512	34.05	0.0002117
192	MAX.chr22.42679 801-42679979	0.8457	46.57	5.42E-07
193	MAX.chr3.128336 893-128336988	0.8505	207.8	3.97E-05
194	MAX.chr3.184868 89-18486958	0.875	45.35	1.268E-07
195	MAX.chr3.440380 12-44038064	0.7214	26.7	0.00005333
196	MAX.chr4.186049 532-186049660	0.7656	31.4	0.000865
197	MAX.chr5.177371 520-177371612	0.8	33.61	0.002158
198	MAX.chr5.429509 01-42951088	0.8615	28.06	0.00005216
199	MAX.chr5.643989 59-64399179	0.6882	27.48	0.00001
200	MAX.chr6.130687 108-130687268	0.7631	53.84	0.0002403
201	MAX.chr6.261719 01-26172479	0.7333	14.26	0.0004651
202	MAX.chr6.261722 25-26172432	0.6614	82.29	0.004157
203	MAX.chr6.309232 80-30923382	0.8799	35.99	1.61E-05

204	MAX.chr7.104624 356-104624730	0.8723	1101	1.93E-05
205	MAX.chr8.142216 090-142216173	0.7464	100.8	0.0007861
206	MAX.chr8.143532 758-143532822	0.741	5.751	0.0001482
207	MAX.chr8.145103 829-145103992	0.9351	26.27	6.522E-08
208	MAX.chr8.145104 263-145104422	0.9004	51.51	0.0001458
209	MAZ	0.7927	125.9	0.0002086
210	MBLAC1	0.7812	15.75	2.83E-08
211	MDFI_A	0.7424	13.66	0.0003535
212	MDFI_B	0.9286	80.17	3.453E-07
213	MFSD2B	0.8432	53.41	0.0003069
214	MIAT_A	0.9264	68.47	4.28E-07
215	MIAT_B	0.8605	47.34	0.0000377
216	MIDN	0.7849	21.42	0.000005938
217	MIR155HG	0.733	36.79	0.008797
218	MMP23B	0.974	87.98	4.161E-10
219	MRPS21	0.6753	11.41	0.001936
220	MRPS33	0.7068	33.47	0.0004814
221	MYOZ3	0.7949	74.89	0.0002419
222	N4BP2L1_A	0.7495	1311	0.0008957
223	N4BP2L1_B	0.704	1324	0.002896
224	NCKIPSD	0.7162	126	0.0009659
225	NCRNA00085	0.6889	194.7	0.000006047
226	NDRG2	0.9789	83.94	1.082E-07
227	NEAT1_A	0.6898	188.9	0.006251
228	NEAT1_B	0.6891	59.78	0.001232
229	NEK9	0.7791	33.3	0.00255
230	NFIC	0.8041	74.17	3.33E-06
231	NR1I2	0.777	46.68	0.0001105
232	NTRK3_A	0.6654	54.09	0.001975
233	NTRK3_B	0.7374	83.81	0.00007934
234	OBSCN_A	0.9324	436.3	5.79E-08
235	OLFM1	0.6928	53.72	0.0005697
236	PALLD_A	0.6628	70.25	0.0001169
237	PALLD_B	0.673	43.51	0.00002727
238	PCOLCE	0.9136	41.3	0.0009516
239	PDGFRA	0.6522	20.49	0.000009416
240	PHLDB1	0.8075	295.8	0.002509
241	PISD	0.8139	209.3	1.30E-06
242	PODN	0.697	119.7	6.84E-06
243	PPP2R5C_A	0.8799	168.5	0.00006792
244	PPP2R5C_B	0.7177	315.6	0.003545

245	PTCH2	0.8664	27.51	0.0009989
246	PTPRN2	0.6926	19.93	7.26E-05
247	PXMP4	0.788	222.5	0.000004164
248	PYCARD	0.9302	335.8	0.0004632
249	RAI1	0.8198	17.29	6.111E-07
250	RBM20	0.7132	500.5	0.0003599
251	RFTN1	0.7375	23.01	0.0005169
252	RHBDL1_A	0.8988	51.18	0.00001338
253	RIMS2	0.6754	5.933	0.009377
254	RLTPR	0.7173	109.6	1.75E-06
255	RTN4RL2	0.7675	20.03	0.0001403
256	SBNO2	0.817	116	0.0001235
257	SEPT11	0.6992	32.13	0.000554
258	SEPT9_A	0.8474	318.8	0.006383
259	SEPT9_B	0.9704	101.2	0.000001335
260	SERPINB9	0.7617	83.53	0.007034
261	SFMBT2_A	0.803	7.161	0.003198
262	SFMBT2_B	0.8359	21.85	1.30E-06
263	SFMBT2_C	0.8994	23.85	3.37E-07
264	SFMBT2_D	0.6765	32.88	0.0006383
265	SIGIRR	0.6811	47.57	0.004517
266	SIX4	0.8312	19.08	2.91E-05
267	SLC12A8	0.7944	19.75	0.0003137
268	SLC13A5_A	0.6719	353	0.0006269
269	SLC43A3	0.7455	27.29	5.534E-08
270	SLC6A3_A	0.9318	24.27	1.074E-07
271	SLC8A3_B	0.9239	55.38	1.944E-09
272	SLCO4C1	0.6786	112.2	0.00007596
273	SMTN	0.8052	42.68	5.47E-05
274	SNTG2	0.7862	14.28	0.0004986
275	SPOCK2_A	0.8486	68.87	2.41E-09
276	SPOCK2_B	0.6956	45.22	1.64E-05
277	SPON1	0.7247	25.58	0.000003926
278	SQSTM1	0.9228	145.7	4.725E-10
279	ST3GAL2_A	0.838	40.37	0.0007039
280	SV2A	0.8137	15.68	7.13E-05
281	TBX1	0.6667	127.2	0.0005607
282	TCF3	0.7783	22.84	7.97E-06
283	TECR	0.6767	203.8	0.001696
284	TEPP	0.8578	33.96	0.00000822
285	TFR2	0.6812	169.5	0.006637
286	THAP4	0.6528	62.88	0.0005633
287	TICAM2	0.6943	35.39	0.001777
288	TMCO1_A	0.7368	27.29	0.00008104

289	TMCO1_B	0.6972	141.8	0.002057
290	TMEM130	0.6622	11.02	0.0001735
291	TMEM163	0.6844	12.78	0.0000597
292	TMEM63B	0.8026	20.36	6.39E-06
293	TNFRSF10D	0.6775	15.68	0.002517
294	TRIM71_A	0.74	18.84	1.78E-05
295	TSHZ3_A	0.8161	13.38	3.93E-05
296	TSHZ3_B	0.8312	30.94	0.001939
297	TSHZ3_C	0.661	71.41	0.007574
298	TSPAN2	0.6647	72.46	0.000005262
299	TTBK1	0.79	29.97	3.99E-05
300	TTC14	0.779	481.4	0.006875
301	UST	0.7114	157.8	0.0004509
302	VILL	0.9293	66.67	5.346E-11
303	WNT1	0.8359	33.69	5.21E-06
304	WNT7B	0.8895	26.27	1.23E-06
305	ZMIZ1_A	0.7273	38.92	0.001658
306	ZMIZ1_B	0.7707	111.2	1.06E-09
307	ZMIZ1_C	0.7664	60.43	0.003325
308	ZNF167	0.722	132.9	0.0002713
309	ZNF292	0.815	531.8	0.008253
310	ZNF302	0.9	46.65	1.08E-05
311	ZNF304	0.8604	142.2	0.0006362
312	ZNF323_A	0.9232	364.4	0.00005473
313	ZNF354C	0.7944	56.82	4.34E-05
314	ZNF506	0.9142	71.02	9.384E-10
315	ZNF568_A	0.7041	73.74	0.0002323
316	ZNF586_B	0.7045	19.73	4.81E-08
317	ZNF880	0.6615	33.53	1.739E-07
318	ZNF90	0.9149	103.9	0.00003791

Such EC DMRs included EC specific regions, EC subtype specific regions, as well as those regions which targeted a more universal cancer spectrum.

The top overall DMRs distinguishing EC and normal endometrial tissue are shown in Table 3. The top overall DMRs distinguishing clear cell EC and normal endometrial tissue are shown in Table 4. The top overall DMRs distinguishing carcinosarcoma EC and normal endometrial tissue are shown in Table 5. The top overall DMRs distinguishing endometrioid EC and normal endometrial tissue are shown in Table 6. The top overall DMRs distinguishing serous EC and normal endometrial tissue are shown in Table 7. The grey-scaled red shading over certain genes in Tables 4, 5, 6, and 7 indicates DMRs which overlap with multiple subtypes.

Table 3. Top methylated regions distinguishing endometrial cancer tissue from normal endometrial tissue.

Gene Name	DMR No.	AUC	FC
EMX2OS	81	0.9309	264
CYTH2	59	0.8856	20.37
C17orf107_A	28	0.8328	64.08
DIDO1_A	63	0.8777	126.3
GDF6	102	0.8772	22.97
NBPF8	162	0.8718	42.83
MAX.chr14.103021656-103021718	174	0.8679	100.9
JSRP1_A	124	0.8642	38.78
GATA2_B	100	0.8639	19.23
SFMBT2_B	262	0.8431	18.31

Table 4. Top overall DMRs distinguishing clear cell EC and normal endometrial tissue.

Gene Name	DMR No.	AUC	FC	p-value
DIDO1_A	63	0.98	238	5.6E-12
NDRG2	226	0.98	84	1.08E-07
MAX.chr14.103021656-103021718	174	0.98	127	5.89E-07
MMP23B	218	0.97	88	4.16E-10
EMX2OS	81	0.97	235	1.49E-07
SEPT9_B	259	0.97	101	1.34E-06
NBPF8	162	0.97	53	1.61E-08
EEF1A2	75	0.95	68	3.22E-06
AIM1_A	11	0.94	369	5.34E-06
BMP4_B	26	0.94	33	1.18E-08
MAX.chr8.145103829-145103992	207	0.94	26	6.52E-08
OBSCN_A	234	0.93	436	5.79E-08
PYCARD	248	0.93	336	0.000463
GDF6	102	0.93	38	7.98E-07
MDFI_B	212	0.93	80	3.45E-07
MIAT_A	214	0.93	68	4.28E-07
SLC8A3	271	0.92	55	1.94E-09
ZNF323_A	312	0.92	364	5.47E-05
SQSTM1	278	0.92	146	4.73E-10
AFF3	7	0.92	32	2.95E-09
C1orf70	34	0.91	252	1.56E-07
GDF7_A	103	0.91	54	2.74E-08
JSRP1_A	124	0.91	72	5.16E-10
LRRC8D_A	152	0.90	27	9.12E-05
FEV	87	0.90	14	1.08E-09
MAX.chr8.145104263-145104422	208	0.90	52	0.000146

Table 5. Top overall DMRs distinguishing carcinosarcoma EC and normal endometrial tissue.

Gene Name	DMR No.	AUC	FC	p-value
-----------	---------	-----	----	---------

EMX2OS	81	0.94	323	4.11E-05
DIDO1_A	63	0.94	143	1.84E-06
SBNO2	256	0.94	129	0.003217
AMIGO3_A	13	0.93	40	8.39E-05
PCOLCE	238	0.91	41	0.000952
CLDN7	55	0.91	62	0.005037
CYTH2	59	0.91	19	4.92E-06
OBSCN_A	234	0.90	159	0.007225
AHSA2	10	0.90	59	0.001032
DLL4	67	0.90	17	0.000177
EMX2	80	0.89	308	0.007177
MAX.chr14.74100620-74100870	177	0.88	49	0.000555
LRRC34	146	0.88	150	0.002837
PPP2R5C_A	243	0.88	169	6.79E-05
SQSTM1	278	0.88	102	0.005911
MAX.chr17.73073716-73073814	180	0.87	586	0.008309
CYP11A1	57	0.86	61	0.001696
ACOXL_A	2	0.86	51	0.007356
AIM1_B	12	0.86	95	0.001099

Table 6. Top overall DMRs distinguishing endometrioid EC and normal endometrial tissue.

Gene Name	DMR No.	AUC	FC	p-value
MAX.chr10.130339363-130339534	165	0.97	29	1.53E-06
SFMBT2_C	263	0.95	33	6.01E-08
CYTH2	59	0.94	25	2.18E-08
SLC6A3	270	0.93	24	1.07E-07
VILL	302	0.93	67	5.35E-11
EMX2OS	81	0.92	299	9.02E-06
MAX.chr10.22624479-22624553	167	0.92	63	1.42E-10
GDF6	102	0.92	28	7.96E-07
ZNF90	318	0.91	104	3.79E-05
ZNF506	314	0.91	71	9.38E-10
JSRP1_A	124	0.91	70	1.24E-10
C5orf52	40	0.90	166	1.66E-07
SFMBT2_B	262	0.90	36	2.01E-09
NBPF8	162	0.90	66	2.95E-07
RHBDL1_A	252	0.90	51	1.34E-05
DIDO1_A	63	0.90	90	1.81E-08
KANK1	126	0.89	135	1.05E-06
GATA2_B	100	0.89	24	9.71E-09

Table 7. Top overall DMRs distinguishing serous EC and normal endometrial tissue.

Gene Name	DMR No.	AUC	FC	p-value
EMX2OS	81	1.00	277	3.71E-10
KANK1	126	0.94	65	3.2E-07
C1orf70_B	35	0.94	49	5.25E-06
AMIGO3_A	13	0.92	23	2.81E-05
DIDO1_A	63	0.92	127	3.83E-07
LRRC41_C	149	0.91	50	7.06E-08

NFIC	230	0.91	46	7.52E-05
FKBP11_A	88	0.91	722	0.001236
C17orf107_A	28	0.91	93	6.96E-12
SMTN	273	0.90	87	2.18E-06
LRRC41_B	148	0.90	93	9.19E-06
LRRC8D_A	152	0.89	59	3.13E-06
OBSCN_A	234	0.87	128	2.48E-05
MAX.chr7.104624356-104624730	204	0.86	403	0.000153
MIAT_B	215	0.86	47	3.77E-05

A tissue to leukocyte (buffy coat) analysis yielded 129 hypermethylated endometrial tissue DMRs with less than 1% noise in WBCs (Table 8). Table 9 shows the area-under-the-curve, fold-change, and p-value in comparison to EC buffy controls for the markers recited in Table 8.

Table 8. Hypermethylated endometrial tissue DMRs with less than 1% noise in WBCs

DMR No.	Gene Annotation	Chromosome No.	Region on Chromosome (starting base-ending base)
319	ACOXL_B	2	111875309-111875359
320	ACTG1	17	79478295-79478468
321	ANKRD35	1	145562791-145562906
499	ARL5C	17	37321564-37321723
322	ARRB1	11	75063559-75063646
323	BCL2L11_A	2	111876440-111876609
324	BCL2L11_B	2	111876958-111877258
325	BCL2L11_C	2	111876624-111876822
326	BEST4	1	45250035-45250159
327	BZRAP1	17	56409702-56409821
328	C14orf169_B	14	73958204-73958363
329	C14orf169_C	14	73958382-73958475
330	C14orf80	14	105954029-105954198
331	C16orf54	16	29757319-29757405
332	C17orf101	17	80358847-80358919
333	C18orf1	18	13641597-13641678
334	C6orf132	6	42072052-42072186
335	C9orf171	9	135285696-135285783
336	CACNA2D4	12	1906260-1906350
337	CCDC61	19	46519515-46519568
338	DEDD2	19	42703469-42703790
339	DGKE	17	54912117-54912243
340	EGFL7	9	139559853-139559951
341	EMB	5	49736982-49737041
342	EOMES	3	27763388-27763413
343	EPS15L1	19	16482437-16482520

344	FAIM2	12	50297582-50297690
345	FAM125B	9	129233651-129233705
346	FAM159A	1	53099143-53099216
347	FAM189B	1	155220306-155220399
348	FAM78A	9	134151289-134151464
349	FMNL1	17	43298726-43298774
350	FOXP4	6	41528837-41528899
351	GAL3ST4	7	99769426-99769470
352	GATA2_C	3	128216774-128216891
353	GP1BB	22	19706153-19706187
354	GYPC_A	2	127413698-127413901
355	GYPC_B	2	127414106-127414189
356	HAAO	2	43019891-43019972
357	HAND2	4	174450783-174450843
358	HDAC7	12	48206687-48206801
359	HOPX_B	4	57522083-57522182
360	HOXA7	7	27196352-27196425
361	HOXB4	17	46659392-46659496
362	HRH2	5	175085144-175085212
363	IFFO1_A	12	6664616-6664694
364	IFFO1_B	12	6664873-6665023
119	IL12RB2	1	67773620-67773674
365	IQSEC3_A	12	187211-187344
366	IQSEC3_B	12	187115-187194
367	ITGA4_B	2	182321830-182321917
368	ITPKA	15	41787637-41787780
369	KLF16	19	1856980-1857037
370	LIMD2	17	61778259-61778367
371	LOC100129726_A	2	43452130-43452229
382	LOC100192379_B	4	122686329-122686394
373	LOC339529	1	244080908-244080979
374	LOC389333	5	138728189-138728287
375	LOC440925_A	2	171570158-171570471
376	LOC646278	15	29077327-29077423
377	LTBP2	14	75078651-75078687
378	LYL1	19	13210058-13210180
379	LYPLAL1	1	219347185-219347277
380	MAX.chr1.228651512-228651589	1	228651512-228651589
381	MAX.chr1.8014264-8014320	1	8014264-8014320
382	MAX.chr10.22541719-22541758	10	22541719-22541758
383	MAX.chr10.94459281-94459353	10	94459281-94459353
384	MAX.chr11.32355226-32355251	11	32355226-32355251
385	MAX.chr11.8041275-8041318	11	8041275-8041318
385	MAX.chr11.8041275-8041318	11	8041275-8041318
386	MAX.chr14.102172621-102172686	14	102172621-102172686
387	MAX.chr14.105512122-105512239	14	105512122-105512239
388	MAX.chr15.65186405-65186481	15	65186405-65186481
389	MAX.chr15.95128144-95128248	15	95128144-95128248
390	MAX.chr16.11327016-11327312	16	11327016-11327312
391	MAX.chr17.77789297-77789347	17	77789297-77789347
392	MAX.chr19.13266870-13266980	19	13266870-13266980

393	MAX.chr19.42028466-42028519	19	42028466-42028519
394	MAX.chr2.231693015-231693073	2	231693015-231693073
395	MAX.chr2.73511979-73512039	2	73511979-73512039
396	MAX.chr3.187676577-187676668	3	187676577-187676668
397	MAX.chr4.174430676-174430847	4	174430676-174430847
398	MAX.chr5.77147757-77147813	5	77147757-77147813
399	MAX.chr6.130088620-130088690	6	130088620-130088690
400	MAX.chr6.42738968-42739055	6	42738968-42739055
401	MAX.chr8.145900783-145900914	8	145900783-145900914
402	MAX.chr8.80804237-80804301	8	80804237-80804301
403	MAX.chr9.33524209-33524289	9	33524209-33524289
404	MPZ_A	1	161275561-161275996
405	N4BP2L1_C	13	33001374-33001575
406	N4BP3	5	177543694-177543863
407	NCOR2	12	124941781-124942044
408	NFATC1_A	18	77159542-77159614
409	NFATC1_B	18	77159813-77159893
410	NKX2-6	8	23564281-23564374
411	NR2F6	19	17346567-17346673
412	NR3C1_A	5	142784971-142785160
413	NR3C1_B	5	142784614-142784698
414	NTN1	17	9143174-9143253
415	OSM	22	30662648-30662807
416	PALLD_C	4	169799226-169799423
417	PHLDB1_B	11	118481753-118481814
418	PIK3CD	1	9777870-9777967
419	PLCL2	3	16925870-16925914
420	PNMAL2	19	46996933-46996985
421	PRDM13	6	100061723-100061766
422	PRKAR1B	7	644126-644332
423	RAD52	12	1059296-1059503
424	SEPT9_C	17	75447656-75447714
425	SNN	16	11763081-11763138
426	SPDYA_A	2	29033287-29033484
427	SPON2	4	1161228-1161298
428	ST8SIA1	12	22487403-22487492
429	STX16_A	20	57224620-57224975
430	SUCLG2	3	67706348-67706568
431	TJP2	9	71788863-71788954
432	TLE4	9	82188097-82188284
433	TNFRSF1B	1	12227425-12227514
434	TNFRSF4	1	1148413-1148487
435	TNRC18	7	5436900-5436991
436	TSPAN33	7	128809205-128809241
437	UST_B	6	149068833-149068925
438	VENTX	10	135050110-135050178
439	WDR86	7	151078576-151078610
440	XKR6	8	11058545-11058598
441	ZDHC18	1	27160118-27160221
442	ZNF227	19	44711531-44711781
315	ZNF568_A	19	37407197-37407284

443	ZNF586_C	19	58281020-58281200
444	ZNF671_A	19	58238740-58238799

Table 9. Area-under-the-curve, fold-change, and p-value for EC in comparison to EC buffy controls for the markers recited in Table 8.

DMR No.	Gene Annotation	AUC EC vs. EC buffy control	Fold Change EC vs. EC buffy control	p-value EC vs. EC buffy control
319	ACOXL_B	0.6786	26080000	0.991
320	ACTG1	0.709	34560000	0.9928
321	ANKRD35	1	627.5	0.005999
499	ARL5C	0.9614	137.5	0.0001678
322	ARRB1	0.9044	59100000	0.9902
323	BCL2L11_A	1	237.1	0.0004125
324	BCL2L11_B	0.9975	370.4	0.002033
325	BCL2L11_C	1	342.4	0.002845
326	BEST4	0.7845	38650000	0.9902
327	BZRAP1	0.9918	2116	0.0002676
328	C14orf169_B	0.7045	71770000	0.9904
329	C14orf169_C	0.7045	141100000	0.9914
330	C14orf80	0.875	162800000	0.9914
331	C16orf54	1	542.3	7.39E-05
332	C17orf101	1	2.27E+09	0.9918
333	C18orf1	0.7738	19.55	0.009107
334	C6orf132	1	593.2	0.001901
335	C9orf171	0.7321	36790000	0.9896
336	CACNA2D4	0.9338	80450000	0.9891
337	CCDC61	0.7109	63800000	0.9915
338	DEDD2	1	527.9	6.12E-08
339	DGKE	0.7426	24970000	0.9924
340	EGFL7	0.7344	72630000	0.9928
341	EMB	0.86	189900000	0.9916
342	EOMES	0.6633	50060000	0.9913
343	EPS15L1	1	725500000	0.99
344	FAIM2	0.9828	330.1	0.00851
345	FAM125B	0.9394	7.61E+08	0.9899
346	FAM159A	0.6889	100800000	0.9924
347	FAM189B	0.995	135.3	0.003158
348	FAM78A	1	1404	9.92E-06
349	FMNL1	0.8333	75120000	0.9918
350	FOXP4	0.9776	582200000	0.9892
351	GAL3ST4	0.8167	90980000	0.9908
352	GATA2_C	0.8492	109200000	0.9901
353	GP1BB	0.7119	42170000	0.9924
354	GYPC_A	0.9924	770700000	0.9901
355	GYPC_B	0.9397	664100000	0.9906
356	HAAO	0.8889	1.53E+08	0.9906

357	HAND2	0.7923	46610000	0.9895
358	HDAC7	0.7537	50550000	0.9898
359	HOPX_B	0.6983	70210000	0.9914
360	HOXA7	0.7404	83950000	0.9909
361	HOXB4	0.697	42010000	0.9915
362	HRH2	0.7419	78270000	0.9913
363	IFFO1_A	0.9692	92880000	0.9902
364	IFFO1_B	0.9701	744200000	0.9913
119	IL12RB2	0.6953	16740000	0.9928
365	IQSEC3_A	0.7576	29400000	0.9894
366	IQSEC3_B	0.7302	45010000	0.9926
367	ITGA4_B	0.7647	129900000	0.992
368	ITPKA	1	499.2	0.003773
369	KLF16	0.9083	165100000	0.9921
370	LIMD2	0.9603	493100000	0.9911
371	LOC100129726_A	0.6692	29650000	0.9887
382	LOC100192379_B	0.6667	3.10E+07	0.9939
373	LOC339529	0.8273	115200000	0.9902
374	LOC389333	0.9545	393300000	0.9917
375	LOC440925_A	0.9959	274.8	0.007478
376	LOC646278	0.9016	86610000	0.9898
377	LTBP2	0.7636	65880000	0.9912
378	LYL1	0.9887	545.8	0.006049
379	LYPLAL1	0.9846	2.10E+09	0.9917
380	MAX.chr1.228651512-228651589	0.7734	51900000	0.9889
381	MAX.chr1.8014264-8014320	0.8929	188300000	0.9925
382	MAX.chr10.22541719-22541758	0.8871	139100000	0.992
383	MAX.chr10.94459281-94459353	0.8364	1.26E+08	0.9927
384	MAX.chr11.32355226-32355251	0.9731	471.5	0.008476
385	MAX.chr11.8041275-8041318	0.6562	50170000	0.9949
386	MAX.chr14.102172621-102172686	0.9224	380600000	0.9916
387	MAX.chr14.105512122-105512239	0.9924	512600000	0.989
388	MAX.chr15.65186405-65186481	0.7769	134800000	0.9917
389	MAX.chr15.95128144-95128248	0.9678	126.9	0.003344
390	MAX.chr16.11327016-11327312	0.9984	837.5	1.85E-05
391	MAX.chr17.77789297-77789347	0.8689	82590000	0.9919
392	MAX.chr19.13266870-13266980	0.7077	104900000	0.993
393	MAX.chr19.42028466-42028519	0.8727	246200000	0.9902

394	MAX.chr2.231693 015-231693073	0.6932	71170000	0.9936
395	MAX.chr2.735119 79-73512039	0.6778	95180000	0.9931
396	MAX.chr3.187676 577-187676668	0.9984	677.2	1.78E-05
397	MAX.chr4.174430 676-174430847	0.9877	105.5	0.00112
398	MAX.chr5.771477 57-77147813	0.6596	31920000	0.9924
399	MAX.chr6.130088 620-130088690	0.7281	75460000	0.9915
400	MAX.chr6.427389 68-42739055	0.6923	41460000	0.9921
401	MAX.chr8.145900 783-145900914	1	1127	2.26E-05
402	MAX.chr8.808042 37-80804301	0.9519	83590000	0.9922
403	MAX.chr9.335242 09-33524289	0.7653	68470000	0.9939
404	MPZ_A	0.8914	26.19	0.0129
405	N4BP2L1_C	0.675	43500000	0.9929
406	N4BP3	1	284.9	0.003001
407	NCOR2	0.9992	334.7	0.002568
408	NFATC1_A	0.9886	360.7	0.003405
409	NFATC1_B	0.9385	73470000	0.9885
410	NKX2-6	0.9889	452800000	0.9932
411	NR2F6	0.9403	1.10E+09	0.9931
412	NR3C1_A	0.7687	42200000	0.9904
413	NR3C1_B	0.6846	41810000	0.9926
414	NTN1	0.8361	100500000	0.9909
415	OSM	0.9906	894.1	0.0004214
416	PALLD_C	1	369.1	0.001153
417	PHLDB1_B	0.6786	42240000	0.9894
418	PIK3CD	0.9731	82.97	0.0002239
419	PLCL2	0.7705	67150000	0.9898
420	PNMAL2	0.8433	117600000	0.9914
421	PRDM13	0.7347	35550000	0.9914
422	PRKAR1B	1	537	0.003643
423	RAD52	0.9252	71.45	0.002206
424	SEPT9_C	0.6909	30860000	0.991
425	SNN	0.71	49210000	0.994
426	SPDYA_A	0.8696	113700000	0.9899
427	SPON2	0.7803	64470000	0.9911
428	ST8SIA1	0.6939	61890000	0.9932
429	STX16_A	1	889.9	0.0002353
430	SUCLG2	1	4174	0.001157
431	TJP2	0.6923	64420000	0.9901
432	TLE4	0.6667	65910000	0.9928
433	TNFRSF1B	0.9196	99080000	0.9908
434	TNFRSF4	0.9615	205500000	0.9893
435	TNRC18	0.8906	186900000	0.9914
436	TSPAN33	0.8125	96600000	0.9903
437	UST_B	0.6885	29650000	0.9931

438	VENTX	0.8016	32390000	0.9904
439	WDR86	0.8939	184500000	0.9874
440	XKR6	0.8021	47230000	0.9913
441	ZDHHC18	0.9926	5.61E+09	0.9902
442	ZNF227	0.7132	51410000	0.9916
315	ZNF568_A	0.6967	59100000	0.9923
443	ZNF586_C	0.7188	42520000	0.9877
444	ZNF671_A	0.9167	200800000	0.9923

From these marker groups 56 candidates were chosen for an initial pilot. Methylation-specific PCR assays were developed and tested on two rounds of samples; those that were sequenced and larger independent cohorts. Short amplicon primers (<150bp) were designed to target the most discriminant CpGs within a DMR and tested on controls to ensure that fully methylated fragments amplified robustly and in a linear fashion, that unmethylated and/or unconverted fragments did not amplify. The 112 primer sequences and annealing temperatures for the 56 candidate markers are listed in Table 10.

Table 10.

Gene Annotation	DM R No.	Forward Primer 5'-3'	Seq ID	Reverse Primer 5'-3'	Seq ID	Annealing Temperature °C / Final
SFMBT2_B	262	GCG CGC GGT TTT GGG AGA TAA GTA C	1	AAA AAA AAC AAC CCC TCG CCT CGA C	2	70
SMTN	273	AGG TTT TTA GGA TAT TTA GTT GAG TGG CGG	3	ACC TCG ATC CCG AAT TCG AAT TCG AC	4	70
SQSTM1	278	GTT TTC GGT TAT TCG GTG ACG G	5	AAA AAA CTA AAA AAC GAA TCG CGC T	6	65
ZNF323_A	312	TTT AAT GAT CGA TTA ATC GTA AAG GTC GG	7	AAC CAA TAA ACT CAA AAC GAC TAA CGC A	8	65
ZNF506	314	TTA GGT TTT TAG GGG GTT TCG GCG T	9	ATC GTC TTC ACT ACT CTA TAC CGT C	10	65
ZNF90	318	AAT TGG GTA AGG AGA AGT CGG TCG T	11	ATA ACG AAA CTT AAA CCT CCC CGC A	12	70

ACOXL_A	2	AGT TAA GTT TTA ACG GGT GTG GCG G	13	AAA CGT CGA TAA AAC GAA CGT CGT A	14	70
CLDN7	55	TAT CGT TGT TTC GAG TCG GGG ACG A	15	AAC CGA AAT TCC GAC GAC TAC ACG T	16	65
LRRC41_B	148	GGT TCG GAG CGG TTT AAA TAA GCG A	17	CTT AAC CCT TCC CGC CTA TCC GTC	18	70
MAX.chr7.1 04624356- 104624730	204	TTG GGG GTT GTC GGT TTT TGG AGA C	19	CCG ATC TAA ATA CCC CAA ACG AAA TCG AA	20	70
NDRG2	226	CGT TTT TAG ATT TAG TGG TGG GAA TCG G	21	TCG AAC GAA AAA AAT CGA ACT CGT A	22	60
CYP11A1	57	TTT TTC GCG GGT CGT TTA TTT TCG T	23	AAA CGA ATA AAC TCG AAC TAT ATC GAA	24	65
FKBP11_A	88	TTA CGA TCG GAT TAT AGG GGT TAC GG	25	TAC CGA ATC TAA AAA CGA AAA CGA A	26	65
MAX.chr8.1 45103829- 145103992	207	GGG GAG TTA TAG GGG TGA AGG TCG C	27	GCC TCC GCC AAA CTC GCT ACG TC	28	70
AHSA2	10	TAT TTG GCG CGT GGG GAG AGG TC	29	TCC CTT CCG AAA ATT CTA CGA CGA A	30	65
CYTH2	59	TTT TAG GGT AAA TAG CGG GTT TCG T	31	CGA CCG CCC TAC ATA CAA TTC ATC CG	32	65
GATA2_B	100	GTG TGA TAG ACG TTA GAG CGG CGG	33	CGT TTT AAT CAA AAA AAT CTC CCG TA	34	65
LRRC8D_A	152	GGG AGA ATT CGA GTA GTA GTT GTA AAC GG	35	AAT AAC CTC GCT ACC AAC CAC CCG C	36	65
MAX.chr8.1 45104263- 145104422	208	GGG CGT TGT TTC GTT TTT TTT ATC GT	37	GAA ACG CGC TTA CCC GTC GAA	38	70

OBSCN_A	234	GTT CGT TAT CGT TTG GTT TTG TAT AAC GT	39	TAT ATC TTA TCA TCC GAC GTC TCG CA	40	65
DIDO1_A	63	TAT TTG GGA TTT AGA GAG GTA GCG G	41	CCA AAA ACC GAA ACC TAA ACG CT	42	70
GDF6	102	TTT TAT TTC GTA GAC GAT TTT TCG T	43	GAA AAA ACC GCA ACT CCG CGC	44	65
MAX.chr10. 130339363- 130339534	165	AAT AAT AGG AAT TAG AGG TTG TCG G	45	AAA TAA CAA ACT CCG CGC GCG AA	46	65
MDFI_B	212	TAC GGT TCG TAC GAG TGA GTG GAC GT	47	ACG CCG AAA ACG AAC AAA AAA CGA T	48	70
DLL4	67	TTT TTC GTA GCG ATC GTA GCG GCG T	51	ACC TAC TAA ACA AAC CAA AAA CGA A	52	65
GDF7_A	103	TTC GTT TAG AAG GCG GGT GGA AGG TC	53	AAA AAA TCT CGC GCG AAA ATA CGC T	54	65
MAX.chr10. 22624479- 22624553	167	GGA AGG TTA GGG GGA AAT TTG TAT TTC GT	55	CGT AAC ATC GTC ATT TCT TAA CCG CGA T	56	70
MIAT_A	214	TTT CGT ATT AAA ATT TTA TGG GCG T	57	TCT AAT CCC GCG AAC GCA ACC G	58	60
PYCARD	248	TAG TTT TGT TTA GGG GTA GGA GGA ATA GAA AGC G	59	ACA CCA ACG CTT ACC CCG CGA A	60	65
BMP4_B	26	TTT TCG ATC GTG GAT GTT CCG AGT C	61	GAA AAC CGC GCG ACT CTT ACC GAA	62	70
JSRP1_A	124	GGG AGG GGT CGT AGG AGT GTT TTC G	63	ATA ACG TTC TAC CGC CTT TCC CCT ACG C	64	70
MAX.chr14. 103021656- 103021718	174	GAA AGC GAA ACG GTT TCG GCG TC	65	CAA ACT TCC GAA TCC TAC CCC CGC	66	70

MIAT_B	215	TCG AGA GAG GTC GGT TTT TTT TAT CGT	67	AAA CTT CCG ATC ACG ACC CCA CGT C	68	70
RHBDL1_A	252	TCG TTG GTA AAT GGA GTT ACG G	69	GAA AAA ACT ATA AAA AAA CGA ACG AT	70	60
EMX2	80	GTA TTT ATC GCG TTT TCG AGT TCG A	71	TAT AAC GCG ACC CCA ACG CT	72	70
KANK1	126	GTA GTC GGA GGG AGA TTT CGT CGG	73	ATA AAC TTA ACC GAC CAC GCT CGA A	74	65
MMP23B	218	CGG GTT GTA ATT CGA GTC GTC GA	75	CAA AAC CTC CGA AAA AAA TCC GAA	76	65
SBNO2	256	GTA TAG GGC GTC GTT TTT AGT TCG A	77	AAA AAA TCT ACC GAA AAA TTC CGA A	78	60
C5orf52	40	TTG GTT TAA TTC GTT ATT CGT TTC GT	79	AAC AAA CCT TTT CCG CTT CGA CGT A	80	65
EMX2OS	81	CGA AGT TCG GGT AGG GTA AGC GTT GC	81	CGA CGT AAA AAT ACG AAA CGC ACG AA	82	65
LRRC34	146	GTG AGG CGG TTA TAC GAG TTT CGG C	83	CAA AAA ACC TCC ACA AAA TAA ACG AT	84	65
MAX.chr17. 73073716- 73073814	180	TTT TTC GAG TCG TTT TAT TTC GCG G	85	GAA CTC CGA ACG CCG CTT AAA CGT A	86	70
NBPF8	162	CGC GTA GGT GTT TAA CGT GAT TAG CGC	87	CTT ACA TCC TCA AAA CCC GCC CGA C	88	65
SEPT9_B	259	TTA TGG TGG CGG TGT CGG GAG TTA C	89	CCC TCT CCT AAA AAC CCC GCT CGA T	90	70
LOC440925 _A	375	AGT TCG CGT TCG GTT TTT TTG TTC G	91	GTC CGT CCC GAT CGC AAT ACG A	92	65

STX16_A	429	CGC GTT GCG CGG AAG TTA GAG TC	93	CCA CAT AAA ATC GAA AAA ACC GCG AA	94	65
ITPKA	368	GGG TTT ATA AGT TCG GAG GTC GA	95	CAC CCA ACA CCT AAC GAC GA	96	65
AIM1_A	11	AGC GTT TTT AGG GAG TTC GGC GTT C	97	AAT CGA AAA AAC GAA AAA AAT CGC A	98	65
EEF1A2	75	TAG GTC GTT TCG TCG TGC GC	101	ATA ACC TTA CCG ACG CCG CCG CT	102	70
FEV	87	TTT TTG AAG AGA TCG TTT TCG ACG G	103	CCC CCT TAA ACC TTA ACC CGA A	104	65
LRRC41_C	149	GGC GTT TCG ATT TTT TCG TTC GG	105	CCG AAA CTC CAA CAT CTA CCT AAC ACG CC	106	65
NFIC	230	CGT AAT TTT TGG CGA GCG ACG TTT GC	107	CAA CCT TCG AAA TCC CCC ATC CGC T	108	70
VILL	302	GGT TTT GGG GGA TTT AGG GTT CGG	49	TCC GCG AAA ACC CCT ACC TAA CGT C	50	70
MPZ_A	404	GGG GCG TAT ATA TTA GTT ATC GAG CGA	99	AAA AAA AAC CCT AAA AAC CGC CGA A	100	65

The results from round one validation were analyzed logistically to determine AUC and fold change. From previous work it was recognized that the epigenetics of cancer subtypes within an organ differ and that the best panels are derived from combinations of subtype markers. Analyses for the tissue and buffy coat controls were run separately. Results are highlighted in Tables 11 (clear cell EC vs. buffy coat), 12 (serous EC vs. buffy coat), 13 (cacinosa sarcoma EC vs. buffy coat), and 14 (endometrioid EC vs. buffy coat). The gray-scaled red shading over certain genes indicates DMRs which overlap with multiple subtypes. The degree of grey-scaled red shading indicates the discrimination strength of the marker assay. A number of assays were 100% discriminant in EC from buffy coat samples and approaching 100% in the EC vs benign endometrium comparison.

Table 11. DMRs distinguishing 1) clear cell EC and buffy coat and 2) clear cell EC and normal endometrium and normal cervicovaginal tissue

DMR No.	Gene Name	AUC / Buffy Coat	FC / Buffy Coat	AUC / normal endometrium and normal cervicovaginal tissue	FC / normal endometrium and normal cervicovaginal tissue
262	SFMBT2_B	0.97	1179.65	0.72	11.52
273	SMTN	0.89	199.57	0.51	7.59
278	SQSTM1	0.91	201.30	0.87	18.50
312	ZNF323_A	1.00	422080.20	0.98	343.83
314	ZNF506	0.94	451.38	0.70	8.09
318	ZNF90	0.93	44.22	0.50	1.77
2	ACOXL_A	0.81	122.93	0.61	1.43
55	CLDN7	0.97	15.54	0.73	0.65
148	LRRC41_B	0.97	142.56	0.68	6.81
204	MAX.chr7.104624356-104624730	0.93	187.02	0.93	100.90
226	NDRG2	0.95	285.41	0.91	111.93
57	CYP11A1	0.94	101.29	0.59	1.83
88	FKBP11_A	0.83	17.00	0.65	4.46
207	MAX.chr8.145103829-145103992	0.93	1107.83	0.74	18.09
10	AHSA2	0.88	61.87	0.72	5.77
59	CYTH2	0.99	152.59	0.81	3.59
100	GATA2_B	0.89	518.49	0.67	12.96
152	LRRC8D_A	0.92	323.21	0.74	11.32
208	MAX.chr8.145104263-145104422	0.96	258.53	0.67	12.62
234	OBSCN_A	1.00	2614.39	0.89	30.04
63	DIDO1_A	0.97	918.19	0.91	16.37
102	GDF6	0.99	203.64	0.62	4.22
165	MAX.chr10.130339363-130339534	0.92	18.64	0.75	3.52
212	MDFI_B	0.94	1749.15	0.90	42.70
67	DLL4	0.96	12.73	0.60	0.31
103	GDF7_A	0.92	224.96	0.84	27.86
167	MAX.chr10.22624479-22624553	0.85	2399.57	0.75	24.84
214	MIAT_A	0.93	1055.89	0.83	98.21
248	PYCARD	0.94	106.61	0.57	6.24
26	BMP4_B	0.95	127.50	0.56	7.73
124	JSRP1_A	0.98	81.87	0.78	4.52
174	MAX.chr14.103021656-103021718	0.98	2953.08	0.97	184.74
215	MIAT_B	0.87	99.67	0.38	3.32
252	RHBDL1_A	0.71	20.30	0.76	12.49

80	EMX2	0.92	422.01	0.85	35.48
126	KANK1	0.73	23.85	0.64	6.84
218	MMP23B	0.97	640.18	0.92	25.53
256	SBNO2	0.83	8.43	0.57	0.51
40	C5orf52	0.59	59.11	0.65	0.68
81	EMX2OS	0.98	154.84	0.89	5.95
146	LRRC34	0.81	62.10	0.61	2.27
180	MAX.chr17.73073716-73073814	1.00	283.78	0.87	22.84
162	NBPF8	0.97	69.67	0.85	7.68
259	SEPT9_B	0.99	1751.41	0.94	70.17
375	LOC440925_A	1.00	304.06	0.49	1.04
429	STX16_A	0.90	173.42	0.94	53.85
368	ITPKA	1.00	1509.47	0.58	0.96
11	AIM1_A	0.79	15826.65	0.78	307.38
75	EEF1A2	0.97	289.12	0.83	41.35
87	FEV	0.94	537.52	0.84	19.39
149	LRRC41_C	0.98	392.66	0.72	18.82
230	NFIC	0.95	107.52	0.69	6.95
302	VILL	0.88	49.58	0.44	3.39
404	MPZ_A	0.85	1112.98	0.61	6.77

Table 12. DMRs distinguishing 1) serous EC and buffy coat and 2) serous EC and normal endometrium and normal cervicovaginal tissue

DMR No.	Gene Name	AUC / Buffy Coat	FC / Buffy Coat	AUC / normal endometrium and normal cervicovaginal tissue	FC / normal endometrium and normal cervicovaginal tissue
262	SFMBT2_B	0.91	594.75	0.65	5.81
273	SMTN	1.00	235.25	0.70	8.95
278	SQSTM1	1.00	155.56	0.80	14.30
312	ZNF323_A	0.88	400850.18	0.88	326.53
314	ZNF506	0.81	181.26	0.62	3.25
318	ZNF90	1.00	124.47	0.63	4.97
2	ACOXL_A	0.87	4248.44	0.63	49.40
55	CLDN7	1.00	15.07	0.58	0.63
148	LRRC41_B	1.00	170.65	0.82	8.15
204	MAX.chr7.104624356-104624730	0.94	435.76	0.94	235.10
226	NDRG2	0.73	108.35	0.75	42.49
57	CYP11A1	0.91	420.04	0.73	7.61
88	FKBP11_A	0.92	153.12	0.84	40.21
207	MAX.chr8.145103829-145103992	1.00	886.56	0.72	14.47
10	AHSA2	0.94	33.32	0.69	3.11
59	CYTH2	0.97	137.39	0.70	3.23

100	GATA2_B	0.81	481.98	0.68	12.05
152	LRRC8D_A	0.98	681.74	0.85	23.87
208	MAX.chr8.145104263-145104422	1.00	236.41	0.70	11.54
234	OBSCN_A	0.93	2837.86	0.76	32.61
63	DIDO1_A	0.83	1663.93	0.80	29.67
102	GDF6	1.00	172.69	0.67	3.58
165	MAX.chr10.130339363-130339534	0.87	5.69	0.61	1.07
212	MDFI_B	0.74	926.85	0.75	22.63
67	DLL4	0.94	34.95	0.62	0.85
103	GDF7_A	0.71	335.86	0.68	41.60
167	MAX.chr10.22624479-22624553	0.77	2245.78	0.65	23.25
214	MIAT_A	0.84	378.27	0.61	35.18
248	PYCARD	1.00	29.18	0.40	1.71
26	BMP4_B	0.97	51.17	0.46	3.10
124	JSRP1_A	0.99	78.15	0.65	4.31
174	MAX.chr14.103021656-103021718	0.76	2225.70	0.65	139.24
215	MIAT_B	0.90	325.27	0.69	10.85
252	RHBDL1_A	0.78	32.70	0.76	20.12
80	EMX2	0.68	439.81	0.71	36.98
126	KANK1	0.91	54.42	0.88	15.60
218	MMP23B	0.77	139.13	0.80	5.55
256	SBNO2	0.78	32.10	0.50	1.93
40	C5orf52	0.74	54.72	0.56	0.63
81	EMX2OS	1.00	286.88	0.91	11.02
146	LRRC34	0.72	316.99	0.60	11.61
180	MAX.chr17.73073716-73073814	0.80	151.03	0.74	12.16
162	NBPF8	0.99	101.15	0.79	11.15
259	SEPT9_B	0.72	508.74	0.64	20.38
375	LOC440925_A	1.00	347.38	0.51	1.18
429	STX16_A	0.76	159.65	0.80	49.58
368	ITPKA	1.00	1869.01	0.50	1.18
11	AIM1_A	0.71	2731.20	0.70	53.05
75	EEF1A2	0.93	59.07	0.63	8.45
87	FEV	0.90	648.38	0.76	23.39
149	LRRC41_C	1.00	530.59	0.94	25.43
230	NFIC	0.92	165.59	0.73	10.71
302	VILL	0.96	120.29	0.66	8.23
404	MPZ_A	0.94	3826.67	0.89	23.28

Table 13. DMRs distinguishing 1) carcinosarcoma EC and buffy coat and 2) carcinosarcoma EC and normal endometrium and normal cervicovaginal tissue

DMR No.	Gene Name	AUC / Buffy Coat	FC / Buffy Coat	AUC / normal endometrium and normal cervicovaginal tissue	FC / normal endometrium and normal cervicovaginal tissue
262	SFMBT2_B	0.99	1428.99	0.68	13.95
273	SMTN	1.00	377.39	0.76	14.36
278	SQSTM1	0.62	284.30	0.58	26.13
312	ZNF323_A	0.85	485857.78	0.86	395.78
314	ZNF506	0.97	536.08	0.79	9.60
318	ZNF90	1.00	114.78	0.77	4.58
2	ACOXL_A	0.73	7752.33	0.64	90.14
55	CLDN7	0.98	115.79	0.46	4.87
148	LRRC41_B	1.00	66.45	0.62	3.17
204	MAX.chr7.104624356-104624730	0.84	745.78	0.85	402.36
226	NDRG2	0.68	29.19	0.69	11.45
57	CYP11A1	0.93	140.16	0.66	2.54
88	FKBP11_A	0.85	25.24	0.73	6.63
207	MAX.chr8.145103829-145103992	0.95	2543.71	0.66	41.53
10	AHSA2	0.96	226.81	0.77	21.16
59	CYTH2	1.00	263.29	0.85	6.19
100	GATA2_B	0.98	576.22	0.61	14.40
152	LRRC8D_A	0.96	776.27	0.75	27.18
208	MAX.chr8.145104263-145104422	0.94	497.10	0.64	24.27
234	OBSCN_A	0.99	3188.04	0.83	36.63
63	DIDO1_A	1.00	2258.45	0.88	40.27
102	GDF6	1.00	298.43	0.79	6.18
165	MAX.chr10.130339363-130339534	0.87	24.92	0.60	4.71
212	MDFI_B	0.62	282.92	0.65	6.91
67	DLL4	1.00	42.28	0.68	1.03
103	GDF7_A	0.76	455.11	0.71	56.37
167	MAX.chr10.22624479-22624553	0.93	4917.08	0.82	50.91
214	MIAT_A	0.80	60.34	0.59	5.61
248	PYCARD	0.98	55.62	0.51	3.25
26	BMP4_B	0.98	270.79	0.52	16.41
124	JSRP1_A	1.00	57.52	0.61	3.18
174	MAX.chr14.103021656-103021718	0.91	4012.26	0.88	251.00
215	MIAT_B	0.92	196.61	0.77	6.56
252	RHBDL1_A	0.64	22.37	0.68	13.76
80	EMX2	0.85	485.41	0.86	40.81
126	KANK1	0.82	194.54	0.79	55.77
218	MMP23B	0.43	102.68	0.57	4.09
256	SBNO2	0.89	297.56	0.73	17.85
40	C5orf52	0.76	3076.88	0.59	35.54

81	EMX2OS	1.00	383.68	0.99	14.74
146	LRRC34	1.00	634.47	0.90	23.23
180	MAX.chr17.73073716-73073814	0.89	618.49	0.83	49.78
162	NBPF8	0.98	115.64	0.86	12.75
259	SEPT9_B	0.64	233.76	0.60	9.37
375	LOC440925_A	1.00	450.23	0.57	1.53
429	STX16_A	0.64	296.41	0.73	92.04
368	ITPKA	1.00	4030.59	0.69	2.55
11	AIM1_A	0.81	5230.38	0.78	101.58
75	EEF1A2	0.85	59.43	0.54	8.50
87	FEV	0.87	295.29	0.68	10.65
149	LRRC41_C	0.84	168.11	0.58	8.06
230	NFIC	1.00	141.82	0.70	9.17
302	VILL	0.99	171.70	0.88	11.74
404	MPZ_A	0.84	2691.51	0.66	16.38

Table 14. DMRs distinguishing 1) endometrioid EC and buffy coat and 2) endometrioid EC and normal endometrium and normal cervicovaginal tissue

DMR No.	Gene Name	AUC / Buffy Coat	FC / Buffy Coat	AUC / normal endometrium and normal cervicovaginal tissue	FC / normal endometrium and normal cervicovaginal tissue
262	SFMBT2_B	0.99	4102.95	0.87	40.06
273	SMTN	1.00	177.04	0.72	6.74
278	SQSTM1	1.00	152.79	0.84	14.04
312	ZNF323_A	0.89	767729.43	0.89	625.39
314	ZNF506	0.94	1764.70	0.87	31.61
318	ZNF90	1.00	286.45	0.84	11.44
2	ACOXL_A	0.72	1420.62	0.62	16.52
55	CLDN7	1.00	18.78	0.55	0.79
148	LRRC41_B	1.00	137.20	0.52	6.55
204	MAX.chr7.104624356-104624730	0.80	189.27	0.81	102.12
226	NDRG2	0.69	189.12	0.72	74.17
57	CYP11A1	0.89	356.99	0.60	6.46
88	FKBP11_A	0.96	63.66	0.83	16.72
207	MAX.chr8.145103829-145103992	1.00	4309.89	0.93	70.36
10	AHSA2	0.93	99.00	0.76	9.24
59	CYTH2	1.00	443.30	0.94	10.42
100	GATA2_B	0.91	1201.79	0.68	30.04
152	LRRC8D_A	0.96	1104.73	0.76	38.68
208	MAX.chr8.145104263-145104422	1.00	1291.27	0.82	63.05
234	OBSCN_A	0.89	2144.25	0.73	24.64
63	DIDO1_A	0.99	1143.24	0.90	20.39

102	GDF6	1.00	182.30	0.73	3.78
165	MAX.chr10.130339363-130339534	0.92	40.14	0.69	7.59
212	MDFI_B	0.83	545.42	0.85	13.31
67	DLL4	0.98	17.08	0.52	0.42
103	GDF7_A	0.59	343.11	0.57	42.50
167	MAX.chr10.22624479-22624553	0.97	12943.30	0.92	134.01
214	MIAT_A	0.91	1058.99	0.66	98.50
248	PYCARD	1.00	47.75	0.55	2.79
26	BMP4_B	0.99	194.14	0.68	11.76
124	JSRP1_A	1.00	136.00	0.91	7.51
174	MAX.chr14.103021656-103021718	0.93	3958.93	0.89	247.66
215	MIAT_B	0.94	436.40	0.73	14.56
252	RHBDL1_A	0.89	35.39	0.86	21.78
80	EMX2	0.75	196.50	0.75	16.52
126	KANK1	0.93	171.50	0.88	49.17
218	MMP23B	0.44	43.50	0.59	1.73
256	SBNO2	1.00	270.32	0.90	16.21
40	C5orf52	0.90	10081.84	0.88	116.45
81	EMX2OS	1.00	413.19	0.88	15.88
146	LRRC34	0.94	1405.18	0.81	51.45
180	MAX.chr17.73073716-73073814	0.88	297.35	0.73	23.93
162	NBPF8	1.00	281.71	0.99	31.05
259	SEPT9_B	0.62	839.24	0.57	33.62
375	LOC440925_A	1.00	370.18	0.46	1.26
429	STX16_A	0.81	147.65	0.83	45.85
368	ITPKA	1.00	3924.69	0.73	2.48
11	AIM1_A	0.67	1141.81	0.65	22.18
75	EEF1A2	0.87	127.52	0.60	18.24
87	FEV	0.89	2127.53	0.77	76.74
149	LRRC41_C	0.85	340.27	0.56	16.31
230	NFIC	0.99	47.68	0.68	3.08
302	VILL	1.00	477.74	0.94	32.67
404	MPZ_A	0.96	9032.17	0.86	54.96

These results provided a rich source of highly performing candidates to take into independent sample testing. Of the original 56 MDMs, 33 were selected. Most fell within the AUC range of 0.90 – 1.00, but others were included which had extremely high FC numbers (very little background) and/or those which exhibited complementarity with other MDMs. All MDM assays demonstrated high analytical performance – linearity, efficiency, sequence specificity (assessed using melt curve analysis), and strong amplification.

In round 2 validation, as in the previous step, experiments were conducted that ran the entire sample and marker set in one batch. ~10 ng of FFPE-derived sample DNA was run per marker – 350 total. EC overall and subtype vs normal tissue (combined) results are listed in

Tables 15, 16, 17, 18 and 19. Multiple MDMs showed marked methylation fold changes (10 to >1000) across all EC histologies vs BE (benign endometrium). Cross validated AUCs are listed in Table 20.

Table 15. DMRs distinguishing EC and normal endometrial tissue.

DMR No.	Gene Annotation	AUC (All EC vs normal endometrial tissue)	FC (All EC vs normal endometrial tissue)
262	SFMBT2_B	0.86194	22.62
278	SQSTM1	0.74307	50.73
312	ZNF323_A	0.69116	481.00
314	ZNF506	0.81957	19.51
318	ZNF90	0.86506	6.43
204	MAX.chr7.104624356-104624730	0.6905	10.48
207	MAX.chr8.145103829-145103992	0.87773	22.51
59	CYTH2	0.8939	16.18
100	GATA2_B	0.8156	170.63
152	LRRC8D_A	0.84946	17.70
208	MAX.chr8.145104263-145104422	0.82487	7.05
234	OBSCN_A	0.85683	14.72
63	DIDO1_A	0.84704	214.16
212	MDFI_B	0.66076	47.95
103	GDF7_A	0.71296	32.35
167	MAX.chr10.22624479-22624553	0.88605	77.62
124	JSRP1_A	0.8661	3.73
174	MAX.chr14.103021656-103021718	0.79749	94.45
80	EMX2	0.79196	8.63
126	KANK1	0.76775	47.74
40	C5orf52	0.7391	69.44
81	EMX2OS	0.94827	29.31
146	LRRC34	0.77664	52.44
162	NBPF8	0.92492	14.57
259	SEPT9_B	0.70265	165.86
375	LOC440925_A	0.5348	1.29
429	STX16_A	0.694	1.50
368	ITPKA	0.77882	2.01
11	AIM1_A	0.59943	41.13
75	EEF1A2	0.62411	14.11
149	LRRC41_C	0.77683	9.42
302	VILL	0.84232	7.49

404	MPZ_A	0.85494	112.07
-----	-------	---------	--------

Table 16. DMRs distinguishing clear cell EC and normal endometrial tissue.

DMR No.	Gene Annotation	AUC (Clear Cell EC vs tissue)
262	SFMBT2_B	0.93333
278	SQSTM1	0.90431
312	ZNF323_A	0.9
314	ZNF506	0.60902
318	ZNF90	0.90353
204	MAX.chr7.104624356-104624730	0.76549
207	MAX.chr8.145103829-145103992	0.9302
59	CYTH2	1
100	GATA2_B	0.76549
152	LRRC8D_A	0.89725
208	MAX.chr8.145104263-145104422	0.79373
234	OBSCN_A	0.98745
63	DIDO1_A	0.91922
212	MDFI_B	0.95059
103	GDF7_A	0.93059
167	MAX.chr10.22624479-22624553	0.87843
124	JSRP1_A	0.92471
174	MAX.chr14.103021656-103021718	0.96627
80	EMX2	0.80863
126	KANK1	0.69098
40	C5orf52	0.70275
81	EMX2OS	0.96863
146	LRRC34	0.90588
162	NBPF8	0.85647
259	SEPT9_B	0.96784
375	LOC440925_A	0.72784
429	STX16_A	0.79608
368	ITPKA	0.7702
11	AIM1_A	0.71216
75	EEF1A2	0.95373
149	LRRC41_C	0.89647
302	VILL	0.89725
404	MPZ_A	0.9098

Table 17. DMRs distinguishing serous EC and normal endometrial tissue.

DMR No.	Gene Annotation	AUC (Serous EC vs tissue)
262	SFMBT2_B	0.78321

278	SQSTM1	0.66049
312	ZNF323_A	0.80716
314	ZNF506	0.75012
318	ZNF90	0.82074
204	MAX.chr7.104624356-104624730	0.78667
207	MAX.chr8.145103829-145103992	0.87654
59	CYTH2	0.89827
100	GATA2_B	0.74963
152	LRRC8D_A	0.8716
208	MAX.chr8.145104263-145104422	0.77235
234	OBSCN_A	0.91407
63	DIDO1_A	0.94321
212	MDFI_B	0.58346
103	GDF7_A	0.63259
167	MAX.chr10.22624479-22624553	0.84049
124	JSRP1_A	0.79407
174	MAX.chr14.103021656-103021718	0.72444
80	EMX2	0.78815
126	KANK1	0.73728
40	C5orf52	0.45728
81	EMX2OS	0.99802
146	LRRC34	0.75506
162	NBPF8	0.85728
259	SEPT9_B	0.57926
375	LOC440925_A	0.56815
429	STX16_A	0.55111
368	ITPKA	0.74617
11	AIM1_A	0.6079
75	EEF1A2	0.68049
149	LRRC41_C	0.9437
302	VILL	0.86963
404	MPZ_A	0.80296

Table 18. DMRs distinguishing carcinosarcoma EC and normal endometrial tissue.

DMR No.	Gene Annotation	AUC (Carcinosarcoma EC vs tissue)
262	SFMBT2_B	0.73095
278	SQSTM1	0.80786
312	ZNF323_A	0.61357
314	ZNF506	0.94381
318	ZNF90	0.90048
204	MAX.chr7.104624356-104624730	0.74429
207	MAX.chr8.145103829-145103992	0.85667
59	CYTH2	0.83048
100	GATA2_B	0.81048
152	LRRC8D_A	0.86429
208	MAX.chr8.145104263-145104422	0.83524

234	OBSCN_A	0.8519
63	DIDO1_A	0.83119
212	MDFI_B	0.56571
103	GDF7_A	0.73905
167	MAX.chr10.22624479-22624553	0.9381
124	JSRP1_A	0.86714
174	MAX.chr14.103021656-103021718	0.82905
80	EMX2	0.75619
126	KANK1	0.8681
40	C5orf52	0.79095
81	EMX2OS	0.95762
146	LRRC34	0.80643
162	NBPF8	0.93429
259	SEPT9_B	0.74738
375	LOC440925_A	0.60571
429	STX16_A	0.64143
368	ITPKA	0.75238
11	AIM1_A	0.54857
75	EEF1A2	0.46333
149	LRRC41_C	0.73667
302	VILL	0.87667
404	MPZ_A	0.83143

Table 19. DMRs distinguishing endometrioid EC and normal endometrial tissue.

DMR No.	Gene Annotation	AUC (Endometrioid grade 3 vs tissue)
262	SFMBT2_B	0.9177
278	SQSTM1	0.66575
312	ZNF323_A	0.7
314	ZNF506	0.79977
318	ZNF90	0.8708
204	MAX.chr7.104624356-104624730	0.64276
207	MAX.chr8.145103829-145103992	0.94253
59	CYTH2	0.8731
100	GATA2_B	0.8092
152	LRRC8D_A	0.80598
208	MAX.chr8.145104263-145104422	0.8777
234	OBSCN_A	0.88736
63	DIDO1_A	0.81655
212	MDFI_B	0.67172
103	GDF7_A	0.71517
167	MAX.chr10.22624479-22624553	0.88138
124	JSRP1_A	0.91218
174	MAX.chr14.103021656-103021718	0.80598
80	EMX2	0.81195
126	KANK1	0.80276
40	C5orf52	0.83264
81	EMX2OS	0.9269

146	LRRC34	0.72552
162	NBPF8	0.96874
259	SEPT9_B	0.69425
375	LOC440925_A	0.42759
429	STX16_A	0.70851
368	ITPKA	0.84276
11	AIM1_A	0.67218
75	EEF1A2	0.58713
149	LRRC41_C	0.71908
302	VILL	0.84483
404	MPZ_A	0.87034

Table 20.

DMR No.	Gene Annotation	AUC	AUC.Lower	AUC.Upper
	Best fit Panel	0.9797	0.9618	0.9976
81	EMX2OS	0.9079	0.8693	0.9465
59	CYTH2	0.885	0.8398	0.9302
162	NBPF8	0.8791	0.835	0.9231
167	MAX.chr10.22624479- 22624553	0.8529	0.804	0.9017
404	MPZ_A	0.8387	0.786	0.8914
262	SFMBT2_B	0.8366	0.7849	0.8884
318	ZNF90	0.8308	0.7771	0.8845
100	GATA2_B	0.8231	0.7693	0.8769
63	DIDO1_A	0.8134	0.7577	0.8691
124	JSRP1_A	0.8041	0.7483	0.8599
234	OBSCN_A	0.804	0.7478	0.8602
207	MAX.chr8.145103829- 145103992	0.8028	0.7467	0.8588
126	KANK1	0.7859	0.7276	0.8442
174	MAX.chr14.103021656- 103021718	0.7821	0.7233	0.841
314	ZNF506	0.7707	0.7103	0.8312
152	LRRC8D_A	0.7631	0.7016	0.8246
368	ITPKA	0.7587	0.6952	0.8221
302	VILL	0.7471	0.6835	0.8108
40	C5orf52	0.741	0.6762	0.8058
312	ZNF323_A	0.7311	0.6662	0.796
103	GDF7_A	0.7182	0.6523	0.7842
259	SEPT9_B	0.7131	0.6443	0.782
146	LRRC34	0.7107	0.6436	0.7779

208	MAX.chr8.145104263-145104422	0.704	0.6365	0.7715
80	EMX2	0.6805	0.6115	0.7495
149	LRRC41_C	0.6747	0.6055	0.744
428	ST8SIA1	0.6465	0.5744	0.7186
429	STX16_A	0.6282	0.5561	0.7004
278	SQSTM1	0.623	0.5502	0.6959
75	EEF1A2	0.5977	0.5233	0.6722
212	MDFI_B	0.5898	0.5155	0.664
204	MAX.chr7.104624356-104624730	0.5781	0.5033	0.6528
11	AIM1_A	0.5764	0.5011	0.6517
375	LOC440925_A	0.4754	0.4	0.5507

Next, the data was plotted in a heat matrix format which allowed complementarity visualization. A cross-validated 3-MDM panel was derived from rPART modeling (*EMX2OS*, *NBPF8*, *SFMBT2*) which discriminated overall EC from BE with 97% specificity and 97% sensitivity with an AUC of 0.98 (see, Fig. 1).

Some MDMs discriminated clear cell histology from BE and all other EC histologies (*MDFI*, *GDF7_A*, *SEPTIN9*, *EEF1A2*) and *C5orf52* discriminated endometrioid histologies (G1/2E, G3E) from BE and all other EC histologies.

In summary, whole methylome sequencing, stringent filtering criteria, and biological validation yielded outstanding candidate MDMs for EC. Some MDMs discriminate all EC histologies from BE with comparably high sensitivity, while others accurately distinguish among histologies.

Example II.

This example describes the materials and methods for Example I.

Samples:

Tissue and blood was obtained from Mayo Clinic biospecimen repositories with institutional IRB oversight. Samples were chosen with strict adherence to subject research authorization and inclusion/exclusion criteria. Cancer sub-types included 1) serous EC, 2) clear cell EC, 3) carcinosarcoma EC, and 4) endometrioid EC. Controls included non-neoplastic tissue and whole blood derived leukocytes. Tissues were macro-dissected and

histology reviewed by an expert GI pathologist. Samples were age sex matched, randomized, and blinded. DNA from 113 frozen tissues (16 grade 1/2 endometrioid (G1/2E), 16 grade 3 endometrioid (G3E), 11 serous, 11 clear cell ECs, 15 uterine carcinosarcomas, 44 benign endometrial (BE) tissues (14 proliferative, 12 atrophic, 18 disordered proliferative), 70 formalin fixed paraffin embedded (FFPE) cervical cancers (CC) (36 squamous cell, 34 adenocarcinomas), and 18 buffy coats from cancer-free females was purified using the QIAamp DNA Tissue Mini kit (frozen tissues), QIAamp DNA FFPE Tissue kit (FFPE tissues), and QIAamp DNA Blood Mini kit (buffy coat samples) (Qiagen, Valencia CA). DNA was re-purified with AMPure XP beads (Beckman-Coulter, Brea CA) and quantified by PicoGreen (Thermo-Fisher, Waltham MA). DNA integrity was assessed using qPCR.

Sequencing:

RRBS sequencing libraries were prepared following the Meissner protocol (see, Gu et al. Nature Protocols 2011) with modifications. Samples were combined in a 4-plex format and sequenced by the Mayo Genomics Facility on the Illumina HiSeq 2500 instrument (Illumina, San Diego CA). Reads were processed by Illumina pipeline modules for image analysis and base calling. Secondary analysis was performed using SAAP-RRBS, a Mayo developed bioinformatics suite. Briefly, reads were cleaned-up using Trim-Galore and aligned to the GRCh37/hg19 reference genome build with BSMAP. Methylation ratios were determined by calculating $C/(C+T)$ or conversely, $G/(G+A)$ for reads mapping to reverse strand, for CpGs with coverage $\geq 10X$ and base quality score ≥ 20 .

Biomarker Selection:

Individual CpGs were ranked by hypermethylation ratio, namely the number of methylated cytosines at a given locus over the total cytosine count at that site. For cases, the ratios were required to be ≥ 0.20 (20%); for tissue controls, ≤ 0.05 (5%); for buffy coat controls, ≤ 0.01 (1%). CpGs which did not meet these criteria were discarded. Subsequently, candidate CpGs were binned by genomic location into DMRs (differentially methylated regions) ranging from approximately 60 – 200bp with a minimum cut-off of 5 CpGs per region. DMRs with excessively high CpG density ($>30\%$) were excluded to avoid GC-related amplification problems in the validation phase. For each candidate region, a 2-D matrix was created which compared individual CpGs in a sample to sample fashion for both cases and controls. We analyzed overall EC vs all benign endometria and/or no-cancer buffy coat, as

well as subtype comparisons. These CpG matrices were then compared back to the reference sequence to assess whether genomically contiguous methylation sites had been discarded during the initial filtering. From this subset of regions, final selections required coordinated and contiguous hypermethylation (in cases) of individual CpGs across the DMR sequence on a per sample level. Conversely, control samples had to have at least 10-fold less methylation than cases and the CpG pattern had to be more random and less coordinated. At least 10% of cancer samples within a subtype cohort were required to have at least a 50% hypermethylation ratio for every CpG site within the DMR.

In a separate analysis, we utilized a proprietary DMR identification pipeline and regression package to derive DMRs based on average methylation values of the CpG. The difference in average methylation percentage was compared between EC cases, tissue controls and buffy coat controls; a tiled reading frame within 100 base pairs of each mapped CpG was used to identify DMRs where control methylation was $<5\%$; DMRs were only analyzed if the total depth of coverage was 10 reads per subject on average and the variance across subgroups was >0 . Assuming a biologically relevant increase in the odds ratio of $>3x$ and a coverage depth of 10 reads, ≥ 18 samples per group were required to achieve 80% power with a two-sided test at a significance level of 5% and assuming binomial variance inflation factor of 1.

Following regression, DMRs were ranked by p-value, area under the receiver operating characteristic curve (AUC) and fold-change difference between cases and all controls. No adjustments for false discovery were made during this phase as independent validation was planned *a priori*.

Biomarker Validation:

A subset of the DMRs was chosen for further development. The criteria were primarily the logistic-derived area under the ROC curve metric which provided a performance assessment of the discriminant potential of the region. An AUC of 0.85 was chosen as the cut-off. In addition, the methylation fold-change ratio (average cancer hypermethylation ratio/average control hypermethylation ratio) was calculated and a lower limit of 10 was employed for tissue vs tissue comparisons and 20 for the tissue vs buffy coat comparisons. P values were required to be less than 0.01. DMRs had to be listed in both the average and individual CpG selection processes. Quantitative methylation specific PCR (qMSP) primers were designed for candidate regions using MethPrimer (Li LC and Dahiya

R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002 Nov;18(11):1427-31 PMID: 12424112) and QC checked on 20ng (6250 equivalents) of positive and negative genomic methylation controls. Multiple annealing temperatures were tested for optimal discrimination. Validation was performed in two stages of qMSP. The first consisted of re-testing the sequenced DNA samples. This was done to verify that the DMRs were truly discriminant and not the result of over-fitting the extremely large next generation datasets. The second utilized a larger set of independent samples:

Group	N
Endometrial Cancer - Carcinosarcoma	36
Endometrial Cancer - Clear Cell	22
Endometrial Cancer - Endometrioid Gr 1/2	36
Endometrial Cancer - Endometrioid Gr 3	36
Endometrial Cancer - Serous	32
Endometrial Benign - Secretory	5
Endometrial Benign - Proliferative	32
Endometrial Benign - Atrophic	28
Endometrial Benign - Disordered Proliferative	19
Cervical Cancer - Squamous	36
Cervical Cancer - Adenocarcinoma	36

These tissues were identified as before, with expert clinical and pathological review. DNA purification was performed as previously described. The EZ-96 DNA Methylation kit (Zymo Research, Irvine CA) was used for the bisulfite conversion step. 10ng of converted DNA (per marker) was amplified using SYBR Green detection on Roche 480 LightCyclers (Roche, Basel Switzerland). Serially diluted universal methylated genomic DNA (Zymo Research) was used as a quantitation standard. A CpG agnostic ACTB (β -actin) assay was used as an input reference and normalization control. Results were expressed as methylated copies (specific marker)/copies of ACTB.

Statistics:

Results were analyzed logistically for individual MDMs (methylated DNA marker) performance. For combinations of markers, two techniques were used. First, the rPart technique was applied to the entire MDM set and limited to combinations of 3 MDMs, upon which an rPart predicted probability of cancer was calculated. The second approach used random forest regression (rForest) which generated 500 individual rPart models that were fit to boot strap samples of the original data (roughly 2/3 of the data for training) and used to

estimate the cross-validation error (1/3 of the data for testing) of the entire MDM panel and was repeated 500 times. to avoid spurious splits that either under- or overestimate the true cross-validation metrics. Results were then averaged across the 500 iterations.

Example III.

This example describes identification of endometrial cancer tissue markers and plasma markers for detecting breast cancer.

Candidate methylation markers for the detection of EC, clear cell EC, serous EC, carcinosarcoma EC, and endometrioid EC were identified by RRBS of EC tissue samples and normal endometrial tissue samples. To identify methylated DNA markers, 165 samples per patient group (i.e., 19 benign, 34 adenocarcinoma, 36 squamous cell carcinoma, 15 endometrial cancer carcinoma, 11 endometrial cancer clear cell, 5 endometrial cancer endometrioid grade 1, 11 endometrial cancer endometrioid grade 2, 16 endometrial cancer endometrioid grade 3, and 18 normal buffy coat) underwent an RRBS process followed by an alignment to a bisulfite converted human genome. CpG regions of high ratios of methylation in endometrial cancer relative to normal endometrium and buffy coat were selected and mapped to their gene names

After markers were selected by RRBS, a total of 61 methylation markers were identified and target enrichment long-probe quantitative amplified signal assays were designed and ordered (see, e.g., WO2017/075061 and U.S. Patent Application Serial No. 15,841,006 for general techniques). Table 21 shows the marker chromosomal regions used for the 61 methylation markers. Tables 22 and 23 shows primer information and probe information for the markers. Fig. 2 further provides marker chromosomal regions used for the 61 methylation markers and related primer and probe information.

Table 21. Identified methylated regions distinguishing EC tissue from normal endometrial tissue.

DMR No.	Gene Annotation	Region on Chromosome (starting base-ending base)
445	AGRN_B	chr1:975957-976046
446	AIM1_C	chr6:106960288-106960380
447	AKR7A3	chr1:19615293-19615389

448	C17orf107_B	chr17:4802690-4802828
449	DIDO1_B	chr20:61560628-61560728
81	EMX2OS	chr10:119294950-119295039
450	FKBP11_B	chr12:49319059-49319168
451	GDF7_B	chr2:20866007-20866135
452	JSRP1_B	chr19:2253227-2253345
453	LHFPL2_B	chr5:77806193-77806301
454	LOC100129726_B	chr2:43452148-43452235
150	LRRC41_D	chr1:46768830-46768913
455	LRRC8D_B	chr1:90308856-90308965
456	MAX.chr10:22624470-22624553	chr10:22624470-22624553
457	MAX.chr14:103021654-103021725	chr14:103021654-103021725
458	MAX.chr7:104624356-104624513	chr7:104624356-104624513
459	MAX.chr7:104624386-104624529	chr7:104624386-104624529
212	MDFI_B	chr6:41606379-41606439
460	OBSCN_B	chr1:228463593-228463689
461	RHBDL1_B	chr16:725588-725658
462	SEPT9_D	chr17:75447656-75447829
463	SFMBT2_E	chr10:7451008-7451110
464	SPDYA_B	chr2:29033347-29033484
465	ST3GAL2_B	chr16:70415003-70415106
302	VILL	chr3:38035645-38035743
466	ZNF323_B	chr6:28303870-28303974
467	SLC13A5_B	chr17:6616765-6616852
468	ZMIZ1_D	chr10:81002927-81003006
469	MAX.chr8:145103900-145103993	chr8:145103900-145103993
470	C8orf73_B	chr8:144650834-144650919
471	KBTBD11_B	chr8:1949507-1949586
472	LOC100192379_C	chr4:122686300-122686377
473	TRIM71_B	chr3:32859592-32859712
474	LOC440925_B	chr2:171570323-171570444
499	ARL5C	chr17:37321564-37321723
475	STX16_B	chr20:57224681-57224845
368	ITPKA	chr15:41787637-41787780
476	IRF4	chr6:393188-393284
477	CNTN4	chr3:2140464-2140527
478	GRIN2A	chr16:10277158-10277320

479	NOTCH3	chr19:15306498-15306625
480	PAX1	chr20:21683741-21683893
481	ZNF521	chr18:22929721-22929795
482	VSX1	chr20:25065266-25065458
483	CRHR2	chr7:30721989-30722099
484	FAM19A5	chr22:48885810-48885908
485	ASCL1	chr12:103352059-103352157
486	GLT1D1	chr12:129338254-129338322
487	T	chr6:166581961-166582112
488	CAPN2	chr1:223936903-223937040
489	RYR2_F	chr1:237205546-237205717
490	SIM2	chr21:38119993-38120059
491	TRH	chr3:129693484-129693575
492	JAM3	chr11:133938908-133939011
493	BARX1	chr9:96721498-96721597
494	ZNF671_B	chr1:161275554-161276006
495	TSPYL5	chr8:98290016-98290134
496	MPZ_B	chr1:161275554-161276006
497	CXCL12	chr10:44881200-44881315
498	PTGDR	chr14:52735270-52735400

Table 22. Primer Information For Markers Shown in Table 21.

DMR No.	Gene Annotation	Forward Primer 5'-3'	Seq ID	Reverse Primer 5'-3'	Seq ID
445	AGRN_B	GGTTGCGAGTACGGTA AGGTTT	109	AAAACTCAAAATACCGAA ACGCC	110
446	AIM1_C	TTGAGAGCGTTGTTAGG GACGAC	111	CGCGTTTAACGCCACCT C	113
447	AKR7A3	CGGGTTTCGTTTATCGG CGG	113	AACGTAAATCGAACTC GTAAACGAC	114
448	C17orf107_B	CGAAGTTTTATTTTCGAT TCGGGTTGTATCG	115	CCACGCCATATCCCCGC	116
449	DIDO1_B	AGGTTATCGGGTAGCG TTTAGG	117	CGTACCCCTCCCCGCT AC	118
81	EMX2OS	GTCGTTTACGCGAGCG ACG	119	CTCGAACAAAACAAACG CTACGTAAC	120
450	FKBP11_B	GGTTTTTATTTGGAGGG TTCGGAC	121	ACTACTCAATACGACGAT ATACCGAAC	122
451	GDF7_B	TCGTTTCGTTTTTCGGT TTTTGGTC	123	CCTTCTAAACGAAAACAA CGACTAACGAAA	124
452	JSRP1_B	TAGCGTTTTGTCGTTTT TTTTTTCGT	125	CGCAAAAATACCCCCGA AAAC	126
453	LHFPL2_B	GGAGGGCGGTTAGTAG CGT	127	ACGATATCGCTACGCGA CGAAA	128

454	LOC100129726_B	GTTGTGGTGTAAATTTGG GTCGC	129	ACACGCGCGATACGTTA CAC	130
150	LRRC41_D	CGTTCGTATAGTTCGAA TAGGGCG	131	CGACGCCAACGAAAAAC TC	132
455	LRRC8D_B	GGAGAATTCGAGTAGTA GTTGTAAACGGA	133	CAACCACCCGCCCGCC	134
456	MAX.chr10:226244 70-22624553	TGTTTACGTGGTATCGT TATTTTTTAATCGC	135	CGACGACCGCGAAAAAA AAAAACC	136
457	MAX.chr14:103021 654-103021725	TCGTGGGGAATAGTAG GACGGC	137	CCTCCCGACAAATAAAC GCGA	138
458	MAX.chr7:1046243 56-104624513	GGAGGTAGGTTGCGCG GG	139	CCAACTCAATTCCTCCTC CGC	140
459	MAX.chr7:1046243 86-104624529	GAGGAGGAATTGAGTT GGCGC	141	CAACCCATAATCCGATC CTATCTTCGA	142
212	MDFI_B	TTCGTACGAGTGAGTG GACG	143	CAAAAAACGATTCCCC GCAAA	144
460	OBSCN_B	TGGAGATTTACGTCGAG GGC	145	CCACGATCGACAAAACC TACGT	146
461	RHBDL1_B	GCGCGTGTGTTTGGTCG C	147	TCGTCCGCCTACCCGCC C	148
462	SEPT9_D	GGAGTTACGTTGTTTT GGGTTTCG	149	CTCTCCTAAAAACCCCG CTC	150
463	SFMBT2_E	GGATCGGGATCGAAGT TTGGAGAA	151	CTTATCTCCAAAACCG CGC	152
464	SPDYA_B	TTGGTTGTTTAATCGAA GGGAAGTAAAC	153	CTACCTCCCTTAAACAC GTCTCG	154
465	ST3GAL2_B	GGGCGTAGTTATTTTAT AGCGC	155	CACCAAAAAAACGAT CGCTACGAAA	156
302	VILL	CGGGGAAGACGGAGGT G	157	AAACCCCTACCTAACGT CTCCC	158
466	ZNF323_B	CGGGGTTGTAGTATTTT AATGATCGA	159	CTTCAACCAATAAACTCA AAACGACTAACG	160
467	SLC13A5_B	GGCGTTTTTTCGCGGTT TTG	161	GCGTCCCACAAACCCCG	162
468	ZMIZ1_D	CGTAGGGTGGGTGGTT ACGTTC	163	AACTTCCCACGACCCCG	164
469	MAX.chr8:1451039 00-145103993	GTTACGCGGTTTTTATT TTTGTGATTTTTCG	165	CTCATTAACCTCCAAAAA ACAACTAACTCGTC	166
470	C8orf73_B	GAGTTCGACGGTCGAG GCG	167	ACTACGCCCTCCACGC	168
471	KBTBD11_B	TCGTTTTAGCGGCGGA AGG	169	CCGCGAACCACCGC	170
472	LOC100192379_C	GGTTGTAGTTGGAGGG CGAG	171	CGAAACGCCCTCGCGA	172
473	TRIM71_B	GTTGTGTAAGGAGATGT GCGGTTTC	173	AAACGACGACGCGAACG AA	174
474	LOC440925_B	CGTAGTGC GTTTTCGC GAGTC	175	CGCCCTAAAACATTAAAA ATACGAAACCG	176
499	ARL5C	GTTTCGGGGTTTGTTAA GAGACG	177	ACTACTACGAATTCCTA CGATTATAACTTCG	178
475	STX16_B	AGTTTTTAGTTCGGTTC GCGC	179	CCCGAAAACGCTTCGCA ACG	180
368	ITPKA	GATAAGGTAGGGAAGT TGTGGCG	181	CCTCTAATATCACTAACA AACCCCATCG	182
476	IRF4	CGCGGTGAGTTGCGGT AAC	183	CGAAATACTTACCGCTAT CGATCTAATCGA	184

477	CNTN4	GGTAGTTCGAATTTTCGG CGC	185	CTCCCTCCCGACGCTCG	186
478	GRIN2A	GTAGTTTTTCGGCGGC GACG	187	CCTTATTTACCGCCGTAC GCT	188
479	NOTCH3	GGTCGCGTTTTGTTTGG CG	189	CGCGCGTCGAAAAAAA CGCG	190
480	PAX1	CGATCGTGTAGAAGGTT GTAGCG	191	TTTCCCGCAACCAACTAT ACGCG	192
481	ZNF521	CGGGATTTAGCGGGTT CGG	193	CCCGAAAACGAAAAACA AAAAACGAC	194
482	VSX1	TCGGGGTGTTCGTCGTAG TTGTTAAATTTAC	195	CATTCTTTTAACCGCCAA AACGCG	196
483	CRHR2	GGGTTTTGGTTTTCGTT AGTTTAGTTTC	197	ACAACCTCTAAACGACCG AAAATAACG	198
484	FAM19A5	GCGGTCGGAGTTTAGT TAGCG	199	ACCTACGACTACCTCCT AAACGCG	200
485	ASCL1	GTCGTAGTTTTAGTAGT TTTTTTGTCGTTTCG	201	CGACCGCCGCGACTAC	202
486	GLT1D1	GACGCGGGGCGTTTAG T	203	CGACTCGAAACGACCCC GA	204
487	T	GGAGTTTTAGGCGGCG TTACG	205	ACCGCGAAAACACCCGA C	206
488	CAPN2	GTTTCGCGCGGTTTTAC GGT	207	CGCCCTTCTCCTCCCGC	208
489	RYR2_F	GGAGGTTTCGCGTTTC GATTA	209	CGAACGATCCCCGCCTA C	210
490	SIM2	GGTTTAGCGCGGGTTTT TCG	211	CCCCGAACCTCCCGAAC T	212
491	TRH	TTTTCGTTGATTTATTC GAGTCGTC	213	GAACCCTCTTCAAATAAA CCGC	214
492	JAM3	TGGTCGTTTTAGCGTTA TGTCG	215	CGAAAACTACAAACCGC GC	216
493	BARX1	CGTTAATTTGTTAGATA GAGGGCG	217	TCCGAACAACCGCCTAC	218
494	ZNF671_B	GTTGTCGGGAGCGGTA GG	219	CCAATATCCCGAAACGC GTCT	220
495	TSPYL5	TTTGTTTCGGTTTTTGG CG	221	CGCCACCATAAACGACC	222
496	MPZ_B	GGTTAGGGGTGGAGTT CGTTA	223	ACTCCGAACCTCTACTCAT CCTTTC	224
497	CXCL12	TCGGCGGTTTTAGTAA AAGCG	225	AAATCTCCCGTCCCACT CC	226
498	PTGDR	GGGTTTCGGGGATTATA ATTACGG	227	CTAAATCACCTCCTACTA CTAACGCTAATAAC	228

Table 23. Probe Information For Markers Shown in Table 21.

DMR No.	Gene Annotation	Probe Sequence	Seq ID
445	AGRN_B	CGCGCCGAGG CCGTACCCACGTCCA/3C6/	229
446	AIM1_C	AGGCCACGGACG CGTCGTGAACACCG/3C6/	230
447	AKR7A3	CGCGCCGAGG CGTCGAACACCTTCGAC/3C6/	231
448	C17orf107_B	AGGCCACGGACG CGACTACGCCACGTAAA/3C6/	232

449	DIDO1_B	CGCGCCGAGG GTTTCGGTTTTTGGGAGG/3C6/	233
81	EMX2OS	AGGCCACGGACG CGACAACATAAACTCCGTACG/3C6/	234
450	FKBP11_B	CGCGCCGAGG CGGGATTTTCGGTTTCGA/3C6/	235
451	GDF7_B	AGGCCACGGACG CGTTTACGTATATAGTCGGTAGT/3C6/	236
452	JSRP1_B	CGCGCCGAGG CGCTCACGAATAAACGATCC/3C6/	237
453	LHFPL2_B	AGGCCACGGACG TCGTTAGTTTTCGTTTCGT/3C6/	238
454	LOC100129726_B	CGCGCCGAGG CGGTTTTTCGCGGGA/3C6/	239
150	LRRC41_D	AGGCCACGGACG CGACCTCGAACCCCAA/3C6/	240
455	LRRC8D_B	CGCGCCGAGG CCGCTCGCTCACAA/3C6/	241
456	MAX.chr10:22624470- 22624553	AGGCCACGGACG CGGTTTTACGAAATGTAAATTT/3C6/	242
457	MAX.chr14:103021654- 103021725	CGCGCCGAGG CGTCGAGGTCGTTTCG/3C6/	243
458	MAX.chr7:104624356- 104624513	AGGCCACGGACG GCGGAAGTGCGTT/3C6/	244
459	MAX.chr7:104624386- 104624529	CGCGCCGAGG CGCGGGTTAGTTGTT/3C6/	245
212	MDFI_B	AGGCCACGGACG ATACGCGCCTCCCA/3C6/	246
460	OBSCN_B	CGCGCCGAGG CGTTTCGTTATCGTTTGGTTT/3C6/	247
461	RHBDL1_B	AGGCCACGGACG CCTACCGCACACGC/3C6/	248
462	SEPT9_D	CGCGCCGAGG CGATCCTACCGACCTCGA/3C6/	249
463	SFMBT2_E	AGGCCACGGACG CGCTCCCGCCCTTCT/3C6/	250
464	SPDYA_B	CGCGCCGAGG CGGTTTTAACGTAAGTTTGATTG/3C6/	251
465	ST3GAL2_B	AGGCCACGGACG CGGTCGAGGTGGGA/3C6/	252
302	VILL	CGCGCCGAGG GCGGGTGGAGAAGG/3C6/	253
466	ZNF323_B	AGGCCACGGACG GCGGGTGGAGAAGG/3C6/	254
467	SLC13A5_B	AGGCCACGGACG GCATTTCCGACCTTTACGA/3C6/	255
468	ZMIZ1_D	CGCGCCGAGG GAAAAATAACCCCGCCC/3C6/	256
469	MAX.chr8:145103900- 145103993	AGGCCACGGACG CGTAGGGTTCGCGAG/3C6/	257
470	C8orf73_B	CGCGCCGAGG CGATACATCCGCGCG/3C6/	258
471	KBTBD11_B	AGGCCACGGACG GCGGATTGAGTTTCGTG/3C6/	259
472	LOC100192379_C	AGGCCACGGACG GCGCGGTTATTTTTTCGT/3C6/	260
473	TRIM71_B	CGCGCCGAGG GCGCGTCGTTTCGTATATTT/3C6/	261
474	LOC440925_B	AGGCCACGGACG CGTCGGCGTCGTTTT/3C6/	262
499	ARL5C	CGCGCCGAGG GCGTTAAAAACCTCGCG/3C6/	263
475	STX16_B	CGCGCCGAGG GCGTTATACTCTTTCTCTAAACAC/3C6/	264
368	ITPKA	AGGCCACGGACG CGGCGATTAGTTTTTTGTCG/3C6/	265
476	IRF4	CGCGCCGAGG GACCTCCGAACCTATAAACCC/3C6/	266

477	CNTN4	AGGCCACGGACG CGGGAAGTTTCGTTAGTGG/3C6/	267
478	GRIN2A	CGCGCCGAGG CGTTAGGTTTTTTTAGTCGTCG/3C6/	268
479	NOTCH3	AGGCCACGGACG TCTCGAAACGAATAACCGC/3C6/	269
480	PAX1	CGCGCCGAGG GCTACGCTAAACGCCG/3C6/	270
481	ZNF521	AGGCCACGGACG GATCGAAAACACACAACCC/3C6/	271
482	VSX1	CGCGCCGAGG GCGGGCGTATTAGT/3C6/	272
483	CRHR2	AGGCCACGGACG CGGGTCGCGTTTAGG/3C6/	273
484	FAM19A5	AGGCCACGGACG CGATTTTTCGGGTAGTTTTTGG/3C6/	274
485	ASCL1	CGCGCCGAGG GGTTTTTCGGTCGAGATG/3C6/	275
486	GLT1D1	AGGCCACGGACG CGACCGTAACAAAAAACAAAC/3C6/	276
487	T	CGCGCCGAGG ACGCGACTAAAAAACCTAAC/3C6/	277
488	CAPN2	AGGCCACGGACG CGCCGAAACAACTAATCC/3C6/	278
489	RYS2_F	CGCGCCGAGG CGCGAACTTCAAAAATACGA/3C6/	279
490	SIM2	AGGCCACGGACG ATTCGCGTTTCGAGCG/3C6/	280
491	TRH	AGGCCACGGACG GCGGTAGTGGTCGTAG/3C6/	281
492	JAM3	AGGCCACGGACG CGTTTGCGGTAGATATAAGC/3C6/	282
493	BARX1	AGGCCACGGACG CCGCGCTACCGCTA/3C6/	283
494	ZNF671_B	CGCGCCGAGG CCGCGCTACCGCTA/3C6/	284
495	TSPYL5	AGGCCACGGACG CGAAAAATCCACGC/3C6/	285
496	MPZ_B	CGCGCCGAGG GCGTTTCGATCGGGG/3C6/	286
497	CXCL12	AGGCCACGGACG GCGGGAGGATTTTCGATTTC/3C6	287
498	PTGDR	CGCGCCGAGG CGTAACTCCATCTCGATAACC/3C6/	288

All developed assays were triplexed with the reference assay B3GALT6 which reports to Quasar670 (see, Table 26). The assays were tested on 156 benign and cancer samples with the following distribution and subtypes: 21 cervical cancer adenocarcinoma, 20 cervical cancer squamous, 13 endometrial cancer carcinosarcoma, 11 endometrial cancer clear cell, 10 endometrial cancer serous, 4 endometrial cancer endometrioid grade 1, 9 endometrial cancer endometrioid grade 2, 16 endometrial cancer endometrioid grade 3, 16 benign cervicovaginal, 6 endometrial benign atrophic, 3 endometrial benign disordered proliferative, 6 endometrial benign proliferative, endometrial benign secretory, 4 endometrial hyperplasia complex no atypia, 10 endometrial hyperplasia complex with atypia, and 2 endometrial hyperplasia simple no atypia.

Sensitivities for each methylation marker were calculated at a 95% cutoff per subtype and listed in Tables 24 and 25. Table 24 shows the endometrial tissue sensitivity at 95% for the markers shown in Table 21 for carcinosarcoma EC, clear cell EC, and serous EC. Table 25 shows the endometrial tissue sensitivity at 95% for the markers shown in Table 21 for endometrioid EC Grade 1, endometrioid EC Grade 2, and endometrioid EC Grade 3.

Table 24. Endometrial tissue sensitivity at 95% for the markers shown in Table 21 for carcinosarcoma EC, clear cell EC, and serous EC.

DMR No.	Marker	Carcinosarcoma EC	Clear Cell EC	Serous EC
495	TSPYL5	77%	55%	70%
496	MPZ_B	46%	27%	70%
491	TRH	85%	55%	50%
497	CXCL12	8%	27%	10%
476	IRF4	38%	45%	40%
477	CNTN4	8%	45%	30%
478	GRIN2A	15%	45%	20%
479	NOTCH3	62%	9%	20%
480	PAX1	23%	45%	20%
481	ZNF521	8%	55%	30%
482	VSX1	23%	55%	30%
492	JAM3	15%	27%	20%
483	CRHR2	23%	45%	10%
484	FAM19A5	15%	36%	10%
485	ASCL1	23%	45%	10%
486	GLT1D1	15%	36%	10%
487	T	23%	45%	10%
488	CAPN2	31%	55%	40%
489	RYR2_F	8%	45%	10%
498	PTGDR	54%	73%	60%
493	BARX1	31%	18%	10%
494	ZNF671_B	54%	55%	80%
490	SIM2	46%	18%	0%
472	LOC100192379_C	0%	0%	30%
446	AIM1_C	31%	55%	40%
445	AGRN_B	38%	82%	60%
459	MAX.chr7:104624386-104624529	92%	91%	80%
81	EMX2OS	100%	91%	90%
449	DIDO1_B	85%	91%	80%
451	GDF7_B	46%	64%	60%
450	FKBP11_B	85%	64%	80%

453	LHFPL2_B	62%	55%	10%
447	AKR7A3	38%	64%	20%
150	LRRC41_D	31%	64%	90%
454	LOC100129726_B	62%	9%	30%
448	C17orf107_B	69%	55%	80%
456	MAX.chr10:22624470-22624553	46%	64%	30%
455	LRRC8D_B	62%	64%	60%
458	MAX.chr7:104624356-104624513	69%	64%	70%
457	MAX.chr14:103021654-103021725	46%	82%	40%
212	MDFI_B	15%	55%	20%
464	SPDYA_B	54%	73%	50%
461	RHBDL1_B	46%	36%	60%
460	OBSCN_B	69%	91%	60%
463	SFMBT2_E	23%	45%	10%
462	SEPT9_D	38%	82%	10%
465	ST3GAL2_B	92%	27%	20%
452	JSRP1_B	46%	82%	70%
368	ITPKA	8%	0%	0%
466	ZNF323_B	62%	55%	40%
302	VILL	54%	18%	40%
468	ZMIZ1_D	23%	64%	20%
467	SLC13A5_B	23%	45%	0%
470	C8orf73_B	38%	82%	40%
469	MAX.chr8:145103900-145103993	38%	64%	30%
471	KBTBD11_B	8%	9%	20%
499	ARL5C	69%	73%	80%
472	LOC100192379_C	15%	0%	40%
475	STX16_B	15%	27%	40%
474	LOC440925_B	54%	36%	30%
473	TRIM71_B	23%	36%	40%

Table 25. Endometrial tissue sensitivity at 95% for the markers shown in Table 21 for endometrioid EC Grade 1, endometrioid EC Grade 2, and endometrioid EC Grade 3.

DMR No.	Marker	Endometrioid EC Grade 1	Endometrioid EC Grade 2	Endometrioid EC Grade 3
495	TSPYL5	100%	89%	94%
496	MPZ_B	75%	89%	88%
491	TRH	100%	89%	88%
497	CXCL12	0%	22%	25%
476	IRF4	50%	67%	63%

477	CNTN4	75%	89%	63%
478	GRIN2A	50%	78%	50%
479	NOTCH3	0%	0%	0%
480	PAX1	75%	78%	38%
481	ZNF521	50%	22%	31%
482	VSX1	75%	67%	63%
492	JAM3	100%	67%	38%
483	CRHR2	50%	78%	50%
484	FAM19A5	100%	89%	56%
485	ASCL1	50%	67%	38%
486	GLT1D1	75%	89%	56%
487	T	50%	67%	44%
488	CAPN2	50%	67%	31%
489	RYR2_F	75%	89%	63%
498	PTGDR	100%	89%	94%
493	BARX1	75%	56%	56%
494	ZNF671_B	50%	56%	69%
490	SIM2	0%	44%	38%
472	LOC100192379_C	25%	33%	31%
446	AIM1_C	0%	0%	19%
445	AGRN_B	0%	22%	38%
459	MAX.chr7:104624386-104624529	0%	44%	69%
81	EMX2OS	75%	89%	81%
449	DIDO1_B	0%	44%	81%
451	GDF7_B	25%	44%	44%
450	FKBP11_B	25%	56%	69%
453	LHFPL2_B	0%	11%	25%
447	AKR7A3	0%	33%	44%
150	LRRC41_D	0%	11%	25%
454	LOC100129726_B	25%	11%	44%
448	C17orf107_B	0%	56%	44%
456	MAX.chr10:22624470-22624553	75%	89%	75%
455	LRRC8D_B	25%	56%	50%
458	MAX.chr7:104624356-104624513	0%	11%	38%
457	MAX.chr14:103021654-103021725	50%	67%	56%
212	MDFI_B	25%	33%	25%
464	SPDYA_B	75%	89%	81%
461	RHBDL1_B	0%	56%	63%

460	OBSCN_B	0%	22%	56%
463	SFMBT2_E	100%	89%	63%
462	SEPT9_D	0%	22%	19%
465	ST3GAL2_B	0%	33%	38%
452	JSRP1_B	100%	100%	75%
368	ITPKA	0%	0%	0%
466	ZNF323_B	0%	11%	50%
302	VILL	50%	67%	81%
468	ZMIZ1_D	0%	67%	31%
467	SLC13A5_B	50%	78%	31%
470	C8orf73_B	0%	56%	56%
469	MAX.chr8:145103900-145103993	50%	78%	69%
471	KBTBD11_B	25%	33%	31%
499	ARL5C	100%	78%	75%
472	LOC100192379_C	25%	56%	38%
475	STX16_B	0%	11%	6%
474	LOC440925_B	25%	11%	19%
473	TRIM71_B	25%	22%	31%

For such tests, multiplex PCR reactions were setup and completed. Each multiplex PCR reaction was setup with an intermediate primer mix containing 2 μ M forward primer and 2 μ M reverse primer of each marker. Multiplex PCR reaction 1 consisted of each of the following markers: AIM1_C, AGRN_B, C17orf107_B, MAX.chr7:104624386-104624529, EMX2OS, DIDO1_B, GDF7_B, FKBP11_B, LHFPL2_B, AKR7A3, LRRC41_D, LOC100129726_B, and B3GALT6. Multiplex PCR reaction 2 consisted of each of the following markers: MAX.chr10:22624470-22624553, LRRC8D_B, MAX.chr7:104624356-104624513, MAX.chr14:103021654-103021725, MDFI_B, SPDYA_B, RHBDL1_B, OBSCN_B, SFMBT2_E, SEPT9_D, ST3GAL2_B, JSRP1_B, ITPKA, and B3GALT6. Multiplex PCR reaction 3 consisted of each of the following markers: ZNF323_B, VILL, ZMIZ1_D, SLC13A5_B, C8orf73_B, MAX.chr8:145103900-145103993, KBTBD11_B, ARL5C, TRIM71_B, LOC100192379_C, STX16_B, LOC440925_B, and B3GALT6. Multiplex PCR reaction 4 consisted of each of the following markers: TSPYL5, MPZ_B, TRH, CXCL12, IRF4, CNTN4, GRIN2A, NOTCH3, PAX1, ZNF521, VSX1, JAM3, and B3GALT6. Multiplex PCR reaction 5 consisted of each of the following markers: CRHR2, FAM19A5, ASCL1, GLT1D1, T, CAPN2, RYR2_F, PTGDR, BARX1, ZNF671_B, SIM2, and B3GALT6.

Each multiplex PCR reaction was setup to a final concentration of 0.2 μ M reaction buffer, 0.075 μ M primer mix, 0.025 μ M Hotstart Go Taq (5U/ μ L) resulting in 25 μ L of master mix that was combined with 50 μ L of DNA template for a final reaction volume of 75 μ L. The thermal profile for the multiplex PCR entailed 12 cycles of a pre-incubation stage of 95° for 5 minutes, a 2-step amplification stage of 95° for 30 seconds, 64° for 60 seconds, and a cooling stage of 4° that was held infinitely. Once the multiplex PCR was complete, the PCR product was diluted 1:10 using Te and subsequently 10 μ L were used for each LQAS reaction. Each LQAS assay was developed in triplex form consisting of 2 methylation markers and B3GALT6 as the reference gene. Each LQAS assay was built using 2 μ M of each primer for each methylation marker and B3GALT6, 5 μ M of each methylation marker probe, 5 μ M of each FRET cassette with 2500 μ M dNTPs.

From multiplex PCR product 1, the following 6 LQAS assays were run (see, Table 26): (1.) AIM1_C, AGRN_B, B3GALT6; (2.) C17orf107_B, MAX.chr7:104624386-104624529, B3GALT6; (3.) EMX2OS, DIDO1_B, B3GALT6; (4.) GDF7_B, FKBP11_B, B3GALT6; (5.) LHFPL2_B, AKR7A3, B3GALT6; (6.) LRRC41_D, LOC100129726_B, B3GALT6. From multiplex PCR product 2, the following 7 LQAS assays were run (see, Table 26): (1.) MAX.chr10:22624470-22624553, LRRC8D_B, B3GALT6; (2.) MAX.chr7:104624356-104624513, MAX.chr14:103021654-103021725, B3GALT6; (3.) MDFI, SPDYA_B, B3GALT6; (4.) RHBDL1_B, OBSCN_B, B3GALT6; (5.) SFMBT2_E, SEPT9_D, B3GALT6; (6.) ST3GAL2_B, JSRP1_B, B3GALT6; (7.) ITPKA, B3GALT6. From multiplex PCR product 3, the following 6 LQAS assays were run (see, Table 26): (1.) ZNF323_B, VILL, B3GALT6; (2.) ZMIZ1_D, SLC13A5_B, B3GALT6; (3.) C8orf73_B, MAX.chr8:145103900-145103993, B3GALT6; (4.) KBTBD11_B, ARL5C, B3GALT6; (5.) TRIM71_B, LOC100192379_C, B3GALT6; (6.) STX16_B, LOC440925_B, and B3GALT6. From multiplex PCR product 4, the following 6 LQAS assays were run (see, Table 26): (1.) TSPYL5, MPZ_B, B3GALT6; (2.) TRH, CXCL12, B3GALT6; (3.) IRF4, CNTN4, B3GALT6; (4.) GRIN2A, NOTCH3, B3GALT6; (5.) PAX1, ZNF521, B3GALT6; (6.) VSX1, JAM3, and B3GALT6. From multiplex PCR product 5, the following 5 LQAS assays were run (see, Table 26): (1.) EMX1, ARHGEF4, BTACT; (2.) OPLAH, CYP26C1, BTACT; (3.) ZNF781, DLX4, BTACT; (4.) PTGDR, KLHDC7B, BTACT; (5.) GRIN2D, chr17_737, and BTACT. From multiplex PCR product 6, the following 6 LQAS assays were run (see, Table 27): (1.) CRHR2, FAM19A5, B3GALT6; (2.) ASCL1, GLT1D1, B3GALT6;

(3.) T, CAPN2, B3GALT6; (4.) RYR2_F, PTGDR, B3GALT6; (5.) BARX1, ZNF671_B, B3GALT6; (6.) SIM2 and B3GALT6.

Table 26. LQAS Triplex Assays

DMR NO.	Marker	LQAS Assay Triplex
445	AGRN_B	AIM1_C-AGRN_B-B3GALT6
446	AIM1_C	
448	C17orf107_B	C17orf107_B-MAX.chr7:104624386-104624529-B3GALT6
459	MAX.chr7:104624386-104624529	
81	EMX2OS	EMX2OS-DIDO1_B-B3GALT6
449	DIDO1_B	
451	GDF7_B	GDF7_B-FKBP11_B-B3GALT6
450	FKBP11_B	
453	LHFPL2_B	LHFPL2_B-AKR7A3-B3GALT6
447	AKR7A3	
150	LRRC41_D	LRRC41_D-LOC100129726_E-B3GALT6
454	LOC100129726_B	
456	MAX.chr10:22624470-22624553	MAX.chr10:22624470-22624553-LRRC8D_B-B3GALT6
455	LRRC8D_B	
458	MAX.chr7:104624356-104624513	MAX.chr7:104624356-104624513-MAX.chr14:103021654-103021725-B3GALT6
457	MAX.chr14:103021654-103021725	
212	MDFI_B	MDFI_B-SPDYA_B-B3GALT6
464	SPDYA_B	
461	RHBDL1_B	RHBDL1_B-OBSCN_B-B3GALT6
460	OBSCN_B	
463	SFMBT2_E	SFMBT2_E-SEPT9_D-B3GALT6
462	SEPT9_D	
465	ST3GAL2_B	ST3GAL2_B-JSRP1_B-B3GALT6
452	JSRP1_B	
368	ITPKA	ITPKA-B3GALT6
466	ZNF323_B	ZNF323_B-VILL-B3GALT6
	VILL	
468	ZMIZ1_D	ZMIZ1_D-SLC13A5_B-B3GALT6
467	SLC13A5_B	
470	C8orf73_B	C8orf73_B-MAX.chr8:145103900-145103993-B3GALT6

469	MAX.chr8:145103900-145103993	
471	KBTBD11_B	KBTBD11_B-ARL5C-B3GALT6
35	ARL5C	
473	TRIM71_B	TRIM71_B-LOC100192379_C-B3GALT6
472	LOC100192379_C	
475	STX16_B	STX16_B-LOC440925_B-B3GALT6
474	LOC440925_B	
495	TSPYL5	TSPYL5-MPZ_B-B3GALT6
496	MPZ_B	
491	TRH	TRH-CXCL12-B3GALT6
497	CXCL12	
476	IRF4	IRF4-CNTN4-B3GALT6
477	CNTN4	
478	GRIN2A	GRIN2A-NOTCH3-B3GALT6
479	NOTCH3	
480	PAX1	PAX1-ZNF521-B3GALT6
481	ZNF521	
482	VSX1	VSX1-JAM3-B3GALT6
492	JAM3	
483	CRHR2	CRHR2-FAM19A5-B3GALT6
484	FAM19A5	
485	ASCL1	ASCL1-GLT1D1-B3GALT6
486	GLT1D1	
487	T	T-CAPN2-B3GALT6
488	CAPN2	
489	RYR2_F	RYR2_F-PTGDR-B3GALT6
498	PTGDR	
493	BARX1	BARX1-ZNF671_B-B3GALT6
494	ZNF671_B	
490	SIM2	SIM2-B3GALT6

All LQAS assays were setup and run with standard, previously published conditions.

Having now fully described the invention, it will be understood by those of skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations, and other parameters without affecting the scope of the invention or any embodiment thereof. All patents, patent applications and publications cited herein are fully incorporated by reference herein in their entirety.

INCORPORATION BY REFERENCE

The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes.

EQUIVALENTS

The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.

CLAIMS**WE CLAIM:**

1. A method, comprising:
 - measuring a methylation level for one or more genes in a biological sample of a human individual through
 - treating genomic DNA in the biological sample with a reagent that modifies DNA in a methylation-specific manner;
 - amplifying the treated genomic DNA using a set of primers for the selected one or more genes; and
 - determining the methylation level of the one or more genes by polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation-specific nuclease, mass-based separation, and target capture;
 - wherein the one or more genes is selected from one of the following groups:
 - (i) AFF3, AIM1_A, AMIGO3_A, BMP4_B, C17orf107_A, C1orf70_B, C5orf52, CLDN7, DIDO1_A, EEF1A2, EMX2OS, FEV, FKBP11_A, GDF6, GDF7_A, JSRP1_A, KCTD15_A, KLHL21, LRRC8D_A, NBPf8, MAX.chr10.130339363-130339534, MAX.chr10.22624479-22624553, MAX.chr14.103021656-103021718, MAX.chr8.145103829-145103992, MAX.chr8.145104263-145104422, MDFI_B, MIAT_A, MMP23B, NDRG2, OBSCN_A, PCOLCE, PYCARD, SEPT9_B, SLC6A3_A, SLC8A3_B, SQSTM1, VILL, ZNF302, ZNF323_A, ZNF506, and ZNF90;
 - (ii) EMX2OS, CYTH2, C17orf107_A, DIDO1_A, GDF6, NBPf8, MAX.chr14.103021656-103021718, JSRP1_A, GATA2_B, and SFMBT2_B;
 - (iii) SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPf8, and MPZ_A;
 - (iv) EMX2OS, CYTH2, NBPf8, MAX.chr10.22624479-22624553;
 - (v) ANKRD35, ARL5C, ARRB1, BCL2L11_A, BCL2L11_B, BCL2L11_C, BZRAP1, C16orf54, C17orf101, C6orf132, CACNA2D4,

DEDD2, EPS15L1, FAIM2, FAM125B, FAM189B, FAM78A, FOXP4, GYPC_A, GYPC_B, IFFO1_A, IFFO1_B, ITPKA, KLF16, LIMD2, LOC389333, LOC440925_A, LOC646278, LYL1, LYPLAL1, MAX.chr11.32355226-32355251, MAX.chr14.102172621-102172686, MAX.chr14.105512122-105512239, MAX.chr15.95128144-95128248, MAX.chr16.11327016-11327312, MAX.chr3.187676577-187676668, MAX.chr4.174430676-174430847, MAX.chr8.145900783-145900914, MAX.chr8.80804237-80804301, N4BP3, NCOR2, NFATC1_A, NFATC1_B, NKX2-6, NR2F6, OSM, PALLD_C, PIK3CD, PRKAR1B, RAD52, STX16_A, SUCLG2, TNFRSF1B, TNFRSF4, ZDHHC18, and ZNF671_A;

(vi) DIDO1_A, NDRG4, MAX.chr14.103021656-103021718, MMP23B, EMX2OS, SEPT9_B, NBPF8, EEF1A2, AIM1_A, BMP4_B, MAX.chr8.145103829-145103992, OBSCN, PYCARD, GDF6, MDFI_B, MIAT_A, SCL8A3, ZNF323_A, SQSTM1, AFF3, C1orf70, GDF7_A, JSRP1_A, LRRC8D_A, FEV, and MAX.chr8.145104263-145104422;

(vii) ZNF323_A, MAX.chr7.104624356-104624730, NDRG2, DIDO1_A, MDFI_B, MAX.chr14.103021656-103021718, MMP23B, SEPT9_B, and STX16_A;

(viii) SFMBT2_B, SQSTM1, ZNF323_A, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MDFI_B, GDF7_A, MAX.chr10.22624479-22624553, JSRP1_A, MAX.chr14.103021656-103021718, EMX2OS, LRRC34, NBPF8, SEPT9_B, EEF1A2, LRRC41_C, VILL, and MPZ_A;

(ix) MAX.chr7.104624386-104624529, EMX2OS, DIDO1_B, and OBSCN_B;

(x) SFMBT2_B, SQSTM1, ZNF323_A, ZNF506, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, NDRG2, CYP11A1, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, MDFI_B, DLL4, GDF7_A, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, EMX2, MMP23B, EMX2OS, MAX.chr17.73073716-73073814, NBPF8, SEPT9_B, LOC440925_A, STX16_A, ITPKA, EEF1A2, FEV, LRRC41_C, and NFIC;

- (xi) EMX2OS, DIDO1_A, SBNO2, AMIGO3_A, PCOLCE, CLDN7, CYTH2, OBSCN_A, AHSA2, DLL4, EMX2, MAX.chr14.74100620-74100870, LRRC4, PPP2R5C_A, SQSTM1, MAX.chr17.73073716-73073814, CYP11A1, ACOXL_A, and AIM1_B;
- (xii) EMX2OS, and LRRC34;
- (xiii) ZNF506, ZNF90, MAX.chr8.145103829-145103992, LRRC8D_A, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and VILL;
- (xiv) TRH, MAX.chr7:104624386-104624529, EMX2OS, DIDO1_B, and ST3GAL2_B;
- (xv) SFMBT2_B, SMTN, ZNF506, ZNF90, CLDN7, LRRC41_B, CYP11A1, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, DLL4, MAX.chr10.22624479-22624553, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, EMX2OS, LRRC34, NBPF8, LOC440925_A, ITPKA, NFIC, and VILL;
- (xvi) EMX2OS, KANK1, C1orf70_B, AMIGO3_A, DIDO1_A, LRRC41_C, NFIC, FKBP11_A, C17orf107_A, SMTN, LRRC41_B, LRRC8D_A, OBSCN_A, MAX.chr7.104624356-104624730, MIAT_B;
- (xvii) MAX.chr7.104624356-104624730, EMX2OS, and LRRC41_C;
- (xviii) MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, EMX2OS, LRRC41_C, and VILL;
- (xix) EMX2OS, and LRRC41_D;
- (xx) SFMBT2_B, SMTN, SQSTM1, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, CYP11A1, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, GDF6, DLL4, PYCARD, BMP4_B, JSRP1_A, MIAT_B, KANK1, EMX2OS, NBPF8, LOC440925_A, ITPKA, EEF1A2, FEV, LRRC41_C, NFIC, VILL, MPZ_A;
- (xxi) MAX.chr10.130339363-130339534, SFMBT2_C, CYTH2, SLC6A3, VILL, EMX2OS, MAX.chr10.22624479-22624553, GDF6, ZNF90,

ZNF506, JSRP1_A, c5orf52, SFMBT2_B, NBPf8, RHBDL1_A, DDO1_A, KANK1, and GATA2_B;

(xxii) MAX.chr8.145103829-145103992, CYTH2, DDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, SBNO2, NBPf8, and VILL;

(xxiii) SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, MAX.chr8.145104263-145104422, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPf8, and MPZ_A;

(xxiv) SFMBT2_B, SMTN, SQSTM1, ZNF506, ZNF90, CLDN7, LRRC41_B, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, DDO1_A, GDF6, MAX.chr10.130339363-130339534, DLL4, MAX.chr10.22624479-22624553, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, KANK1, SBNO2, c5orf52, EMX2O6, LRRC34, NBPf8, LOC440925_A, ITPKA, NFIC, VILL, and MPZ_A;

(xxv) TSPYL5, TRH, JAM3, FAM19A5, PTGDR, SFMBT2_E, JSRP1_B, and ARL5C;

(xxvi) TSPYL5, MPZ_B, TRH, CNTN4, FAM19A5, GLT1D1, RYR2_F, PTGDR, EMX2OS, MAX.chr10:22624470-22624553, SPDYA_B, SFMBT2_E, and JSRP1_B; and

(xxvii) TSPYL5, MPZ_B, TRH, and PTGDR.

2. The method of claim 1, wherein the DNA is treated with a reagent that modifies DNA in a methylation-specific manner.
3. The method of claim 2, wherein the reagent comprises one or more of a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent.
4. The method of claim 3, wherein the DNA is treated with a bisulfite reagent to produce bisulfite-treated DNA.
5. The method of claim 1, wherein the measuring comprises multiplex amplification.

6. The method of claim 1, wherein measuring the amount of at least one methylated marker gene comprises using one or more methods selected from the group consisting of methylation-specific PCR, quantitative methylation-specific PCR, methylation-specific DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, flap endonuclease assay, PCR-flap assay, and bisulfite genomic sequencing PCR.
7. The method of claim 1, wherein the sample comprises one or more of a plasma sample, a blood sample, or a tissue sample (e.g., endometrial tissue).
8. The method of claim 1, wherein the set of primers for the selected one or more genes is recited in Table 10 or 22.
9. A method of characterizing a sample, comprising:
 - a) measuring an amount of at least one methylated marker gene in DNA from the sample, wherein the at least one methylated marker gene is one or more genes selected from one of the following groups:
 - (i) AFF3, AIM1_A, AMIGO3_A, BMP4_B, C17orf107_A, C1orf70_B, C5orf52, CLDN7, DIDO1_A, EEF1A2, EMX2OS, FEV, FKBP11_A, GDF6, GDF7_A, JSRP1_A, KCTD15_A, KLHL21, LRRC8D_A, NBPF8, MAX.chr10.130339363-130339534, MAX.chr10.22624479-22624553, MAX.chr14.103021656-103021718, MAX.chr8.145103829-145103992, MAX.chr8.145104263-145104422, MDFI_B, MIAT_A, MMP23B, NDRG2, OBSCN_A, PCOLCE, PYCARD, SEPT9_B, SLC6A3_A, SLC8A3_B, SQSTM1, VILL, ZNF302, ZNF323_A, ZNF506, and ZNF90;
 - (ii) EMX2OS, CYTH2, C17orf107_A, DIDO1_A, GDF6, NBPF8, MAX.chr14.103021656-103021718, JSRP1_A, GATA2_B, and SFMBT2_B;
 - (iii) SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and MPZ_A;
 - (iv) EMX2OS, CYTH2, NBPF8, MAX.chr10.22624479-22624553;

(v) ANKRD35, ARL5C, ARRB1, BCL2L11_A, BCL2L11_B, BCL2L11_C, BZRAP1, C16orf54, C17orf101, C6orf132, CACNA2D4, DEDD2, EPS15L1, FAIM2, FAM125B, FAM189B, FAM78A, FOXP4, GYPC_A, GYPC_B, IFFO1_A, IFFO1_B, ITPKA, KLF16, LIMD2, LOC389333, LOC440925_A, LOC646278, LYL1, LYPLAL1, MAX.chr11.32355226-32355251, MAX.chr14.102172621-102172686, MAX.chr14.105512122-105512239, MAX.chr15.95128144-95128248, MAX.chr16.11327016-11327312, MAX.chr3.187676577-187676668, MAX.chr4.174430676-174430847, MAX.chr8.145900783-145900914, MAX.chr8.80804237-80804301, N4BP3, NCOR2, NFATC1_A, NFATC1_B, NKX2-6, NR2F6, OSM, PALLD_C, PIK3CD, PRKAR1B, RAD52, STX16_A, SUCLG2, TNFRSF1B, TNFRSF4, ZDHHC18, and ZNF671_A;

(vi) DIDO1_A, NDRG4, MAX.chr14.103021656-103021718, MMP23B, EMX2OS, SEPT9_B, NBPF8, EEF1A2, AIM1_A, BMP4_B, MAX.chr8.145103829-145103992, OBSCN, PYCARD, GDF6, MDFI_B, MIAT_A, SCL8A3, ZNF323_A, SQSTM1, AFF3, C1orf70, GDF7_A, JSRP1_A, LRRC8D_A, FEV, and MAX.chr8.145104263-145104422;

(vii) ZNF323_A, MAX.chr7.104624356-104624730, NDRG2, DIDO1_A, MDFI_B, MAX.chr14.103021656-103021718, MMP23B, SEPT9_B, and STX16_A;

(viii) SFMBT2_B, SQSTM1, ZNF323_A, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MDFI_B, GDF7_A, MAX.chr10.22624479-22624553, JSRP1_A, MAX.chr14.103021656-103021718, EMX2OS, LRRC34, NBPF8, SEPT9_B, EEF1A2, LRRC41_C, VILL, and MPZ_A;

(ix) MAX.chr7.104624386-104624529, EMX2OS, DIDO1_B, and OBSCN_B;

(x) SFMBT2_B, SQSTM1, ZNF323_A, ZNF506, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, NDRG2, CYP11A1, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, MDFI_B, DLL4, GDF7_A, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, EMX2,

MMP23B, EMX2OS, MAX.chr17.73073716-73073814, NBPF8, SEPT9_B, LOC440925_A, STX16_A, ITPKA, EEF1A2, FEV, LRRC41_C, and NFIC;

(xi) EMX2OS, DIDO1_A, SBNO2, AMIGO3_A, PCOLCE, CLDN7, CYTH2, OBSCN_A, AHSA2, DLL4, EMX2, MAX.chr14.74100620-74100870, LRRC4, PPP2R5C_A, SQSTM1, MAX.chr17.73073716-73073814, CYP11A1, ACOXL_A, and AIM1_B;

(xii) EMX2OS, and LRRC34;

(xiii) ZNF506, ZNF90, MAX.chr8.145103829-145103992, LRRC8D_A, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and VILL;

(xiv) TRH, MAX.chr7.104624386-104624529, EMX2OS, DIDO1_B, and ST3GAL2_B;

(xv) SFMBT2_B, SMTN, ZNF506, ZNF90, CLDN7, LRRC41_B, CYP11A1, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, DLL4, MAX.chr10.22624479-22624553, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, EMX2OS, LRRC34, NBPF8, LOC440925_A, ITPKA, NFIC, and VILL;

(xvi) EMX2OS, KANK1, C1orf70_B, AMIGO3_A, DIDO1_A, LRRC41_C, NFIC, FKBP11_A, C17orf107_A, SMTN, LRRC41_B, LRRC8D_A, OBSCN_A, MAX.chr7.104624356-104624730, MIAT_B;

(xvii) MAX.chr7.104624356-104624730, EMX2OS, and LRRC41_C;

(xviii) MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, EMX2OS, LRRC41_C, and VILL;

(xix) EMX2OS, and LRRC41_D;

(xx) SFMBT2_B, SMTN, SQSTM1, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, CYP11A1, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, GDF6, DLL4, PYCARD, BMP4_B, JSRP1_A, MIAT_B, KANK1, EMX2OS, NBPF8, LOC440925_A, ITPKA, EEF1A2, FEV, LRRC41_C, NFIC, VILL, MPZ_A;

(xxi) MAX.chr10.130339363-130339534, SFMBT2_C, CYTH2, SLC6A3, VILL, EMX2OS, MAX.chr10.22624479-22624553, GDF6, ZNF90, ZNF506, JSRP1_A, c5orf52, SFMBT2_B, NBPF8, RHBDL1_A, DIDO1_A, KANK1, and GATA2_B;

(xxii) MAX.chr8.145103829-145103992, CYTH2, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, SBNO2, NBPF8, and VILL;

(xxiii) SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, MAX.chr8.145104263-145104422, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and MPZ_A;

(xxiv) SFMBT2_B, SMTN, SQSTM1, ZNF506, ZNF90, CLDN7, LRRC41_B, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, DLL4, MAX.chr10.22624479-22624553, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, KANK1, SBNO2, c5orf52, EMX2O6, LRRC34, NBPF8, LOC440925_A, ITPKA, NFIC, VILL, and MPZ_A;

(xxv) TSPYL5, TRH, JAM3, FAM19A5, PTGDR, SFMBT2_E, JSRP1_B, and ARL5C;

(xxvi) TSPYL5, MPZ_B, TRH, CNTN4, FAM19A5, GLT1D1, RYR2_F, PTGDR, EMX2OS, MAX.chr10:22624470-22624553, SPDYA_B, SFMBT2_E, and JSRP1_B; and

(xxvii) TSPYL5, MPZ_B, TRH, and PTGDR;

- b) measuring the amount of at least one reference marker in the DNA; and
- c) calculating a value for the amount of the at least one methylated marker gene measured in the DNA as a percentage of the amount of the reference marker gene measured in the DNA, wherein the value indicates the amount of the at least one methylated marker DNA measured in the sample.

10. The method of claim 9, wherein the at least one reference marker comprises one or more reference marker selected from *B3GALT6* DNA and β -actin DNA.

11. The method of claim 9, wherein the sample comprises one or more of a plasma sample, a blood sample, or a tissue sample (e.g., endometrial tissue).
12. The method of claim 9, wherein the DNA is extracted from the sample.
13. The method of claim 9, wherein the DNA is treated with a reagent that modifies DNA in a methylation-specific manner.
14. The method of claim 13, wherein the reagent comprises one or more of a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent.
15. The method of claim 14 wherein the DNA is treated with a bisulfite reagent to produce bisulfite-treated DNA.
16. The method of claim 14, wherein the modified DNA is amplified using a set of primers for the selected one or more genes.
17. The method of claim 16, wherein the set of primers for the selected one or more genes is recited in Table 10 or 22.
18. The method of claim 9 wherein measuring amounts of a methylated marker gene comprises using one or more of polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation-specific nuclease, mass-based separation, and target capture.
19. The method of claim 18, wherein the measuring comprises multiplex amplification.
20. The method of claim 18, wherein measuring the amount of at least one methylated marker gene comprises using one or more methods selected from the group consisting of methylation-specific PCR, quantitative methylation-specific PCR, methylation-specific DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, flap endonuclease assay, PCR-flap assay, and bisulfite genomic sequencing PCR.

21. A method for characterizing a biological sample comprising:

(a) measuring a methylation level of a CpG site for one or more genes selected from one of the following groups:

- (i) AFF3, AIM1_A, AMIGO3_A, BMP4_B, C17orf107_A, C1orf70_B, C5orf52, CLDN7, DIDO1_A, EEF1A2, EMX2OS, FEV, FKBP11_A, GDF6, GDF7_A, JSRP1_A, KCTD15_A, KLHL21, LRRC8D_A, NBPf8, MAX.chr10.130339363-130339534, MAX.chr10.22624479-22624553, MAX.chr14.103021656-103021718, MAX.chr8.145103829-145103992, MAX.chr8.145104263-145104422, MDFI_B, MIAT_A, MMP23B, NDRG2, OBSCN_A, PCOLCE, PYCARD, SEPT9_B, SLC6A3_A, SLC8A3_B, SQSTM1, VILL, ZNF302, ZNF323_A, ZNF506, and ZNF90;
- (ii) EMX2OS, CYTH2, C17orf107_A, DIDO1_A, GDF6, NBPf8, MAX.chr14.103021656-103021718, JSRP1_A, GATA2_B, and SFMBT2_B;
- (iii) SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPf8, and MPZ_A;
- (iv) EMX2OS, CYTH2, NBPf8, MAX.chr10.22624479-22624553; and
- (v) ANKRD35, ARL5C, ARRB1, BCL2L11_A, BCL2L11_B, BCL2L11_C, BZRAP1, C16orf54, C17orf101, C6orf132, CACNA2D4, DEDD2, EPS15L1, FAIM2, FAM125B, FAM189B, FAM78A, FOXP4, GYPC_A, GYPC_B, IFFO1_A, IFFO1_B, ITPKA, KLF16, LIMD2, LOC389333, LOC440925_A, LOC646278, LYL1, LYPLAL1, MAX.chr11.32355226-32355251, MAX.chr14.102172621-102172686, MAX.chr14.105512122-105512239, MAX.chr15.95128144-95128248, MAX.chr16.11327016-11327312, MAX.chr3.187676577-187676668, MAX.chr4.174430676-174430847, MAX.chr8.145900783-145900914, MAX.chr8.80804237-

80804301, N4BP3, NCOR2, NFATC1_A, NFATC1_B, NKX2-6, NR2F6, OSM, PALLD_C, PIK3CD, PRKAR1B, RAD52, STX16_A, SUCLG2, TNFRSF1B, TNFRSF4, ZDHHC18, and ZNF671_A in a biological sample of a human individual through treating genomic DNA in the biological sample with bisulfite; amplifying the bisulfite-treated genomic DNA using a set of primers for the selected one or more genes; and determining the methylation level of the CpG site by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, or bisulfite genomic sequencing PCR;

(b) comparing the methylation level to a methylation level of a corresponding set of genes in control samples without EC; and

(c) determining that the individual has EC when the methylation level measured in the one or more genes is higher than the methylation level measured in the respective control samples.

22. The method of claim 21 wherein the set of primers for the selected one or more genes is recited in Table 10 or 22.

23. The method of claim 21, wherein the biological sample is a plasma sample, a blood sample, or a tissue sample (e.g., endometrial tissue).

24. The method of claim 21, wherein the one or more genes is described by the genomic coordinates shown in Tables 1, 8 or 21.

25. The method of claim 21, wherein said CpG site is present in a coding region or a regulatory region.

26. The method of claim 21, wherein said measuring the methylation level a CpG site for one or more genes comprises a determination selected from the group consisting of determining the methylation score of said CpG site and determining the methylation frequency of said CpG site.

27. A method for characterizing a biological sample comprising:

(a) measuring a methylation level of a CpG site for one or more genes selected from one of the following groups:

- (i) DIDO1_A, NDRG4, MAX.chr14.103021656-103021718, MMP23B, EMX2OS, SEPT9_B, NBPF8, EEF1A2, AIM1_A, BMP4_B, MAX.chr8.145103829-145103992, OBSCN, PYCARD, GDF6, MDFI_B, MIAT_A, SCL8A3, ZNF323_A, SQSTM1, AFF3, C1orf70, GDF7_A, JSRP1_A, LRRC8D_A, FEV, and MAX.chr8.145104263-145104422;
- (ii) ZNF323_A, MAX.chr7.104624356-104624730, NDRG2, DIDO1_A, MDFI_B, MAX.chr14.103021656-103021718, MMP23B, SEPT9_B, and STX16_A;
- (iii) SFMBT2_B, SQSTM1, ZNF323_A, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MDFI_B, GDF7_A, MAX.chr10.22624479-22624553, JSRP1_A, MAX.chr14.103021656-103021718, EMX2OS, LRRC34, NBPF8, SEPT9_B, EEF1A2, LRRC41_C, VILL, and MPZ_A;
- (iv) MAX.chr7:104624386-104624529, EMX2OS, DIDO1_B, and OBSCN_B; and
- (v) SFMBT2_B, SQSTM1, ZNF323_A, ZNF506, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, NDRG2, CYP11A1, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, MDFI_B, DLL4, GDF7_A, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, EMX2, MMP23B, EMX2OS, MAX.chr17.73073716-73073814, NBPF8, SEPT9_B, LOC440925_A, STX16_A, ITPKA, EEF1A2, FEV, LRRC41_C, and NFIC

in a biological sample of a human individual through
treating genomic DNA in the biological sample with bisulfite;
amplifying the bisulfite-treated genomic DNA using a set of primers for the
selected one or more genes; and
determining the methylation level of the CpG site by methylation-specific
PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction

enzyme analysis, quantitative bisulfite pyrosequencing, or bisulfite genomic sequencing PCR;

(b) comparing the methylation level to a methylation level of a corresponding set of genes in control samples without EC; and

(c) determining that the individual has clear cell EC when the methylation level measured in the one or more genes is higher than the methylation level measured in the respective control samples.

28. The method of claim 27 wherein the set of primers for the selected one or more genes is recited in Table 10 or 22.

29. The method of claim 27, wherein the biological sample is a plasma sample, a blood sample, or a tissue sample (e.g., endometrial tissue).

30. The method of claim 27, wherein the one or more genes is described by the genomic coordinates shown in Tables 1, 8 or 21.

31. The method of claim 27,
 wherein if the biological sample is a tissue sample than the one or more genes is selected from groups i, ii, iii or iv;
 wherein if the biological sample is a plasma sample than the one or more genes is within group v.

32. The method of claim 27, wherein said measuring the methylation level a CpG site for one or more genes comprises a determination selected from the group consisting of determining the methylation score of said CpG site and determining the methylation frequency of said CpG site.

33. A method for characterizing a biological sample comprising:

(a) measuring a methylation level of a CpG site for one or more genes selected from one of the following groups:

(i) EMX2OS, DIDO1_A, SBNO2, AMIGO3_A, PCOLCE,
 CLDN7, CYTH2, OBSCN_A, AHSA2, DLL4, EMX2,

MAX.chr14.74100620-74100870, LRRC4, PPP2R5C_A, SQSTM1,
MAX.chr17.73073716-73073814, CYP11A1, ACOXL_A, and AIM1_B;

(ii) EMX2OS, and LRRC34;

(iii) ZNF506, ZNF90, MAX.chr8.145103829-145103992,
LRRC8D_A, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A,
EMX2OS, NBPF8, and VILL;

(iv) TRH, MAX.chr7:104624386-104624529, EMX2OS,
DIDO1_B, and ST3GAL2_B; and

(v) SFMBT2_B, SMTN, ZNF506, ZNF90, CLDN7, LRRC41_B,
CYP11A1, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B,
LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A,
GDF6, DLL4, MAX.chr10.22624479-22624553, PYCARD, BMP4_B,
JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, EMX2OS,
LRRC34, NBPF8, LOC440925_A, ITPKA, NFIC, and VILL

in a biological sample of a human individual through
treating genomic DNA in the biological sample with bisulfite;
amplifying the bisulfite-treated genomic DNA using a set of primers for the
selected one or more genes; and

determining the methylation level of the CpG site by methylation-specific
PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction
enzyme analysis, quantitative bisulfite pyrosequencing, or bisulfite genomic
sequencing PCR;

(b) comparing the methylation level to a methylation level of a corresponding set
of genes in control samples without EC; and

(c) determining that the individual has carcinosarcoma EC when the methylation
level measured in the one or more genes is higher than the methylation level measured in the
respective control samples.

34. The method of claim 33 wherein the set of primers for the selected one or more genes
is recited in Table 10 or 22.

35. The method of claim 33, wherein the biological sample is a plasma sample, a blood
sample, or a tissue sample (e.g., endometrial tissue).

36. The method of claim 33, wherein the one or more genes is described by the genomic coordinates shown in Tables 1, 8 or 21.
37. The method of claim 33,
 wherein if the biological sample is a tissue sample than the one or more genes is selected from groups i, ii, iii or iv;
 wherein if the biological sample is a plasma sample than the one or more genes is within group v.
38. The method of claim 33, wherein said measuring the methylation level a CpG site for one or more genes comprises a determination selected from the group consisting of determining the methylation score of said CpG site and determining the methylation frequency of said CpG site.
39. A method for characterizing a biological sample comprising:
 (a) measuring a methylation level of a CpG site for one or more genes selected from one of the following groups:
- (i) EMX2OS, KANK1, C1orf70_B, AMIGO3_A, DIDO1_A, LRRC41_C, NFIC, FKBP11_A, C17orf107_A, SMTN, LRRC41_B, LRRC8D_A, OBSCN_A, MAX.chr7.104624356-104624730, MIAT_B;
 - (ii) MAX.chr7.104624356-104624730, EMX2OS, and LRRC41_C;
 - (iii) MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, EMX2OS, LRRC41_C, and VILL;
 - (iv) EMX2OS, and LRRC41_D; and
 - (v) SFMBT2_B, SMTN, SQSTM1, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, CYP11A1, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, GDGF6, DLL4, PYCARD, BMP4_B, JSRP1_A, MIAT_B, KANK1, EMX2OS, NBPf8, LOC440925_A, ITPKA, EEF1A2, FEV, LRRC41_C, NFIC, VILL, MPZ_A
 in a biological sample of a human individual through

treating genomic DNA in the biological sample with bisulfite;
amplifying the bisulfite-treated genomic DNA using a set of primers for the selected one or more genes; and
determining the methylation level of the CpG site by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, or bisulfite genomic sequencing PCR;

- (b) comparing the methylation level to a methylation level of a corresponding set of genes in control samples without EC; and
- (c) determining that the individual has serous EC when the methylation level measured in the one or more genes is higher than the methylation level measured in the respective control samples.

40. The method of claim 39 wherein the set of primers for the selected one or more genes is recited in Table 10 or 22.

41. The method of claim 39, wherein the biological sample is a plasma sample, a blood sample, or a tissue sample (e.g., endometrial tissue).

42. The method of claim 39, wherein the one or more genes is described by the genomic coordinates shown in Tables 1, 8 or 21.

43. The method of claim 39,
wherein if the biological sample is a tissue sample than the one or more genes is selected from groups i, ii, iii or iv;
wherein if the biological sample is a plasma sample than the one or more genes is within group v.

44. The method of claim 39, wherein said measuring the methylation level a CpG site for one or more genes comprises a determination selected from the group consisting of determining the methylation score of said CpG site and determining the methylation frequency of said CpG site.

45. A method for characterizing a biological sample comprising:

(a) measuring a methylation level of a CpG site for one or more genes selected from one of the following groups:

(i) MAX.chr10.130339363-130339534, SFMBT2_C, CYTH2, SLC6A3, VILL, EMX2OS, MAX.chr10.22624479-22624553, GDF6, ZNF90, ZNF506, JSRP1_A, c5orf52, SFMBT2_B, NBPF8, RHBDL1_A, DIDO1_A, KANK1, and GATA2_B;

(ii) MAX.chr8.145103829-145103992, CYTH2, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, SBNO2, NBPF8, and VILL;

(iii) SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, MAX.chr8.145104263-145104422, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and MPZ_A;

(iv) SFMBT2_B, SMTN, SQSTM1, ZNF506, ZNF90, CLDN7, LRRC41_B, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, DLL4, MAX.chr10.22624479-22624553, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, KANK1, SBNO2, c5orf52, EMX2O6, LRRC34, NBPF8, LOC440925_A, ITPKA, NFIC, VILL, and MPZ_A;

(v) TSPYL5, TRH, JAM3, FAM19A5, PTGDR, SFMBT2_E, JSRP1_B, and ARL5C;

(vi) TSPYL5, MPZ_B, TRH, CNTN4, FAM19A5, GLT1D1, RYR2_F, PTGDR, EMX2OS, MAX.chr10:22624470-22624553, SPDYA_B, SFMBT2_E, and JSRP1_B; and

(vii) TSPYL5, MPZ_B, TRH, and PTGDR

in a biological sample of a human individual through treating genomic DNA in the biological sample with bisulfite; amplifying the bisulfite-treated genomic DNA using a set of primers for the selected one or more genes; and

determining the methylation level of the CpG site by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction

enzyme analysis, quantitative bisulfite pyrosequencing, or bisulfite genomic sequencing PCR;

(b) comparing the methylation level to a methylation level of a corresponding set of genes in control samples without EC; and

(c) determining that the individual has endometrioid EC when the methylation level measured in the one or more genes is higher than the methylation level measured in the respective control samples.

46. The method of claim 45 wherein the set of primers for the selected one or more genes is recited in Table 10 or 22.

47. The method of claim 45, wherein the biological sample is a plasma sample, a blood sample, or a tissue sample (e.g., endometrial tissue).

48. The method of claim 45, wherein the one or more genes is described by the genomic coordinates shown in Tables 1, 8 or 21.

49. The method of claim 45,
wherein if the biological sample is a tissue sample than the one or more genes is selected from groups i, ii, iii, v, vi, and vii;
wherein if the biological sample is a plasma sample than the one or more genes is within group iv.

50. The method of claim 45, wherein said measuring the methylation level a CpG site for one or more genes comprises a determination selected from the group consisting of determining the methylation score of said CpG site and determining the methylation frequency of said CpG site.

51. A method, comprising:

(a) measuring a methylation level of a CpG site for one or more genes selected from one of the following groups:

(i) AFF3, AIM1_A, AMIGO3_A, BMP4_B, C17orf107_A,
C1orf70_B, C5orf52, CLDN7, DIDO1_A, EEF1A2, EMX2OS, FEV,

FKBP11_A, GDF6, GDF7_A, JSRP1_A, KCTD15_A, KLHL21, LRRC8D_A, NBPf8, MAX.chr10.130339363-130339534, MAX.chr10.22624479-22624553, MAX.chr14.103021656-103021718, MAX.chr8.145103829-145103992, MAX.chr8.145104263-145104422, MDFI_B, MIAT_A, MMP23B, NDRG2, OBSCN_A, PCOLCE, PYCARD, SEPT9_B, SLC6A3_A, SLC8A3_B, SQSTM1, VILL, ZNF302, ZNF323_A, ZNF506, and ZNF90;

(ii) EMX2OS, CYTH2, C17orf107_A, DIDO1_A, GDF6, NBPf8, MAX.chr14.103021656-103021718, JSRP1_A, GATA2_B, and SFMBT2_B;

(iii) SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPf8, and MPZ_A;

(iv) EMX2OS, CYTH2, NBPf8, MAX.chr10.22624479-22624553;

(v) ANKRD35, ARL5C, ARRB1, BCL2L11_A, BCL2L11_B, BCL2L11_C, BZRAP1, C16orf54, C17orf101, C6orf132, CACNA2D4, DEDD2, EPS15L1, FAIM2, FAM125B, FAM189B, FAM78A, FOXP4, GYPC_A, GYPC_B, IFFO1_A, IFFO1_B, ITPKA, KLF16, LIMD2, LOC389333, LOC440925_A, LOC646278, LYL1, LYPLAL1, MAX.chr11.32355226-32355251, MAX.chr14.102172621-102172686, MAX.chr14.105512122-105512239, MAX.chr15.95128144-95128248, MAX.chr16.11327016-11327312, MAX.chr3.187676577-187676668, MAX.chr4.174430676-174430847, MAX.chr8.145900783-145900914, MAX.chr8.80804237-80804301, N4BP3, NCOR2, NFATC1_A, NFATC1_B, NKX2-6, NR2F6, OSM, PALLD_C, PIK3CD, PRKAR1B, RAD52, STX16_A, SUCLG2, TNFRSF1B, TNFRSF4, ZDHHC18, and ZNF671_A;

(vi) DIDO1_A, NDRG4, MAX.chr14.103021656-103021718, MMP23B, EMX2OS, SEPT9_B, NBPf8, EEF1A2, AIM1_A, BMP4_B, MAX.chr8.145103829-145103992, OBSCN, PYCARD, GDF6, MDFI_B, MIAT_A, SCL8A3, ZNF323_A, SQSTM1, AFF3, C1orf70, GDF7_A, JSRP1_A, LRRC8D_A, FEV, and MAX.chr8.145104263-145104422;

(vii) ZNF323_A, MAX.chr7.104624356-104624730, NDRG2, DIDO1_A, MDFI_B, MAX.chr14.103021656-103021718, MMP23B, SEPT9_B, and STX16_A;

- (viii) SFMBT2_B, SQSTM1, ZNF323_A, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MDFI_B, GDF7_A, MAX.chr10.22624479-22624553, JSRP1_A, MAX.chr14.103021656-103021718, EMX2OS, LRRC34, NBPF8, SEPT9_B, EEF1A2, LRRC41_C, VILL, and MPZ_A;
- (ix) MAX.chr7:104624386-104624529, EMX2OS, DIDO1_B, and OBSCN_B;
- (x) SFMBT2_B, SQSTM1, ZNF323_A, ZNF506, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, NDRG2, CYP11A1, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, MDFI_B, DLL4, GDF7_A, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, EMX2, MMP23B, EMX2OS, MAX.chr17.73073716-73073814, NBPF8, SEPT9_B, LOC440925_A, STX16_A, ITPKA, EEF1A2, FEV, LRRC41_C, and NFIC;
- (xi) EMX2OS, DIDO1_A, SBNO2, AMIGO3_A, PCOLCE, CLDN7, CYTH2, OBSCN_A, AHSA2, DLL4, EMX2, MAX.chr14.74100620-74100870, LRRC4, PPP2R5C_A, SQSTM1, MAX.chr17.73073716-73073814, CYP11A1, ACOXL_A, and AIM1_B;
- (xii) EMX2OS, and LRRC34;
- (xiii) ZNF506, ZNF90, MAX.chr8.145103829-145103992, LRRC8D_A, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and VILL;
- (xiv) TRH, MAX.chr7:104624386-104624529, EMX2OS, DIDO1_B, and ST3GAL2_B;
- (xv) SFMBT2_B, SMTN, ZNF506, ZNF90, CLDN7, LRRC41_B, CYP11A1, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, DLL4, MAX.chr10.22624479-22624553, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, EMX2OS, LRRC34, NBPF8, LOC440925_A, ITPKA, NFIC, and VILL;

- (xvi) EMX2OS, KANK1, C1orf70_B, AMIGO3_A, DIDO1_A, LRRC41_C, NFIC, FKBP11_A, C17orf107_A, SMTN, LRRC41_B, LRRC8D_A, OBSCN_A, MAX.chr7.104624356-104624730, MIAT_B;
- (xvii) MAX.chr7.104624356-104624730, EMX2OS, and LRRC41_C;
- (xviii) MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, EMX2OS, LRRC41_C, and VILL;
- (xix) EMX2OS, and LRRC41_D;
- (xx) SFMBT2_B, SMTN, SQSTM1, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, CYP11A1, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, GDF6, DLL4, PYCARD, BMP4_B, JSRP1_A, MIAT_B, KANK1, EMX2OS, NBPf8, LOC440925_A, ITPKA, EEF1A2, FEV, LRRC41_C, NFIC, VILL, MPZ_A;
- (xxi) MAX.chr10.130339363-130339534, SFMBT2_C, CYTH2, SLC6A3, VILL, EMX2OS, MAX.chr10.22624479-22624553, GDF6, ZNF90, ZNF506, JSRP1_A, c5orf52, SFMBT2_B, NBPf8, RHBdl1_A, DIDO1_A, KANK1, and GATA2_B;
- (xxii) MAX.chr8.145103829-145103992, CYTH2, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, SBNO2, NBPf8, and VILL;
- (xxiii) SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, MAX.chr8.145104263-145104422, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPf8, and MPZ_A;
- (xxiv) SFMBT2_B, SMTN, SQSTM1, ZNF506, ZNF90, CLDN7, LRRC41_B, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, DLL4, MAX.chr10.22624479-22624553, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, KANK1, SBNO2, c5orf52, EMX2O6, LRRC34, NBPf8, LOC440925_A, ITPKA, NFIC, VILL, and MPZ_A;
- (xxv) TSPYL5, TRH, JAM3, FAM19A5, PTGDR, SFMBT2_E, JSRP1_B, and ARL5C;

(xxvi) TSPYL5, MPZ_B, TRH, CNTN4, FAM19A5, GLT1D1, RYR2_F, PTGDR, EMX2OS, MAX.chr10:22624470-22624553, SPDYA_B, SFMBT2_E, and JSRP1_B; and

(xxvii) TSPYL5, MPZ_B, TRH, and PTGDR in a biological sample of a human individual through treating genomic DNA in the biological sample with bisulfite; amplifying the bisulfite-treated genomic DNA using a set of primers for the selected one or more genes; and

determining the methylation level of the CpG site by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, or bisulfite genomic sequencing PCR.

52. The method of claim 51 wherein the set of primers for the selected one or more genes is recited in Table 10 or 22.

53. The method of claim 51, wherein the biological sample is a plasma sample, a blood sample, or a tissue sample (e.g., endometrial tissue).

54. The method of claim 51, wherein the one or more genes is described by the genomic coordinates shown in Tables 1, 8 or 21.

55. The method of claim 51,
wherein if the biological sample is a tissue sample than the one or more genes is selected from groups i, ii, iii, vi, vii, viii, ix, xi, xii, xiii, xiv, xvi, xvii, xviii, xix, xxi, xxii, xxiii, xxv, xxvi, or xxvii;
wherein if the biological sample is a plasma sample than the one or more genes is within group v, x, xv or xxiv.

56. The method of claim 51, wherein said measuring the methylation level a CpG site for one or more genes comprises a determination selected from the group consisting of determining the methylation score of said CpG site and determining the methylation frequency of said CpG site.

57. A method of screening for endometrial cancer in a sample obtained from a subject, the method comprising:
- 1) assaying a methylation state of a DNA methylation marker comprising a chromosomal region having an annotation selected from the group consisting of one of the following groups:
 - (i) AFF3, AIM1_A, AMIGO3_A, BMP4_B, C17orf107_A, C1orf70_B, C5orf52, CLDN7, DIDO1_A, EEF1A2, EMX2OS, FEV, FKBP11_A, GDF6, GDF7_A, JSRP1_A, KCTD15_A, KLHL21, LRRC8D_A, NBPf8, MAX.chr10.130339363-130339534, MAX.chr10.22624479-22624553, MAX.chr14.103021656-103021718, MAX.chr8.145103829-145103992, MAX.chr8.145104263-145104422, MDFI_B, MIAT_A, MMP23B, NDRG2, OBSCN_A, PCOLCE, PYCARD, SEPT9_B, SLC6A3_A, SLC8A3_B, SQSTM1, VILL, ZNF302, ZNF323_A, ZNF506, and ZNF90;
 - (ii) EMX2OS, CYTH2, C17orf107_A, DIDO1_A, GDF6, NBPf8, MAX.chr14.103021656-103021718, JSRP1_A, GATA2_B, and SFMBT2_B;
 - (iii) SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPf8, and MPZ_A;
 - (iv) EMX2OS, CYTH2, NBPf8, MAX.chr10.22624479-22624553; and
 - (v) ANKRD35, ARL5C, ARRB1, BCL2L11_A, BCL2L11_B, BCL2L11_C, BZRAP1, C16orf54, C17orf101, C6orf132, CACNA2D4, DEDD2, EPS15L1, FAIM2, FAM125B, FAM189B, FAM78A, FOXP4, GYPC_A, GYPC_B, IFFO1_A, IFFO1_B, ITPKA, KLF16, LIMD2, LOC389333, LOC440925_A, LOC646278, LYL1, LYPLAL1, MAX.chr11.32355226-32355251, MAX.chr14.102172621-102172686, MAX.chr14.105512122-105512239, MAX.chr15.95128144-95128248, MAX.chr16.11327016-11327312, MAX.chr3.187676577-187676668, MAX.chr4.174430676-174430847, MAX.chr8.145900783-145900914, MAX.chr8.80804237-80804301, N4BP3, NCOR2, NFATC1_A, NFATC1_B, NKX2-6, NR2F6, OSM, PALLD_C, PIK3CD, PRKAR1B, RAD52,

STX16_A, SUCLG2, TNFRSF1B, TNFRSF4, ZDHHC18, and ZNF671_A,
and

- 2) identifying the subject as having endometrial cancer when the methylation state of the marker is different than a methylation state of the marker assayed in a subject that does not have endometrial cancer.

58. The method of claim 57 comprising assaying a plurality of markers.
59. The method of claim 57 wherein the marker is in a high CpG density promoter.
60. The method of claim 57 wherein the sample is a stool sample, a tissue sample, an endometrial tissue sample, a plasma sample, or a urine sample.
61. The method of claim 57 wherein the assaying comprises using methylation specific polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation specific nuclease, mass-based separation, or target capture.
62. The method of claim 57 wherein the assaying comprises use of a methylation specific oligonucleotide.
63. The method of claim 57,
wherein if the sample is a tissue sample than the one or more genes is selected from groups i, ii, iii, v, vi, or vii;
wherein if the sample is a plasma sample than the one or more genes is within group iv.
64. A method of screening for clear cell endometrial cancer in a sample obtained from a subject, the method comprising:
 - 1) assaying a methylation state of a DNA methylation marker comprising a chromosomal region having an annotation selected from the group consisting of one of the following groups:
 - (i) DIDO1_A, NDRG4, MAX.chr14.103021656-103021718, MMP23B, EMX2OS, SEPT9_B, NBPF8, EEF1A2, AIM1_A, BMP4_B,

MAX.chr8.145103829-145103992, OBSCN, PYCARD, GDF6, MDFI_B, MIAT_A, SCL8A3, ZNF323_A, SQSTM1, AFF3, C1orf70, GDF7_A, JSRP1_A, LRRC8D_A, FEV, and MAX.chr8.145104263-145104422;

(ii) ZNF323_A, MAX.chr7.104624356-104624730, NDRG2, DIDO1_A, MDFI_B, MAX.chr14.103021656-103021718, MMP23B, SEPT9_B, and STX16_A;

(iii) SFMBT2_B, SQSTM1, ZNF323_A, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MDFI_B, GDF7_A, MAX.chr10.22624479-22624553, JSRP1_A, MAX.chr14.103021656-103021718, EMX2OS, LRRC34, NBPF8, SEPT9_B, EEF1A2, LRRC41_C, VILL, and MPZ_A;

(iv) MAX.chr7:104624386-104624529, EMX2OS, DIDO1_B, and OBSCN_B; and

(v) SFMBT2_B, SQSTM1, ZNF323_A, ZNF506, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, NDRG2, CYP11A1, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, MDFI_B, DLL4, GDF7_A, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, EMX2, MMP23B, EMX2OS, MAX.chr17.73073716-73073814, NBPF8, SEPT9_B, LOC440925_A, STX16_A, ITPKA, EEF1A2, FEV, LRRC41_C, and NFIC, and

- 2) identifying the subject as having clear cell endometrial cancer when the methylation state of the marker is different than a methylation state of the marker assayed in a subject that does not have clear cell endometrial cancer.

65. The method of claim 64 comprising assaying a plurality of markers.

66. The method of claim 64 wherein the marker is in a high CpG density promoter.

67. The method of claim 64 wherein the sample is a stool sample, a tissue sample, an endometrial tissue sample, a plasma sample, or a urine sample.

68. The method of claim 64 wherein the assaying comprises using methylation specific polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation specific nuclease, mass-based separation, or target capture.
69. The method of claim 64 wherein the assaying comprises use of a methylation specific oligonucleotide.
70. The method of claim 64,
wherein if the sample is a tissue sample than the one or more genes is selected from groups i, ii, iii, v, vi, or vii;
wherein if the sample is a plasma sample than the one or more genes is within group iv.
71. A method of screening for carcinosarcoma endometrial cancer in a sample obtained from a subject, the method comprising:
- 1) assaying a methylation state of a DNA methylation marker comprising a chromosomal region having an annotation selected from the group consisting of one of the following groups:
 - (i) EMX2OS, DIDO1_A, SBNO2, AMIGO3_A, PCOLCE, CLDN7, CYTH2, OBSCN_A, AHSA2, DLL4, EMX2, MAX.chr14.74100620-74100870, LRRC4, PPP2R5C_A, SQSTM1, MAX.chr17.73073716-73073814, CYP11A1, ACOXL_A, and AIM1_B;
 - (ii) EMX2OS, and LRRC34;
 - (iii) ZNF506, ZNF90, MAX.chr8.145103829-145103992, LRRC8D_A, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and VILL;
 - (iv) TRH, MAX.chr7:104624386-104624529, EMX2OS, DIDO1_B, and ST3GAL2_B; and
 - (v) SFMBT2_B, SMTN, ZNF506, ZNF90, CLDN7, LRRC41_B, CYP11A1, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, DLL4, MAX.chr10.22624479-22624553, PYCARD, BMP4_B,

- JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, EMX2OS, LRRC34, NBPF8, LOC440925_A, ITPKA, NFIC, and VILL, and
- 2) identifying the subject as having carcinoarcoma endometrial cancer when the methylation state of the marker is different than a methylation state of the marker assayed in a subject that does not have carcinosarcoma endometrial cancer.
72. The method of claim 71 comprising assaying a plurality of markers.
73. The method of claim 71 wherein the marker is in a high CpG density promoter.
74. The method of claim 71 wherein the sample is a stool sample, a tissue sample, an endometrial tissue sample, a plasma sample, or a urine sample.
75. The method of claim 71 wherein the assaying comprises using methylation specific polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation specific nuclease, mass-based separation, or target capture.
76. The method of claim 71 wherein the assaying comprises use of a methylation specific oligonucleotide.
77. The method of claim 71,
wherein if the sample is a tissue sample than the one or more genes is selected from groups i, ii, iii, v, vi, or vii;
wherein if the sample is a plasma sample than the one or more genes is within group iv.
78. A method of screening for serous endometrial cancer in a sample obtained from a subject, the method comprising:
- 1) assaying a methylation state of a DNA methylation marker comprising a chromosomal region having an annotation selected from the group consisting of one of the following groups:

- (i) EMX2OS, DIDO1_A, SBNO2, AMIGO3_A, PCOLCE, CLDN7, CYTH2, OBSCN_A, AHSA2, DLL4, EMX2, MAX.chr14.74100620-74100870, LRRC4, PPP2R5C_A, SQSTM1, MAX.chr17.73073716-73073814, CYP11A1, ACOXL_A, and AIM1_B;
 - (ii) EMX2OS, and LRRC34;
 - (iii) ZNF506, ZNF90, MAX.chr8.145103829-145103992, LRRC8D_A, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and VILL;
 - (iv) TRH, MAX.chr7:104624386-104624529, EMX2OS, DIDO1_B, and ST3GAL2_B; and
 - (v) SFMBT2_B, SMTN, ZNF506, ZNF90, CLDN7, LRRC41_B, CYP11A1, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, DLL4, MAX.chr10.22624479-22624553, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, EMX2OS, LRRC34, NBPF8, LOC440925_A, ITPKA, NFIC, and VILL, and
- 2) identifying the subject as having serous endometrial cancer when the methylation state of the marker is different than a methylation state of the marker assayed in a subject that does not have serous endometrial cancer.

79. The method of claim 78 comprising assaying a plurality of markers.
80. The method of claim 78 wherein the marker is in a high CpG density promoter.
81. The method of claim 78 wherein the sample is a stool sample, a tissue sample, an endometrial tissue sample, a plasma sample, or a urine sample.
82. The method of claim 78 wherein the assaying comprises using methylation specific polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation specific nuclease, mass-based separation, or target capture.
83. The method of claim 78 wherein the assaying comprises use of a methylation specific oligonucleotide.

84. The method of claim 78,
 wherein if the sample is a tissue sample than the one or more genes is selected from groups i, ii, iii, v, vi, or vii;
 wherein if the sample is a plasma sample than the one or more genes is within group iv.
85. A method of screening for endometrioid endometrial cancer in a sample obtained from a subject, the method comprising:
- 1) assaying a methylation state of a DNA methylation marker comprising a chromosomal region having an annotation selected from the group consisting of one of the following groups:
 - (i) MAX.chr10.130339363-130339534, SFMBT2_C, CYTH2, SLC6A3, VILL, EMX2OS, MAX.chr10.22624479-22624553, GDF6, ZNF90, ZNF506, JSRP1_A, c5orf52, SFMBT2_B, NBPF8, RHBDL1_A, DIDO1_A, KANK1, and GATA2_B;
 - (ii) MAX.chr8.145103829-145103992, CYTH2, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, SBNO2, NBPF8, and VILL;
 - (iii) SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, MAX.chr8.145104263-145104422, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and MPZ_A;
 - (iv) SFMBT2_B, SMTN, SQSTM1, ZNF506, ZNF90, CLDN7, LRRC41_B, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, DLL4, MAX.chr10.22624479-22624553, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, KANK1, SBNO2, c5orf52, EMX2O6, LRRC34, NBPF8, LOC440925_A, ITPKA, NFIC, VILL, and MPZ_A;
 - (v) TSPYL5, TRH, JAM3, FAM19A5, PTGDR, SFMBT2_E, JSRP1_B, and ARL5C;

- (vi) TSPYL5, MPZ_B, TRH, CNTN4, FAM19A5, GLT1D1, RYR2_F, PTGDR, EMX2OS, MAX.chr10:22624470-22624553, SPDYA_B, SFMBT2_E, and JSRP1_B; and
 - (vii) TSPYL5, MPZ_B, TRH, and PTGDR, and
 - 2) identifying the subject as having endometrioid endometrial cancer when the methylation state of the marker is different than a methylation state of the marker assayed in a subject that does not have endometrioid endometrial cancer.
- 86. The method of claim 85 comprising assaying a plurality of markers.
- 87. The method of claim 85 wherein the marker is in a high CpG density promoter.
- 88. The method of claim 85 wherein the sample is a stool sample, a tissue sample, an endometrial tissue sample, a plasma sample, or a urine sample.
- 89. The method of claim 85 wherein the assaying comprises using methylation specific polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation specific nuclease, mass-based separation, or target capture.
- 90. The method of claim 85 wherein the assaying comprises use of a methylation specific oligonucleotide.
- 91. The method of claim 85,
 - wherein if the sample is a tissue sample than the one or more genes is selected from groups i, ii, iii, v, vi, or vii;
 - wherein if the sample is a plasma sample than the one or more genes is within group iv.
- 92. A method for characterizing a sample from a human patient comprising:
 - a) obtaining DNA from a sample of a human patient;

b) assaying a methylation state of a DNA methylation marker comprising a chromosomal region having an annotation selected from the group consisting of one of the following groups:

- (i) AFF3, AIM1_A, AMIGO3_A, BMP4_B, C17orf107_A, C1orf70_B, C5orf52, CLDN7, DIDO1_A, EEF1A2, EMX2OS, FEV, FKBP11_A, GDF6, GDF7_A, JSRP1_A, KCTD15_A, KLHL21, LRRC8D_A, NBPf8, MAX.chr10.130339363-130339534, MAX.chr10.22624479-22624553, MAX.chr14.103021656-103021718, MAX.chr8.145103829-145103992, MAX.chr8.145104263-145104422, MDFI_B, MIAT_A, MMP23B, NDRG2, OBSCN_A, PCOLCE, PYCARD, SEPT9_B, SLC6A3_A, SLC8A3_B, SQSTM1, VILL, ZNF302, ZNF323_A, ZNF506, and ZNF90;
- (ii) EMX2OS, CYTH2, C17orf107_A, DIDO1_A, GDF6, NBPf8, MAX.chr14.103021656-103021718, JSRP1_A, GATA2_B, and SFMBT2_B;
- (iii) SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPf8, and MPZ_A;
- (iv) EMX2OS, CYTH2, NBPf8, MAX.chr10.22624479-22624553;
- (v) ANKRD35, ARL5C, ARRB1, BCL2L11_A, BCL2L11_B, BCL2L11_C, BZRAP1, C16orf54, C17orf101, C6orf132, CACNA2D4, DEDD2, EPS15L1, FAIM2, FAM125B, FAM189B, FAM78A, FOXP4, GYPC_A, GYPC_B, IFFO1_A, IFFO1_B, ITPKA, KLF16, LIMD2, LOC389333, LOC440925_A, LOC646278, LYL1, LYPLAL1, MAX.chr11.32355226-32355251, MAX.chr14.102172621-102172686, MAX.chr14.105512122-105512239, MAX.chr15.95128144-95128248, MAX.chr16.11327016-11327312, MAX.chr3.187676577-187676668, MAX.chr4.174430676-174430847, MAX.chr8.145900783-145900914, MAX.chr8.80804237-80804301, N4BP3, NCOR2, NFATC1_A, NFATC1_B, NKX2-6, NR2F6, OSM, PALLD_C, PIK3CD, PRKAR1B, RAD52, STX16_A, SUCLG2, TNFRSF1B, TNFRSF4, ZDHHC18, and ZNF671_A;
- (vi) DIDO1_A, NDRG4, MAX.chr14.103021656-103021718, MMP23B, EMX2OS, SEPT9_B, NBPf8, EEF1A2, AIM1_A, BMP4_B, MAX.chr8.145103829-145103992, OBSCN, PYCARD, GDF6, MDFI_B,

- MIAT_A, SCL8A3, ZNF323_A, SQSTM1, AFF3, C1orf70, GDF7_A, JSRP1_A, LRRC8D_A, FEV, and MAX.chr8.145104263-145104422;
- (vii) ZNF323_A, MAX.chr7.104624356-104624730, NDRG2, DIDO1_A, MDFI_B, MAX.chr14.103021656-103021718, MMP23B, SEPT9_B, and STX16_A;
- (viii) SFMBT2_B, SQSTM1, ZNF323_A, ZNF90, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, MDFI_B, GDF7_A, MAX.chr10.22624479-22624553, JSRP1_A, MAX.chr14.103021656-103021718, EMX2OS, LRRC34, NBPF8, SEPT9_B, EEF1A2, LRRC41_C, VILL, and MPZ_A;
- (ix) MAX.chr7:104624386-104624529, EMX2OS, DIDO1_B, and OBSCN_B;
- (x) SFMBT2_B, SQSTM1, ZNF323_A, ZNF506, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, NDRG2, CYP11A1, MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, MDFI_B, DLL4, GDF7_A, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, EMX2, MMP23B, EMX2OS, MAX.chr17.73073716-73073814, NBPF8, SEPT9_B, LOC440925_A, STX16_A, ITPKA, EEF1A2, FEV, LRRC41_C, and NFIC;
- (xi) EMX2OS, DIDO1_A, SBNO2, AMIGO3_A, PCOLCE, CLDN7, CYTH2, OBSCN_A, AHSA2, DLL4, EMX2, MAX.chr14.74100620-74100870, LRRC4, PPP2R5C_A, SQSTM1, MAX.chr17.73073716-73073814, CYP11A1, ACOXL_A, and AIM1_B;
- (xii) EMX2OS, and LRRC34;
- (xiii) ZNF506, ZNF90, MAX.chr8.145103829-145103992, LRRC8D_A, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and VILL;
- (xiv) TRH, MAX.chr7:104624386-104624529, EMX2OS, DIDO1_B, and ST3GAL2_B;
- (xv) SFMBT2_B, SMTN, ZNF506, ZNF90, CLDN7, LRRC41_B, CYP11A1, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, DIDO1_A,

GDF6, DLL4, MAX.chr10.22624479-22624553, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, EMX2OS, LRRC34, NBPF8, LOC440925_A, ITPKA, NFIC, and VILL;

(xvi) EMX2OS, KANK1, C1orf70_B, AMIGO3_A, DIDO1_A, LRRC41_C, NFIC, FKBP11_A, C17orf107_A, SMTN, LRRC41_B, LRRC8D_A, OBSCN_A, MAX.chr7.104624356-104624730, MIAT_B;

(xvii) MAX.chr7.104624356-104624730, EMX2OS, and LRRC41_C;

(xviii) MAX.chr8.145103829-145103992, CYTH2, LRRC8D_A, OBSCN_A, DIDO1_A, EMX2OS, LRRC41_C, and VILL;

(xix) EMX2OS, and LRRC41_D;

(xx) SFMBT2_B, SMTN, SQSTM1, ZNF90, CLDN7, LRRC41_B, MAX.chr7.104624356-104624730, CYP11A1, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, LRRC8D_A, MAX.chr8.145104263-145104422, OBSCN_A, GDGF6, DLL4, PYCARD, BMP4_B, JSRP1_A, MIAT_B, KANK1, EMX2OS, NBPF8, LOC440925_A, ITPKA, EEF1A2, FEV, LRRC41_C, NFIC, VILL, MPZ_A;

(xxi) MAX.chr10.130339363-130339534, SFMBT2_C, CYTH2, SLC6A3, VILL, EMX2OS, MAX.chr10.22624479-22624553, GDF6, ZNF90, ZNF506, JSRP1_A, c5orf52, SFMBT2_B, NBPF8, RHBDL1_A, DIDO1_A, KANK1, and GATA2_B;

(xxii) MAX.chr8.145103829-145103992, CYTH2, DIDO1_A, MAX.chr10.22624479-22624553, JSRP1_A, SBNO2, NBPF8, and VILL;

(xxiii) SFMBT2_B, ZNF90, MAX.chr8.145103829-145103992, CYTH2, MAX.chr8.145104263-145104422, OBSCN_A, MAX.chr10.22624479-22624553, JSRP1_A, EMX2OS, NBPF8, and MPZ_A;

(xxiv) SFMBT2_B, SMTN, SQSTM1, ZNF506, ZNF90, CLDN7, LRRC41_B, FKBP11_A, MAX.chr8.145103829-145103992, AHSA2, CYTH2, GATA2_B, LRRC8D_A, MAX.chr8.145104263-145104422, DIDO1_A, GDF6, MAX.chr10.130339363-130339534, DLL4, MAX.chr10.22624479-22624553, MIAT_A, PYCARD, BMP4_B, JSRP1_A, MAX.chr14.103021656-103021718, MIAT_B, KANK1, SBNO2, c5orf52,

EMX2O6, LRRC34, NBPf8, LOC440925_A, ITPKA, NFIC, VILL, and MPZ_A;

(xxv) TSPYL5, TRH, JAM3, FAM19A5, PTGDR, SFMBT2_E, JSRP1_B, and ARL5C;

(xxvi) TSPYL5, MPZ_B, TRH, CNTN4, FAM19A5, GLT1D1, RYR2_F, PTGDR, EMX2OS, MAX.chr10:22624470-22624553, SPDYA_B, SFMBT2_E, and JSRP1_B; and

(xxvii) TSPYL5, MPZ_B, TRH, and PTGDR;

- c) comparing the assayed methylation state of the one or more DNA methylation markers with methylation level references for the one or more DNA methylation markers for human patients not having endometrial cancer, clear cell endometrial cancer, carcinosarcoma endometrial cancer, endometrioid endometrial cancer, and/or serous endometrial cancer.

93. The method of claim 92 wherein the sample is a stool sample, a tissue sample, an endometrial tissue sample, a plasma sample, or a urine sample.

94. The method of claim 92 comprising assaying a plurality of DNA methylation markers.

95. The method of claim 92,
wherein if the biological sample is a tissue sample than the one or more genes is selected from groups i, ii, iii, vi, vii, viii, ix, xi, xii, xiii, xiv, xvi, xvii, xviii, xix, xxi, xxii, xxiii, xxv, xxvi, or xxvii;

wherein if the biological sample is a plasma sample than the one or more genes is within group v, x, xv or xxiv.

96. The method of claim 92 wherein the assaying comprises using methylation specific polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation specific nuclease, mass-based separation, or target capture.

97. The method of claim 92 wherein the assaying comprises use of a methylation specific oligonucleotide.

98. The method of claim 92 wherein the methylation specific oligonucleotide is selected from a set of primers for the selected one or more genes is recited in Table 10 or 22 or a probe selected from Table 23.

99. A method for characterizing a sample obtained from a human subject, the method comprising reacting a nucleic acid comprising a DMR with a bisulfite reagent to produce a bisulfite-reacted nucleic acid; sequencing the bisulfite-reacted nucleic acid to provide a nucleotide sequence of the bisulfite-reacted nucleic acid; comparing the nucleotide sequence of the bisulfite-reacted nucleic acid with a nucleotide sequence of a nucleic acid comprising the DMR from a subject who does not have endometrial cancer to identify differences in the two sequences.

100. A system for characterizing a sample obtained from a human subject, the system comprising an analysis component configured to determine the methylation state of a sample, a software component configured to compare the methylation state of the sample with a control sample or a reference sample methylation state recorded in a database, and an alert component configured to determine a single value based on a combination of methylation states and alert a user of a endometrial cancer-associated methylation state.

101. The system of claim 100 wherein the EC-associated methylation state is for one or more of endometrial cancer, clear cell endometrial cancer, carcinosarcoma endometrial cancer, endometrioid endometrial cancer, and serous endometrial cancer.

102. The system of claim 100 wherein the sample comprises a nucleic acid comprising a DMR.

103. The system of claim 100 further comprising a component for isolating a nucleic acid.

104. The system of claim 100 further comprising a component for collecting a sample.

105. The system of claim 100 wherein the sample is a stool sample, a tissue sample, a endometrial tissue sample, a plasma sample, or a urine sample.

106. The system of claim 100 wherein the database comprises nucleic acid sequences comprising a DMR.
107. The system of claim 100 wherein the database comprises nucleic acid sequences from subjects who do not have at least one of endometrial cancer, clear cell endometrial cancer, carcinosarcoma endometrial cancer, endometrioid endometrial cancer, and/or serous endometrial cancer.
108. A kit comprising:
 - 1) a bisulfite reagent; and
 - 2) a control nucleic acid comprising a sequence from a DMR selected from a group consisting of DMR 1–499 from Table 1, 8 and 21, and having a methylation state associated with a subject who does not have endometrial cancer.
109. A kit comprising a bisulfite reagent and an oligonucleotide according to SEQ ID NOS 1-288.
110. A kit comprising a sample collector for obtaining a sample from a subject; reagents for isolating a nucleic acid from the sample; a bisulfite reagent; and an oligonucleotide according to SEQ ID NOS 1-288.
111. The kit according to claim 110 wherein the sample is a stool sample, a tissue sample, an endometrial tissue sample, a plasma sample, or a urine sample.
112. A composition comprising a nucleic acid comprising a DMR and a bisulfite reagent.
113. A composition comprising a nucleic acid comprising a DMR and an oligonucleotide according to SEQ ID NOS 1-288.
114. A composition comprising a nucleic acid comprising a DMR and a methylation-sensitive restriction enzyme.

115. A composition comprising a nucleic acid comprising a DMR and a polymerase.
116. A method for screening for endometrial cancer in a sample obtained from a subject, the method comprising reacting a nucleic acid comprising a DMR with a bisulfite reagent to produce a bisulfite-reacted nucleic acid; sequencing the bisulfite-reacted nucleic acid to provide a nucleotide sequence of the bisulfite-reacted nucleic acid; comparing the nucleotide sequence of the bisulfite-reacted nucleic acid with a nucleotide sequence of a nucleic acid comprising the DMR from a subject who does not have endometrial cancer to identify differences in the two sequences; and identifying the subject as having endometrial cancer when a difference is present.
117. A system for screening for endometrial cancer in a sample obtained from a subject, the system comprising an analysis component configured to determine the methylation state of a sample, a software component configured to compare the methylation state of the sample with a control sample or a reference sample methylation state recorded in a database, and an alert component configured to determine a single value based on a combination of methylation states and alert a user of a endometrial cancer-associated methylation state.
118. The system of claim 117 wherein the sample comprises a nucleic acid comprising a DNA methylation marker comprising a base in a differentially methylated region (DMR) selected from a group consisting of DMR 1–499 from Tables 1, 8 and 21.
119. The system of claim 118 further comprising a component for isolating a nucleic acid.
120. The system of claim 118 further comprising a component for collecting a sample.
121. The system of claim 118 further comprising a component for collecting a stool sample, an endometrial tissue sample, and/or a plasma sample.
122. The system of claim 118 wherein the database comprises nucleic acid sequences from subjects who do not have endometrial cancer.

FIG. 1




FIG. 2

1. AGRN
2. AIM1
3. AKR7A3
4. C17orf107
5. DIDO1
6. EMX2OS
7. FKBP11
8. GDF7
9. JSRP1
10. LHFPL2
11. LOC100129726
12. LRRC41
13. LRRC8D
14. MAX.chr10.2262
15. MAX.chr14.1030
16. MAX.chr7.10462
17. MAX.chr7.10462B
18. MDF1
19. OBSCN
20. RHBDL1
21. SEPT9
22. SFMBT2
23. SPDYA
24. ST3GAL2
25. VILL
26. ZNF323
27. SLC13A5
28. ZMIZ1
29. MAX.chr8.1451
30. C8orf73
31. KBTBD11
32. LOC100192379
33. TRIM71
34. LOC440925
35. ARL5C
36. STX16
37. ITPKA
38. IRF4
39. CNTN4
40. GRIN2A
41. NOTCH3
42. PAX1
43. ZNF521
44. VSX1
45. CRHR2
46. FAM19A5
47. ASCL1
48. GLT1D1
49. T
50. CAPN2
51. RYR2_F
52. SIM2
53. TRH
54. JAM3
55. BARX1
56. ZNF671
57. TSPYL5
58. MFZ_5554
59. CXCL12
60. PTGDR

AGRN

>hg19_dna range=chr1:975957-976046 5'pad=0 3'pad=0 strand=+
 GGGCTGCGAGCACGGCAAGGTCTCTCAGGCTTGTGGACGTGGGTACGGGCGTCTCGGCACCCTGAGCTTTCTCCCCACCCGCCCCAGCG
 (SEQ ID NO:289)

BST:

GGGTTGCGAGTACGGTAAGGTTTTTTAGGTTTGTGGACGTGGGTACGGGCGTTTCGGTATTTTGAGTTTTTTTTTTTATTCGTTTTAGCG
 (SEQ ID NO:290)

AGRN_FP GGTGCGAGTACGGTAAGGTTT (SEQ ID NO:291)

AGRN_RP AAAACTCAAATAACCGAAACGCC (SEQ ID NO:292)

AGRN_Pb_A1 CGCGCCGAGG CCGTACCCACGTCCA/3C6/ (SEQ ID NO:293)

FIG. 2 (cont'd)

AIM1
 >hg19_dna range=chr6:106960288-106960380 5'pad=0 3'pad=0 strand=+
 CGCGGACGCCGAGCTCCCTGAGAGCGCTGCCAGGGACGACGCGGTGTTTCGACGACGAGGTGGCGCCAAACGCGGCCAGCGATAACGCCTCGGC
 (SEQ ID NO:294)

BST:
 CGCGGACGTCGAGTTTTTTGAGAGCGTTGTTAGGGACGACGCGGTGTTTCGACGACGAGGTGGCGTTAAACGCGTTAGCGATAACGTTTCGGT
 (SEQ ID NO:295)

AIM1_FP TTGAGAGCGTTGTTAGGGACGAC (SEQ ID NO:296)
 AIM1_RP CGCGTTTAAACGCCACCTC (SEQ ID NO:297)
 AIM1_Pb_A5 AGGCCACGGACG CGTCGTCGAACACCG/3C6/ (SEQ ID NO:298)

AKR7A3
 >hg19_dna range=chr1:19615293-19615389 5'pad=0 3'pad=0 strand=+
 GAGACGGGCTCGGGCCCCCGCCACCGCGGGTGCAGCTGAGGGCGCGGCCGAAGGTGCCCCGACGCCGCCACGAGCTCGACTCCACGCTCGGCT
 ACT (SEQ ID NO:299)

BST:
 GAGACGGGTTTCGGGTTTCGTTTATCGGCGGGTGTAGTTGAGGGCGCGGTGCAAGGTGTTTCGACGTCGTTTACGAGTTTCGATTTTACGTTTCGGT
 ATT (SEQ ID NO:300)

AKR7A3_FP CGGGTTTCGTTTATCGGCGG (SEQ ID NO:301)
 AKR7A3_RP AACGTAAATCGAACTCGTAAACGAC (SEQ ID NO:302)
 AKR7A3_Pb_A1 CGCGCCGAGG CGTCGAACACCTTCGAC/3C6/ (SEQ ID NO:303)

C17orf107
 >hg19_dna range=chr17:4802690-4802828 5'pad=0 3'pad=0 strand=+
 GGCGGGGCTTAGGGGACGAGTTAGTACGAAGCCCCACCCGACCGGGCTGCACCGCCCCCTCCGCGCTTACGTGGCGCAGCCGCGGGACAT
 GCGTGGGTGGTGGGCGTCCGCTGGGACAGTTGAGCAGATGAC (SEQ ID NO:304)

BST:
 GGCGGGGTTTAGGGGACGAGTTAGTACGAAGTTTTATTTTCGATTTCGGGTTGTATCGTTTTTTTCGCGTTTACGTGGCGTAGTCGCGGGGATAT
 GGCGTGGGTGGTGGGCGTTCGTTGGGATACGTTGAGTACGATGAT (SEQ ID NO:305)

C17orf107_FP CGAAGTTTTATTTTCGATTTCGGGTTGTATCG (SEQ ID NO:306)
 C17orf107_RP CCACGCCATATCCCCG (SEQ ID NO:307)
 C17orf107_Pb_A5 AGGCCACGGACG CGACTACGCCACGTAAA/3C6/ (SEQ ID NO:308)

DID01
 >hg19_dna range=chr20:61560628-61560728 5'pad=0 3'pad=0 strand=+
 GCCGAGGCCACCGGGCAGCGTCCAGGTCTCGGCCTTTGGGAGGGGAGCAGCGGGGAGGGGCACGGGAGGGGCGAGGGCGGGCGCGCCTGGG
 CCTCGGC (SEQ ID NO:309)

BST:
 GCCGAGGTTATCGGGTAGCGTTTAGGTTTCGGTTTTTTGGGAGGGGAGTAGCGGGGAGGGGTACGGGAGGGGCGAGGGCGGGCGCGTTTGGG
 TTTCCGT (SEQ ID NO:310)

DID01_FP AGGTTATCGGGTAGCGTTTAGG (SEQ ID NO:311)
 DID01_RP CGTACCCCTCCCCCGCTAC (SEQ ID NO:312)
 DID01_Pb_A1 CGCGCCGAGG GTTTCGGTTTTTTGGGAGG/3C6/ (SEQ ID NO:313)

EMX20S
 >hg19_dna range=chr10:119294950-119295039 5'pad=0 3'pad=0 strand=+
 CGCTGTGAGTCGCCCACGCGAGCGAGCTGGGGATACGGGGCGCAGGAGTCTCAGCTGCCGCCACGCAGCGCTTGCCCTGCCCGAGCTTC
 (SEQ ID NO:314)

BST:
 CGTTGTGAGTCGTTTACGCGAGCGACGTGGGGATACGGGGCGTACGGAGTTTTAGTTGTCGTTACGTAGCGTTTGTGTTTTCGAGTTTT
 (SEQ ID NO:315)

EMX20S_FP GTCGTTTACGCGAGCGACG (SEQ ID NO:316)
 EMX20S_RP CTCGAACAAACAAACGCTACGTAAC (SEQ ID NO:317)
 EMX20S_Pb_A5 AGGCCACGGACG CGACAATAAACTCCGTACG/3C6/ (SEQ ID NO:318)

FIG. 2 (cont'd)

FKBP11
 >hg19_dna range=chr12:49319059-49319168 5'pad=0 3'pad=0 strand=+
 TGAGGGTCGGGACTATCTCCTCACCAGGGTCTCCACTTGGAGGGTCCGGACGGGACTTTCGGTTTCGAGCCCAGCCTCAGCCCGGCACACCGCC
 GCACTGAGCAGCAGCA (SEQ ID NO:319)

BST:
 TGAGGGTCGGGATTATTTTTTATTAGGGTTTTTATTGGAGGGTTCGGACGGGATTTCGGTTTCGAGTTTAGTTTTAGTTCGGTATATCGTC
 GTATTGAGTAGTAGTA (SEQ ID NO:320)

FKBP11_FP GGTTTTTATTGGAGGGTTCGGAC (SEQ ID NO:321)
 FKBP11_RP ACTACTCAATACGACGATATACCGAAC (SEQ ID NO:322)
 FKBP11_Pb_A1 CGCGCCGAGG CGGGATTTTCGGTTTCGA/3C6/ (SEQ ID NO:323)

GDF7
 >hg19_dna range=chr2:20866007-20866135 5'pad=0 3'pad=0 strand=+
 GCCATCCCGGGGCTCTGCGCCGTCCTCGCTCCTCGGCTCCTGGCCGCTCAGGCACACAGCCGGTAGCTGGTTTTCGTTAGCCGCTGCCCTCGCCC
 AGAAGCGGGTGGAAGGTCGCCAGTTGGACGCACA (SEQ ID NO:324)

BST:
 GTTATTTTCGGGGTTTTGCGTCGTTTCGTTTTTCGGTTTTTGGTCGTTTACGTATATAGTCGGTAGTTGGTTTTCGTTAGTCGTTGTTTTCGTTT
 AGAAGCGGGTGGAAGGTCGTTAGTTGGACGTATA (SEQ ID NO:325)

GDF7_FP TCGTTCGTTTTTCGGTTTTTGGTC (SEQ ID NO:326)
 GDF7_RP CCTTCTAAACGAAAACAACGACTAACGAAA (SEQ ID NO:327)
 GDF7_Pb_A5 AGGCCACGGACG CGTTTACGTATATAGTCGGTAGT/3C6/ (SEQ ID NO:328)

JSRP1
 >hg19_dna range=chr19:2253227-2253345 5'pad=0 3'pad=0 strand=-
 GTAGCGTTCTGCGCCTTTCCCTGCGCCCTCTCTGGGGAGCGCTCAGCTCGTGAGCGCCCCCGGGGGCACTCCTGCGACCCCTCCCTTGCTA
 GGGGCTCCTACAGCCCGTGGTCGG (SEQ ID NO:329)

GTAGCGTTTTGTCGTTTTTTTTTTCGTTTTTTGGGATCGTTTAGTTCGTGAGCGTTTTTCGGGGGTATTTTTGCGATTTTTTTTTTTGTTA
 GGGTTTTTTATAGTTCGTGGTCGG (SEQ ID NO:330)

JSRP1_FP TAGCGTTTTGTCGTTTTTTTTTTCGCT (SEQ ID NO:331)
 JSRP1_RP CGCAAAAATACCCCGAAAAAC (SEQ ID NO:332)
 JSRP1_Pb_A1 CGCGCCGAGG CGCTCACGAATAAACGATCC/3C6/ (SEQ ID NO:333)

LHFPL2
 >hg19_dna range=chr5:77806193-77806301 5'pad=0 3'pad=0 strand=+
 CGGACCCAGAGCACCCTGCGGCCTCACCTAGGGGAGAGGGAGGGCGGTTAGCAGCGCCGCCAGGCCCCCGCCCTCCCGCCGCGCAGCG
 ACACCGTCCAAGTCC (SEQ ID NO:334)

BST:
 CGGATTTAGAGTATCGTTTTCGCGTTTTATTTAGGGGAGAGGGAGGGCGGTTAGTAGCGTCGTTAGGTTTCGTTTCGTTTTTCGTCGCGTAGCG
 ATATCGTTTAAGTTT (SEQ ID NO:335)

LHFPL2_FP GGAGGGCGGTTAGTAGCGT (SEQ ID NO:336)
 LHFPL2_RP ACGATATCGCTACGCGACGAAA (SEQ ID NO:337)
 LHFPL2_Pb_A5 AGGCCACGGACG TCCTTAGGTTTCGTTTCGT/3C6/ (SEQ ID NO:338)

LOC100129726
 >hg19_dna range=chr2:43452148-43452235 5'pad=0 3'pad=0 strand=+
 CGACGGGAAGCCCGAGAAGCTGAGGCTGTGGTGAACCTTGGGCCGCGGCTCCCGCGGAAGCCAGGTGCAACGCATCGCGCGTGCCA
 (SEQ ID NO:339)

BST:
 CGACGGGAAGTTTCGAGAAGTTGAGGTTGTGGTGAATTTGGGTCGCGGTTTTTCGCGGAAGTTTAGGTGTAACGTATCGCGCGTGTTA
 (SEQ ID NO:340)

LOC100129726_FP GTTGTGGTGAATTTGGGTCGC (SEQ ID NO:341)
 LOC100129726_RP ACACGCGGATACGTTACAC (SEQ ID NO:342)
 LOC100129726_Pb_A1 CGCGCCGAGG CGGTTTTCGCGGGA/3C6/ (SEQ ID NO:343)

LRRC41
 >hg19_dna range=chr1:46768830-46768913 5'pad=0 3'pad=0 strand=+
 GCTCACCGCCCGCCGACAGCTCGAACAGGGCGGGGGAGCGTTGGGGCCGAGGCGAGCTCTTCGCTGGCGCCGCTCCCG
 (SEQ ID NO:344)

BST:
 GTTTATCGTTTCGTTATAGTTCGAATAGGGCGGGGGAGCGTTGGGGTTCGAGTCGAGTTTTTCGTTGGCGTCGTTTTTCG
 (SEQ ID NO:345)

FIG. 2 (cont'd)

LRRC41_FP CGTTTCGTATAGTTCTGAATAGGGCG (SEQ ID NO:346)
 LRRC41_RP CGACGCCAACGAAAACTC (SEQ ID NO:347)
 LRRC41_Pb_A5 AGGCCACGGACG CGACCTCGAACCCAA/3C6/ (SEQ ID NO:348)

LRRC8D
 >hg19_dna range=chr1:90308856-90308965 5'pad=0 3'pad=0 strand=+ repeatMasking=none
 CGGCGGAGGAAGCGTGGAGTCCATTGATCTAGGTACTTGTGGGAGGGGAGAACCCGAGCAGCAGCTGCAAACGGAAGGGCTGTGAGCGAGCGG
 GCGGGCGGGTGGCTGG (SEQ ID NO:349)

BST:
 CGGCGGAGGAAGCGTGGAGTTTATTGATTTAGGTATTTGTGGGAGGGGAGAATTCGAGTAGTAGTTGTAAACGGAAGGGTTGTGAGCGAGCGG
 GCGGGCGGGTGGTTGG (SEQ ID NO:350)

LRRC8D_FP GGAGAATTCGAGTAGTAGTTGTAAACGGA (SEQ ID NO:351)
 LRRC8D_RP CAACCAACCGCCCGCC (SEQ ID NO:352)
 LRRC8D_Pb_A1 CGCGCCGAGG CCGCTCGCTCACA/3C6/ (SEQ ID NO:353)

MAX.chr10.2262
 >hg19_dna range=chr10:22624470-22624553 5'pad=0 3'pad=0 strand=+
 CTTGCTACGTGGCATCGTCAATTTCTTAACCGCGTTTACGAAATGCAAATTTCCCTCCGCGGCGTCGACC
 (SEQ ID NO:354)

BST:
 TTTGTTTACGTGGTATCGTTATTTTTTAATCGCGTTTACGAAATGTAAATTTTTTTTGGTTTTTTTTTCGCGGTCGTCGATT
 (SEQ ID NO:355)

MAX.chr10.2262_FP TGTTTACGTGGTATCGTTATTTTTTAATCGC (SEQ ID NO:356)
 MAX.chr10.2262_RP CGACGACCGCGAAAAAAAACC (SEQ ID NO:357)
 MAX.chr10.2262_Pb_A5 AGGCCACGGACG CGGTTTACGAAATGTAAATTT/3C6/ (SEQ ID NO:358)

MAX.chr14.1030
 >hg19_dna range=chr14:103021654-103021725 5'pad=0 3'pad=0 strand=+
 CCGCCCCGTGGGAACAGCAGGACGGCGCGAGGCCGTTTCGCTTTCCTCCGCGCCCATTTGCCGGGAGGGG (SEQ ID NO:359)

BST:
 TCGTTTCGTGGGAATAGTAGGACGGCGTCGAGGTCGTTTTCGTTTTTTTCGCGTTTATTTGTCGGGAGGGG (SEQ ID NO:360)

MAX.chr14.1030_FP TCGTGGGGAATAGTAGGACGGC (SEQ ID NO:361)
 MAX.chr14.1030_RP CCTCCGACAAATAAACGCGA (SEQ ID NO:362)
 MAX.chr14.1030_Pb_A1 CGCGCCGAGG CGTCGAGGTCGTTTCG/3C6/ (SEQ ID NO:363)

MAX.chr7.1046
 >hg19_dna range=chr7:104624386-104624513 5'pad=0 3'pad=0 strand=+
 CGGCCTAGGACGCGCCTGCGTGGAGGACGGCCCGCGCGGGAAGTGCCTTTCTGGGCTCCTCTGAAGAATGCGGAGGAGGAATGAGCTG
 GCGCGCGGCCAGCTGCTCTCTTCTGATCCGAAG (SEQ ID NO:364)

BST:
 CGGTTTAGGACGCGTTTTTCGCTGGAGGTAGGTTTCGCGCGGCGGAAGTGCCTTTTGGGTTTTTTTGAAGAATGCGGAGGAGGAATTGAGTTG
 GCGCGCGGTTAGTTGTTTTTTTTTTTGAATTTCGAAG (SEQ ID NO:365)

MAX.chr7.1046_FP GGAGGTAGGTTTCGCGCGG (SEQ ID NO:366)
 MAX.chr7.1046_RP CCAACTCAATTCCTCTCCGC (SEQ ID NO:367)
 MAX.chr7.1046_Pb_A5 AGGCCACGGACG GCGGAAGTGCCTT/3C6/ (SEQ ID NO:368)

MAX.chr7.1046B
 >hg19_dna range=chr7:104624386-104624529 5'pad=0 3'pad=0 strand=+
 GCCGCGCGCGGGAAGTGCCTTTCTGGGCTCCTCTGAAGAATGCGGAGGAGGAATGAGCTGGCGCGGGCCAGCTGCTCTCTTCTGAT
 CCCGAAGACAGGATCGGATTATGGGTTGTTACCGGCTTGTGCGGCCCTGG (SEQ ID NO:369)

BST:
 GTTCGCGCGCGGAAGTGCCTTTTTGGGTTTTTTTTGAAGAATGCGGAGGAGGAATTGAGTTGGCGCGGGTTAGTTGTTTTTTTTTTGAT
 TTCGAAGATAGGATCGGATTATGGGTTGTTATCGGTTGTGCGGTTTTGG (SEQ ID NO:370)

MAX.chr7.1046B_FP GAGGAGGAATTGAGTTGGCGC (SEQ ID NO:371)
 MAX.chr7.1046B_RP CAACCCATAATCCGATCCTATCTTCGA (SEQ ID NO:372)
 MAX.chr7.1046B_Pb_A1 CGCGCCGAGG CGCGGTTAGTTGTT/3C6/ (SEQ ID NO:373)

FIG. 2 (cont'd)

MDFI
 >hg19_dna range=chr6:41606379-41606439 5'pad=0 3'pad=0 strand=+
 CCGCTCGCAGTGAGTGAGTGGACGTGGGAGGCGCGCATCTGCGGGGAATCGCCCTTGCCC (SEQ ID NO:374)

BST:
 CGGTTCGTACGAGTGAGTGGACGTGGGAGGCGCGTATTTGCGGGGAATCGTTTTTGT (SEQ ID NO:375)

MDFI_FP TTCGTACGAGTGAGTGGACG (SEQ ID NO:376)
 MDFI_RF CAAAAACGATTCCCCCGCAA (SEQ ID NO:377)
 MDFI_Pb_A5 AGGCCACGGACG ATACGCGCTCCCA/3C6/ (SEQ ID NO:378)

OBSCN
 >hg19_dna range=chr1:228463593-228463689 5'pad=0 3'pad=0 strand=+
 CGGGAAAGAACGTGGAGATCCACGCCGAGGGCGCCCGCCACCGCTGGTTCTGCACACGTAGGTTTTGCCGACCGTGGCTTCTTTGGCTGCGA
 GAC (SEQ ID NO:379)

BST:
 CGGGAAAGAACGTGGAGATTTACGTCGAGGGCGTTTCGTTATCGTTTGGTTTTGTATAACGTAGGTTTTGTGATCGTGGTTTTTTGGTTGCGA
 GAT (SEQ ID NO:380)

OBSCN_FP TGGAGATTTACGTCGAGGGC (SEQ ID NO:381)
 OBSCN_RF CCACGATCGACAAAACCTACGT (SEQ ID NO:382)
 OBSCN_Pb_A1 CGCGCCGAGG CGTTCGTTATCGTTTGGTTT/3C6/ (SEQ ID NO:383)

RHBDL1
 >hg19_dna range=chr16:725588-725658 5'pad=0 3'pad=0 strand=+
 GCGTGACGGGTGCGCGCGTGTCTTGGCCGCGCGTGGCGCGGTGTGCGGCAGGGCGGGCAGGCGGGCGACTCG (SEQ ID NO:384)

BST:
 GCGTGTAGGGTGCGCGCGTGTCTTGGTTCGCGCGTGGCGCGGTGTGCGGTAGGGCGGGTAGGCGGGCGATTCTG (SEQ ID NO:385)

RHBDL1_FP_V2 GCGCGTGTCTTGGTTCGC (SEQ ID NO:386)
 RHBDL1_RF_V2 TCGTCCGCTACCCGCC (SEQ ID NO:387)
 RHBDL1_Pb_A5_V2 AGGCCACGGACG CCTACCGCACACGC/3C6/ (SEQ ID NO:388)

SEPT9
 >hg19_dna range=chr17:75447656-75447829 5'pad=0 3'pad=0 strand=+
 GGGGGCTCTCAGGTGGCGCGCGCGCGAGGCGGACCTGATGGCCATGGTGCGGTGCGGGAGCCACGCTGTCCCTGGGCCCCGGCCCCGAGGCC
 GGCAGGACCGAGCGGGTCCCCAGGAGAGGGGTGGCGGGGAGCTCGATCTCCACGCGGGGACCAGATTTTCGGCCTCAA (SEQ ID
 NO:389)

BST:
 GGGGGTTTTTAGGTGGCGCGGTGCGAGGCGGATTTTGATGGTTATGGTGCGGTGTCGGGAGTTACGTTGTTTTGGGTTTCGGTTTCGAGGTC
 GGTAGGATCGAGCGGGTTTTTAGGAGAGGGGTGGCGGGGAGTTCGATTTTTACGCGGGGATTAGATTTTCGGTTTTAAA (SEQ ID
 NO:390)

SEPT9_FP GGAGTTACGTTGTTTTGGGTTTCG (SEQ ID NO:391)
 SEPT9_RF CTCTCCTAAAAACCCGCTC (SEQ ID NO:392)
 SEPT9_Pb_A1 CGCGCCGAGG CGATCCTACCGACCTCGA/3C6/ (SEQ ID NO:393)

SFMBT2_745
 >hg19_dna range=chr10:7451008-7451110 5'pad=0 3'pad=0 strand=-
 GAGGTGGGGACCGGACCGAAGCTTGAGAAGACCAAAGTGGTGGTGGTGGTGGGTGGGGCAGAAGGGCGGGAGCGCGCGGCTCTGGGA
 GACAAGCAC (SEQ ID NO:394)

BST:
 GAGGTGGGGATCGGGATCGAAGTTTGAGAAGATTAAAGTGGTGGTGGTGGTGGGTGGGGTAGAAGGGCGGGAGCGCGCGGTTTTGGGA
 GATAAGTAT (SEQ ID NO:395)

SFMBT2_745_FP GGATCGGGATCGAAGTTTGAGAA (SEQ ID NO:396)
 SFMBT2_745_RF CTTATCTCCCAAACCGCGC (SEQ ID NO:397)
 SFMBT2_745_Pb_A5 AGGCCACGGACG CGTCCCGCCCTTCT/3C6/ (SEQ ID NO:398)

FIG. 2 (cont'd)

SPDYA
 >hg19_dna range=chr2:29033347-29033484 5'pad=0 3'pad=0 strand=+
 AACACGCTGTGCCCCGTGTGCCGGCGGGGAGGGAGGCCGAGCCCCAGCCCCGGGGGCTGTTGTCTAATCGAAGGGAAGTAAACGGCC
 CCAACGCAAGCCTGACTGCGAGACGTGCCCAAGGGAGGTAGGTC (SEQ ID NO:399)

BST:
 AATTACGTTTGTTCGCGTGTGTCCGGCGGGGAGGGAGGTCGTAGTTTTAGTTTCGGGGGTTTGGTTGTTTAAATCGAAGGGAAGTAAACGGTT
 TTAACGTAAGTTTGATTGCGGAGACGTGTTTAAAGGGAGGTAGGTT (SEQ ID NO:400)

SPDYA_FP TTGTTTGTAAATCGAAGGGAAGTAAAC (SEQ ID NO:401)
 SPDYA_RP CTACCTCCCTTAAACACGTCTCG (SEQ ID NO:402)
 SPDYA_Pb_A1 CGCGCCGAGG CGGTTTTAACGTAAGTTTGATTG/3C6/ (SEQ ID NO:403)

ST3GAL2
 >hg19_dna range=chr16:70415003-70415106 5'pad=0 3'pad=0 strand=+
 CGCAGGAAGCCCTGGGGGCGCAGCCATCCACAGCGCGCCGAGGTGGGACTGGGGGTCCCGCAGCGACCGCTTTTCTTTGGTGGGTCTGCACG
 CACCTATCCG (SEQ ID NO:404)

BST:
 CGTAGGAAGTTTGGGGGCGTAGTTATTTTATAGCGCGTTCGAGGTGGGATTGGGGGTTTCGTAGCGATCGTTTTTTTTTGGTGGGTTTGTACG
 TATTTATTCG (SEQ ID NO:405)

ST3GAL2_FP GGGCGTAGTTATTTTATAGCGC (SEQ ID NO:406)
 ST3GAL2_RP CACCAAAAAAAAAACGATCGCTACGAAA (SEQ ID NO:407)
 ST3GAL2_Pb_A5 AGGCCACGGACG CGGTTCGAGGTGGGA/3C6/ (SEQ ID NO:408)

VILL
 >hg19_dna range=chr3:38035645-38035743 5'pad=0 3'pad=0 strand=- repeatMasking=none
 CGGGTGTTTGTGTATATGTGTTCGGGGAAGACGGAGGTGCGGGTGGAGAAGGGGAGGATGTACCAAGGGCCATGGGGAGACGCTAGGCAGGGG
 CTTCC (SEQ ID NO:409)

CGGGTGTTTGTGTATATGTGTTCGGGGAAGACGGAGGTGCGGGTGGAGAAGGGGAGGATGTATTAAGGGTTATGGGGAGACGTTAGGTAGGGG
 TTTTT (SEQ ID NO:410)

VILL_FP CGGGGAAGACGGAGGTG (SEQ ID NO:411)
 VILL_RP AAACCCCTACCTAACGTCTCCC (SEQ ID NO:412)
 VILL_Pb_A1 CGCGCCGAGG GCGGGTGGAGAAGG/3C6/ (SEQ ID NO:413)
 VILL_Pb_A5 AGGCCACGGACG GCGGGTGGAGAAGG/3C6/ (SEQ ID NO:414)

ZNF323
 >hg19_dna range=chr6:28303870-28303974 5'pad=0 3'pad=0 strand=+
 CGGCAAGCTACGGAACAGGTGGCGGGCTGCAGCACCCCAATGACCGATCAACCGCAAAGGCCGGAATGCGTCAGCCGTTCTGAGCCCACTGG
 CTGAAGCCAGG (SEQ ID NO:415)

BST:
 CGGTAAGTTACGGAATAGGTGGCGGGGTTGTAGTATTTTAAATGATCGATTAATCGTAAAGGTCGGAATGCGTTAGTCGTTTTGAGTTTATTGG
 TTGAAGTTAGG (SEQ ID NO:416)

ZNF323_FP CGGGGTTGTAGTATTTTAAATGATCGA (SEQ ID NO:417)
 ZNF323_RP CTTCAACCAATAAACTCAAAACGACTAACG (SEQ ID NO:418)
 ZNF323_Pb_A5 AGGCCACGGACG GCATTTCCGACCTTTACGA/3C6/ (SEQ ID NO:419)

SLC13A5
 >hg19_dna range=chr17:6616765-6616852 5'pad=0 3'pad=0 strand=+
 CCCCACACGGGGCGCCTCCCCGCGGCCCTGGGGCGGGGCCACCCCTCGGGGTCTGTGGGACGCGCCTGCCCAATTCTGCCACCCG (SEQ
 ID NO:420)

BST:
 TTTCTACGGGGCGTTTTTTCGCGGTTTTGGGGCGGGGTTATTTTCGGGGTTTGTGGGACGCGTTTGTTTTTAATTTTGTATTTCG (SEQ
 ID NO:421)

SLC13A5_FP GCGGTTTTTTCGCGGTTTTG (SEQ ID NO:422)
 SLC13A5_RP GCGTCCCAAAACCCG (SEQ ID NO:423)
 SLC13A5_Pb_A1 CGCGCCGAGG GAAAAATAACCCGCC/3C6/ (SEQ ID NO:424)

FIG. 2 (cont'd)

ZMIZ1
 >hg19_dna range=chr10:81002927-81003006 5'pad=0 3'pad=0 strand=+
 GCGGGACACGAGGGTGGGTGGTACGCCCCGAGGGTCCGCGAGCGCGGCGAGAGCGGGGCCGTGGGAAGTTTCTCC (SEQ ID NO:425)

BST:
 GCGGGTATACGTAGGGTGGGTGGTTACGTTTCGTAGGGTTCGCGAGCGCGGCTAGAGCGGGTCTGTGGGAAGTTTTTTT (SEQ ID NO:426)

ZMIZ1_FP CGTAGGGTGGGTGGTTACGTTT (SEQ ID NO:427)
 ZMIZ1_RP AACTTCCCACGACCCG (SEQ ID NO:428)
 ZMIZ1_Pb_A5 AGGCCACGGACG CGTAGGGTTCGCGAG/3C6/ (SEQ ID NO:429)

MAX.chr8.1451
 >hg19_dna range=chr8:145103900-145103993 5'pad=0 3'pad=0 strand=+
 GTGCCACGCGGCCTTCCACCCCTGTGACTCCCCGAGCTCGCGCGGATGCACCGACGAGTCAGCTTGTCTCTGGAAGCCAATGAGTCTCCCCGG (SEQ ID NO:430)

BST:
 GTGTTACGCGGTTTTTATTTTTGTGATTTTTCGTAGTTCGCGCGGATGTATCGACGAGTTAGTTTGTTTTTTGAAGTTAATGAGTTTTTTCGG (SEQ ID NO:431)

MAX.chr8.1451_FP GTTACGCGGTTTTTATTTTTGTGATTTTTTCG (SEQ ID NO:432)
 MAX.chr8.1451_RP CTCATTAACCTCCAAAAACAACTAACTCGTC (SEQ ID NO:433)
 MAX.chr8.1451_Pb_A1 CGCGCCGAGG CGATACATCCGCGCG/3C6/ (SEQ ID NO:434)

C8orf73
 >hg19_dna range=chr8:144650834-144650919 5'pad=0 3'pad=0 strand=+
 CGGCGCAGCAGAGTCCCAAGGAGCCCGACGGCCGAGGCGCGGATTGAGTCCCGTGTCTGCGTGGGAGGGCGCAGTCAGGGCAGGCG (SEQ ID NO:435)

BST:
 CGGCGTATTAGAGTTTTAAGGAGTTCGACGGTCGAGGCGCGGATTGAGTTTCGTGTTTTCGCTGGGAGGGCGTAGTTAGGGTAGGCG (SEQ ID NO:436)

C8orf73_FP GAGTTCGACGGTCGAGGCG (SEQ ID NO:437)
 C8orf73_RP ACTACGCCCTCCACGC (SEQ ID NO:438)
 C8orf73_Pb_A5 AGGCCACGGACG GCGGATTGAGTTTCGTG/3C6/ (SEQ ID NO:439)

KBTBD11
 >hg19_dna range=chr8:1949507-1949586 5'pad=0 3'pad=0 strand=+
 CGCCGAGTCCCTCGCCTCAGCGCGGAAGGCGCGGCCACCTCCCGCCCTCCAGCGGTGCCCCGGGTGGTGGAGCGG (SEQ ID NO:440)

BST:
 CGTCGTAGTTTTTCGTTTTAGCGCGGAAGGCGCGGTTATTTTTTCGTTTTTAGCGGTGGTTCGCGGGTGGTGGAGCGG (SEQ ID NO:441)

KBTBD11_FP TCGTTTTAGCGCGGAAGG (SEQ ID NO:442)
 KBTBD11_RP CCGGAACCACCGC (SEQ ID NO:443)
 KBTBD11_Pb_A5 AGGCCACGGACG GCGCGGTTATTTTTTCGT/3C6/ (SEQ ID NO:444)

LOC100192379
 >hg19_dna range=chr4:122686300-122686377 5'pad=0 3'pad=0 strand=+
 GCGGGCTGCAGCTGGAGGGCGAGCGCGCCGCCGACACCCACCTCCCGCACTCCCGCCCCCTCGCGAGGGCGTCCCCG (SEQ ID NO:445)

BST
 GCGGGTTGTAGTTGGAGGGCGAGCGCGTCGTTTCGTATATTTATTTTTTCGTATTTTCGTTTTTCGCGAGGGCGTTTCGT (SEQ ID NO:446)

LOC100192379_FP GTTGTAGTTGGAGGGCGAG (SEQ ID NO:447)
 LOC100192379_RP_v2 CGAAACGCCCTCGCGA (SEQ ID NO:448)
 LOC100192379_Pb_A1 CGCGCCGAGG GCGCGTCGTTTCGTATTT/3C6/ (SEQ ID NO:449)

TRIM71
 >hg19_dna range=chr3:32859592-32859712 5'pad=0 3'pad=0 strand=+
 CCGATTTCAGATCTGCTTGCTGTGCAAGGAGATGTGCGGCTCGCCGCGCCGCTCTCCTCCAACCTCGTCCGCGTCGTCGTCCTCCTCGCAGAC GTCCACGTCGTCGGGGGCGCGCGCGG (SEQ ID NO:450)

BST:
 TCGATTTTATAGTTTGTGTTGTGTAAGGAGATGTGCGGTTTCGTCGGCGTCGTTTTTTTTTAATTCGTTTCGCGTCGTCGTTTTTTTCGTAGAC GTTTACGTCGTCGGGGGCGCGCGCGG (SEQ ID NO:451)

TRIM71_FP GTTGTGTAAGGAGATGTGCGGTT (SEQ ID NO:452)
 TRIM71_RP_v3 AAACGACGACGCGAACGAA (SEQ ID NO:453)
 TRIM71_Pb_A5 AGGCCACGGACG CGTCGGCGTCGTTTT/3C6/ (SEQ ID NO:454)

FIG. 2 (cont'd)

LOC440925
 >hg19_dna range=chr2:171570323-171570444 5'pad=0 3'pad=0 strand=+
 GGGCGAGCTCCGGCGGCCACTCCGCAGTGGCTCTCGCGAGCCGGGGCCGCGAGGCCCTCAACGCGGTTCCGCACCCCTAATGCCCCAGGGCGG
 TGAGCACCCCGCGGTTCCCCGCCCGCCT (SEQ ID NO:455)

BST:
 GGTGAGTTTCGGCGGTTATTTTCGTAGTGGTTTTTCGCGAGTCGGGGTCGCGAGGTTTTTAACGCGGTTTCGTATTTTTAATGTTTTAGGGCGG
 TGAGTATTTTCGGGTTTTTCGTTTCGTTT (SEQ ID NO:456)

LOC440925_FP CGTAGTGGCTTTTCGCGAGTC (SEQ ID NO:457)
 LOC440925_RP CGCCCTAAACATTAAAAATACGAAACCG (SEQ ID NO:458)
 LOC440925_Pb_A1 CGCGCCGAGG GCGTTAAAAACCTCGCG/3C6/ (SEQ ID NO:459)

ARL5C
 >hg19_dna range=chr17:37321564-37321723 5'pad=0 3'pad=0 strand=+
 CGGTGGAAAAGACAGCTGAGCCCCCACCCTCCCTTCACATTCCAGAAAAGTGTCTGAAAGGCCCGGGCGCTTCGGGGCTTGCCAAGAGACGGTG
 TTTAGAGAAAAGAGCATAACGCGAAGTCACAATCGCAGGAACTCGCAGCAGCCCCCATCCCCGCC (SEQ ID NO:460)

BST:
 CGGTGGAAAAGATAGTTGAGTTTTTATTTTTTTTATATTTTAGAAAAGTGTGTAAGAGTTTCGGGGCTTCGGGGTTTGTAAAGAGACGGTG
 TTTAGAGAAAAGAGTATAACGCGAAGTTATAATCGTAGGAAATTCGTAGTAGTTTTTATTTTCGTT (SEQ ID NO:461)

ARL5C_FP GTTTCGGGGTTTGTAAAGAGACG (SEQ ID NO:462)
 ARL5C_RP ACTACTACGAATTTCTACGATTATAACTTCG (SEQ ID NO:463)
 ARL5C_Pb_A1 CGCGCCGAGG GCGTTATACTCTTCTCTAAACAC/3C6/ (SEQ ID NO:464)

STX16_57224
 >hg19_dna range=chr20:57224681-57224845 5'pad=0 3'pad=0 strand=+
 CTGCAGCTCCAGCCCGGCCCGCGCGGACCCAGTCCCTGTGCGCCGAATCTCCACCGCTGCGAAGCGTCCCGGGCGAGCGCCCTGCTCT
 CCGCGCTGCGCGGAAGCCAGAGCCGCTCCTCACAGTGAATCGCCAGCCCTGCTCGCGGCTCTCTCGATT (SEQ ID NO:465)

BST:
 TTGTAGTTTTTAGTTCGGTTCGCGCGCGGATTTAGTTTTTTGTGCTTCGAATTTTTTATCGTTGCGAAGCGTTTTTCGGGGCGAGCGTTTTGTTTT
 TCGCGTTGCGCGGAAGTTAGAGTCGGTTTTTATAGTGAATTCGTTAGTTTTGTTTCGGGTTTTTTCGATT (SEQ ID NO:466)

STX16_57224_FP AGTTTTTAGTTCGGTTCGCGC (SEQ ID NO:467)
 STX16_57224_RP CCCGAAAACGCTTCGCAACG (SEQ ID NO:468)
 STX16_57224_Pb_A5 AGGCCACGGACG CGGCGATTAGTTTTTTGTGCG/3C6/ (SEQ ID NO:469)

ITPKA
 >hg19_dna range=chr15:41787637-41787780 5'pad=0 3'pad=0 strand=+
 CGCACAAATCGGCTGGGACAAGGCAAGGAGCTGTGGCGACCTGCAGGGGTTTACAAAGCCCGAGGCCGATGGGGTTTGTAGTGACACCAGAGG
 GAAAAGCCTCACAGAGCAGGAACACCCCCCGCCGCGAGGTGCTGGGTGC (SEQ ID NO:470)

BST:
 CGTATAATCGGTTGGGATAAGGTAGGGAAGTTGTGGCGATTGTAGGGGTTTATAAGTTCGGAGGTCGATGGGGTTTGTAGTGATATTAGAGG
 GAAAAGTTTTATAGAGTAGGAATATTTTTCTGCTAGGTGTTGGGTGT (SEQ ID NO:471)

ITPKA_FP GATAAGGTAGGGAAGTTGTGGCG (SEQ ID NO:472)
 ITPKA_RP CCTCTAATATCACTAACAACCCCATCG (SEQ ID NO:473)
 ITPKA_Pb_A1 CGCGCCGAGG GACCTCCGAATTATAAACC/3C6/ (SEQ ID NO:474)

IRF4
 >hg19_dna range=chr6:393188-393284 strand=+
 CGGCATGAGCGCGGTGAGCTGCGGCAACGGGAAGCTCCGCCAGTGGCTGATCGACCAGATCGACAGCGGCAAGTACCCCGGCTGGTGTGGGAG
 AAC (SEQ ID NO:475)

BST:
 CGGTATGAGCGCGGTGAGTTGCGGTAACGGGAAGTTTCGTTAGTGTTGATCGATTAGATCGATAGCGGTAAGTATTTTCGGGTTGGTGTGGGAG
 AAT (SEQ ID NO:476)

IRF4_FP CGCGGTGAGTTGCGGTAAC (SEQ ID NO:477)
 IRF4_RP CGAAATACTTACCGTATCGATCTAATCGA (SEQ ID NO:478)
 IRF4_Pb_A5 AGGCCACGGACG CGGGAAGTTTCGTTAGTGG/3C6/ (SEQ ID NO:479)

FIG. 2 (cont'd)

CNTN4
>hg19_dna range=chr3:2140464-2140527 strand=+
GGCAGCCCGAACTCCGGCGCGCCAGGTTTTTCCAGCCGCCGAGCGCCGGGAGGGAGGGCAGC (SEQ ID NO:480)

BST:
GGTAGTTCGAATTTCCGGCGCTTAGGTTTTTTTAGTCGTCGCGAGCGTCGGGAGGGAGGGTAGT (SEQ ID NO:481)

CNTN4_FP GGTAGTTCGAATTTCCGGCGC (SEQ ID NO:482)
CNTN4_RP CTCCTCCCCGACGCTCG (SEQ ID NO:483)
CNTN4_Pb_A1 CGCGCCGAGG CGTAGGTTTTTTTAGTCGTCG/3C6/ (SEQ ID NO:484)

GRIN2A
>hg19_dna range=chr16:10277158-10277320 strand=+
CGCAGTCCCTCGGCGGCGACGCGGAGCGCGGCCACCCGTTCCGAGAGCGCACGGCGGCAATAAGGCCAGGATAGGTGGCTGGCTGGCGACGGG
GGCGCCTCGGCGGCGCGCTGCTGTCCGTGGTGTGGAACACGCTCTCCGCCCGCTCCCGGGCGTC (SEQ ID NO:485)

BST:
CGTAGTTTTTTCGGCGGCGACGCGGAGCGCGGTTATTCTGTTTCGAGAGCGTACGCGCGTAAATAAGGTTAGGATAGGTGGTGGTGGCGACGGG
GGCGTTTTCGGCGGCGCGCTGTTGTTCTGTTGGTGTGGAATTACGTTTTTCTGTTCTGTTTCGGGCGTT (SEQ ID NO:486)

GRIN2A_FP GTAGTTTTTTCGGCGGCGACG (SEQ ID NO:487)
GRIN2A_RP CCTTATTTACCGCCGTACGCT (SEQ ID NO:488)
GRIN2A_Pb_A5 AGGCCACGGACG TCTCGAAACGAATAACCGC/3C6/ (SEQ ID NO:489)

NOTCH3
>hg19_dna range=chr19:15306498-15306625 strand=-
CGCCCGGGGCGTCGGGAGGGGGCCGCGCGGGTCGCGCCCTGCCTGGCGGTGGGACCAGCTATCCTCGGCGCCAGCGCAGCGCCCCCTCCC
GACGCGCGGTTCGGGCGCGCAGTGGTCGCCCTGCG (SEQ ID NO:490)

BST:
CGTTCGGGGCGTCGGGAGGGGGTTCGCGCGGGTCGCGTTTTGTTTGGCGGTGGGATTAGTTATTTTCGGCGTTTAGCGTAGCGCGTTTTTTTTC
GACGCGCGGTTCGGGGTCGTAGTGGTCTGTTTTCG (SEQ ID NO:491)

NOTCH3_FP GGTGCGTTTTTGTGTTGGCG (SEQ ID NO:492)
NOTCH3_RP CGCGCGTCGAAAAAAACGCG (SEQ ID NO:493)
NOTCH3_Pb_A1 CGCGCCGAGG GCTACGCTAAACCGC/3C6/ (SEQ ID NO:494)

PAX1
>hg19_dna range=chr20:21683741-21683893 strand=+
AGCTCGGGAACCCGCGATACCCGGCGGGGGACGACAGGGGGCGACAACTGTAAGTTTTCCCTATGCCCGACCGTCAGAAAGGCTGCAGCGA
GGGCTGTGTCTCCCGATCGCGCACAGCTGGCTGCGGGAAGGGGCCAGGATTGAGACG (SEQ ID NO:495)

BST:
AGTTCGGGAATTCGCGATATTCGGTTCGGGGACGATAGGGGGCGATAAATTGTAAGTTTTTTTATGTTTCGATCGTGTAGAAGGTTGTAGCGA
GGTTTGTGTGTTTTTCGATCGCGTATAGTTGTTGCGGGAAGGGGTAGGATTGAGACG (SEQ ID NO:496)

PAX1_FP CGATCGTGTAGAAGGTTGTAGCG (SEQ ID NO:497)
PAX1_RP TTTCCCGCAACCAACTATACGCG (SEQ ID NO:498)
PAX1_Pb_A5 AGGCCACGGACG GATCGAAAACACACAACCC/3C6/ (SEQ ID NO:499)

ZNF521
>hg19_dna range=chr18:22929721-22929795 strand=+
GGGCGCGCGGACCTCGGCGGGACCCAGCGGGCCCGGGCGCGCACGACCGCCCTTGTCTCCGCCTCCGGG (SEQ ID NO:500)

BST:
GGGTGCGCGGATTTTCGGCGGGATTTAGCGGGTTCGGGCGGGCGTATTAGTCGTTTTTTGTTTTTCGTTTTTCGGG (SEQ ID NO:501)

ZNF521_FP CGGGATTTAGCGGGTTCGG (SEQ ID NO:502)
ZNF521_RP CCCGAAAACGAAAAACAAAAACGAC (SEQ ID NO:503)
ZNF521_Pb_A1 CGCGCCGAGG GCGGGCGTATTAGT/3C6/ (SEQ ID NO:504)

VSX1
>hg19_dna range=chr20:25065266-25065458 strand=+
GTCTGCAAGAGATAAAAAGCTAGCCACGATCCACCCACAATCCTCGTGTCCCGGGGTGCCCTCGCAGTTGCCAAACCTACGGGCGCGTTTA
GGGAAGCCTCCGCGTCTGGCGGCCAAAAGAATGGGCTCCTCCAGCTTCCCTACCGGATACCACTGCAAATCTATTGCCAGAGGCGCAG
CTCCC (SEQ ID NO:505)

FIG. 2 (cont'd)

BST:
 GTTTGTAAGAGATAAAAAAGTTAGTTTACGATTTATTTATAATTTTCGTGTTTTCGGGGTGTTTTCGTAGTTGTTAAATTTACGGGTCGCGTTTA
 GGGGAAGTTTTTCGCGTTTTGGCGGTTAAAGAATGGGTTTTTTTAGTTTTTTTATCGGATATTATTTGTAAATTTATTGTTAGAGGCGTAG
 (SEQ ID NO:506)
 TTTTT

VSX1_FP TCGGGGTGTTTTCGTAGTTGTTAAATTTAC (SEQ ID NO:507)
 VSX1_RP CATTCTTTTAACCGCCAAAACGCG (SEQ ID NO:508)
 VSX1_Pb_A5 AGGCCACGGACG CGGGTCGCGTTTAGG/3C6/ (SEQ ID NO:509)
 -

CRHR2
 >hg19_dna range=chr7:30721989-30722099 strand=+
 GCGGGGTCTGCCCCCGCCAGCCAGCCCCGATCTCCCGGCAGCCTTTGGGCGCCACCTCCGGTCGCCCAGAGCTGTCAAGTGGGGACCTTC
 CCGGAGAGGAGCCGCG (SEQ ID NO:510)

BST:
 GCGGGGTTTTGTTTTCGTTAGTTTAGTTTTCGGTTAGTTTTTGGGCGTTATTTTCGGTCGTTTAGAGTTGTTAAGTGGGGATTTTT
 TCGGAGAGGATCGTCG (SEQ ID NO:511)

CRHR2_FP GGGTTTTGTTTTCGTTAGTTTAGTTTC (SEQ ID NO:512)
 CRHR2_RP ACAACTCTAAACGACCGAAAATAACG (SEQ ID NO:513)
 CRHR2_Pb_A5 AGGCCACGGACG CGATTTTTCGGTAGTTTTTG/3C6/ (SEQ ID NO:514)

FAM19A5
 >hg19_dna range=chr22:48885810-48885908 strand=+
 CGGCGGTGCGAGCCAGCCAGCGGCTTCCCGCCGAGATGCGCGCTCAGGAGGCAGCCGAGGTCGCGGAGGGCGGGCGGCGCTGCCGGGTGT
 CTGCG (SEQ ID NO:515)

BST:
 CGGCGGTGCGAGTTTAGTTAGCGTTTTTTCGGTCGAGATGCGCGTTTAGGAGGTAGTCGTAGGTCGCGGAGGGCGGGCGGCGTTGTGCGGGTGT
 TTGCG (SEQ ID NO:516)

FAM19A5_FP GCGGTGCGAGTTTAGTTAGCG (SEQ ID NO:517)
 FAM19A5_RP ACCTACGACTACCTCCTAAACGCG (SEQ ID NO:518)
 FAM19A5_Pb_A1 CGGCGCGAGG GGTTTTTCGGTGAGATG/3C6/ (SEQ ID NO:519)

ASCL1
 >hg19_dna range=chr12:103352059-103352157 strand=+
 GGCCAGCAGCCCCAGCCGACGCCCCAGCAGCCCTTCCTGCCGCCGACGCTGTTTCTTTGCCACGGCCGACGCCGCGCGCGCCGACGCCGCC
 CAGCG (SEQ ID NO:520)

BST:
 GGTTAGTAGTTTTAGTCGTAGTTTTAGTAGTTTTTTTGTGTCGTTCGTAGTTGTTTTTTGTTACGGTCGTAGTCGCGCGGTCGTAGTCGTG
 TAGCG (SEQ ID NO:521)

ASCL1_FP GTCGTAGTTTTAGTAGTTTTTTTGTGCTTCG (SEQ ID NO:522)
 ASCL1_RP CGACCGCCGCGACTAC (SEQ ID NO:523)
 ASCL1_Pb_A5 AGGCCACGGACG CGACCGTAACAAAAAACAAAC/3C6/ (SEQ ID NO:524)

GLT1D1
 >hg19_dna range=chr12:129338254-129338322 strand=+
 GGGACCCGGGACGCGGGGCGCTCAGCCAGGCCCTCCAGCCGCGCGGGGCGCTCCCGAGCCGCGCG (SEQ ID NO:525)

BST:
 GGGATTCCGGGACGCGGGGCGTTTAGTTAGGTTTTTTTTAGTCGCGTCGGGTCGTTTCGAGTCGCGCG (SEQ ID NO:526)

GLT1D1_FP GACGCGGGGCGTTTAGT (SEQ ID NO:527)
 GLT1D1_RP CGACTCGAAACGACCCGA (SEQ ID NO:528)
 GLT1D1_Pb_A1 CGCGCCGAGG ACGCGACTAAAAAACCTAAC/3C6/ (SEQ ID NO:529)

T
 >hg19_dna range=chr6:166581961-166582112 strand=+
 GGTCACCTGTCCCCACAGTCCCTCGCCACGAGAGCCAGGCGCGTTACGCACACCCAGGATCGTGGATCAGCCTGCCCGGCGTCGGGTG
 TCCCCGCGCTCTCACCATCTGAAAAGGAAGGTCCGCGCGCAGAGGGAAATGGAC (SEQ ID NO:530)

BST:
 GGTGTATTTGTTTTTATACGTTTTTCGTTTACGGAGTTTTAGGCGGCGTTACGTATATTTAGGATCGTGGATTAGTTTGTTCGGCGTCGGGTG
 TTTTCGCGGTTTTTATATATTGAAAAGGAAGGTTCCGCGCTAGAGAGGAAATGGAT (SEQ ID NO:531)

FIG. 2 (cont'd)

T_FP GGAGTTTTAGGCGCGTTACG (SEQ ID NO:532)
 T_RP ACCGCGAAAAACCCGAC (SEQ ID NO:533)
 T_Pb_A5 AGGCCACGGACG CGCCGAAACAACTAATCC/3C6/ (SEQ ID NO:534)

CAPN2
 >hg19_dna range=chr1:223936903-223937040 strand=+
 GGGCCCGCGCGCCCCACGGTGGTCCAGTTTACACTCGGGCCCCGCACCTCCTGAAGTTCCGCGGGGAGGAGAAGGGCGTCCCTTTTCGCAGCTC
 GGGCGCCGGGTGCGCCGCGCTGCCACCTGGTGGCCGAGTGGCC (SEQ ID NO:535)

BST:
 GGGTTCGCGCGGTTTTACGGTGGTTTTAGTTTATATTCGGGTTTCGTATTTTTGAAGTTTCGCGGGGAGGAGAAGGGCGTTTTTTTCGTAGTTTC
 GGGCGTCGGGTGCGTTCGCTGCTTATTATTTGGTGGTTCGTAGTGGTT (SEQ ID NO:536)

CAPN2_FP GTTCGCGCGGTTTTACGGT (SEQ ID NO:537)
 CAPN2_RP CGCCCTTCTCTCCCGC (SEQ ID NO:538)
 CAPN2_Pb_A1 CGCGCCGAGG CGCGAACTTCAAAAATACGA/3C6/ (SEQ ID NO:539)

RYR2_F:
 chr1:237205546-237205717 strand=+
 TGCGGGGCTGCTTCCCGCGTCTCCGGGCGCGGCCCTCTCCCGCACAGTGCAGGAGAGGGAGGCCCCGCGCTCGACCACCCGCGCCC
 GAGCGTCCGCGCTCTCTCTCCGCTCTGCAGGCGGGGACCGCCGCGCTCGGCACCCGGCAGCGCGGCCCCCTCCAG (SEQ ID NO:540)

BST:
 TGCGGGGTTGTTTTTCGCGTTTTTCGGGTTTCGGTTCGTTTTTTTTTCGTATAGTGCAGGAGTAGGGAGGTTTCGCGTTTCGATTATTCGCGTTTC
 GAGCGTTCGCGTTTTTTTTTCGTTTTGTAGCGGGGATCGTTTCGCGTTCGGTATTCGGTAGCGCGGTTTTTTTTTAG (SEQ ID NO:541)

RYR2_F_FP_v2 GGAGGTTTCGCGTTTCGATTA (SEQ ID NO:542)
 RYR2_F_RP_v2 CGAACGATCCCCGCTAC (SEQ ID NO:543)
 RYR2_F_LQ_Pb_A5 AGGCCACGGACG ATTCGCGTTCGAGCG/3C6/ (SEQ ID NO:544)

SIM2
 >hg19_dna range=chr21:38119993-38120059 5'pad=0 3'pad=0 strand=-
 GGGCCAGCGCGGGTCTCTCGCGTAGTGCCCGCAGCTCGGGAAGCTCGGGGCGCGGTGTCCTCGC (SEQ ID NO:545)

BST:
 GGGTTTAGCGCGGTTTTTCGCGGTAGTGGTCGTAGTTCGGGAAGTTTCGGGGCGCGGTGTTTTTCGT (SEQ ID NO:546)

SIM2_FP_v2 GGTTTAGCGCGGTTTTTCG (SEQ ID NO:547)
 SIM2_RP_v2 CCCCAGAACTTCCCGAACT (SEQ ID NO:548)
 SIM2_Pb_LQ_A5 AGGCCACGGACG GCGGTAGTGGTCGTAG/3C6/ (SEQ ID NO:549)

TRH
 >hg19_dna range=chr3:129693484-129693575 5'pad=0 3'pad=0 strand=+
 GGCCGCGACCCCTCCCGCTGACCTCACTCGAGCCGCGCCTGGCGCAGATATAAGCGCGCGCCATCTGAAGAGGGCTCGGCAGGCGCCCG
 (SEQ ID NO:550)

BST:
 GGTTCGCGATTTTTTTTCGTTGATTTTATTCGAGTCGTCGTTTGGCGTAGATATAAGCGCGGTTTATTTGAAGAGGGTTCGGTAGGCGTTTCG
 (SEQ ID NO:551)

TRH_FP TTTTCGTTGATTTTATTCGAGTCGTC (SEQ ID NO:552)
 TRH_RP GAACCTCTTCAAATAAACCGC (SEQ ID NO:553)
 TRH_Pb_A5_63 AGGCCACGGACG CGTTTGGCGTAGATATAAGC/3C6/ (SEQ ID NO:554)

JAM3
 >hg19_dna range=chr11:133938908-133939011 strand=-
 GAGCCGAGTCGCGGTGGCGCCTCAGCGCCATGTGAGGGTTGCTGAGGGGCCAGCGGCAGCGCGCGCGGCTTGTAGTCCCCGCGCGCATGC
 GCCAGCCTG (SEQ ID NO:555)

BST:
 GAGTCGGAGTCGCGGTGGTTCGTTTTAGCGTTATGTCGAGGGTTGTTGAGGGGTTAGCGGTAGCGCGCGCGGTTTGTAGTTTTTCGCGCGTATGC
 GTTTAGTTTG (SEQ ID NO:556)

JAM3_FP TGGTCGTTTTAGCGTTATGTCG (SEQ ID NO:557)
 JAM3_RP CGAAACTACAAACCGCGC (SEQ ID NO:558)
 JAM3_Pb_A5_LQ AGGCCACGGACG CCGCGCTACCGCTA/3C6/ (SEQ ID NO:559)

FIG. 2 (cont'd)

JAM3_Pb_A1_LQ CGCGCCGAGG CCGCGCTACCGCTA/3C6/ (SEQ ID NO:560)

BARX1

>hg19_dna range=chr9:96721498-96721597 strand=-
 GGCCCGGGCGCCCTGGGCCCTAGGGCTGGACGTCAACCTGTTAGATAGAGGGCGTGGGACCCCCGAGGCGGCTGCTCGGACACCGCAT
 CCGGAG (SEQ ID NO:561)

BST:

GGTTCGGGTCGTTTGGGTTTTAGGGTTGGACGTTAATTTGTTAGATAGAGGGCGTGGGATTTTTCTAGGCGGTTGTTCCGACGATCGTAT
 TCGGAG (SEQ ID NO:562)

BARX1_FP CGTTAATTTGTTAGATAGAGGGCG (SEQ ID NO:563)
 BARX1_RP_universal TCCGAACAACCGCCTAC (SEQ ID NO:564)
 BARX1_Pb_A5_63_v6 AGGCCACGGACG CGAAAAATCCACGC/3C6/ (SEQ ID NO:565)

ZNF671

>hg19_dna range=chr19:58238790-58238906 strand=+
 CCGTGGGCGCGGACAGCTGCCGGGAGCGGCAGCGTCTCGATCGGGGACGCAGGCACTCCCTCCCTGCAGAGCATCAGACGCGTCTCGGACA
 CTGGGGACAACATCTCCTCCGCG (SEQ ID NO:566)

BST:

TCGTGGGCGCGGATAGTTGTCCGGAGCGGTAGCGTTTCGATCGGGACGTAGGTATTTTCGTTTTGTAGAGTATTAGACGCGTTTCGGGATA
 TTGGGGATAATATTTTTTTCGCG (SEQ ID NO:567)

ZNF671_FP GTTGTCCGGAGCGGTAGG (SEQ ID NO:568)
 ZNF671_RP CCAATATCCCGAAACGCGTCT (SEQ ID NO:569)
 ZNF671_Pb_A1_LQ CGCGCCGAGG GCGTTTCGATCGGG/3C6/ (SEQ ID NO:570)

MPZ_5554

>hg19_dna range=chr1:16127554-161276006 5'pad=0 3'pad=0 strand=- repeatMasking=none
 TTAGCGGGCGGGCGGGGATCGGGGTTAGGGTGGAGTCCGCCAAAGGCCAAAGGTGATGGTCATCGAGATGGAGCTACGAAAGGATGAGC
 AGAGCCCGAGCTCC (SEQ ID NO:571)

BST:

TTAGCGGGTCGGGCGGGGATCGGGGTTAGGGTGGAGTTCGTTAAAGGTTTAAAGGTGATGGTTATCGAGATGGAGTTACGAAAGGATGAGT
 AGAGTTCGGAGTTTT (SEQ ID NO:572)

MPZ_5554_FP GGTAGGGTGGAGTTCGTTA (SEQ ID NO:573)
 MPZ_5554_RP ACTCCGAACCTACTCATCCTTC (SEQ ID NO:574)
 MPZ_5554_Pb_A1_63 CGCGCCGAGG CGTAACTCCATCTCGATAACC/3C6/ (SEQ ID NO:575)

CXCL12

>hg19_dna range=chr10:44881200-44881315 5'pad=0 3'pad=0 strand=+
 AAGGCGCGGGCGGCTCTCAGTAAAGCGAATGTAGCCTTTGTACTTCGACCTCTCAATGGTGAATGAGCTAATCACAGGCCACCCCGCGGA
 GTGGGACGGGAGATTCAATGAG (SEQ ID NO:576)

BST:

AAGGCGTCGGCGGTTTTTAGTAAAGCGAATGTAGTTTTGTATTTTCGATTTTTTAATGGTGAATGAGTTAATTATAGGTTTATTTTCGCGGA
 GTGGGACGGGAGATTTAATGAG (SEQ ID NO:577)

CXCL12_FP TCGGCGGTTTTTAGTAAAGCG (SEQ ID NO:578)
 CXCL12_RP AAATCTCCCGTCCCACTCC (SEQ ID NO:579)
 CXCL12_Pb_A1 CGCGCCGAGG CGCGAAATAAACCTATAATTAACCTCA/3C6/ (SEQ ID NO:580)

TSPYL5

>hg19_dna range=chr8:98290016-98290134 strand=+
 GCCTTTGCCCCGTTTTTGGCGCGGGAGGACTTTCGACCCCGACTTCGGCCGCTCATGGTGGCGGCGGAGGAGCTTCAAAGACACGCTGTGAC
 CCTCGCGTCTCTGACGCCAGCTCTC (SEQ ID NO:581)

BST:

GTTTTTGTTCGGTTTTTGGCGCGGGAGGATTTTCGATTTTCGATTTTCGGTCGTTTATGGTGGCGGCGGAGGTAGTTTTAAAGATACGTTGTGAT
 TTTGCGGTTTTTGACGTTAGTTTTT (SEQ ID NO:582)

TSPYL5_FP_V2 TTTGTTTCGGTTTTTGGCG (SEQ ID NO:583)
 TSPYL5_RP_v4 CGCCACCATAAACGACC (SEQ ID NO:584)
 TSPYL5_Pb_A5_63_v4 AGGCCACGGACG GCGGGAGGATTTTCGATTTC/3C6 (SEQ ID NO:585)

FIG. 2 (cont'd)

PTGDR
>hg19_dna range=chr14:52735270-52735400 5'pad=0 3'pad=0 strand=- repeatMasking=none
GCCTCGGGGCCCCGGGACTCACAAATTACGGGCAGAGAACACATAGTGAAGAGCACGGTCATCAGCGCCAGCAGCAGGAGGTGATCCAGCTCCTC
CAGGGGCTGAGGG (SEQ ID NO:586)

BST:
GTTTCGGGGTTTCGGGGATTTATAATTACGGGTAGAGAATATATAGTGAAGAGTACGGTTATTAGCGTTAGTAGTAGGAGGTGATTTAGTTTTTT
TAGGGGTTGAGGG (SEQ ID NO:587)

PTGDR_FP GGGTTCGGGGATTTATAATTACGG (SEQ ID NO:588)
PTGDR_RP CTAATCACCTCCTACTACTAACGCTAATAAC (SEQ ID NO:589)
PTGDR_Pb_LQ_A1 CGCGCCGAGG CCGTACTCTTCACTATATATTCTCT/3C6/ (SEQ ID NO:590)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 20/15059

A. CLASSIFICATION OF SUBJECT MATTER

IPC - C12Q 1/68; C12Q 1/6886 (2020.01)

CPC - C12N 2600/154; C12Q 1/6886; C12N 2600/112; C12Q 2600/158

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ---	NELSON et al. Key epigenetic changes associated with lung cancer development: results from dense methylation array profiling. Epigenetics, 1 June 2012, Vol 7, No 6, Pages 559-566. Especially abstract, pg 563 table 1, pg 564 col 2 para 5, pg 565 col 1 para 1, pg 565 col 1 para 4-5.	1-4, 6, 7, 9, 11-16, 18, 20, 51, 53, 55, 56 ----- 10, 21, 23-27, 29-32, 54, 99, 116
Y	US 2016/0040246 A1 (MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH) 11 February 2016 (11.02.2016) para [0276].	10
Y	CHANG et al. Increased epithelial stem cell traits in advanced endometrial endometrioid carcinoma. BMC Genomics, 16 December 2009, Vol 10, No 613, Pages 1-17. Especially pg 6 fig 2, pg 9 table 4.	21, 23-27, 29-32
Y	NCBI Reference Sequence: NC_000002.11. Homo sapiens chromosome 2, GRCh37.p13 Primary Assembly, 13 August 2013 [online]. [Retrieved 18 May 2020]. Retrieved from the internet: <URL: https://www.ncbi.nlm.nih.gov/nuccore/NC_000002.11/ >. Coordinated with Genome Data Viewer. Human AFF3 for NC_000002.11 GRCh37.p13 Primary Assembly [online] retrieved [18 May 2020]. Available on the internet:<URL: https://www.ncbi.nlm.nih.gov/genome/gdv/browser/gene/?id=3899 > Especially pg 1 and 2	24, 30, 54
Y	ZHANG et al. Comparative DNA methylome analysis of endometrial carcinoma reveals complex and distinct deregulation of cancer promoters and enhancers. BMC Genomics. 6 October 2014, Vol 15, No 1, Pages 868 1-21. Especially abstract.	99, 116

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

18 May 2020

Date of mailing of the international search report

22 JUN 2020

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Lee Young

Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 20/15059

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
-----Go to Extra Sheet for continuation-----

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-4, 6, 7, 9-16, 18, 20, 21, 23-27, 29-32, 51, 53-56, 99, 116 limited to the gene AFF3.

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/US 20/15059

Continuation of Box III: Observations where Unity of Invention is lacking

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I+: Claims 1-99, 116, drawn to a method of measuring the methylation level of one or more genes implicated in endometrial cancer. The method of measuring the methylation level will be searched to the extent that the gene is the first one named, AFF3 (claim 1). It is believed that claims 1-4, 6, 7, 9-16, 18, 20, 21, 23-27, 29-32, 51, 53-56, 99, 116 read on this first named invention and thus these claims will be searched without fee to the extent that they encompass AFF3. [note: Claims 8, 17, 22, 28, 52 are excluded from the first invention because AFF3 primer pairs are not listed in pg 127 Table 10 or pg 149 Table 22. Claims 5 and 19, are excluded from the first invention because the claims require multiplex gene assays. Claims 57-98 are excluded from the first invention because the language of the claim "region having an annotation" in independent claims 57, 64, 71, 78, 85, 92 indicates selecting all genes in a subgroup (i), (ii), or (iii), etc. See also claims 58, 65, 72, 79, 86, 94]. Additional genes will be searched upon payment of additional fees. Applicant must specify the claims that encompass any additional genes. Applicants must further indicate, if applicable, the claims which read on the first named invention if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched/examined. An exemplary election would be: EMX2OS (claims 1-56, 116).

Group II: Claims 100-107, 117-122, drawn to a system comprising an analysis component, a comparison component, and an alert component.

Group III: Claims 108-115, drawn to a kit or composition comprising reagents, control samples, and oligonucleotides for measuring methylation levels of a DNA sample.

The inventions listed as Groups I+, II, III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Special Technical Features:

Group I+ has the special technical feature of specific method steps for measuring the methylation level of one or more genes or chromosomal regions, not required by Groups II or III.

Group II has the special technical feature of a system comprising an analysis component configured to determine the methylation state of a sample, and an alert component configured to determine a single value based on a combination of methylation states and alert a user of an endometrial cancer-associated methylation state, not required by Groups I+ or III.

Group II has the special technical feature of the methylation levels of a control or reference recorded in a database, not required by Groups I+ or III.

Group III has the special technical feature of a kit or composition comprising reagents, control samples, and specific oligonucleotides, not required by Groups I+ or II.

Common Technical Feature:

Group I+ inventions share the following common technical features:

1. treating genomic DNA in a biological sample with bisulfite
2. amplifying the bisulfite treated gene or genomic region with specific primers
3. quantitating the methylation level of the gene(s) to a control sample without endometrial cancer (EC), by PCR, nucleic acid sequencing, mass spectrometry, etc.
4. Specific genes or chromosomal regions whose level of methylation is correlated with endometrial cancer.
5. subtypes of endometrial cancer: clear cell, carcinosarcoma, serous, endometrioid
6. CpG sites and/or DMRs (differentially methylated regions)

Groups I+ and II share the common technical feature of:
7. methylation levels of a sample, control or reference

Group I+ and III share the common technical features of:

8. a bisulfite reagent
9. control nucleic acid sequences having a methylation state not associated with endometrial cancer
10. oligonucleotides useful for amplification of a specific gene.

However, said common technical features do not represent a contribution over the prior art, and are previously disclosed by the publication titled "Quantitative DNA methylation analysis of selected genes in endometrial carcinogenesis" by Chen et al. (hereinafter "Chen") [published October 2015 in Taiwan J Obstet Gynecol Vol 54 No 5 Pages 572-579].

-----continued on next sheet-----

-----continued from previous sheet-----

Chen discloses common technical feature #1, treating genomic DNA in a biological sample with bisulfite (pg 573 col 2 para 4; "The DNA from the tumor specimens was subjected to bisulfite methylation analysis. We treated DNA with bisulfite using the EZ DNA Methylation Kit").

Common technical feature #2, amplifying the bisulfite treated gene or genomic region with specific primers (pg 573 col 1 para 4; "We used a quantitative methylation polymerase chain reaction (qMSP) with validation analysis using additional EC tissues, tissues with hyperplasia of the endometrium, and tissues from normal controls"; pg 574 col 1 para 1; "SYBR Green-based quantitative methylation polymerase chain reaction (qMSP; SuperArray Bioscience, Frederick, USA) was performed after the bisulfite treatment on the denatured genomic DNA. The primers and probes for each gene were ZNF177, COL14A1, HOXA9, and TMEFF2").

Common technical feature #3, quantitating the methylation level of the gene(s) to a control sample without endometrial cancer (EC), by PCR (pg 573 col 1 para 4; "We used a quantitative methylation polymerase chain reaction (qMSP) with validation analysis using additional EC tissues, tissues with hyperplasia of the endometrium, and tissues from normal controls"), nucleic acid sequencing (pg 576 fig 3; Figure 3. The sequencing of the methylation-specific polymerase chain reaction (MS-PCR) product, compared to MS-PCR. The samples are from the normal endometrium (case #79), hyperplasia of endometrium (case #6), and endometrial cancer (case #15)).

Common technical feature #4; Specific genes or annotated chromosomal regions whose level of methylation is correlated with endometrial cancer (abstract; "Promoter methylation of ZNF177, COL14A1, HOXA9, DPYSL4, and TMEFF2 genes is a frequent epigenetic event in EC").

Common technical feature #5, subtypes of endometrial cancer: clear cell, carcinosarcoma, serous, endometrioid (pg 573 col 2 para 1; patients with an endometrial malignancy other than endometrioid adenocarcinoma (e.g., serous or clear cell type)).

Common technical feature #6; "CpG sites and/or DMRs (differentially methylated regions) (pg 573 col 1 para 2; Like many cancers, EC is a complex disease affected by genetic, epigenetic, and environmental factors. One type of epigenetic modification is DNA methylation. Aberrant hypermethylation of cytosine-phosphate-guanine (CpG) islands present in the promoters of genes is associated with gene silencing. Tumorigenesis may be initiated by the epigenetic silencing of genes").

Common technical feature #7; methylation levels of a sample, control or reference (pg 575 fig 1; Figure 1. The methylation index (MI) values for the genes ZNF177, COL14A1, DPYSL4, HOXA9, and TMEFF2, as determined from scrapings of the normal endometrium and tissues of endometrial hyperplasia, and endometrial cancer").

Common technical feature #8, a bisulfite reagent (pg 573 col 2 para 4).

Common technical feature #9, control nucleic acid sequences having a methylation state not associated with endometrial cancer (pg 573 col 1 para 4; pg 574 col 1 para 1).

Common technical feature #10, oligonucleotides useful for amplification of a specific gene (pg 574 col 1 para 1).

As the common technical features were known in the art at the time of the invention, they cannot be considered common special technical features that would otherwise unify the groups. The inventions lack unity with one another.

Therefore, Groups I+, II, III lack unity of invention under PCT Rule 13 because they do not share a same or corresponding special technical feature.